{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "b69188af",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "from bs4 import BeautifulSoup\n",
    "import requests\n",
    "import numpy as np\n",
    "pd.options.display.max_colwidth = 100000"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f71c87f9",
   "metadata": {},
   "outputs": [],
   "source": [
    "# getting links from multiple pages\n",
    "a_z = soup.find('div', {'id':'A_Z'})\n",
    "a_z_links = [link['href'] for link in a_z.find_all('a', href=True)]\n",
    "\n",
    "alphabet = []\n",
    "for elements in a_z_links:\n",
    "    alpha = f'{root}' + elements\n",
    "    alphabet.append(alpha)\n",
    "    \n",
    "alphabet"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "6ad41a7f",
   "metadata": {},
   "outputs": [],
   "source": [
    "links=[]\n",
    "\n",
    "for j in alphabet:\n",
    "    \n",
    "    website = j\n",
    "    headers = {'accept': '*/*','User-Agent': 'Mozilla/5.0 (Macintosh; Intel Mac OS X 10_15_7) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/101.0.4951.64 Safari/537.36 Edg/101.0.1210.53','Accept-Language': 'en-US,en;q=0.9,it;q=0.8,es;q=0.7','referer': 'https://www.google.com/','cookie': 'DSID=AAO-7r4OSkS76zbHUkiOpnI0kk-X19BLDFF53G8gbnd21VZV2iehu-w_2v14cxvRvrkd_NjIdBWX7wUiQ66f-D8kOkTKD1BhLVlqrFAaqDP3LodRK2I0NfrObmhV9HsedGE7-mQeJpwJifSxdchqf524IMh9piBflGqP0Lg0_xjGmLKEQ0F4Na6THgC06VhtUG5infEdqMQ9otlJENe3PmOQTC_UeTH5DnENYwWC8KXs-M4fWmDADmG414V0_X0TfjrYu01nDH2Dcf3TIOFbRDb993g8nOCswLMi92LwjoqhYnFdf1jzgK0'}\n",
    "    result = requests.get(website, headers=headers)\n",
    "    content = result.text\n",
    "    soup = BeautifulSoup(content, 'lxml')\n",
    "    \n",
    "    div = soup.find('div', class_='AZ_results')\n",
    "    for li in div.find_all('li'):\n",
    "        a = li.find('a')\n",
    "        if 'href' in a.attrs:\n",
    "            url = a.get('href')\n",
    "            links.append(url)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "5e466b9b",
   "metadata": {},
   "outputs": [],
   "source": [
    "root = 'https://www.rxlist.com'                         \n",
    "website = f'{root}/drugs/alpha_a.htm'\n",
    "headers = {'accept': '*/*','User-Agent': 'Mozilla/5.0 (Macintosh; Intel Mac OS X 10_15_7) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/101.0.4951.64 Safari/537.36 Edg/101.0.1210.53','Accept-Language': 'en-US,en;q=0.9,it;q=0.8,es;q=0.7','referer': 'https://www.google.com/','cookie': 'DSID=AAO-7r4OSkS76zbHUkiOpnI0kk-X19BLDFF53G8gbnd21VZV2iehu-w_2v14cxvRvrkd_NjIdBWX7wUiQ66f-D8kOkTKD1BhLVlqrFAaqDP3LodRK2I0NfrObmhV9HsedGE7-mQeJpwJifSxdchqf524IMh9piBflGqP0Lg0_xjGmLKEQ0F4Na6THgC06VhtUG5infEdqMQ9otlJENe3PmOQTC_UeTH5DnENYwWC8KXs-M4fWmDADmG414V0_X0TfjrYu01nDH2Dcf3TIOFbRDb993g8nOCswLMi92LwjoqhYnFdf1jzgK0'}\n",
    "result = requests.get(website, headers=headers)\n",
    "content = result.text\n",
    "soup = BeautifulSoup(content, 'lxml')\n",
    "\n",
    "links=[]\n",
    "\n",
    "div = soup.find('div', class_='AZ_results')\n",
    "for li in div.find_all('li'):\n",
    "    a = li.find('a')\n",
    "    if 'href' in a.attrs:\n",
    "        url = a.get('href')\n",
    "        links.append(url)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "baf15e59",
   "metadata": {},
   "outputs": [],
   "source": [
    "titles = []\n",
    "description = []\n",
    "indication = []\n",
    "dosage = []\n",
    "side_efects_and_drug_intratns = []\n",
    "warning = []\n",
    "precautions = []\n",
    "ovdose_contdtons = []\n",
    "clinical_pharmacology = []\n",
    "medication_guide = []\n",
    "\n",
    "\n",
    "for link in links:\n",
    "    result = requests.get(link)\n",
    "    content = result.text\n",
    "    soup = BeautifulSoup(content, 'lxml')\n",
    "    \n",
    "    text = soup.find('div', class_='hero')\n",
    "    titles.append(text.find('h1').get_text(strip=True))\n",
    "        \n",
    "    div = soup.find_all('div', class_='pgContent')\n",
    "    for i in range(len(div)):\n",
    "        for x in div[i].find_all('p'):\n",
    "            if i == 0:\n",
    "                description.append(x.get_text(separator=' ', strip=True))\n",
    "                \n",
    "            elif i == 1:\n",
    "                indication.append(x.get_text(separator=' ', strip=True))\n",
    "                \n",
    "            elif i == 2:\n",
    "                dosage.append(x.get_text(separator=' ', strip=True))\n",
    "                \n",
    "            elif i == 3:\n",
    "                side_efects_and_drug_intratns.append(x.get_text(separator=' ', strip=True))\n",
    "                \n",
    "            elif i == 4:\n",
    "                warning.append(x.get_text(separator=' ', strip=True))\n",
    "                \n",
    "            elif i == 5:\n",
    "                precautions.append(x.get_text(separator=' ', strip=True))\n",
    "                \n",
    "            elif i == 6:\n",
    "                ovdose_contdtons.append(x.get_text(separator=' ', strip=True))\n",
    "                \n",
    "            elif i == 7:\n",
    "                clinical_pharmacology.append(x.get_text(separator=' ', strip=True))\n",
    "                \n",
    "            else:\n",
    "                medication_guide.append(x.get_text(separator=' ', strip=True))            "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "7bd292a2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['A-Methapred',\n",
       " 'Kivexa',\n",
       " 'Ziagen',\n",
       " 'Epzicom',\n",
       " 'Trizivir',\n",
       " 'Triumeq',\n",
       " 'Tymlos',\n",
       " 'Xeglyze',\n",
       " 'Plenaxis',\n",
       " 'Orencia',\n",
       " 'ReoPro',\n",
       " 'Abecma',\n",
       " 'Abelcet',\n",
       " 'Verzenio',\n",
       " 'Abilify',\n",
       " 'Abilify Maintena',\n",
       " 'Abilify MyCite',\n",
       " 'Zytiga',\n",
       " 'Yonsa',\n",
       " 'Ablavar',\n",
       " 'Ablysinol',\n",
       " 'Dysport',\n",
       " 'Abraxane',\n",
       " 'Abreva',\n",
       " 'Abrilada',\n",
       " 'Cibinqo',\n",
       " 'Gelfoam Compressed Sponge',\n",
       " 'Gelfoam Dental Sponge',\n",
       " 'Gelfoam',\n",
       " 'Gelfoam Sponge',\n",
       " 'Gelfilm',\n",
       " 'Absorica',\n",
       " 'Absorica LD',\n",
       " 'Abstral',\n",
       " 'Calquence',\n",
       " 'ACAM2000',\n",
       " 'Campral',\n",
       " 'Acanya',\n",
       " 'Precose',\n",
       " 'Accolate',\n",
       " 'Accretropin',\n",
       " 'Accrufer',\n",
       " 'AccuNeb',\n",
       " 'Accupril',\n",
       " 'Accuretic',\n",
       " 'Accutane',\n",
       " 'Accuzyme',\n",
       " 'Sectral',\n",
       " 'Clanza CR',\n",
       " 'Aceon',\n",
       " 'Acephen',\n",
       " 'Acetadote',\n",
       " 'Tylenol',\n",
       " 'Tylenol-Codeine',\n",
       " 'Acephen',\n",
       " 'Trezix',\n",
       " 'Midrin',\n",
       " 'Ofirmev',\n",
       " 'Acetazolamide Injection',\n",
       " 'Acetazolamide',\n",
       " 'Diamox Tablets and Injection',\n",
       " 'Diamox Sequels',\n",
       " 'Acetic Acid',\n",
       " 'Lithostat',\n",
       " 'Gantrisin',\n",
       " 'Miochol-E',\n",
       " 'Cetylev',\n",
       " 'Acetadote',\n",
       " 'Acetylcysteine Solution',\n",
       " 'Achromycin V',\n",
       " 'Aci-Jel',\n",
       " 'Acidul',\n",
       " 'Aciphex',\n",
       " 'Aciphex Sprinkle',\n",
       " 'Soriatane',\n",
       " 'Tudorza Pressair',\n",
       " 'Duaklir Pressair',\n",
       " 'Aclovate',\n",
       " 'Acova',\n",
       " 'Semprex D',\n",
       " 'Actemra',\n",
       " 'Acthib',\n",
       " 'Acthrel',\n",
       " 'Acticin',\n",
       " 'Acticlate',\n",
       " 'Actidose with Sorbitol and Actidose-Aqua',\n",
       " 'Actigall',\n",
       " 'Actimmune',\n",
       " 'Actiq',\n",
       " 'Actisite',\n",
       " 'Activase',\n",
       " 'Actidose with Sorbitol and Actidose-Aqua',\n",
       " 'Activella',\n",
       " 'Actonel',\n",
       " 'Actonel with Calcium',\n",
       " 'Actoplus MET',\n",
       " 'Actos',\n",
       " 'Acular',\n",
       " 'Acular LS',\n",
       " 'Acuvail',\n",
       " 'ACUVUE Theravision with Ketotifen',\n",
       " 'Zovirax',\n",
       " 'Zovirax Suspension',\n",
       " 'Xerese',\n",
       " 'Sitavig',\n",
       " 'Zovirax Cream',\n",
       " 'Zovirax Injection',\n",
       " 'Zovirax Ointment',\n",
       " 'Avaclyr',\n",
       " 'Aczone Gel',\n",
       " 'Adacel',\n",
       " 'Adagen',\n",
       " 'Adakveo',\n",
       " 'Adalat',\n",
       " 'Humira',\n",
       " 'Cyltezo',\n",
       " 'Abrilada',\n",
       " 'Yusimry',\n",
       " 'Amjevita',\n",
       " 'Hadlima',\n",
       " 'Hulio',\n",
       " 'Imraldi',\n",
       " 'Differin Gel .3',\n",
       " 'Epiduo',\n",
       " 'Epiduo Forte',\n",
       " 'Differin Cream',\n",
       " 'Differin Gel .1',\n",
       " 'Differin Lotion .1',\n",
       " 'Adasuve',\n",
       " 'Adbry',\n",
       " 'Adcetris',\n",
       " 'Adcirca',\n",
       " 'Adderall',\n",
       " 'Adderall XR Capsules',\n",
       " 'Addyi',\n",
       " 'Hepsera',\n",
       " 'Adempas',\n",
       " 'Adenocard',\n",
       " 'Adenoscan',\n",
       " 'Adenocard',\n",
       " 'Adenoscan',\n",
       " 'Adenovirus',\n",
       " 'Adenovirus',\n",
       " 'Adhansia XR',\n",
       " 'Adipex-P',\n",
       " 'Adlarity',\n",
       " 'Adlyxin',\n",
       " 'Admelog',\n",
       " 'Kadcyla',\n",
       " 'Adoxa',\n",
       " 'Adrenaclick',\n",
       " 'Adrenalin',\n",
       " 'AdreView',\n",
       " 'Adriamycin PFS',\n",
       " 'Adrucil',\n",
       " 'Aduhelm',\n",
       " 'Aduhelm',\n",
       " 'Advair Diskus',\n",
       " 'Advair HFA',\n",
       " 'Advate',\n",
       " 'Advicor',\n",
       " 'Adynovate',\n",
       " 'Adzenys ER',\n",
       " 'Adzenys XR-ODT',\n",
       " 'Aemcolo',\n",
       " 'Aerobid',\n",
       " 'Aerospan HFA',\n",
       " 'Scenesse',\n",
       " 'Gilotrif',\n",
       " 'Afeditab CR',\n",
       " 'Afinitor',\n",
       " 'Afinitor-Disperz',\n",
       " 'Afirmelle',\n",
       " 'Eylea',\n",
       " 'Afluria',\n",
       " 'Afluria Quadrivalent',\n",
       " 'Afluria Quadrivalent 2020',\n",
       " 'Afrezza',\n",
       " 'Afstyla',\n",
       " 'Aftera',\n",
       " 'AfterPill',\n",
       " 'Fabrazyme',\n",
       " 'Agenerase',\n",
       " 'Agenerase Oral Solution',\n",
       " 'Aggrastat',\n",
       " 'Aggrenox',\n",
       " 'Agriflu',\n",
       " 'Agrylin',\n",
       " 'Aimovig',\n",
       " 'ExEm Foam',\n",
       " 'Airduo Digihaler',\n",
       " 'AirDuo RespiClick',\n",
       " 'Ajovy',\n",
       " 'Ak-Fluor',\n",
       " 'AK-Pentolate',\n",
       " 'Akineton',\n",
       " 'Aklief',\n",
       " 'Akovaz',\n",
       " 'Akten',\n",
       " 'Aktipak',\n",
       " 'Akynzeo',\n",
       " 'Alamast',\n",
       " 'Albenza',\n",
       " 'Albenza',\n",
       " 'Tanzeum',\n",
       " 'Albuked',\n",
       " 'Albuminar',\n",
       " 'Buminate 5%',\n",
       " 'Kedbumin',\n",
       " 'Flexbumin',\n",
       " 'Albutein',\n",
       " 'AlbuRx',\n",
       " 'Albuked',\n",
       " 'Plasbumin',\n",
       " 'Albuminex',\n",
       " 'Buminate',\n",
       " 'Abraxane',\n",
       " 'Albuminar',\n",
       " 'Albuminex',\n",
       " 'AlbuRx',\n",
       " 'Albutein',\n",
       " 'Proventil',\n",
       " 'Albuterol Sulfate',\n",
       " 'VoSpire ER',\n",
       " 'Proair',\n",
       " 'Ventolin HFA',\n",
       " 'ProAir Respiclick',\n",
       " 'Proair Digihaler',\n",
       " 'Ventolin Solution',\n",
       " 'Albuterol Sulfate',\n",
       " 'AccuNeb',\n",
       " 'Ventolin Syrup',\n",
       " 'Albuterol Sulfate Tablets',\n",
       " 'Lastacaft',\n",
       " 'Alcaine',\n",
       " 'Aclovate',\n",
       " 'Aldactazide',\n",
       " 'Aldactone',\n",
       " 'Aldara',\n",
       " 'Proleukin',\n",
       " 'Aldomet',\n",
       " 'Aldoril',\n",
       " 'Aldurazyme',\n",
       " 'Alecensa',\n",
       " 'Alecensa',\n",
       " 'Amevive',\n",
       " 'Campath',\n",
       " 'Lemtrada',\n",
       " 'Fosamax',\n",
       " 'Fosamax Plus D',\n",
       " 'Binosto',\n",
       " 'Alesse',\n",
       " 'Alfenta',\n",
       " 'Alfentanil',\n",
       " 'Alfenta',\n",
       " 'Alfentanil',\n",
       " 'Uroxatral',\n",
       " 'Ceredase',\n",
       " 'Myozyme',\n",
       " 'Lumizyme',\n",
       " 'Alimta',\n",
       " 'Hyrimoz',\n",
       " 'Alinia',\n",
       " 'Aliqopa',\n",
       " 'Praluent',\n",
       " 'Tekamlo',\n",
       " 'Valturna',\n",
       " 'Tekturna',\n",
       " 'Amturnide',\n",
       " 'Tekturna HCT',\n",
       " 'Panretin',\n",
       " 'Alka-Seltzer',\n",
       " 'Alkeran',\n",
       " 'Alkeran Injection',\n",
       " 'Alkindi Sprinkle',\n",
       " 'Allegra',\n",
       " 'Allegra-D',\n",
       " 'Allegra-D 24 Hour',\n",
       " 'Center-Al',\n",
       " 'AllerNaze',\n",
       " 'Alli',\n",
       " 'Allocord',\n",
       " 'Rethymic',\n",
       " 'Zyloprim',\n",
       " 'Aloprim',\n",
       " 'Allzital',\n",
       " 'Allzital',\n",
       " 'Axert',\n",
       " 'Alocril',\n",
       " 'Kazano',\n",
       " 'Oseni',\n",
       " 'Nesina',\n",
       " 'Alomide',\n",
       " 'Aloprim',\n",
       " 'Alora',\n",
       " 'Lotronex',\n",
       " 'Alosetron Hydrochloride',\n",
       " 'Alosetron Hydrochloride',\n",
       " 'Aloxi',\n",
       " 'Aloxi Capsules',\n",
       " 'Piqray',\n",
       " 'Vijoice',\n",
       " 'Prolastin',\n",
       " 'Zemaira',\n",
       " 'Aralast NP',\n",
       " 'Alphagan-P',\n",
       " 'Alphanate',\n",
       " 'Xanax',\n",
       " 'Niravam',\n",
       " 'Xanax XR',\n",
       " 'Alprolix',\n",
       " 'Prostin VR Pediatric',\n",
       " 'Caverject Impulse',\n",
       " 'Edex',\n",
       " 'Caverject',\n",
       " 'Caverject Powder',\n",
       " 'Muse',\n",
       " 'Alrex',\n",
       " 'Alsuma',\n",
       " 'Altabax',\n",
       " 'Altace',\n",
       " 'Altace Capsules',\n",
       " 'Altafluor',\n",
       " 'Altavera',\n",
       " 'Activase',\n",
       " 'Cathflo Activase',\n",
       " 'Altocor',\n",
       " 'Altoprev',\n",
       " 'Altreno',\n",
       " 'Hexalen',\n",
       " 'Alunbrig',\n",
       " 'Alupent',\n",
       " 'Alvesco',\n",
       " 'Entereg',\n",
       " 'Alymsys',\n",
       " 'Alyq',\n",
       " 'Amabelz',\n",
       " 'Osmolex ER',\n",
       " 'Gocovri',\n",
       " 'Symmetrel',\n",
       " 'Amaryl',\n",
       " 'Mytelase',\n",
       " 'Ambien',\n",
       " 'Ambien CR',\n",
       " 'Ambisome',\n",
       " 'Letairis',\n",
       " 'Cyclocort',\n",
       " 'Amcinonide',\n",
       " 'Amcinonide',\n",
       " 'Amcinonide Lotion',\n",
       " 'Ameluz',\n",
       " 'Amerge',\n",
       " 'Americaine',\n",
       " 'Amethia',\n",
       " 'Amevive',\n",
       " 'Amicar',\n",
       " 'Amidate',\n",
       " 'Firdapse',\n",
       " 'Ruzurgi',\n",
       " 'Ethyol',\n",
       " 'Amikin',\n",
       " 'Arikayce',\n",
       " 'Amikacin Sulfate Injection',\n",
       " 'Amikacin Sulfate Injection',\n",
       " 'Amikin',\n",
       " 'Midamor',\n",
       " 'Moduretic',\n",
       " 'Amiloride hydrochloride',\n",
       " 'HepatAmine',\n",
       " 'Procalamine',\n",
       " 'Aminosyn II Injection',\n",
       " 'FreAmine',\n",
       " 'Aminosyn PF 10',\n",
       " 'Aminosyn II 5',\n",
       " 'Aminosyn RF 5.2',\n",
       " 'Aminosyn PF 7',\n",
       " 'Aminosyn HF 8',\n",
       " 'Aminosyn HBC 7% Sulfite Free',\n",
       " 'Aminosyn II in Dextrose Injection',\n",
       " 'Aminosyn II 4.25',\n",
       " 'Aminosyn II 3.5',\n",
       " 'Aminosyn II 3.5 in 25 Dextrose',\n",
       " 'Aminosyn II',\n",
       " 'TrophAmine',\n",
       " 'Travasol',\n",
       " 'Prosol',\n",
       " 'Clinimix E',\n",
       " 'Kabiven',\n",
       " 'Perikabiven',\n",
       " 'Amicar',\n",
       " 'Cytadren',\n",
       " 'Aminohippurate',\n",
       " 'Aminohippurate',\n",
       " 'Levulan Kerastick',\n",
       " 'Gleolan',\n",
       " 'Ameluz',\n",
       " 'Paser',\n",
       " 'Aminosyn Electrolytes',\n",
       " 'Aminosyn HBC 7% Sulfite Free',\n",
       " 'Aminosyn HF 8',\n",
       " 'Aminosyn II 3.5 in 25 Dextrose',\n",
       " 'Aminosyn II 3.5',\n",
       " 'Aminosyn II 4.25',\n",
       " 'Aminosyn II 5',\n",
       " 'Aminosyn II',\n",
       " 'Aminosyn II in Dextrose Injection',\n",
       " 'Aminosyn II Injection',\n",
       " 'Aminosyn PF 10',\n",
       " 'Aminosyn PF 7',\n",
       " 'Aminosyn RF 5.2',\n",
       " 'Aminosyn Sulfite Free',\n",
       " 'Amiodarone HCl Injection',\n",
       " 'Nexterone',\n",
       " 'Cordarone',\n",
       " 'Pacerone',\n",
       " 'Cordarone IV',\n",
       " 'Barhemsys',\n",
       " 'Amitiza',\n",
       " 'Elavil',\n",
       " 'Rybrevant',\n",
       " 'Amjevita',\n",
       " 'Aphthasol',\n",
       " 'Amlobenz',\n",
       " 'Consensi',\n",
       " 'Concensi',\n",
       " 'Azor',\n",
       " 'Exforge',\n",
       " 'Norvasc',\n",
       " 'Lotrel',\n",
       " 'Amlobenz',\n",
       " 'Caduet',\n",
       " 'Norliqva',\n",
       " 'Katerzia',\n",
       " 'Exforge HCT',\n",
       " 'Lac-Hydrin Cream',\n",
       " 'Ammonul',\n",
       " 'Amnesteem',\n",
       " 'Amytal Sodium',\n",
       " 'Amondys 45',\n",
       " 'Amoxapine',\n",
       " 'Amoxapine',\n",
       " 'Amoxicillin',\n",
       " 'Augmentin',\n",
       " 'Augmentin ES',\n",
       " 'Augmentin Chewable Tablets',\n",
       " 'Augmentin XR',\n",
       " 'Moxatag',\n",
       " 'Amoxicillin',\n",
       " 'Amphadase',\n",
       " 'Dyanavel XR',\n",
       " 'Adzenys ER',\n",
       " 'Adzenys XR-ODT',\n",
       " 'Evekeo',\n",
       " 'Adderall XR Capsules',\n",
       " 'Adderall',\n",
       " 'Ambisome',\n",
       " 'Fungizone',\n",
       " 'Abelcet',\n",
       " 'Principen',\n",
       " 'Unasyn',\n",
       " 'Agenerase',\n",
       " 'Agenerase Oral Solution',\n",
       " 'Ampyra',\n",
       " 'Amrix',\n",
       " 'Amturnide',\n",
       " 'Amvuttra',\n",
       " 'Amyl Nitrite',\n",
       " 'Amyl Nitrite',\n",
       " 'Amytal Sodium',\n",
       " 'Amyvid',\n",
       " 'Amzeeq',\n",
       " 'An-Sulfur Colloid',\n",
       " 'Ana-Kit',\n",
       " 'Winstrol',\n",
       " 'Anadrol-50',\n",
       " 'Anafranil',\n",
       " 'Agrylin',\n",
       " 'Kineret',\n",
       " 'Analpram HC',\n",
       " 'Anascorp',\n",
       " 'Anascorp',\n",
       " 'Arimidex',\n",
       " 'Ancobon',\n",
       " 'Andexxa',\n",
       " 'Androderm',\n",
       " 'AndroGel',\n",
       " 'AndroGel 1.62',\n",
       " 'Androxy',\n",
       " 'Anectine',\n",
       " 'Angeliq',\n",
       " 'Angiomax',\n",
       " 'Giapreza',\n",
       " 'Paregoric',\n",
       " 'Eraxis',\n",
       " 'Saphnelo',\n",
       " 'Miradon',\n",
       " 'Anjeso',\n",
       " 'Annovera',\n",
       " 'Anoro Ellipta',\n",
       " 'Ansaid',\n",
       " 'Ebanga',\n",
       " 'Insect Allergenic Extracts',\n",
       " 'Antabuse',\n",
       " 'Antara',\n",
       " 'Anthim',\n",
       " 'Dritho-Scalp',\n",
       " 'Zithranol Cream',\n",
       " 'Zithranol Shampoo',\n",
       " 'Anthrasil',\n",
       " 'Anthrasil',\n",
       " 'BioThrax',\n",
       " 'Feiba',\n",
       " 'Autoplex-T',\n",
       " 'Feiba Vh',\n",
       " 'Thymoglobulin',\n",
       " 'Bioclate',\n",
       " 'Alphanate',\n",
       " 'Koate',\n",
       " 'Monoclate-P',\n",
       " 'Refacto',\n",
       " 'Xyntha',\n",
       " 'Helixate FS',\n",
       " 'Kogenate FS',\n",
       " 'Recombinate',\n",
       " 'Kovaltry',\n",
       " 'Novoeight',\n",
       " 'Eloctate',\n",
       " 'Adynovate',\n",
       " 'Jivi',\n",
       " 'Obizur',\n",
       " 'Nuwiq',\n",
       " 'Afstyla',\n",
       " 'Humate-P',\n",
       " 'Auralgan',\n",
       " 'Thrombate',\n",
       " 'Rattlesnake Antivenin',\n",
       " 'Antivert',\n",
       " 'Antizol',\n",
       " 'Anturane',\n",
       " 'Anturol',\n",
       " 'Anusol Hc',\n",
       " 'Anusol Rectal',\n",
       " 'Anzemet Injection',\n",
       " 'Anzemet Tablets',\n",
       " 'Apadaz',\n",
       " 'Erleada',\n",
       " 'ApexiCon E',\n",
       " 'Evekeo ODT',\n",
       " 'Aphrodyne',\n",
       " 'Aphthasol',\n",
       " 'Apidra',\n",
       " 'Eliquis',\n",
       " 'Aplenzin',\n",
       " 'Aplisol',\n",
       " 'Apokyn',\n",
       " 'Apokyn',\n",
       " 'Kynmobi',\n",
       " 'Iopidine Eye',\n",
       " 'Otezla',\n",
       " 'Emend',\n",
       " 'Cinvanti',\n",
       " 'Apresazide',\n",
       " 'Apresoline',\n",
       " 'Apretude',\n",
       " 'Apri',\n",
       " 'Apriso',\n",
       " 'Trasylol',\n",
       " 'Aptensio XR',\n",
       " 'Aptiom',\n",
       " 'Aptivus',\n",
       " 'AquaMEPHYTON',\n",
       " 'Aquasol A',\n",
       " 'vitamin k1 injection',\n",
       " 'Arakoda',\n",
       " 'Aralast NP',\n",
       " 'Aralen',\n",
       " 'Aramine',\n",
       " 'Aranelle',\n",
       " 'Aranesp',\n",
       " 'Arava',\n",
       " 'Arazlo',\n",
       " 'Arcalyst',\n",
       " 'Arcapta Neohaler',\n",
       " 'Aredia',\n",
       " 'Arestin',\n",
       " 'Brovana',\n",
       " 'Argatroban',\n",
       " 'Acova',\n",
       " 'Argatroban',\n",
       " 'R-Gene 10',\n",
       " 'Aricept',\n",
       " 'Aridol',\n",
       " 'Arikayce',\n",
       " 'Arimidex',\n",
       " 'Abilify',\n",
       " 'Abilify Maintena',\n",
       " 'Aristada',\n",
       " 'Aristada Initio',\n",
       " 'Aripiprazole Oral Solution',\n",
       " 'Aripiprazole Tablets',\n",
       " 'Abilify MyCite',\n",
       " 'Aristada',\n",
       " 'Aristada Initio',\n",
       " 'Aristocort',\n",
       " 'Aristocort Forte',\n",
       " 'Aristospan Injection 5',\n",
       " 'Aristospan Injection 20',\n",
       " 'Arixtra',\n",
       " 'Nuvigil',\n",
       " 'ArmonAir Digihaler',\n",
       " 'ArmonAir RespiClick',\n",
       " 'Armour Thyroid',\n",
       " 'Arnuity Ellipta',\n",
       " 'Aromasin',\n",
       " 'Arranon',\n",
       " 'Trisenox',\n",
       " 'Artane',\n",
       " 'Coartem',\n",
       " 'Artesunate',\n",
       " 'Arthrotec',\n",
       " 'Articadent',\n",
       " 'Ultacan',\n",
       " 'Orabloc',\n",
       " 'Articadent',\n",
       " 'Septocaine',\n",
       " 'Artiss',\n",
       " 'Arymo ER',\n",
       " 'Arzerra',\n",
       " 'Asacol',\n",
       " 'Asacol HD',\n",
       " 'Asceniv',\n",
       " 'Scemblix',\n",
       " 'Asclera',\n",
       " 'Ascomp with Codeine',\n",
       " 'Ascor',\n",
       " 'Ascorbic Acid',\n",
       " 'Ascor',\n",
       " 'Saphris',\n",
       " 'Secuado',\n",
       " 'Strensiq',\n",
       " 'Asmanex',\n",
       " 'Asmanex Twisthaler',\n",
       " 'Elspar',\n",
       " 'Erwinaze',\n",
       " 'Rylaze',\n",
       " 'Asparlas',\n",
       " 'Aspirin',\n",
       " 'Yosprala',\n",
       " 'Percodan',\n",
       " 'Durlaza',\n",
       " 'Synalgos-DC',\n",
       " 'Aggrenox',\n",
       " 'Aspruzyo Sprinkle',\n",
       " 'Astagraf XL',\n",
       " 'Astelin',\n",
       " 'Hismanal',\n",
       " 'Astepro',\n",
       " 'Atacand',\n",
       " 'Atacand HCT',\n",
       " 'Atarax',\n",
       " 'Evotaz',\n",
       " 'Reyataz',\n",
       " 'Atelvia',\n",
       " 'Tenoretic',\n",
       " 'Tenormin IV Injection',\n",
       " 'Atenolol',\n",
       " 'Tecentriq',\n",
       " 'Atgam',\n",
       " 'Athentia Next',\n",
       " 'Ativan',\n",
       " 'Ativan Injection',\n",
       " 'ATNAA',\n",
       " 'Qulipta',\n",
       " 'Inmazeb',\n",
       " 'Strattera',\n",
       " 'Lipitor',\n",
       " 'Mepron',\n",
       " 'Malarone',\n",
       " 'Tracrium',\n",
       " 'Atracurium Besylate Injection',\n",
       " 'Atralin',\n",
       " 'Atridox',\n",
       " 'Atripla',\n",
       " 'Atropen',\n",
       " 'Atropine',\n",
       " 'Atropen',\n",
       " 'Atropine Solution',\n",
       " 'DuoDote',\n",
       " 'ATNAA',\n",
       " 'Atropine Solution',\n",
       " 'Isopto Atropine',\n",
       " 'Atrovent HFA',\n",
       " 'Atrovent Nasal Spray',\n",
       " 'Atrovent Nasal Spray .06',\n",
       " 'Atryn',\n",
       " 'Attenuvax',\n",
       " 'Aubagio',\n",
       " 'Audenz',\n",
       " 'Augmentin',\n",
       " 'Augmentin Chewable Tablets',\n",
       " 'Augmentin ES',\n",
       " 'Augmentin XR',\n",
       " 'Auralgan',\n",
       " 'Ridaura',\n",
       " 'Aurovela',\n",
       " 'Auryxia',\n",
       " 'Austedo',\n",
       " 'Laviv',\n",
       " 'Carticel',\n",
       " 'Autoplex-T',\n",
       " 'Auvi-Q',\n",
       " 'Avaclyr',\n",
       " 'Tavneos',\n",
       " 'Avagard Foam',\n",
       " 'Avagard Foam',\n",
       " 'Avagard Lotion',\n",
       " 'Avagard Lotion',\n",
       " 'Avage',\n",
       " 'Nexviazyme',\n",
       " 'Avalide',\n",
       " 'Stendra',\n",
       " 'Avandamet',\n",
       " 'Avandaryl',\n",
       " 'Avandia',\n",
       " 'Ayvakit',\n",
       " 'Avapro',\n",
       " 'Avastin',\n",
       " 'Doptelet',\n",
       " 'Aveed',\n",
       " 'Avelox',\n",
       " 'Bavencio',\n",
       " 'Aviane',\n",
       " 'Avinza',\n",
       " 'Avita',\n",
       " 'Avita Cream',\n",
       " 'Avodart',\n",
       " 'Avonex',\n",
       " 'Avsola',\n",
       " 'Avycaz',\n",
       " 'Axert',\n",
       " 'Yescarta',\n",
       " 'Axid',\n",
       " 'Axid Oral Solution',\n",
       " 'Axiron',\n",
       " 'Inlyta',\n",
       " 'Axona',\n",
       " 'Axumin',\n",
       " 'Aygestin',\n",
       " 'Ayuna',\n",
       " 'Ayvakit',\n",
       " 'Vidaza',\n",
       " 'Onureg',\n",
       " 'Azactam Injection',\n",
       " 'Azasan',\n",
       " 'Azasite',\n",
       " 'Imuran',\n",
       " 'Azasan',\n",
       " 'Azedra',\n",
       " 'Finacea',\n",
       " 'Azelex',\n",
       " 'Finacea Foam',\n",
       " 'Astelin',\n",
       " 'Optivar',\n",
       " 'Ticlast',\n",
       " 'Dymista',\n",
       " 'Astepro',\n",
       " 'Azelastine Nasal Spray',\n",
       " 'Azelastine Nasal Spray',\n",
       " 'Azelex',\n",
       " 'Azilect',\n",
       " 'Edarbi',\n",
       " 'Edarbyclor',\n",
       " 'Zithromax Injection',\n",
       " 'Zithromax',\n",
       " 'Zmax',\n",
       " 'Azasite',\n",
       " 'Azmacort',\n",
       " 'Azopt',\n",
       " 'Azor',\n",
       " 'Azstarys',\n",
       " 'Cayston',\n",
       " 'Azactam Injection',\n",
       " 'Azulfidine',\n",
       " 'Azulfidine EN-tabs',\n",
       " 'Azurette']"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "titles"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "f3d5026b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "785"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(titles)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "fd5f7377",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['A-Methapred is a prescription medicine used to treat the symptoms of Allergic Conditions and Acute Exacerbation of Multiple Sclerosis . A-Methapred may be used alone or with other medications.',\n",
       " 'A-Methapred\\xa0belongs to a class of drugs called Corticosteroids; Anti-Inflammatory Agents.',\n",
       " 'It is not known if A-Methapred is safe and effective in children younger than 12 years of age.',\n",
       " 'A-Methapred\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of A-Methapred\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of A-Methapred. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'A-Methapred (methylprednisolone sodium succinate for injection, USP) sterile powder contains methylprednisolone sodium succinate as the active ingredient. Methylprednisolone sodium succinate, USP, occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone .',\n",
       " 'The chemical name for methylprednisolone sodium succinate is pregna-1,4-diene-3,20-dione,21-(3-carboxy-1-oxo-propoxy)-11,17-dihydroxy-6-methyl-monosodium salt, (6a, 11ß), and the molecular weight is 496.53.',\n",
       " 'The structural formula is represented below:',\n",
       " '',\n",
       " '',\n",
       " 'Methylprednisolone sodium succinate is so extremely soluble in water that it may be administered in a small volume of diluent and is especially well suited for intravenous use in situations in which high blood levels of methylprednisolone are required rapidly.',\n",
       " 'A-Methapred (methylprednisolone sodium succinate) is available in several strengths and packages for intravenous or intramuscular administration.',\n",
       " '40 mg Single-Dose Vial - Each mL (when mixed) contains methylprednisolone sodium succinate equivalent to 40 mg methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; 17.46 mg dibasic sodium phosphate anhydrous; 25 mg lactose anhydrous; 8.8 mg benzyl alcohol added as preservative.',\n",
       " '125 mg Single-Dose Vial - Each 2 mL (when mixed) contains methylprednisolone sodium succinate equivalent to 125 mg methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; 17.4 mg dibasic sodium phosphate anhydrous; 17.6 mg benzyl alcohol added as preservative.',\n",
       " 'When necessary, the pH of each formula was adjusted with sodium hydroxide so that the pH of the reconstituted solution is within the USP specified range of 7 to 8 and the tonicities are, for the 40 mg per mL solution, 0.50 osmolar ; for the 125 mg per 2 mL, 0.40 osmolar; (Isotonic saline = 0.28 osmolar).',\n",
       " 'IMPORTANT - Use only Bacteriostatic Water For Injection with Benzyl Alcohol when reconstituting A-Methapred (methylprednisolone sodium succinate) .',\n",
       " 'Use within 48 hours after mixing.',\n",
       " 'Kivexa is a prescription medicine used to treat the symptoms of HIV Infection. Kivexa may be used alone or with other medications.',\n",
       " 'Kivexa\\xa0belongs to a class of drugs called HIV, ART Combos.',\n",
       " 'It is not known if Kivexa is safe and effective in children weighing less than 25 kilos.',\n",
       " 'Kivexa\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Kivexa\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Kivexa. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'WARNING',\n",
       " 'Abacavir, a component of KIVEXA tablets, is associated with hypersensitivity reactions, which can be life-threatening, and in rare cases fatal. KIVEXA tablets, or any other medicinal product containing abacavir (TRIUMEQ, TRIZIVIR and ZIAGEN), MUST NEVER be restarted following a hypersensitivity reaction (see Section WARNINGS AND PRECAUTIONS and Section ADVERSE REACTIONS ).',\n",
       " 'magnesium stearate microcrystalline cellulose sodium starch glycollate',\n",
       " 'Opadry Orange YS-1-13065-A contains:',\n",
       " 'The chemical name of abacavir sulfate is (1S,cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol sulfate (salt) (2:1). Abacavir sulfate is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. It has a molecular formula of (C 14 H 18 N 6 O)2•H 2 SO 4 and a molecular weight of 670.76 daltons.',\n",
       " 'The chemical name of lamivudine is (2R,cis)-4-amino-1-[2- (hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone. Lamivudine is the (-)enantiomer of a dideoxy analogue of cytidine. Lamivudine has also been referred to as (-)2’,3’-dideoxy, 3’-thiacytidine. It has a molecular formula of C 8 H 11 N 3 O 3 S and a molecular weight of 229.3 daltons.',\n",
       " 'Abacavir sulfate has the following structural formula:',\n",
       " '',\n",
       " '',\n",
       " 'Lamivudine has the following structural formula:',\n",
       " '',\n",
       " '',\n",
       " '188062-50-2 (abacavir sulfate); 134678-17-4 (lamivudine)',\n",
       " 'Find Lowest Prices on',\n",
       " 'Ziagen is a prescription medicine used to treat the symptoms of HIV Infection. Ziagen may be used alone or with other medications.',\n",
       " 'Ziagen\\xa0belongs to a class of drugs called HIV, NRTIs; Antiretroviral Agents.',\n",
       " 'It is not known if Ziagen is safe and effective in children younger than 3 months of age.',\n",
       " 'Ziagen\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Ziagen\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Ziagen. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'WARNING',\n",
       " 'HYPERSENSITIVITY REACTIONS, and LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS',\n",
       " 'Serious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with ZIAGEN (abacavir).',\n",
       " 'Patients who carry the HLA-B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'ZIAGEN is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients [see CONTRAINDICATIONS , WARNINGS AND PRECAUTIONS ]. All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with ZIAGEN or reinitiation of therapy with ZIAGEN, unless patients have a previously documented HLA-B*5701 allele assessment. Discontinue ZIAGEN immediately if a hypersensitivity reaction is suspected, regardless of HLA-B*5701 status and even when other diagnoses are possible [see CONTRAINDICATIONS , WARNINGS AND PRECAUTIONS ].',\n",
       " 'Following a hypersensitivity reaction to ZIAGEN, NEVER restart ZIAGEN or any other abacavir-containing product because more severe symptoms, including death can occur within hours. Similar severe reactions have also occurred rarely following the reintroduction of abacavir-containing products in patients who have no history of abacavir hypersensitivity [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues and other antiretrovirals. Discontinue ZIAGEN if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'ZIAGEN is the brand name for abacavir sulfate, a synthetic carbocyclic nucleoside analogue with inhibitory activity against HIV -1. The chemical name of abacavir sulfate is (1S,cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol sulfate (salt) (2:1). Abacavir sulfate is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. It has a molecular formula of (C 14 H 18 N 6 O) 2 •H 2 SO 4 and a molecular weight of 670.76 g per mol. It has the following structural formula:',\n",
       " '',\n",
       " '',\n",
       " 'Abacavir sulfate is a white to off-white solid and is soluble in water.',\n",
       " 'ZIAGEN tablets are for oral administration. Each tablet contains abacavir sulfate equivalent to 300 mg of abacavir as active ingredient and the following inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The tablets are coated with a film that is made of hypromellose, polysorbate 80, synthetic yellow iron oxide, titanium dioxide, and triacetin.',\n",
       " 'ZIAGEN oral solution is for oral administration. Each milliliter (1 mL) of ZIAGEN oral solution contains abacavir sulfate equivalent to 20 mg of abacavir (i.e., 20 mg per mL) as active ingredient and the following inactive ingredients: artificial strawberry and banana flavors, citric acid (anhydrous), methylparaben and propylparaben (added as preservatives), propylene glycol, saccharin sodium, sodium citrate (dihydrate), sorbitol solution, and water.',\n",
       " 'In vivo, abacavir sulfate dissociates to its free base, abacavir. Dosages are expressed in terms of abacavir.',\n",
       " 'Find Lowest Prices on',\n",
       " 'Epzicom is a prescription medicine used to treat the symptoms of HIV Infection. Epzicom may be used alone or with other medications.',\n",
       " 'Epzicom\\xa0belongs to a class of drugs called HIV, ART Combos.',\n",
       " 'It is not known if Epzicom is safe and effective in children weighing less than 55 lbs (25 kgs).',\n",
       " 'Epzicom\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Epzicom\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Epzicom. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'WARNING',\n",
       " 'HYPERSENSITIVITY REACTIONS AND EXACERBATIONS OF HEPATITIS B',\n",
       " 'Serious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir, a component of EPZICOM (abacavir and lamivudine). Patients who carry the HLA B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA B*5701 allele [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'EPZICOM is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA B*5701-positive patients [see CONTRAINDICATIONS , WARNINGS AND PRECAUTIONS ]. All patients should be screened for the HLA B*5701 allele prior to initiating therapy with EPZICOM or reinitiation of therapy with EPZICOM, unless patients have a previously documented HLA B*5701 allele assessment. Discontinue EPZICOM immediately if a hypersensitivity reaction is suspected, regardless of HLA-B*5701 status and even when other diagnoses are possible [see CONTRAINDICATIONS , WARNINGS AND PRECAUTIONS ].',\n",
       " 'Following a hypersensitivity reaction to EPZICOM, NEVER restart EPZICOM or any other abacavir containing product because more severe symptoms, including death, can occur within hours. Similar severe reactions have also occurred rarely following the reintroduction of abacavir-containing products in patients who have no history of abacavir hypersensitivity [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Severe acute exacerbations of hepatitis B have been reported in patients who are co infected with hepatitis B virus ( HBV ) and human immunodeficiency virus (HIV 1) and have discontinued lamivudine, which is a component of EPZICOM. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue EPZICOM and are co-infected with HIV 1 and HBV. If appropriate, initiation of anti hepatitis B therapy may be warranted [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'EPZICOM tablets contain the following 2 synthetic nucleoside analogues: abacavir (ZIAGEN, also a component of TRIZIVIR) and lamivudine (also known as EPIVIR or 3TC) with inhibitory activity against HIV 1.',\n",
       " 'EPZICOM tablets are for oral administration. Each orange, film coated tablet contains the active ingredients 600 mg of abacavir as abacavir sulfate and 300 mg of lamivudine, and the inactive ingredients magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The tablets are coated with a film (OPADRY orange YS-1-13065-A) that is made of FD&C Yellow No. 6, hypromellose, polyethylene glycol 400, polysorbate 80, and titanium dioxide.',\n",
       " 'The chemical name of abacavir sulfate is (1 S , cis )-4-[2-amino-6-(cyclopropylamino)-9 H -purin-9-yl]-2- cyclopentene-1-methanol sulfate (salt) (2:1). Abacavir sulfate is the enantiomer with 1S , 4R absolute configuration on the cyclopentene ring. It has a molecular formula of (C 14 H 18 N 6 O) 2 •H 2 SO 4 and a molecular weight of 670.76 g per mol. It has the following structural formula:',\n",
       " '',\n",
       " '',\n",
       " 'Abacavir sulfate is a white to off white solid and is soluble in water.',\n",
       " 'In vivo , abacavir sulfate dissociates to its free base, abacavir. Dosages are expressed in terms of abacavir.',\n",
       " \"The chemical name of lamivudine is (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)- pyrimidin-2-one. Lamivudine is the ( )enantiomer of a dideoxy analogue of cytidine. Lamivudine has also been referred to as ( )2',3'-dideoxy, 3'-thiacytidine. It has a molecular formula of C 8 H 11 N 3 O 3 S and a molecular weight of 229.3 g per mol. It has the following structural formula:\",\n",
       " '',\n",
       " '',\n",
       " 'Lamivudine is a white to off white crystalline solid and is soluble in water.',\n",
       " 'Find Lowest Prices on',\n",
       " 'Trizivir is a prescription medicine used to treat the symptoms of HIV Infection. Trizivir may be used alone or with other medications.',\n",
       " 'Trizivir\\xa0belongs to a class of drugs called HIV, ART Combos.',\n",
       " 'It is not known if Trizivir is safe and effective in children weighing less than 88 pounds (40 kilos).',\n",
       " 'Trizivir\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Trizivir\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Trizivir. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'WARNING',\n",
       " 'HYPERSENSITIVITY REACTIONS, HEMATOLOGIC TOXICITY, MYOPATHY, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS, and EXACERBATIONS OF HEPATITIS B',\n",
       " 'Serious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir, a component of TRIZIVIR (abacavir, lamivudine, and zidovudine). Patients who carry the HLA B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA B*5701 allele [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'TRIZIVIR is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA B*5701-positive patients [see CONTRAINDICATIONS , WARNINGS AND PRECAUTIONS ]. All patients should be screened for the HLA ï¿½B*5701 allele prior to initiating therapy with TRIZIVIR or reinitiation of therapy with TRIZIVIR, unless patients have a previously documented HLA B*5701 allele assessment. Discontinue TRIZIVIR immediately if a hypersensitivity reaction is suspected, regardless of HLA-B*5701 status and even when other diagnoses are possible [see CONTRAINDICATIONS , WARNINGS AND PRECAUTIONS ].',\n",
       " 'Following a hypersensitivity reaction to TRIZIVIR, NEVER restart TRIZIVIR or any other abacavircontaining product because more severe symptoms, including death, can occur within hours. Similar severe reactions have also occurred rarely following the reintroduction of abacavir-containing products in patients who have no history of abacavir hypersensitivity [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Zidovudine, a component of TRIZIVIR, has been associated with hematologic toxicity, including neutropenia and severe anemia, particularly in patients with advanced Human Immunodeficiency Virus (HIV1) disease [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Prolonged use of zidovudine has been associated with symptomatic myopathy [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues, including abacavir, lamivudine, and zidovudine (components of TRIZIVIR). Discontinue TRIZIVIR if clinical or laboratory findings suggestive of lactic acidos is or pronounced hepatotoxicity occur [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with hepatitis B virus (HBV) and HIV1 and have discontinued lamivudine, a component of TRIZIVIR. Hepatic function should be monitored closely with both clinical and laboratory follow-up for atleast several months in patients who discontinue TRIZIVIR and are co-infected with HIV1 and HBV. If appropriate, initiation of antihepatitis B therapy may be warranted [see WARNINGS AND PRECAUTIONS ] .',\n",
       " 'TRIZIVIR tablets contain the following 3 synthetic nucleoside analogues: abacavir (ZIAGEN), lamivudine (also known as EPIVIR or 3TC), and zidovudine (also known as RETROVIR, azidothymidine, or ZDV) with inhibitory activity against HIV-1.',\n",
       " 'TRIZIVIR tablets are for oral administration. Each film-coated tablet contains the active ingredients 300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine, and the inactive ingredients magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The tablets are coated with a film (OPADRY green 03B11434) that is made of FD&C Blue No. 2, hypromellose, polyethylene glycol, titanium dioxide, and yellow iron oxide.',\n",
       " 'The chemical name of abacavir sulfate is (1 S , cis )-4-[2-amino-6-(cyclopropylamino)- 9 H -purin-9-yl]-2-cyclopentene-1-methanol sulfate (salt) (2:1). Abacavir sulfate is the enantiomer with 1S , 4R absolute configuration on the cyclopentene ring. It has a molecular formula of (C 14 H 18 N 6 O) 2 •H 2 SO 4 and a molecular weight of 670.76 g per mol. It has the following structural formula:',\n",
       " '',\n",
       " '',\n",
       " 'Abacavir sulfate is a white to off-white solid and soluble in water. Dosages are expressed in terms of abacavir.',\n",
       " \"The chemical name of lamivudine is (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3- oxathiolan-5-yl)-(1H)-pyrimidin-2-one. Lamivudine is the (-)enantiomer of a dideoxy analogue of cytidine. Lamivudine has also been referred to as (-)2',3'-dideoxy, 3'-thiacytidine. It has a molecular formula of C 8 H 11 N 3 O 3 S and a molecular weight of 229.3 g per mol. It has the following structural formula:\",\n",
       " '',\n",
       " '',\n",
       " 'Lamivudine is a white to off-white crystalline solid and is soluble in water.',\n",
       " \"The chemical name of zidovudine is 3'-azido-3'-deoxythymidine. It has a molecular formula of C 10 H 13 N 5 O 4 and a molecular weight of 267.24 g per mol. It has the following structural formula:\",\n",
       " '',\n",
       " '',\n",
       " 'Zidovudine is a white to beige, odorless, crystalline solid with a solubility of 20.1 mg per mL in water at 25°C.',\n",
       " 'Find Lowest Prices on',\n",
       " 'Triumeq is a prescription medicine used to treat the symptoms of HIV-1 Infection. Triumeq may be used alone or with other medications.',\n",
       " 'Triumeq\\xa0belongs to a class of drugs called HIV, ART Combos.',\n",
       " 'It is not known if Triumeq is safe and effective in children weigh less than 88 lbs (40 kg).',\n",
       " 'Triumeq\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Triumeq\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Triumeq. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'WARNING',\n",
       " 'HYPERSENSITIVITY REACTIONS, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY, and EXACERBATIONS OF HEPATITIS B',\n",
       " 'Serious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir, a component of TRIUMEQ (abacavir, dolutegravir, and lamivudine). Patients who carry the HLA-B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'TRIUMEQ is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients [see CONTRAINDICATIONS , WARNINGS AND PRECAUTIONS ]. All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with TRIUMEQ or reinitiation of therapy with TRIUMEQ, unless patients have a previously documented HLA-B*5701 allele assessment. Discontinue TRIUMEQ immediately if a hypersensitivity reaction is suspected, regardless of HLA-B*5701 status and even when other diagnoses are possible [see CONTRAINDICATIONS , WARNINGS AND PRECAUTIONS ].',\n",
       " 'Following a hypersensitivity reaction to TRIUMEQ, NEVER restart TRIUMEQ or any other abacavir-containing product because more severe symptoms, including death can occur within hours. Similar severe reactions have also occurred rarely following the reintroduction of abacavir-containing products in patients who have no history of abacavir hypersensitivity [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including abacavir, lamivudine, and other antiretrovirals. Discontinue TRIUMEQ if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1) and have discontinued lamivudine, a component of TRIUMEQ. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue TRIUMEQ and are co-infected with HIV-1 and HBV. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'TRIUMEQ contains an INSTI (dolutegravir) and 2 nucleoside analogues (abacavir and lamivudine) with inhibitory activity against HIV .',\n",
       " 'Each film-coated tablet contains abacavir sulfate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg of dolutegravir, and 300 mg of lamivudine. TRIUMEQ tablets are purple, biconvex, oval, debossed with “572 Tr1” on one side and contain the inactive ingredients D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate. The tablet film-coating (OPADRY® II Purple 85F90057) contains the inactive ingredients iron oxide black, iron oxide red, macrogol/PEG, polyvinyl alcohol-part hydrolyzed, talc, and titanium oxide.',\n",
       " 'The chemical name of abacavir sulfate is (1S,cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9yl]-2-cyclopentene-1-methanol sulfate (salt) (2:1). It has a molecular formula of (C 14 H 18 N 6 O) 2 •H 2 SO 4 and a molecular weight of 670.76 g per mol. It has the following structural formula:',\n",
       " '',\n",
       " '',\n",
       " 'Abacavir sulfate is a white to off-white solid and is soluble in water.',\n",
       " \"The chemical name of dolutegravir sodium is sodium (4R,12aS)-9-{[(2,4difluorophenyl)methyl]carbamoyl}-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2Hpyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-olate. The empirical formula is C 20 H 18 F 2 N 3 NaO 5 and the molecular weight is 441.36 g per mol. It has the following structural formula:\",\n",
       " '',\n",
       " '',\n",
       " 'Dolutegravir sodium is a white to light yellow powder and is slightly soluble in water.',\n",
       " \"The chemical name of lamivudine is (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)(1H)-pyrimidin-2-one. Lamivudine is the (-)enantiomer of a dideoxy analogue of cytidine. Lamivudine has also been referred to as (-)2',3'-dideoxy, 3'-thiacytidine. It has a molecular formula of C 8 H 11 N 3 O 3 S and a molecular weight of 229.3 g per mol. It has the following structural formula:\",\n",
       " '',\n",
       " '',\n",
       " 'Lamivudine is a white to off-white crystalline solid and is soluble in water.',\n",
       " 'Find Lowest Prices on',\n",
       " 'What is TYMLOS and how is it used?',\n",
       " 'TYMLOS is a prescription medicine used to:',\n",
       " 'It is not known if TYMLOS is safe and effective for children 18 years and younger.',\n",
       " 'It is not recommended that people use TYMLOS for more than 2 years during their lifetime.',\n",
       " 'TYMLOS should not be used in children and young adults whose bones are still growing.',\n",
       " 'What are the possible side effects of TYMLOS?',\n",
       " 'TYMLOS can cause serious side effects including:',\n",
       " 'The most common side effects of TYMLOS include:',\n",
       " 'These are not all the possible side effects of TYMLOS. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'WARNING',\n",
       " 'RISK OF OSTEOSARCOMA',\n",
       " 'TYMLOS injection for subcutaneous administration contains abaloparatide, a synthetic 34 amino acid peptide . Abaloparatide is an analog of human parathyroid hormone related peptide, PTHrP(1-34). It has 41% homology to hPTH(1-34) (human parathyroid hormone 1-34) and 76% homology to hPTHrP(1-34) (human parathyroid hormone-related peptide 1-34).',\n",
       " 'Abaloparatide has a molecular formula of C 174 H 300 N 56 O 49 and a molecular weight of 3961 daltons with the amino acid sequence shown below:',\n",
       " 'Ala- Val - Ser - Glu -His- Gln - Leu -Leu-His- Asp -Lys- Gly -Lys-Ser- Ile -Gln-Asp-Leu-Arg-Arg-Arg-Glu-Leu-Leu-Glu-Lys-Leu-Leu-Aib-Lys-Leu-His- Thr -Ala-NH 2',\n",
       " 'TYMLOS injection is supplied as a sterile, colorless, clear solution in a glass cartridge which is preassembled into a disposable single-patient-use pen. The pen is intended to deliver 30 once daily abaloparatide doses of 80 mcg in 40 mcL. Each cartridge contains 1.56 mL of TYMLOS solution. Each mL contains 2000 mcg abaloparatide and the following inactive ingredients: 5 mg phenol , 5.08 mg sodium acetate trihydrate, 6.38 mg acetic acid , and water for injection.',\n",
       " 'What is XEGLYZE and how is it used?',\n",
       " 'XEGLYZE is a prescription medicine used to get rid of head lice in people 6 months of age and older.',\n",
       " 'After XEGLYZE is rinsed off, a fine-tooth comb may be used to remove dead lice and nits from the hair and scalp. All personal items exposed to the hair or lice should be washed in hot water or dry-cleaned. See “How do I stop the spread of lice?” at the end of the XEGLYZE Instructions for Use.',\n",
       " 'It is not known if XEGLYZE is safe and effective in children under 6 months of age.',\n",
       " 'What are the possible side effects of XEGLYZE?',\n",
       " 'The most common side effects of XEGLYZE include:',\n",
       " 'Tell your healthcare provider if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of XEGLYZE. For more information, ask your healthcare provider or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.',\n",
       " \"The active pharmacological ingredient in XEGLYZE (abametapir) Lotion is the pediculicide , abametapir, which is a dipyridyl compound. The chemical name of abametapir is 5,5'-dimethyl2,2'-bipyridinyl.\",\n",
       " 'The structural formula is:',\n",
       " '',\n",
       " '',\n",
       " 'The empirical formula is C 12 H 12 N 2 and the molecular weight is 184.24.',\n",
       " 'XEGLYZE is a white to off-white oil in water emulsion, containing 0.74% [weight by weight] of abametapir, intended for topical administration. XEGLYZE contains the following inactive ingredients: benzyl alcohol, butylated hydroxytoluene, carbomer 980, light mineral oil, polysorbate 20, trolamine and water.',\n",
       " 'Plenaxis is a prescription medicine used to treat the symptoms of Prostate Cancer. Plenaxis may be used alone or with other medications.',\n",
       " 'Plenaxis\\xa0belongs to a class of drugs called GnRH Analogue; GnRH Antagonist ; Antigonadotropin.',\n",
       " 'It is not known if Plenaxis is safe and effective in children.',\n",
       " 'Plenaxis\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Plenaxis\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Plenaxis. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'WARNING',\n",
       " 'Immediate-onset systemic allergic reactions, some resulting in hypotension and syncope, have occurred after administration of Plenaxis™ . These immediate-onset reactions have been reported to occur following any administration of Plenaxis™ , including after the initial dose. The cumulative risk of such a reaction increases with the duration of treatment (see WARNINGS ). Following each injection of Plenaxis™ , patients should be observed for at least 30 minutes in the office and in the event of an allergic reaction, managed appropriately.',\n",
       " 'Abarelix for injectable suspension (Plenaxis™ ) is a synthetic decapeptide with potent antagonistic activity against naturally occurring gonadotropin releasing-hormone (GnRH). Plenaxis™ inhibits gonadotropin and related androgen production by directly and competitively blocking GnRH receptors in the pituitary .',\n",
       " 'Abarelix is chemically described as acetyl-D-β-naphthylalanyl-D-4-chlorophenylalanyl- D-3-pyridylalanyl-L-seryl-L-N-methyl-tyrosyl-D-asparagyl-L-leucyl-L-N(ε)-isopropyllysyl- L-prolyl-D-alanyl-amide. It is initially manufactured as an acetate water complex and converted to a carboxymethylcellulose (CMC) water complex in manufacturing the drug product. The molecular weight for abarelix anhydrous free base is 1416.06.',\n",
       " 'The structural formula for abarelix peptide is:',\n",
       " '',\n",
       " '',\n",
       " 'Abarelix for injectable suspension is supplied as a white to off-white sterile dry powder which, when mixed with the diluent, 0.9% Sodium Chloride Injection, USP, becomes a depot suspension intended for intramuscular (IM) injection. The single-dose vial contains 113 mg of anhydrous free base abarelix peptide (net) supplied in an abarelix CMC complex. This complex also contains 19.1 to 31 mg of CMC. After the vial is reconstituted with 2.2 mL of 0.9% sodium chloride injection, 2 mL is administered to deliver a dose of 100 mg of abarelix (net) as the abarelix CMC complex at a pH of 5±1.',\n",
       " 'Orencia is a prescription medicine used to treat the symptoms of Moderate-to-Severe Rheumatoid Arthritis and Psoriatic Arthritis . Orencia may be used alone or with other medications.',\n",
       " 'Orencia\\xa0belongs to a class of drugs called DMARDs, Immunomodulators; Immunosuppressants.',\n",
       " 'It is not known if Orencia is safe and effective in children younger than 2 years of age.',\n",
       " 'Orencia\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Orencia\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Orencia. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " '',\n",
       " 'ORENCIA® (abatacept) is a selective T cell costimulation modulator. ORENCIA is a soluble fusion protein that consists of the extracellular domain of human cytotoxic T-lymphocyteassociated antigen 4 (CTLA-4) linked to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Abatacept is produced by recombinant DNA technology in a mammalian cell expression system. The apparent molecular weight of abatacept is 92 kilodaltons.',\n",
       " 'ORENCIA for Injection is a lyophilized powder for intravenous infusion. ORENCIA for Injection is supplied as a sterile, white, preservative-free, lyophilized powder for reconstitution and dilution prior to intravenous administration. Following reconstitution of the lyophilized powder with 10 mL of Sterile Water for Injection, USP, the solution of ORENCIA is clear, colorless to pale yellow, with a pH range of 7.2 to 7.8. Each single-use vial of ORENCIA for Injection provides 250 mg abatacept, maltose (500 mg), monobasic sodium phosphate (17.2 mg), and sodium chloride (14.6 mg) for administration.',\n",
       " 'ORENCIA Injection is a sterile, preservative-free, clear to slightly opalescent, colorless to paleyellow solution with a pH range of 6.8 to 7.4 for subcutaneous administration. ORENCIA Injection is supplied as a single-dose prefilled syringe or as a single-dose ClickJect autoinjector (see Table 4).',\n",
       " 'Table 4: Contents of ORENCIA Subcutaneous Injection',\n",
       " '',\n",
       " 'Unlike the lyophilized formulation for intravenous use, the ORENCIA solutions for subcutaneous administration contain no maltose.',\n",
       " 'ReoPro (abciximab) is a prescription medicine used to treat the symptoms of Unstable Angina (Chest Pain) and Adjunct to PCI. ReoPro may be used alone or with other medications.',\n",
       " 'ReoPro belongs to a class of drugs called Antiplatelet Agents, Cardiovascular ; Glycoprotein IIB/IIIa Inhibitors.',\n",
       " 'It is not known if ReoPro is safe and effective in children.',\n",
       " 'ReoPro\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of ReoPro\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of ReoPro. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'Abciximab, ReoPro®, is the Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation . Abciximab also binds to the vitronectin (α v β 3 ) receptor found on platelets and vessel wall endothelial and smooth muscle cells.',\n",
       " 'The chimeric 7E3 antibody is produced by continuous perfusion in mammalian cell culture. The 47,615 dalton Fab fragment is purified from cell culture supernatant by a series of steps involving specific viral inactivation and removal procedures, digestion with papain and column chromatography.',\n",
       " 'ReoPro® is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use. Each single use vial contains 2 mg/mL of Abciximab in a buffered solution (pH 7.2) of 0.01 M sodium phosphate, 0.15 M sodium chloride and 0.001% polysorbate 80 in Water for Injection. No preservatives are added.',\n",
       " 'What is ABECMA and how is it used?',\n",
       " 'ABECMA is for the treatment of multiple myeloma in patients who have received at least four kinds of treatment regimens that have not worked or have stopped working. ABECMA is a medicine made from your own white blood cells; the cells are genetically modified to recognize and attack your multiple myeloma cells.',\n",
       " 'What are the possible or reasonably likely side effects of ABECMA?',\n",
       " 'The most common side effects of ABECMA are:',\n",
       " 'ABECMA can cause a very common side effect called cytokine release syndrome or CRS, which can be severe or fatal. Symptoms of CRS include fever, difficulty breathing, dizziness or light-headedness, nausea, headache, fast heartbeat, low blood pressure , or fatigue. Tell your healthcare provider right away if you develop fever or any of these other symptoms after receiving ABECMA.',\n",
       " 'ABECMA can increase the risk of life-threatening infections that may lead to death. Tell your healthcare provider right away if you develop fever, chills, or any signs or symptoms of an infection.',\n",
       " 'ABECMA can lower one or more types of your blood cells ( red blood cells , white blood cells, or platelets), which may make you feel weak or tired or increase your risk of severe infection or bleeding. After treatment, your healthcare provider will test your blood to check for this. Tell your healthcare provider right away if you get a fever, are feeling tired, or have bruising or bleeding.',\n",
       " 'Having ABECMA in your blood may cause a false-positive human immunodeficiency virus ( HIV ) test result by some commercial tests.',\n",
       " 'These are not all the possible side effects of ABECMA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'WARNING',\n",
       " 'CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, HLH/MAS, AND PROLONGED CYTOPENIA',\n",
       " 'ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy product consisting of a patientâ€™s own T cells that are harvested and genetically modified ex vivo through transduction with an anti-BCMA02 chimeric antigen receptor (CAR) lentiviral vector (LVV). Autologous T cells transduced with the anti-BCMA02 CAR LVV express the anti-BCMA CAR on the T cell surface. The CAR is comprised of a murine extracellular single-chain variable fragment (scFv) specific for recognizing B cell maturation antigen (BCMA) followed by a human CD8α hinge and transmembrane domain fused to the T cell cytoplasmic signaling domains of CD137 (4-1BB) and CD3ζ chain, in tandem. Binding of ABECMA to BCMA-expressing target cells leads to signaling initiated by CD3ζ and 4-1BB domains, and subsequent CAR-positive T cell activation. Antigen-specific activation of ABECMA results in CAR-positive T cell proliferation, cytokine secretion, and subsequent cytolytic killing of BCMA-expressing cells.',\n",
       " 'ABECMA is prepared from the patientâ€™s peripheral blood mononuclear cells (PBMCs), which are obtained via a standard leukapheresis procedure. The mononuclear cells are enriched for T cells, through activation with anti-CD3 and anti-CD28 antibodies in the presence of IL-2 , which are then transduced with the replication-incompetent lentiviral vector containing the anti-BCMA CAR transgene. The transduced T cells are expanded in cell culture, washed, formulated into a suspension, and cryopreserved. The product must pass a sterility test before release for shipping as a frozen suspension in one or more patient-specific infusion bag(s). The product is thawed prior to infusion back into the patient [see DOSAGE AND ADMINISTRATION and HOW SUPPLIED / Storage And Handling ].',\n",
       " 'The ABECMA formulation contains 50% Plasma-Lyte A and 50% CryoStor® CS10, resulting in a final DMSO concentration of 5%.',\n",
       " 'Find Lowest Prices on',\n",
       " 'Abelcet is a prescription medicine used to treat the symptoms of Systemic Fungal Infection. Abelcet may be used alone or with other medications.',\n",
       " 'Abelcet\\xa0belongs to a class of drugs called Antifungals, Systemic.',\n",
       " 'Abelcet\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Abelcet\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Abelcet. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'ABELCET ® is a sterile, pyrogen-free suspension for intravenous infusion. ABELCET ® consists of amphotericin B complexed with two phospholipids in a 1:1 drug-to- lipid molar ratio. The two phospholipids, l-α-dimyristoylphosphatidylcholine (DMPC) and l-α-dimyristoylphosphatidylglycerol (DMPG), are present in a 7:3 molar ratio. ABELCET ® is yellow and opaque in appearance, with a pH of 5 - 7.',\n",
       " 'NOTE:Liposomal encapsulation or incorporation in a lipid complex can substantially affect a drug’s functional properties relative to those of the unencapsulated or nonlipid-associated drug. In addition, different liposomal or lipid-complexed products with a common active ingredient may vary from one another in the chemical composition and physical form of the lipid component. Such differences may affect functional properties of these drug products.',\n",
       " 'Amphotericin B is a polyene, antifungal antibiotic produced from a strain of Streptomyces nodosus. Amphotericin B is designated chemically as [1R-(1R*, 3S*, 5R*, 6R*, 9R*, 11R*, 15S*, 16R*, 17R*, 18S*, 19E, 21E, 23E, 25E, 27E, 29E, 31E, 33R*, 35S*, 36R*, 37S*)]-33-[(3-Amino-3, 6-dideoxy- β-Dmannopyranosyl) oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39- dioxabicyclo[33.3.1] nonatriaconta-19, 21, 23, 25, 27, 29, 31-heptaene-36-carboxylic acid.',\n",
       " 'It has a molecular weight of 924.09 and a molecular formula of C 47 H 73 NO 17 . The structural formula is:',\n",
       " '',\n",
       " '',\n",
       " 'ABELCET ® is provided as a sterile, opaque suspension in 20 mL glass, single-use vials. Each 20 mL vial contains 100 mg of amphotericin B (see DOSAGE AND ADMINISTRATION ), and each mL of ABELCET ® contains:',\n",
       " 'Amphotericin B USP 5.0 mg l-α-dimyristoylphosphatidylcholine (DMPC) 3.4 mg l-α-dimyristoylphosphatidylglycerol (DMPG) 1.5 mg Sodium Chloride USP 9.0 mg Water for Injection USP, q.s. 1 mL',\n",
       " 'Find Lowest Prices on',\n",
       " 'What is Verzenio and how is it used?',\n",
       " 'Verzenio is a prescription medicine used:',\n",
       " 'It is not known if Verzenio is safe and effective in children.',\n",
       " 'What are the possible side effects of Verzenio?',\n",
       " 'Verzenio may cause serious side effects, including:',\n",
       " 'The most common side effects of Verzenio include:',\n",
       " 'Verzenio may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if this is a concern for you.',\n",
       " 'These are not all the possible side effects of Verzenio. For more information, ask your healthcare provider or pharmacist.',\n",
       " 'Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " '',\n",
       " 'Abemaciclib is a kinase inhibitor for oral administration. It is a white to yellow powder with the empirical formula C 27 H 32 F 2 N 8 and a molecular weight 506.59.',\n",
       " 'The chemical name for abemaciclib is 2-Pyrimidinamine, N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-. Abemaciclib has the following structure:',\n",
       " '',\n",
       " '',\n",
       " 'VERZENIO (abemaciclib) tablets are provided as immediate-release oval white, beige, or yellow tablets. Inactive ingredients are as follows: Excipients-microcrystalline cellulose 102, microcrystalline cellulose 101, lactose monohydrate, croscarmellose sodium, sodium stearyl fumarate, silicon dioxide. Color mixture ingredients-polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide yellow, and iron oxide red.',\n",
       " 'Find Lowest Prices on',\n",
       " '',\n",
       " '',\n",
       " 'What is Abilify and how is it used?',\n",
       " 'Abilify is a prescription medicine used to treat the symptoms of schizophrenia, bipolar I disorder (manic depression), and major depressive disorder. Abilify may be used alone or with other medications. Abilify is an antipsychotic, antimanic agent.',\n",
       " 'What are the possible side effects of Abilify?',\n",
       " 'Abilify may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Abilify include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Abilify. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'WARNING',\n",
       " 'INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS WITH ANTIDEPRESSANT DRUGS',\n",
       " 'Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY is not approved for the treatment of patients with dementia-related psychosis [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for the emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Aripiprazole is a psychotropic drug that is available as ABILIFY® (aripiprazole) Tablets, ABILIFY DISCMELT® (aripiprazole) Orally Disintegrating Tablets, ABILIFY® (aripiprazole) Oral Solution, and ABILIFY® (aripiprazole) Injection, a solution for intramuscular injection. Aripiprazole is 7-[4-[4-(2,3dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril. The empirical formula is C 23 H 27 Cl 2 N 3 O 2 and its molecular weight is 448.38. The chemical structure is:',\n",
       " '',\n",
       " '',\n",
       " 'ABILIFY Tablets are available in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg strengths. Inactive ingredients include cornstarch, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. Colorants include ferric oxide (yellow or red) and FD&C Blue No. 2 Aluminum Lake.',\n",
       " 'ABILIFY DISCMELT Orally Disintegrating Tablets are available in 10 mg and 15 mg strengths. Inactive ingredients include acesulfame potassium , aspartame , calcium silicate, croscarmellose sodium, crospovidone, crème de vanilla (natural and artificial flavors), magnesium stearate, microcrystalline cellulose, silicon dioxide, tartaric acid, and xylitol . Colorants include ferric oxide (yellow or red) and FD&C Blue No. 2 Aluminum Lake.',\n",
       " 'ABILIFY Oral Solution is a clear, colorless to light-yellow solution available in a concentration of 1 mg/mL. The inactive ingredients for this solution include disodium edetate, fructose , glycerin, dl-lactic acid, methylparaben, propylene glycol, propylparaben, sodium hydroxide, sucrose, and purified water. The oral solution is flavored with natural orange cream and other natural flavors.',\n",
       " 'ABILIFY Injection is available in single-dose vials as a ready-to-use, 9.75 mg/1.3 mL (7.5 mg/mL) clear, colorless, sterile, aqueous solution for intramuscular use only. Inactive ingredients for this solution include 199.5mg of sulfobutylether β-cyclodextrin (SBECD), 10.4 mg of tartaric acid, qs to pH 4.3 of sodium hydroxide, and qs to 1.33 mL of water for injection.',\n",
       " 'Find Lowest Prices on',\n",
       " 'Abilify Maintena is a prescription medicine used to treat the symptoms of Schizophrenia, Bipolar Mania and Major Depressive Disorder. Abilify Maintena may be used alone or with other medications.',\n",
       " 'Abilify Maintena belongs to a class of drugs called Antipsychotics, 2nd Generation; Antimanic Agents.',\n",
       " 'It is not known if Abilify Maintena is safe and effective in children younger than 6 years of age.',\n",
       " 'Abilify Maintena may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Abilify Maintena include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Abilify Maintena. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'WARNING',\n",
       " 'INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS',\n",
       " 'Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY MAINTENA is not approved for the treatment of patients with dementia-related psychosis [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Aripiprazole is an atypical antipsychotic which is present in ABILIFY MAINTENA as its monohydrate polymorphic form. Aripiprazole monohydrate is 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl] butoxy]-3,4 dihydrocarbostyril monohydrate. The empirical formula is C 23 H 27 Cl 2 N 3 O 2 •H 2 O and its molecular weight is 466.40. The chemical structure is:',\n",
       " '',\n",
       " '',\n",
       " 'ABILIFY MAINTENA (aripiprazole) is an extended-release injectable suspension available in 400-mg or 300-mg strength pre-filled dual chamber syringes and 400-mg or 300-mg strength vials. The labeled strengths are calculated based on the anhydrous form (aripiprazole). Inactive ingredients (per administered dose) for 400 mg and 300 mg strength products, respectively, include carboxymethyl cellulose sodium (16.64 mg and 12.48 mg), mannitol (83.2 mg and 62.4 mg), sodium phosphate monobasic monohydrate (1.48 mg and 1.11 mg) and sodium hydroxide (pH adjuster).',\n",
       " 'Abilify MyCite is a prescription medicine used to treat the symptoms of Schizophrenia , Bipolar Mania , and Major Depressive Disorder. Abilify MyCite may be used alone or with other medications.',\n",
       " 'Abilify MyCite\\xa0belongs to a class of drugs called Antipsychotics, 2nd Generation; Antimanic Agents.',\n",
       " 'It is not known if Abilify MyCite is safe and effective in children.',\n",
       " 'Abilify MyCite\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Abilify MyCite\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Abilify MyCite. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'WARNING',\n",
       " 'INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS',\n",
       " 'Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY MYCITE is not approved for the treatment of patients with dementia-related psychosis [see WARNINGS AND PRECAUTIONS ] .',\n",
       " 'Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see WARNINGS AND PRECAUTIONS ]. The safety and efficacy of ABILIFY MYCITE have not been established in pediatric patients [see Use In Specific Populations ] .',\n",
       " 'ABILIFY MYCITE is a drug-device combination product containing aripiprazole, an atypical antipsychotic , embedded with an Ingestible Event Marker (IEM) sensor.',\n",
       " 'Aripiprazole is 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril. The empirical formula is C 23 H 27 Cl 2 N 3 O 2 and its molecular weight is 448.38. The chemical structure is:',\n",
       " '',\n",
       " '',\n",
       " 'ABILIFY MYCITE is available in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg strength tablets with sensor. Inactive ingredients of the tablets include cornstarch, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. Colorants include ferric oxide (yellow or red) and FD&C Blue No. 2 Aluminum Lake. Ingredients of the IEM include aluminum, cuprous chloride, ethyl cellulose, gold, hydroxypropyl cellulose, magnesium, silicon, silicon dioxide, silicon nitride, titanium-tungsten, titanium and triethyl citrate.',\n",
       " 'The ABILIFY MYCITE System is a drug-device combination product composed of the following components:',\n",
       " 'Find Lowest Prices on',\n",
       " 'Zytiga is a prescription medicine used to treat the symptoms of Prostate Cancer . Zytiga may be used alone or with other medications.',\n",
       " 'Zytiga\\xa0belongs to a class of drugs called Antineoplastics, Antiandrogen .',\n",
       " 'It is not known if Zytiga is safe and effective in children.',\n",
       " 'Zytiga\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Zytiga\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Zytiga. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'Abiraterone acetate, the active ingredient of ZYTIGA is the acetyl ester of abiraterone. Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains either 250 mg or 500 mg of abiraterone acetate. Abiraterone acetate is designated chemically as (3β)-17-(3-pyridinyl) androsta-5,16-dien-3-yl acetate and its structure is:',\n",
       " '',\n",
       " '',\n",
       " 'Abiraterone acetate is a white to off-white, non-hygroscopic, crystalline powder. Its molecular formula is C 26 H 33 NO 2 and it has a molecular weight of 391.55. Abiraterone acetate is a lipophilic compound with an octanol-water partition coefficient of 5.12 (Log P) and is practically insoluble in water. The pKa of the aromatic nitrogen is 5.19.',\n",
       " 'ZYTIGA tablets are available in 500 mg film-coated tablets, 250 mg film-coated tablets and 250 mg uncoated tablets with the following inactive ingredients:',\n",
       " 'Yonsa is a prescription medicine used to treat the symptoms of Prostate Cancer . Yonsa may be used alone or with other medications.',\n",
       " 'Yonsa\\xa0belongs to a class of drugs called Antineoplastics, Antiandrogen .',\n",
       " 'It is not known if Yonsa is safe and effective in children.',\n",
       " 'Yonsa\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Yonsa\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Yonsa. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'Abiraterone acetate, the active ingredient of YONSA tablet is the acetyl ester of abiraterone. Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each YONSA Tablet contains 125 mg of abiraterone acetate. Abiraterone acetate is designated chemically as (3β)17-(3-pyridinyl) androsta-5,16-dien-3-yl acetate and its structure is:',\n",
       " '',\n",
       " '',\n",
       " 'Abiraterone acetate is micronized (smaller particle size) white to off-white, non-hygroscopic, crystalline powder. Its molecular formula is C 26 H 33 NO 2 and it has a molecular weight of 391.55. Abiraterone acetate is a lipophilic compound with an octanol-water partition coefficient of 5.12 (Log P) and is practically insoluble in water. The pKa of the aromatic nitrogen is 5.19.',\n",
       " 'Inactive ingredients in the tablets are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, sodium stearyl fumarate, butylated hydroxyanisole, butylated hydroxytoluene.',\n",
       " 'ABLAVAR (gadofosveset trisodium) Injection',\n",
       " 'WARNING',\n",
       " 'NEPHROGENIC SYSTEMIC FIBROSIS (NSF)',\n",
       " 'Gadolinium-based contrast agents (GBCAs) increase the\\r\\nrisk for NSF among patients with impaired elimination of the drugs. Avoid use\\r\\nof GBCAs in these patients unless the diagnostic information is essential and\\r\\nnot available with non-contras ted MRI or other modalities. NSF may result in\\r\\nfatal or debilitating fibrosis affecting the skin, muscle and internal organs.',\n",
       " 'ABLAVAR (gadofosveset trisodium) Injection is a sterile,\\r\\nnonpyrogenic, formulation of a stable gadolinium diethylenetriaminepentaacetic\\r\\nacid (GdDTPA) chelate derivative with a diphenylcyclohexylphosphate group. Each\\r\\nmL of ABLAVAR Injection contains 244 mg of gadofosveset trisodium (0.25 mmol),\\r\\n0.268 mg of fosveset, and water for injection.',\n",
       " 'It contains no preservative and the solution pH ranges\\r\\nbetween 6.5 and 8.0.',\n",
       " 'Gadofosveset trisodium is chemically\\r\\ntrisodium-{(2-(R)-[(4,4-diphenylcyclohexyl) phosphonooxymethyl]-diethylenetriaminepentaacetato)(aquo)\\r\\ngadolinium(III),with a molecular weight of 975.88 g/mol, and an empirical\\r\\nformula of C 33 H 40 GdN 3 Na 3 O 15 P.\\r\\nIt has a structural formula:',\n",
       " '',\n",
       " 'Pertinent physiochemical data of ABLAVAR Injection are\\r\\nprovided below:',\n",
       " 'Table 3: Physiochemical Characteristics',\n",
       " 'Ablysinol is a prescription medicine used to treat the symptoms of Symptomatic Hypertrophic Obstructive Cardiomyopathy (HOCM). Ablysinol may be used alone or with other medications.',\n",
       " 'Ablysinol\\xa0belongs to a class of drugs called Clerosing Agent.',\n",
       " 'It is not known if Ablysinol is safe and effective in children.',\n",
       " 'Ablysinol\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Ablysinol\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Ablysinol. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'ABLYSINOL (dehydrated alcohol) injection is a sterile, preservative free solution of ≥ 99% by volume ethyl alcohol and no excipients. ABLYSINOL is for cardiac septal branch intra-arterial use. It has a molecular formula of C 2 H 6 O and a molecular weight of 46.07.',\n",
       " 'Dehydrated Alcohol Injection, USP is a potent tissue toxin . Ethanol is a clear, colorless, volatile, and flammable liquid miscible with water. It has the following structural formula:',\n",
       " '',\n",
       " '',\n",
       " 'Find Lowest Prices on',\n",
       " 'Dysport is a prescription medicine used to treat the symptoms of Cervical Dystonia , Glabellar Lines and Spasticity . Dysport may be used alone or with other medications.',\n",
       " 'Dysport belongs to a class of drugs called Neuromuscular Blockers, Botulinum Toxins.',\n",
       " 'It is not known if Dysport is safe and effective in children younger than 2 years of age.',\n",
       " 'Dysport may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Dysport include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Dysport. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'WARNING',\n",
       " 'DISTANT SPREAD OF TOXIN EFFECT',\n",
       " 'Postmarketing reports indicate that the effects of DYSPORT® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including upper limb spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Botulinum toxin type A, the active ingredient in DYSPORT® (abobotulinumtoxinA), is a purified neurotoxin type A complex produced by fermentation of the bacterium Clostridium botulinum type A, Hall Strain. It is purified from the culture supernatant by a series of precipitation, dialysis , and chromatography steps. The neurotoxin complex is composed of the neurotoxin, hemagglutinin proteins and non- toxin non-hemagglutinin protein.',\n",
       " \"DYSPORT® is supplied in a single-use, sterile vial for reconstitution intended for intramuscular injection. Each vial contains 300 Units or 500 Units of lyophilized abobotulinumtoxinA, human serum albumin (125 mcg) and lactose (2.5 mg). DYSPORT® may contain trace amounts of cow's milk proteins [see CONTRAINDICATIONS ].\",\n",
       " \"One unit of DYSPORT® corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice. The method for performing the assay is specific to Ipsen's product DYSPORT® . Due to differences in specific details such as vehicle, dilution scheme and laboratory protocols for various mouse LD50 assays, Units of biological activity of DYSPORT® are not interchangeable with Units of any other botulinum toxin or any toxin assessed with any other specific assay method [see Dosage Forms and Strengths ].\",\n",
       " 'Find Lowest Prices on',\n",
       " 'What is ABRAXANE and how is it used?',\n",
       " 'ABRAXANE is a prescription medicine used to treat:',\n",
       " 'It is not known if ABRAXANE is safe or effective in children.',\n",
       " 'What are the possible side effects of ABRAXANE?',\n",
       " 'ABRAXANE may cause serious side effects, including:',\n",
       " 'The most common side effects of ABRAXANE in people with breast cancer include:',\n",
       " 'The most common side effects of ABRAXANE in people with non-small cell lung cancer include:',\n",
       " 'The most common side effects of ABRAXANE in people with pancreatic cancer include:',\n",
       " 'Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of ABRAXANE. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'WARNING',\n",
       " 'NEUTROPENIA',\n",
       " 'Do not administer ABRAXANE therapy to patients who have baseline neutrophil counts of less than 1,500 cells/mm³. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving ABRAXANE [see CONTRAINDICATIONS , WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS ].',\n",
       " \"Note: An albumin form of paclitaxel may substantially affect a drug's functional properties relative to those of drug in solution. DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL FORMULATIONS.\",\n",
       " 'ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) ( albumin -bound) is paclitaxel formulated as albumin-bound nanoparticles with a mean particle size of approximately 130 nanometers. Paclitaxel exists in the particles in a non-crystalline, amorphous state. ABRAXANE is supplied as a white to yellow, sterile, lyophilized powder for reconstitution with 20 mL of 0.9% Sodium Chloride Injection, USP prior to intravenous infusion. Each single-use vial contains 100 mg of paclitaxel (bound to human albumin) and approximately 900 mg of human albumin (containing sodium caprylate and sodium acetyltryptophanate). Each milliliter (mL) of reconstituted suspension contains 5 mg paclitaxel formulated as albumin-bound particles. ABRAXANE is free of solvents.',\n",
       " 'The active agent in ABRAXANE is paclitaxel, a microtubule inhibitor. The chemical name for paclitaxel is 5β,20-Epoxy- 1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine.',\n",
       " 'Paclitaxel has the following structural formula:',\n",
       " '',\n",
       " '',\n",
       " 'Paclitaxel is a white to off-white crystalline powder with the empirical formula C 47 H 51 NO 14 and a molecular weight of 853.91. It is highly lipophilic, insoluble in water, and melts at approximately 216°C to 217°C.',\n",
       " 'Find Lowest Prices on',\n",
       " 'Abreva is a prescription medicine used to treat the symptoms of Cold Sores/ Fever Blister . Abreva may be used alone or with other medications.',\n",
       " 'Abreva belongs to a class of drugs called Antivirals, Topical.',\n",
       " 'It is not known if Abreva is safe and effective in children younger than 12 years of age.',\n",
       " 'Abreva may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Abreva include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Abreva. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'Abrilada is a prescription medicine used to treat the symptoms of Rheumatoid Arthritis , Psoriatic Arthritis , Ankylosing Spondylitis , Plaque Psoriasis , Crohn Disease, and Ulcerative Colitis . Abrilada may be used alone or with other medications.',\n",
       " 'Abrilada\\xa0belongs to a class of drugs called Antipsoriatics, Systemic; DMARDs, TNF Inhibitors; Monoclonal Antibodies; Inflammatory Bowel Disease Agents.',\n",
       " 'It is not known if Abrilada is safe and effective in children younger than 2 years of age.',\n",
       " 'Abrilada\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Abrilada\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Abrilada. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " '',\n",
       " 'WARNING',\n",
       " 'SERIOUS INFECTIONS and MALIGNANCY',\n",
       " 'Patients treated with adalimumab products including ABRILADA are at increased risk for developing serious infections that may lead to hospitalization or death [see WARNINGS AND PRECAUTIONS ]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.',\n",
       " 'Discontinue ABRILADA if a patient develops a serious infection or sepsis.',\n",
       " 'Reported infections include:',\n",
       " 'Carefully consider the risks and benefits of treatment with ABRILADA prior to initiating therapy in patients with chronic or recurrent infection.',\n",
       " 'Monitor patients closely for the development of signs and symptoms of infection during and after treatment with ABRILADA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS ].',\n",
       " \"Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products [see WARNINGS AND PRECAUTIONS ]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see WARNINGS AND PRECAUTIONS ].\",\n",
       " 'Adalimumab-afzb is a tumor necrosis factor (TNF) blocker. Adalimumab-afzb is a recombinant human IgG1 monoclonal antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions. Adalimumab-afzb is produced by recombinant DNA technology in Chinese hamster ovary cells and is purified by a process that includes specific viral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.',\n",
       " 'ABRILADA (adalimumab-afzb) injection is supplied as a sterile, preservative-free solution for subcutaneous administration. The drug product is supplied as either a single-dose prefilled pen (ABRILADA pen), as a single-dose 1 mL prefilled glass syringe, or as a single-dose institutional use vial. Enclosed within the pen is a single-dose 1 mL prefilled glass syringe. The solution of ABRILADA is clear and colorless to very light brown, with a pH of about 5.5.',\n",
       " 'Each 40 mg/0.8 mL prefilled syringe, prefilled pen, or single-dose institutional use vial delivers 0.8 mL (40 mg) of drug product. Each 0.8 mL of ABRILADA contains adalimumab-afzb (40 mg), edetate disodium dihydrate \\xa0(0.04 mg), L- histidine (0.63mg), L-histidine hydrochloride monohydrate (2.51 mg), L- methionine (0.16 mg), polysorbate 80 (0.16 mg), sucrose (68 mg), and Water for Injection, USP.',\n",
       " 'Each 20 mg/0.4 mL prefilled syringe delivers 0.4 mL (20 mg) of drug product. Each 0.4 mL of ABRILADA contains adalimumab-afzb (20 mg), edetate disodium dihydrate (0.02 mg), L-histidine (0.314 mg), L-histidine hydrochloride monohydrate (1.253 mg), L-methionine (0.08 mg), polysorbate 80 (0.08 mg), sucrose (34 mg), and Water for Injection, USP.',\n",
       " 'Each 10 mg/0.2 mL prefilled syringe delivers 0.2 mL (10 mg) of drug product. Each 0.2 mL of ABRILADA contains adalimumab-afzb (10 mg), edetate disodium dihydrate (0.01 mg), L-histidine (0.157 mg), L-histidine hydrochloride monohydrate (0.626 mg), L-methionine (0.04 mg), polysorbate 80 (0.04 mg), sucrose (17 mg), and Water for Injection, USP.',\n",
       " 'Cibinqo is a prescription medicine used to treat the symptoms of Atopic Dermatitis . Cibinqo may be used alone or with other medications.',\n",
       " 'Cibinqo\\xa0belongs to a class of drugs called Dermatologics, JAK Inhibitors.',\n",
       " 'It is not known if Cibinqo is safe and effective in children.',\n",
       " 'Cibinqo\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Cibinqo\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Cibinqo. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " '',\n",
       " '',\n",
       " 'WARNING',\n",
       " 'SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS',\n",
       " 'Patients treated with CIBINQO may be at increased risk for developing serious infections that may lead to hospitalization or death; The most frequent serious infections reported with CIBINQO were herpes simplex, herpes zoster, and pneumonia [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS ].',\n",
       " 'If a serious or opportunistic infection develops, discontinue CIBINQO and control the infection.',\n",
       " 'Reported infections from Janus kinase (JAK) inhibitors used to treat inflammatory conditions:',\n",
       " 'Avoid use of CIBINQO in patients with an active, serious infection including localized infections. The risks and benefits of treatment with CIBINQO should be carefully considered prior to initiating therapy in patients with chronic or recurrent infections.',\n",
       " 'Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with CIBINQO, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'In a large, randomized, postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another JAK inhibitor to TNF blocker treatment, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor. CIBINQO is not approved for use in RA patients [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Malignancies were reported in patients treated with CIBINQO. Lymphoma and other malignancies have been observed in patients receiving JAK inhibitors used to treat inflammatory conditions. In RA patients treated with another JAK inhibitor, a higher rate of malignancies (excluding nonmelanoma skin cancer (NMSC)) was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Major adverse cardiovascular events were reported in patients treated with CIBINQO. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke), was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk. Discontinue CIBINQO in patients that have experienced a myocardial infarction or stroke [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Deep venous thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients treated with CIBINQO. Thrombosis, including PE, DVT, and arterial thrombosis have been reported in patients receiving JAK inhibitors used to treat inflammatory conditions. Many of these adverse reactions were serious and some resulted in death. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of thrombosis was observed when compared with TNF blockers. Avoid CIBINQO in patients at risk. If symptoms of thrombosis occur, discontinue CIBINQO and treat appropriately [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'CIBINQO (abrocitinib) tablets contain the free base of abrocitinib, a Janus kinase (JAK) inhibitor, for oral administration.',\n",
       " 'Abrocitinib is a white to pale colored powder with the following chemical name: N -((1s,3s)-3-(methyl(7 H -pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide',\n",
       " 'The solubility of abrocitinib in water is 0.04 mg/mL at 25°C.',\n",
       " 'Abrocitinib has a molecular weight of 323.42 g/mol and a molecular formula of C 14 H 21 N 5 O 2 S. The structural formula of abrocitinib is:',\n",
       " '',\n",
       " '',\n",
       " 'Each film-coated tablet contains 50 mg or 100 mg or 200 mg of abrocitinib and the following inactive ingredients: dibasic calcium phosphate anhydrous, hypromellose, iron oxide red, lactose monohydrate, Macrogol, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, titanium dioxide, and triacetin.',\n",
       " 'Gelfoam Compressed Sponge is a medical devise intended for application to bleeding during surgical procedures. Gelfoam Compressed Sponge may be used alone or with other medications.',\n",
       " 'Gelfoam Compressed Sponge\\xa0belongs to a class of drugs called Hemostatic Device.',\n",
       " 'It is not known if Gelfoam Compressed Sponge is safe and effective in children.',\n",
       " 'Gelfoam Compressed Sponge\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Gelfoam Compressed Sponge\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Gelfoam Compressed Sponge. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'GELFOAM Sterile Compressed Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product prepared from purified porcine skin, Gelatin USP Granules and Water for Injection, USP. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids.',\n",
       " 'Gelfoam® absorbable gelatin sponge, USP',\n",
       " 'GELFOAM Dental Sponges are small, sterile, surgical\\r\\nsponges prepared from specially treated and purified gelatin solution which is\\r\\nbeaten to desired porosity, dried, sectioned, packaged, sealed, and sterilized\\r\\nby dry heat. GELFOAM is pliable, and is capable of absorbing and holding within\\r\\nits meshes many times its weight in whole blood. It is used as a hemostatic\\r\\ndevice.',\n",
       " 'Find Lowest Prices on',\n",
       " 'Gelfoam Sponge is a medical device used in oral surgery as an aid in providing hemostasis. Gelfoam Sponge may be used alone or with other medications.',\n",
       " 'Gelfoam Sponge\\xa0belongs to a class of drugs called Hemostatic Device.',\n",
       " 'Gelfoam Sponge\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Gelfoam Sponge\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Gelfoam Sponge. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'GELFOAM is a medical device intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product prepared from purified pork Skin Gelatin USP Granules and Water for Injection, USPand is able to absorb and hold within its interstices, many times its weight of blood and other fluids. GELFOAM Sterile Powder is a fine, dry, heat-sterilized light powder prepared by milling absorbable gelatin sponge.',\n",
       " 'Gelfoam® absorbable gelatin sponge, USP',\n",
       " 'GELFOAM Sterile Sponge is a medical device intended for\\r\\napplication to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white,\\r\\nnonelastic, porous, pliable product prepared from purified pork Skin Gelatin\\r\\nUSP Granules and Water for Injection, USP. It may be cut without fraying and is\\r\\nable to absorb and hold within its interstices, many times its weight of blood\\r\\nand other fluids.',\n",
       " 'Gelfilm is a prescription medicine used in surgical procedures as a Hemostatic Device. Gelfilm may be used alone or with other medications.',\n",
       " 'Gelfilm\\xa0belongs to a class of drugs called Absorbable Hemostatic Agent and Dressing.',\n",
       " 'It is not known if Gelfilm is safe and effective in children.',\n",
       " 'Gelfilm\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Gelfilm\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Gelfilm. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'GELFILM Sterile Film and GELFILM Sterile Ophthalmic Film are absorbable gelatin film approximately 0.075 mm in thickness, designed for use as an absorbable gelatin implant in neurosurgery and thoracic and ocular surgery. In the dry state absorbable gelatin film has the appearance and texture of cellophane of equivalent thickness; when moistened, it assumes a rubbery consistency and can be cut to desired size and shape and fitted to rounded or irregular surfaces.',\n",
       " 'Find Lowest Prices on',\n",
       " 'What are Absorica and Absorica LD and how do they work?',\n",
       " 'Absorica and Absorica LD are prescription medicines used in patients 12 years of age and older, who are not pregnant, for the treatment of severe acne ( nodular acne) that cannot be cleared up by any other acne treatments, including antibiotics. Absorica and Absorica LD can cause serious side effects.',\n",
       " 'Absorica and Absorica LD can only be:',\n",
       " 'It is not known if Absorica and Absorica LD are safe and effective in children less than 12 years of age.',\n",
       " 'What are the possible side effects of Absorica and Absorica LD?',\n",
       " 'Absorica and Absorica LD can cause serious side effects, including:',\n",
       " 'Stop Absorica or Absorica LD and call your healthcare provider right away if you have muscle weakness. Muscle weakness with or without pain can be a sign of serious muscle damage.',\n",
       " 'Absorica and Absorica LD may stop long bone growth in teenagers who are still growing.',\n",
       " 'The most common side effects of Absorica and Absorica LD include:',\n",
       " 'These are not all of the possible side effects of Absorica and Absorica LD. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or Sun Pharmaceutical Industries, Inc. at 1- 800-818-4555.',\n",
       " 'WARNING',\n",
       " 'CAUSES BIRTH DEFECTS',\n",
       " 'ABSORICA (isotretinoin) Capsules contain 10 mg, 20 mg, 25 mg, 30 mg, 35 mg or 40 mg of isotretinoin (a retinoid ) in hard gelatin capsules for oral administration. In addition to the active ingredient, isotretinoin, each capsule contains the following inactive ingredients: propyl gallate, sorbitan monooleate, soybean oil and stearoyl polyoxylglycerides. The gelatin capsules contain the following dye systems:',\n",
       " 'Chemically, isotretinoin is 13-cis-retinoic acid and is related to both retinoic acid and retinol ( vitamin A ). It is a yellow to orange crystalline powder with a molecular weight of 300.44. It is practically insoluble in water, soluble in chloroform and sparingly soluble in alcohol and in isopropyl alcohol. The structural formula is:',\n",
       " '',\n",
       " '',\n",
       " 'Meets USP Dissolution Test 3',\n",
       " 'Absorica LD is a prescription medicine used to treat the symptoms of Severe, Recalcitrant Nodular Acne. Absorica LD may be used alone or with other medications.',\n",
       " 'Absorica LD\\xa0belongs to a class of drugs called Acne Agents, Systemic; Retinoid -like Agents.',\n",
       " 'It is not known if Absorica LD is safe and effective in children younger than 12 years of age.',\n",
       " 'Absorica LD\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Absorica LD\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Absorica LD. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'ABSORICA LD™ (isotretinoin) capsules, for oral use',\n",
       " 'WARNING',\n",
       " 'EMBRYO-FETAL TOXICITY CONTRAINDICATED IN PREGNANCY',\n",
       " 'ABSORICA/ABSORICA LD can cause severe life-threatening birth defects and is contraindicated in pregnancy.',\n",
       " 'There is an extremely high risk that severe birth defects will result if pregnancy occurs while taking any amount of ABSORICA/ABSORICA LD even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining prenatally whether an exposed fetus has been affected. If pregnancy occurs, discontinue ABSORICA/ABSORICA LD immediately and refer the patient to an Obstetrician- Gynecologist experienced in reproductive toxicity for further evaluation and counseling [see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and Use In Specific Populations].',\n",
       " 'Because of the risk of embryo-fetal toxicity, ABSORICA and ABSORICA LD are available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the iPLEDGE REMS [see WARNINGS AND PRECAUTIONS].',\n",
       " 'ABSORICA (isotretinoin) Capsules contain 10 mg, 20 mg, 25 mg, 30 mg, 35 mg or 40 mg of isotretinoin (a retinoid) in hard gelatin capsules for oral administration. In addition to the active ingredient, isotretinoin, each capsule contains the following inactive ingredients: propyl gallate, sorbitan monooleate, soybean oil and stearoyl polyoxylglycerides. The gelatin capsules contain the following dye systems:',\n",
       " 'ABSORICA LD (isotretinoin) Capsules contain 8 mg, 16 mg, 20 mg, 24 mg, 28 mg and 32 mg of micronized isotretinoin (a retinoid) in suspension filled in hard gelatin capsules for oral administration. In addition to the active ingredient, isotretinoin, USP each capsule contains the following inactive ingredients: butylated hydroxy anisole, gelatin, hard gelatin capsule shell, polysorbate 80 and soybean oil. The gelatin capsules contain the following dye systems:',\n",
       " 'The imprinting ink of 8 mg, 16 mg, 24 mg and 32 mg capsules contain the following ingredients: potassium hydroxide, propylene glycol, shellac and titanium dioxide.',\n",
       " 'The imprinting ink of 20 mg and 28 mg capsules contain the following ingredients: ferrosoferric oxide, propylene glycol and shellac glaze.',\n",
       " 'Chemically, isotretinoin is 13-cis-retinoic acid and is related to both retinoic acid and retinol ( vitamin A ). It is a yellow to orange crystalline powder with a molecular weight of 300.44. It is practically insoluble in water, soluble in chloroform and sparingly soluble in alcohol and in isopropyl alcohol. The structural formula is:',\n",
       " '',\n",
       " '',\n",
       " 'ABSORICA meets USP Dissolution Test 3.',\n",
       " 'For ABSORICA LD, FDA approved dissolution test differs from the USP.',\n",
       " 'Abstral is a prescription medicine used to treat the symptoms of Breakthrough Cancer Pain. Abstral may be used alone or with other medications.',\n",
       " 'Abstral\\xa0belongs to a class of drugs called Opioid Analgesics; Opioids, Anilidopiperidine.',\n",
       " 'It is not known if Abstral is safe and effective in children younger than 18 years of age.',\n",
       " 'Abstral\\xa0may cause serious side effects including:',\n",
       " 'The most common side effects of Abstral\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Abstral. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'WARNING',\n",
       " 'RISK OF RESPIRATORY DEPRESSION, MEDICATION ERRORS, ABUSE POTENTIAL',\n",
       " 'Fatal respiratory depression has occurred in patients treated with immediate-release transmucosal fentanyl, including following use in opioid non-tolerant patients and improper dosing. The substitution of ABSTRAL for any other fentanyl product may result in fatal overdose.',\n",
       " 'Due to the risk of respiratory depression, ABSTRAL is contraindicated in the management of acute or postoperative pain including headache/migraine and in opioid non-tolerant patients. [see CONTRAINDICATIONS ]',\n",
       " 'ABSTRAL must be kept out of reach of children. [see Patient Counseling Information and HOW SUPPLIED /Storage and Handling]',\n",
       " 'The concomitant use of ABSTRAL with CYP3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression. [see DRUG INTERACTIONS ]',\n",
       " 'Substantial differences exist in the pharmacokinetic profile of ABSTRAL compared to other fentanyl products that result in clinically important differences in the extent of absorption of fentanyl that could result in fatal overdose.',\n",
       " 'ABSTRAL contains fentanyl, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. ABSTRAL can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing ABSTRAL in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion.',\n",
       " 'Because of the risk for misuse, abuse, addiction, and overdose, ABSTRAL is available only through a restricted program, required by the Food and Drug Administration, called a Risk Evaluation and Mitigation Strategy (REMS). Under the TIRF (Transmucosal Immediate Release Fentanyl) REMS Access program, outpatients, healthcare professionals who prescribe to outpatients, pharmacies, and distributors must enroll in the program [see WARNINGS AND PRECAUTIONS ]. Further information is available at www.TIRFREMSAccess.com or by calling1-866-822-1483.',\n",
       " 'ABSTRAL (fentanyl) sublingual tablet is a solid formulation of fentanyl citrate, a potent opioid analgesic intended for oral sublingual administration. ABSTRAL is formulated as a white tablet available in six strengths, distinguishable by the shape of the tablet and by de-bossing on the tablet surface.',\n",
       " 'Active Ingredient: Fentanyl citrate, USP is N-(1-Phenethyl-4-piperidyl) propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic solvents and sparingly soluble in water (1:40). The molecular weight of the free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens are 7.3 and 8.4. The compound has the following structural formula:',\n",
       " '',\n",
       " '',\n",
       " 'All tablet strengths are expressed as the amount of fentanyl free base, e.g., the 100 mcg strength tablet contains 100 mcg of fentanyl free base.',\n",
       " 'Inactive Ingredients: Croscarmellose sodium, magnesium stearate, mannitol, and silicified microcrystalline cellulose.',\n",
       " 'Calquence is a prescription medicine used to treat the symptoms of Mantle Cell Lymphoma , Chronic Lymphocytic Leukemia , Small Lymphocytic Lymphoma . Calquence may be used alone or with other medications.',\n",
       " 'Calquence\\xa0belongs to a class of drugs called Antineoplastics, Tyrosine Kinase Inhibitor.',\n",
       " 'It is not known if Calquence is safe and effective in children.',\n",
       " 'Calquence\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Calquence\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Calquence. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'CALQUENCE (acalabrutinib) is an inhibitor of Bruton tyrosine kinase (BTK). The molecular formula for acalabrutinib is C 26 H 23 N 7 O 2 , and the molecular weight is 465.51. The chemical name is 4-{8-amino-3- [(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl)}-N-(pyridine-2-yl)benzamide.',\n",
       " 'The chemical structure of acalabrutinib is shown below:',\n",
       " '',\n",
       " '',\n",
       " 'Acalabrutinib is a white to yellow powder with pH-dependent solubility. It is freely soluble in water at pH values below 3 and practically insoluble at pH values above 6.',\n",
       " 'CALQUENCE capsules for oral administration contains 100 mg acalabrutinib and the following inactive ingredients: silicified microcrystalline cellulose, partially pregelatinized starch, magnesium stearate, and sodium starch glycolate. The capsule shell contains gelatin, titanium dioxide, yellow iron oxide, FD&C Blue 2 and is imprinted with edible black ink.',\n",
       " 'ACAM2000 is a prescription medicine used as a vaccine to prevent Smallpox. ACAM2000 may be used alone or with other medications.',\n",
       " 'ACAM2000\\xa0belongs to a class of drugs called Vaccines, Live, Viral.',\n",
       " 'It is not known if ACAM2000 is safe and effective in children younger than 16 years of age.',\n",
       " 'ACAM2000\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of ACAM2000\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of ACAM2000. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " '',\n",
       " 'WARNING',\n",
       " 'ACAM2000 is a live vaccinia virus that can be transmitted to persons who have close contact with the vaccinee and the risks in contacts are the same as those for the vaccinee.',\n",
       " 'The risk for experiencing serious vaccination complications must be weighed against the risks for experiencing a potentially fatal smallpox infection.',\n",
       " 'ACAM2000, Smallpox (Vaccinia) Vaccine, Live, is a live vaccinia virus derived from plaque purification cloning from Dryvax® (Wyeth Laboratories, Marietta, PA, calf lymph vaccine, New York City Board of Health Strain) and grown in African Green Monkey kidney (Vero) cells and tested to be free of adventitious agents.',\n",
       " 'ACAM2000 is provided as a lyophilized preparation of purified live virus containing the following non-active excipients: 6-8 mM HEPES (pH 6.5-7.5), 2% human serum albumin USP, 0.5 – 0.7% sodium chloride USP, 5% mannitol USP, and trace amounts of neomycin and polymyxin B.',\n",
       " 'Diluent for ACAM2000 contains 50% (v/v) Glycerin USP, 0.25% (v/v) Phenol USP in Water for Injection USP, supplied in 3 mL clear glass vials containing 0.6 mL of diluent.',\n",
       " 'After reconstitution, each vial of ACAM2000 vaccine contains approximately 100 doses (0.0025 mL/dose). The concentration of vaccinia virus is 1.0-5.0 x 10 8 plaque-forming units (PFU)/mL or 2.5-12.5 x 10 5 PFU/dose determined by plaque assay in Vero cells. ACAM2000 is administered by the percutaneous route ( scarification ) using 15 jabs of a stainless steel bifurcated needle that has been dipped into the vaccine.',\n",
       " 'Campral is a prescription medicine used to treat the symptoms of Alcoholism and Renal Impairment. Campral may be used alone or with other medications.',\n",
       " 'Campral belongs to a class of drugs called Psychiatry Agents, Other; GABA Analogs.',\n",
       " 'It is not known if Campral is safe and effective in children.',\n",
       " 'Side effects of Campral include:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Campral include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Campral. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'Campral® (acamprosate calcium) is supplied in an enteric-coated tablet for oral administration. Acamprosate calcium is a synthetic compound with a chemical structure similar to that of the endogenous amino acid homotaurine , which is a structural analogue of the amino acid neurotransmitter γ-aminobutyric acid and the amino acid neuromodulator taurine . Its chemical name is calcium acetylaminopropane sulfonate. Its chemical formula is C H N O S C a and molecular weight is 400.48. Its structural formula is:',\n",
       " '',\n",
       " '',\n",
       " 'Acamprosate calcium is a white, odorless or nearly odorless powder. It is freely soluble in water, and practically insoluble in absolute ethanol and dichloromethane.',\n",
       " 'Each Campral® tablet contains acamprosate calcium 333 mg, equivalent to 300 mg of acamprosate. Inactive ingredients in Campral tablets include: crospovidone, microcrystalline cellulose, magnesium silicate, sodium starch glycolate, colloidal anhydrous silica, magnesium stearate, talc, propylene glycol and Eudragit L 30 D or equivalent. Sulfites were used in the synthesis of the drug substance and traces of residual sulfites may be present in the drug product.',\n",
       " 'Find Lowest Prices on',\n",
       " 'Acanya is a prescription medicine used to treat the symptoms of Acne Vulgaris . Acanya may be used alone or with other medications.',\n",
       " 'Acanya\\xa0belongs to a class of drugs called Acne Agents, Topical Combos.',\n",
       " 'It is not known if Acanya is safe and effective in children younger than 12 years of age.',\n",
       " 'Acanya\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Acanya\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Acanya. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'ACANYA (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5% is a combination product with two active ingredients in a white to off-white, opaque, smooth, aqueous gel formulation intended for topical use. Clindamycin phosphate is a water-soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin.',\n",
       " 'The chemical name for clindamycin phosphate is Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)- 1-thio-L-threo- α-D-galactooctopyranoside 2 -(dihydrogen phosphate). The structural formula for clindamycin phosphate is represented below:',\n",
       " 'Clindamycin phosphate :',\n",
       " '',\n",
       " '',\n",
       " 'Benzoyl peroxide is an antibacterial and keratolytic agent. The structural formula for benzoyl peroxide is represented below:',\n",
       " 'Benzoyl peroxide :',\n",
       " '',\n",
       " '',\n",
       " 'ACANYA Gel contains the following inactive ingredients: purified water, carbomer 980, propylene glycol, and potassium hydroxide. Each gram of ACANYA Gel contains 1.2% of clindamycin phosphate which is equivalent to 1% clindamycin.',\n",
       " 'Find Lowest Prices on',\n",
       " 'Precose (acarbose tablets) is an oral alpha-glucosidase inhibitor used to treat type 2 diabetes . Precose is sometimes used in combination with insulin or other diabetes medications you take by mouth. Precose is available in generic form.',\n",
       " 'Common side effects of Precose include:',\n",
       " 'Other side effects of Precose include skin rash or itching. Tell your doctor if you have rare but very serious side effects of Precose including:',\n",
       " 'PRECOSE® (acarbose tablets) is an oral alpha-glucosidase inhibitor for use in the management of type 2 diabetes mellitus. Acarbose is an oligosaccharide which is obtained from fermentation processes of a microorganism, Actinoplanes utahensis, and is chemically known as O-4,6-dideoxy4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino] α-D-glucopyranos yl-(1 → 4)-O-α-D-glucopyranosyl-(1 →4)-D-glucose. It is a white to off-white powder with a molecular weight of 645.6. Acarbose is soluble in water and has a pKa of 5.1. Its empirical formula is C 25 H 43 NO 18 and its chemical structure is as follows:',\n",
       " '',\n",
       " 'PRECOSE is available as 25 mg, 50 mg and 100 mg tablets for oral use. The inactive ingredients are starch, microcrystalline cellulose, magnesium stearate, and colloidal silicon dioxide.',\n",
       " 'Find Lowest Prices on',\n",
       " 'Accolate is a prescription medicine used to treat the symptoms of Asthma. Accolate may be used alone or with other medications.',\n",
       " 'Accolate belongs to a class of drugs called Leukotriene Receptor Antagonists.',\n",
       " 'It is not known if Accolate is safe and effective in children younger than 5 years of age.',\n",
       " 'Accolate may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Accolate include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Accolate. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'Zafirlukast is a synthetic, selective peptide leukotriene receptor antagonist (LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-otolylsulfonylbenzamide. The molecular weight of zafirlukast is 575.7 and the structural formula is:',\n",
       " '',\n",
       " '',\n",
       " 'The empirical formula is: C 31 H 33 N 3 O 6 S',\n",
       " 'Zafirlukast, a fine white to pale yellow amorphous powder, is practically insoluble in water. It is slightly soluble in methanol and freely soluble in tetrahydrofuran, dimethylsulfoxide, and acetone.',\n",
       " 'ACCOLATE is supplied as 10 and 20 mg tablets for oral administration.',\n",
       " 'Film-coated tablets containing croscarmellose sodium, lactose, magnesium stearate, microcrystalline cellulose, povidone, hypromellose, and titanium dioxide.',\n",
       " 'Accretropin is a prescription medicine used to treat the symptoms of Growth Hormone Deficiency. Accretropin may be used alone or with other medications.',\n",
       " 'Accretropin\\xa0belongs to a class of drugs called Growth Hormone Analogs.',\n",
       " 'Accretropin\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Accretropin\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Accretropin. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'Accretropin™ ( recombinant human growth hormone (r-hGH); somatropin) is a protein produced by recombinant DNA technology . It is produced during fermentation in E. coli yielding a protein containing 192 amino acids. The N-terminal amino acid , methionine , is later removed to yield a protein that is chemically and physicochemically identical to pituitary derived human growth hormone, consisting of 191 amino acids in a single polypeptide chain.',\n",
       " 'Accretropin™ (somatropin injection) is distributed in a liquid solution containing 1 mL of a 5 mg/mL solution of growth hormone (15 IU/mL). The formulation also contains 0.75% NaCl, 0.34% Phenol (as preservative), 0.2% Pluronic F-68 (a non-ionic surfactant ) and is designed for subcutaneous administration. Accretropin™ (somatropin injection) is stabilized to pH 6.0 with 10 mM NaPO 4 buffer.',\n",
       " 'Accrufer is a prescription medicine used to treat the symptoms of Iron Deficiency . Accrufer may be used alone or with other medications.',\n",
       " 'Accrufer belongs to a class of drugs called Iron Products.',\n",
       " 'It is not known if Accrufer is safe and effective in children.',\n",
       " 'Accrufer may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Accrufer include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Accrufer. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'ACCRUFER (ferric maltol) capsules, an iron replacement product for oral administration, contain 30 mg iron and 201.5 mg maltol. Ferric maltol contains iron in a stable ferric state as a complex with a trimaltol ligand . Ferric maltol is 3-hydroxy-2-methyl-4H-pyrane-4-one iron (III) complex (3:1) and has the molecular formula (C 6 H 5 O 3 ) 3 Fe and a molecular mass of 431.2.',\n",
       " 'Each red capsule, printed with “30”, contains colloidal anhydrous silica , crospovidone (Type A), lactose monohydrate, magnesium stearate and sodium lauryl sulfate as inactive ingredients. In addition, the capsule shell contains FD&C Blue No. 1, FD&C Red No. 40, FD&C Yellow No.6, gelatin and titanium dioxide. The ink used for printing the marking contains ammonium hydroxide, ethanol, iron oxide black and propylene glycol.',\n",
       " '',\n",
       " '',\n",
       " 'AccuNeb® (albuterol sulfate) 1.25 mg*/3 mL and 0.63 mg*/3 mL Inhalation Solution',\n",
       " '*(Potency expressed as albuterol, equivalent to 1.5 mg and 0.75 mg albuterol\\r\\n  sulfate)',\n",
       " \"AccuNeb® (albuterol sulfate) inhalation solution is a sterile, clear, colorless\\r\\n  solution of the sulfate salt of racemic albuterol, albuterol sulfate. Albuterol\\r\\n  sulfate is a relatively selective beta2-adrenergic bronchodilator (see CLINICAL\\r\\n  PHARMACOLOGY ). The chemical name for albuterol sulfate is α1 [(tert-butylamino)\\r\\n  methyl]-4-hydroxy-mxylene-α, α'-diol sulfate (2:1) (salt), and its\\r\\n  established chemical structure is as follows:\",\n",
       " '',\n",
       " 'The molecular weight of albuterol sulfate is 576.7 and the empirical formula\\r\\n  is (C 13 H 21 NO 3 )2•H 2 SO 4 .\\r\\n  Albuterol sulfate is a white crystalline powder, soluble in water and slightly\\r\\n  soluble in ethanol. The World Health Organization recommended name for albuterol\\r\\n  is salbutamol.',\n",
       " 'AccuNeb (albuterol sulfate) Inhalation Solution is supplied in two strengths\\r\\n  in unit dose vials. Each unit dose vial contains either 0.75 mg of albuterol\\r\\n  sulfate (equivalent to 0.63 mg of albuterol) or 1.50 mg of albuterol sulfate\\r\\n  (equivalent to 1.25 mg of albuterol) with sodium chloride and sulfuric acid\\r\\n  in a 3-mL isotonic, sterile, aqueous solution. Sodium chloride is added to adjust\\r\\n  isotonicity of the solution and sulfuric acid is added to adjust pH of the solution\\r\\n  to 3.5 (see HOW SUPPLIED ).',\n",
       " 'AccuNeb (albuterol sulfate) Inhalation Solution does not require dilution prior\\r\\n  to administration by nebulization. For AccuNeb (albuterol sulfate inhalation solution) , like all other nebulized treatments,\\r\\n  the amount delivered to the lungs will depend on patient factors, the jet nebulizer utilized, and compressor performance. Using the Pari LC Plus™ nebulizer\\r\\n  (with face mask or mouthpiece) connected to a Pari PRONEB™ compressor,\\r\\n  under in vitro conditions, the mean delivered dose from the mouth piece\\r\\n  (% nominal dose) was approximately 43% of albuterol (1.25 mg strength) and 39%\\r\\n  of albuterol (0.63 mg strength) at a mean flow rate of 3.6 L/min. The mean nebulization\\r\\n  time was 15 minutes or less. AccuNeb (albuterol sulfate inhalation solution)  should be administered from a jet nebulizer\\r\\n  at an adequate flow rate, via a mouthpiece or face mask (see DOSAGE AND ADMINISTRATION ).',\n",
       " 'Find Lowest Prices on',\n",
       " 'Accupril (quinapril) is an angiotensin converting enzyme (ACE) inhibitor used for treating high blood pressure and heart failure . Generic formulations of Accupril are available.',\n",
       " 'Common side effects of Accupril include:',\n",
       " 'WARNING',\n",
       " 'FETAL TOXICITY',\n",
       " 'ACCUPRIL ® (quinapril hydrochloride) is the hydrochloride salt of quinapril, the ethyl ester of a non-sulfhydryl, angiotensin -converting enzyme (ACE) inhibitor, quinaprilat.',\n",
       " 'Quinapril hydrochloride is chemically described as [3S-[2[R*(R*)], 3R*]]-2-[2-[[1(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3isoquinolinecarboxylic acid, monohydrochloride. Its empirical formula is C 25 H 30 N 2 O 5 •HCl and its structural formula is:',\n",
       " '',\n",
       " '',\n",
       " 'Quinapril hydrochloride is a white to off-white amorphous powder that is freely soluble in aqueous solvents.',\n",
       " 'ACCUPRIL tablets contain 5 mg, 10 mg, 20 mg, or 40 mg of quinapril for oral administration. Each tablet also contains candelilla wax, crospovidone, gelatin, lactose, magnesium carbonate, magnesium stearate, synthetic red iron oxide, and titanium dioxide.',\n",
       " 'Find Lowest Prices on',\n",
       " 'Accuretic is a prescription medicine used to treat the symptoms of High Blood Pressure (Hypertension). Accuretic may be used alone or with other medications.',\n",
       " 'Accuretic\\xa0belongs to a class of drugs called ACEI / Diuretic Combos; ACEI/HCTZ Combos.',\n",
       " 'It is not known if Accuretic is safe and effective in children younger than 18 years of age.',\n",
       " 'Accuretic\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Accuretic\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Accuretic. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'WARNING',\n",
       " 'FETAL TOXICITY',\n",
       " 'ACCURETIC is a fixed-combination tablet that combines an angiotensin-converting enzyme (ACE) inhibitor, quinapril hydrochloride, and a thiazide diuretic, hydrochlorothiazide.',\n",
       " 'Quinapril hydrochloride is chemically described as [3S-[2[R*(R*)], 3R*]]-2-[2-[[1(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3isoquinolinecarboxylic acid, monohydrochloride. Its empirical formula is C 25 H 30 N 2 O 5 • HCl and its structural formula is:',\n",
       " '',\n",
       " '',\n",
       " 'Quinapril hydrochloride is a white to off-white amorphous powder that is freely soluble in aqueous solvents.',\n",
       " 'Hydrochlorothiazide is chemically described as: 6-Chloro-3,4-dihydro-2H-1,2,4benzothiadiazine-7-sulfonamide 1,1-dioxide. Its empirical formula is C 7 H 8 CIN 3 O 4 S 2 and its structural formula is:',\n",
       " '',\n",
       " '',\n",
       " 'Hydrochlorothiazide is a white to off-white, crystalline powder which is slightly soluble in water but freely soluble in sodium hydroxide solution.',\n",
       " 'ACCURETIC is available for oral use as fixed combination tablets in three strengths of quinapril with hydrochlorothiazide: 10 mg with 12.5 mg (ACCURETIC 10/12.5), 20 mg with 12.5 mg (ACCURETIC 20/12.5), and 20 mg with 25 mg (ACCURETIC 20/25). Inactive ingredients: candelilla wax, crospovidone, hydroxypropyl cellulose, hypromellose, iron oxide red, iron oxide yellow, lactose, magnesium carbonate, magnesium stearate, polyethylene glycol, povidone, and titanium dioxide.',\n",
       " 'Find Lowest Prices on',\n",
       " 'Accutane is a prescription medicine used to treat the symptoms of severe, recalcitrant Nodular Acne. Accutane may be used alone or with other medications.',\n",
       " 'Accutane\\xa0belongs to a class of drugs called Acne Agents, Systemic; Retinoid -like Agents.',\n",
       " 'It is not known if Accutane is safe and effective in children younger than 12 years of age.',\n",
       " 'Accutane\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Accutane\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Accutane. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'CONTRAINDICATIONS AND WARNINGS',\n",
       " 'Accutane must not be used by female patients who are or may become pregnant. There is an extremely high risk that severe birth defects will result if pregnancy occurs while taking Accutane in any amount, even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining whether an exposed fetus has been affected.',\n",
       " 'Birth defects which have been documented following Accutane exposure include',\n",
       " 'Cases of IQ scores less than 85 with or without other abnormalities have been reported. There is an increased risk of spontaneous abortion, and premature births have been reported.',\n",
       " 'Documented external abnormalities include:',\n",
       " 'Documented internal abnormalities include:',\n",
       " 'In some cases death has occurred with certain of the abnormalities previously noted.',\n",
       " 'If pregnancy does occur during treatment of a female patient who is taking Accutane, Accutane must be discontinued immediately and she should be referred to an Obstetrician-Gynecologist experienced in reproductive toxicity for further evaluation and counseling.',\n",
       " 'Special Prescribing Requirements',\n",
       " 'Because of Accutane’s teratogenicity and to minimize fetal exposure, Accutane is approved for marketing only under a special restricted distribution program approved by the Food and Drug Administration. This program is called iPLEDGE™. Accutane must only be prescribed by prescribers who are registered and activated with the iPLEDGE program. Accutane must only be dispensed by a pharmacy registered and activated with iPLEDGE, and must only be dispensed to patients who are registered and meet all the requirements of iPLEDGE (see PRECAUTIONS ).',\n",
       " 'Table 1 : Monthly Required iPLEDGE Interactions',\n",
       " '',\n",
       " 'Isotretinoin, a retinoid, is available as Accutane in 10-mg, 20-mg and 40-mg soft gelatin capsules for oral administration. Each capsule contains beeswax, butylated hydroxyanisole, edetate disodium, hydrogenated soybean oil flakes, hydrogenated vegetable oil, and soybean oil. Gelatin capsules contain glycerin and parabens (methyl and propyl), with the following dye systems:',\n",
       " 'Chemically, isotretinoin is 13- cis -retinoic acid and is related to both retinoic acid and retinol (vitamin A). It is a yellow to orange crystalline powder with a molecular weight of 300.44. The structural formula is:',\n",
       " '',\n",
       " '',\n",
       " 'Accuzyme is a prescription medicine used for wound debridement caused by pressure ulcer, burns , postoperative wounds and miscellaneous traumatic or infected wounds. Accuzyme may be used alone or with other medications.',\n",
       " 'Accuzyme\\xa0belongs to a class of drugs called Topical Debriding Agents.',\n",
       " 'It is not known if Accuzyme is safe and effective in children.',\n",
       " 'Accuzyme\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Accuzyme\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Accuzyme. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " '',\n",
       " 'ACCUZYME ( papain and urea) enzymatic debriding ointment contains papain, USP (8.3 x 105 USP units of activity per gram ) and urea , USP 10% in a hydrophilic ointment base composed of emulsifying wax, fragrance, glycerin, isopropyl palmitate , lactose , methylparaben, potassium phosphate monobasic, propylparaben, and purified water.',\n",
       " 'Find Lowest Prices on',\n",
       " 'Sectral (acebutolol hydrochloride)\\xa0 is a prescription medicine used to treat the symptoms of High Blood Pressure (Hypertension), Chest Pain ( Angina ) and Heart Rhythm Disorders (Ventricular Arrhythmias ). Sectral may be used alone or with other medications.',\n",
       " 'Sectral\\xa0belongs to a class of drugs called Antidysrhythmics, II; Beta-Blockers, Intrinsic Sympathomimetic.',\n",
       " 'It is not known if Sectral is safe and effective in children.',\n",
       " 'Sectral\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Sectral\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Sectral. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'Sectral (acebutolol HCl) is a selective, hydrophilic beta-adrenoreceptor blocking agent with mild intrinsic sympathomimetic activity for use in treating patients with hypertension and ventricular arrhythmias . It is marketed in capsule form for oral administration. Sectral capsules are provided in two dosage strengths which contain 200 or 400 mg of acebutolol as the hydrochloride salt. The inactive ingredients present are D&C Red 22, FD&C Blue 1, FD&C Yellow 6, gelatin , povidone, starch, stearic acid, and titanium dioxide. The 200 mg dosage strength also contains D&C Red 28 and the 400 mg dosage strength also contains FD&C Red 40. Acebutolol HCl has the following structural formula:',\n",
       " '',\n",
       " '',\n",
       " 'Acebutolol HCl is a white or slightly off-white powder freely soluble in water, and less soluble in alcohol. Chemically it is defined as the hydrochloride salt of (±)N-[3-Acetyl-4-[2- hydroxy-3-[(1- methylethyl)amino]propoxy]phenyl] butanamide.',\n",
       " 'What is Clanza CR and how is it used?',\n",
       " 'Clanza CR (aceclofenac) is used to treat rheumatoid arthritis , ankylosing spondylitis , osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism.',\n",
       " 'What are side effects of Clanza CR?',\n",
       " 'Side effects of Clanza CR include:',\n",
       " 'White, oblong, film-coated tablet, engraved with \"UT\" on one side and \"CL CR\" on the other side.',\n",
       " 'Find Lowest Prices on',\n",
       " 'Aceon is a prescription medicine used to treat the symptoms of High Blood Pressure (Hypertension) and Stable Coronary Artery Disease ( CAD ). Aceon may be used alone or with other medications.',\n",
       " 'Aceon belongs to a class of drugs called ACE Inhibitors.',\n",
       " 'It is not known if Aceon is safe and effective in children.',\n",
       " 'Aceon may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Aceon include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Aceon. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'WARNING',\n",
       " 'FETAL TOXICITY',\n",
       " 'ACEON ® (perindopril erbumine) Tablets contain the tert-butylamine salt of perindopril, the ethyl ester of a non-sulfhydryl angiotensin -converting enzyme (ACE) inhibitor. Perindopril erbumine is chemically described as (2S,3DS,7DS)-1-[(S)-N-[(S)-1-Carboxy-butyl]alanyl]hexahydro-2-indolinecarboxylic acid, 1-ethyl ester, compound with tert-butylamine (1:1). Its molecular formula is C 19 H 32 N 2 O 5 C 4 H 11 N. Its structural formula is:',\n",
       " '',\n",
       " '',\n",
       " 'Perindopril erbumine is a white, crystalline powder with a molecular weight of 368.47 (free acid) or 441.61 (salt form). It is freely soluble in water (60% w/w), alcohol and chloroform .',\n",
       " 'Perindopril is the free acid form of perindopril erbumine, is a pro -drug and metabolized in vivo by hydrolysis of the ester group to form perindoprilat, the biologically active metabolite.',\n",
       " 'ACEON is available in 2 mg, 4 mg and 8 mg strengths for oral administration. In addition to perindopril erbumine, each tablet contains the following inactive ingredients: colloidal silica (hydrophobic), lactose, magnesium stearate and microcrystalline cellulose. The 4 mg and 8 mg tablets also contain iron oxide.',\n",
       " 'Find Lowest Prices on',\n",
       " 'Acephen is a prescription medicine used to treat the symptoms of Fever and Pain ( Antipyretic / Analgesic ). Acephen may be used alone or with other medications.',\n",
       " 'Acephen\\xa0belongs to a class of drugs called Analgesics, Other.',\n",
       " 'It is not known if Acephen is safe and effective in children younger than 3 months of age.',\n",
       " 'Acephen\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Acephen\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Acephen. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'Acetaminophen 650 mg',\n",
       " 'glyceryl stearate, hydrogenated vegetable oil, polyethylene glycol 100 stearate, sorbitan monooleate',\n",
       " 'Find Lowest Prices on',\n",
       " 'Acetadote is a prescription medicine used to treat the symptoms of Acetaminophen Overdose. Acetadote may be used alone or with other medications.',\n",
       " 'Acetadote belongs to a class of drugs called Antidotes, Other.',\n",
       " 'Acetadote may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Acetadote include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Acetadote. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'Acetylcysteine injection is an intravenous antidote for the treatment of acetaminophen overdose. Acetylcysteine is the nonproprietary name for the N-acetyl derivative of the naturally occurring amino acid , L- cysteine (N-acetyl-L-cysteine). The compound is a white crystalline powder, which melts in the range of 104° to 110°C and has a very slight odor. The molecular formula of the compound is C 5 H 9 NO 3 S, and its molecular weight is 163.2. Acetylcysteine has the following structural formula:',\n",
       " '',\n",
       " '',\n",
       " 'Acetadote is supplied as a sterile solution in vials containing 20% w/v (200 mg/mL) acetylcysteine. The pH of the solution ranges from 6.0 to 7.5. Acetadote contains the following inactive ingredients: sodium hydroxide (used for pH adjustment), and Sterile Water for Injection, USP.',\n",
       " 'Find Lowest Prices on',\n",
       " 'Tylenol is an over-the-counter ( OTC ) medicine used to treat reduce symptoms of pain and as a fever reducer. Tylenol may be used alone or with other medications.',\n",
       " 'Tylenol\\xa0belongs to a class of drugs called Analgesics, Other.',\n",
       " 'Tylenol\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Tylenol\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Tylenol. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " '',\n",
       " 'Acetaminophen Regular Strength',\n",
       " 'Active Ingredient (in each caplet) Acetaminophen 325 mg',\n",
       " 'Find Lowest Prices on',\n",
       " 'Tylenol -Codeine is a prescription opioid medicine used to treat the symptoms of moderate to severe pain. Tylenol-Codeine may be used alone or with other medications.',\n",
       " 'Tylenol-Codeine\\xa0is an analgesic, opioid combo.',\n",
       " 'It is not known if Tylenol-Codeine is safe and effective in children younger than 12 years of age.',\n",
       " 'Tylenol-Codeine\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Tylenol-Codeine\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Tylenol-Codeine. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " '',\n",
       " 'TYLENOL® with Codeine is supplied in tablet form for oral administration.',\n",
       " \"Acetaminophen, 4'-hydroxyacetanilide, a slightly bitter, white, odorless, crystalline powder, is a non- opiate , non-salicylate analgesic and antipyretic . It has the following structural formula:\",\n",
       " '',\n",
       " '',\n",
       " 'C 8 H 9 NO 2 M.W. 151.16',\n",
       " 'Codeine phosphate, 7,8-didehydro-4, 5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol phosphate (1:1) (salt) hemihydrate, a white crystalline powder, is a narcotic analgesic and antitussive. It has the following structural formula:',\n",
       " '',\n",
       " '',\n",
       " 'C 18 H 21 NO 3 •H 3 PO 4 •1/2 H 2 O \\xa0\\xa0M.W. 406.37',\n",
       " 'Each tablet contains:',\n",
       " 'Acetaminophen. . . . . . . . . . . . . . . . . . . 300 mg No. 3 Codeine Phosphate . . . . . . . . . . . 30 mg (Warning: May be habit forming)',\n",
       " 'Acetaminophen. . . . . . . . . . . . . . . . . . . 300 mg No. 4 Codeine Phosphate . . . . . . . . . . . 60 mg (Warning: May be habit forming)',\n",
       " 'In addition, each tablet contains the following inactive ingredients:',\n",
       " 'TYLENOL® with Codeine (acetaminophen and codeine) No. 3 contains powdered cellulose, magnesium stearate, sodium metabisulfite†, pregelatinized starch (corn), and modified starch (corn).',\n",
       " 'TYLENOL® with Codeine (acetaminophen and codeine) No. 4 contains powdered cellulose, magnesium stearate, sodium metabisulfite†, pregelatinized starch (corn), and corn starch.',\n",
       " '†See WARNINGS',\n",
       " 'Find Lowest Prices on',\n",
       " 'Acephen is a prescription medicine used to treat the symptoms of Fever and Pain ( Antipyretic / Analgesic ). Acephen may be used alone or with other medications.',\n",
       " 'Acephen\\xa0belongs to a class of drugs called Analgesics, Other.',\n",
       " 'It is not known if Acephen is safe and effective in children younger than 3 months of age.',\n",
       " 'Acephen\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Acephen\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Acephen. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'Acetaminophen 650 mg',\n",
       " 'glyceryl stearate, hydrogenated vegetable oil, polyethylene glycol 100 stearate, sorbitan monooleate',\n",
       " 'Find Lowest Prices on',\n",
       " 'Trezix is a prescription medicine used to treat the symptoms of Moderate-to-Severe Pain. Trezix may be used alone or with other medications.',\n",
       " 'Trezix belongs to a class of drugs called Analgesics, Opioid Combos.',\n",
       " 'It is not known if Trezix is safe and effective in children.',\n",
       " 'Trezix may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Trezix include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Trezix. For more information, ask your doctor or pharmacist.',\n",
       " 'Hepatotoxicity',\n",
       " 'Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen containing product.',\n",
       " 'TREZIX™ capsules are supplied in capsule form for oral administration. Each red capsule contains:',\n",
       " '',\n",
       " '',\n",
       " \"Acetaminophen (4'-hydroxyacetanilide), a slightly bitter, white, odorless, crystalline powder, is a nonopiate, non-salicylate analgesic and antipyretic . It has the following structural formula:\",\n",
       " '',\n",
       " '',\n",
       " 'Caffeine (1,3,7-trimethylxanthine), a bitter, white crystalline powder or white glistening needles, is a central nervous system stimulant. It has the following structural formula:',\n",
       " '',\n",
       " '',\n",
       " 'Dihydrocodeine Bitartrate (4,5 _-epoxy-3-methoxy-17-methylmorphinan-6 _-ol (+)-tartrate), an odorless, fine white powder is an opioid analgesic. It has the following structural formula:',\n",
       " '',\n",
       " '',\n",
       " 'In addition, each capsule contains the following inactive ingredients: crospovidone, magnesium stearate, povidone, pregelatinized starch, stearic acid. The capsule is composed of FD&C Red #40, and gelatin. Imprinting ink is composed of ammonium hydroxide, isopropyl alcohol, n-butyl alcohol, pharmaceutical glaze (modified) in SD-45, propylene glycol, simethicone, and titanium dioxide.',\n",
       " 'MIDRIN® (isometheptene mucate, dichloralphenazone and acetaminophen) Capsules',\n",
       " 'Each red capsule contains Isometheptene Mucate USP, 65 mg, Dichloralphenazone USP, 100 mg, and Acetaminophen USP, 325 mg.',\n",
       " 'Isometheptene Mucate is a white crystalline powder having a characteristic aromatic odor and bitter taste. It is an unsaturated aliphatic amine with sympathomimetic \\r\\n  properties.',\n",
       " 'Dichloralphenazone is a white, microcrystalline powder, with slight odor and tastes saline at first, becoming acrid. It is a mild sedative .',\n",
       " 'Acetaminophen, a non-salicylate, occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste.',\n",
       " 'Midrin (acetaminophen, isometheptene and dichloralphenazone)  capsules contain FD&C Yellow No. 6 as a color additive.',\n",
       " 'Find Lowest Prices on',\n",
       " 'Ofirmev is a prescription medicine used to treat the symptoms of Pain and Fever. Ofirmev may be used alone or with other medications.',\n",
       " 'Ofirmev\\xa0belongs to a class of drugs called Analgesics, Other.',\n",
       " 'It is not known if Ofirmev is safe and effective in children younger than 2 years of age for pain.',\n",
       " 'Ofirmev\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Ofirmev\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Ofirmev. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'WARNING',\n",
       " 'Risk of Medication Errors and Hepatotoxicity',\n",
       " 'Take care when prescribing, preparing, and administering OFIRMEV Injection to avoid dosing errors which could result in accidental overdose and death. In particular, be careful to ensure that:',\n",
       " 'OFIRMEV contains acetaminophen. Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed the maximum daily limits, and often involve more than one acetaminophen-containing product [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent. Its chemical name is N-acetyl-p-aminophenol. Acetaminophen has a molecular weight of 151.16. Its structural formula is:',\n",
       " '',\n",
       " '',\n",
       " 'OFIRMEV injection is a sterile, clear, colorless, non pyrogenic, isotonic formulation of acetaminophen intended for intravenous infusion. It has a pH of approximately 5.5 and an osmolality of approximately 290 mOsm/kg. Each 100 mL contains 1000 mg acetaminophen, USP, 3850 mg mannitol, USP, 25 mg cysteine hydrochloride, monohydrate, USP, and 10.4 mg dibasic sodium phosphate, USP. pH is adjusted with hydrochloric acid and/or sodium hydroxide.',\n",
       " 'Acetazolamide Injection is a prescription medicine used to treat the symptoms of Glaucoma, Acute Altitude Sickness , Congestive Heart Failure , Seizures, Drug-induced Edema, and Epilepsy. Acetazolamide Injection may be used alone or with other medications.',\n",
       " 'Acetazolamide Injection\\xa0belongs to a class of drugs called Anticonvulsants, Other; Antiglaucoma, Carbonic Anhydrase Inhibitors.',\n",
       " 'It is not known if Acetazolamide Injection is safe and effective in children younger than 12 years of age.',\n",
       " 'Acetazolamide Injection\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Acetazolamide Injection\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Acetazolamide Injection. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'Acetazolamide, an inhibitor of the enzyme carbonic anhydrase, is a white to faintly yellowish white crystalline, odorless powder, weakly acidic, very slightly soluble in water and slightly soluble in alcohol. The chemical name for acetazolamide is N-(5-Sulfamoyl-1,3,4-thiadiazol-2yl)-acetamide and has the following structural formula:',\n",
       " '',\n",
       " '',\n",
       " 'M.W. 222.24\\xa0 \\xa0 \\xa0 \\xa0C 4 H 6 N 4 O 3 S 2',\n",
       " 'Acetazolamide is available for intravenous use, and is supplied as a sterile powder requiring reconstitution. Each vial contains acetazolamide sodium equivalent to 500 mg of acetazolamide. The bulk solution is adjusted to pH 9.6 using sodium hydroxide and, if necessary, hydrochloric acid prior to lyophilization .',\n",
       " 'Find Lowest Prices on',\n",
       " 'Acetazolamide is a prescription medicine used to treat the symptoms of Epilepsy, seizures, drug-induced Edema, acute altitude sickness, and Glaucoma. Acetazolamide may be used alone or with other medications.',\n",
       " 'Acetazolamide belongs to a class of drugs called Anticonvulsants, Other; Antiglaucoma, Carbonic Anhydrase Inhibitors.',\n",
       " 'It is not known if Acetazolamide is safe and effective in children young than 12 years of age.',\n",
       " 'Acetazolamide may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Acetazolamide include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Acetazolamide. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'Acetazolamide, an inhibitor of the enzyme carbonic anhydrase, is a white to faintly yellowish whitecrystalline, odorless powder, weakly acidic, very slightly soluble in water and slightly soluble in alcohol. The chemical name for acetaZOLAMIDE is N-(5-Sulfamoyl-1,3,4-thiadiazol-2yl)-acetamide and has the following structural formula:',\n",
       " '',\n",
       " '',\n",
       " 'Each tablet, for oral administration, contains 250 mg of acetaZOLAMIDE. In addition, each tablet contains the following inactive ingredients: lactose monohydrate, sodium starch glycolate, corn starch, and calcium stearate.',\n",
       " 'Diamox Tablets and Injection is a prescription medicine used to treat the symptoms of Glaucoma , Acute Altitude Sickness , Congestive Heart Failure , Seizure , Epilepsy and Drug-Induced Edema. Diamox Tablets and Injection may be used alone or with other medications.',\n",
       " 'Diamox Tablets and Injection\\xa0belongs to a class of drugs called Anticonvulsants, Other; Antiglaucoma, Carbonic Anhydrase Inhibitors.',\n",
       " 'It is not known if Diamox Tablets and Injection is safe and effective in children younger than 12 years of age.',\n",
       " 'Diamox Tablets and Injection\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Diamox Tablets and Injection\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Diamox Tablets and Injection. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'DIAMOX, an inhibitor of the enzyme carbonic anhydrase is a white to faintly yellowish white crystalline, odorless powder, weakly acidic, very slightly soluble in water and slightly soluble in alcohol. The chemical name for DIAMOX is N -(5-Sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide and has the following chemical structure:',\n",
       " '',\n",
       " '',\n",
       " 'DIAMOX is available as oral tablets containing 125 mg and 250 mg of acetazolamide respectively and the following inactive ingredients: Corn Starch, Dibasic Calcium Phosphate, Magnesium Stearate, Povidone, and Sodium Starch Glycolate.',\n",
       " 'DIAMOX is also available for intravenous use, and is supplied as a sterile powder requiring reconstitution. Each vial contains an amount of acetazolamide sodium equivalent to 500 mg of acetazolamide. The bulk solution is adjusted to pH 9.2 using sodium hydroxide and, if necessary, hydrochloric acid prior to lyophilization.',\n",
       " 'Diamox Sequels is a prescription medicine used to treat the symptoms of Glaucoma, Acute Altitude Sickness, Congestive Heart Failure , Seizure , Epilepsy and Drug-Induced Edema. Diamox Sequels may be used alone or with other medications.',\n",
       " 'Diamox Sequels\\xa0belongs to a class of drugs called Anticonvulsants, Other; Antiglaucoma, Carbonic Anhydrase Inhibitors.',\n",
       " 'It is not known if Diamox Sequels is safe and effective in children younger than 12 years of age.',\n",
       " 'Diamox Sequels\\xa0may cause serious side effects including:',\n",
       " 'Get medical help right away, if you have any of the symptoms listed above.',\n",
       " 'The most common side effects of Diamox Sequels\\xa0include:',\n",
       " 'Tell the doctor if you have any side effect that bothers you or that does not go away.',\n",
       " 'These are not all the possible side effects of Diamox Sequels. For more information, ask your doctor or pharmacist.',\n",
       " 'Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.',\n",
       " 'DIAMOX SEQUELS (Acetazolamide Extended-Release Capsules) are an inhibitor of the enzyme carbonic anhydrase.',\n",
       " 'DIAMOX is a white to faintly yellowish white crystalline, odorless powder, weakly acidic, very slightly soluble in water and slightly soluble in alcohol. The chemical name for DIAMOX is N-(5-Sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide and has the following chemical structure:',\n",
       " '',\n",
       " '',\n",
       " 'DIAMOX SEQUELS (acetazolamide xr) are extended-release capsules, for oral administration, each containing 500 mg of acetazolamide and the following inactive ingredients:',\n",
       " 'Microcrystalline cellulose, sodium lauryl sulfate and talc.',\n",
       " 'The ingredients in the capsule shell are D&C red no. 28, D&C yellow no. 10, FD&C red no. 40, gelatin and titanium dioxide.',\n",
       " 'The ingredients in the imprinting ink are D&C yellow no. 10 aluminum lake, FD&C blue no. 1 aluminum lake, FD&C blue no. 2 aluminum lake, FD&C red no. 40 aluminum lake, pharmaceutical glaze, propylene glycol and synthetic iron oxide.',\n",
       " ...]"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "description"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "29855c58",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "12102"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(description)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "346b4cd8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['When oral therapy is not feasible, and the strength, dosage form and route \\r\\n  of administration of the drug reasonably lend the preparation to the treatment \\r\\n  of the condition, A-Methapred (methylprednisolone sodium succinate)  sterile powder is indicated for intravenous or \\r\\n  intramuscular use in the following conditions:',\n",
       " 'KIVEXA tablets are a combination of two nucleoside analogues (abacavir and lamivudine). KIVEXA is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and adolescents from 12 years of age.',\n",
       " 'KIVEXA is supplied as film-coated tablets each containing 600 mg of abacavir as abacavir sulfate and 300 mg lamivudine.',\n",
       " 'Abacavir sulfate is a white to off-white crystalline powder with a solubility of approximately 77 mg/mL in water at 25°C.',\n",
       " 'Lamivudine is a white to off-white crystalline solid which is highly soluble in water.',\n",
       " 'For the full list of excipients, see Section DESCRIPTION .',\n",
       " 'Therapy should be initiated by a physician experienced in the management of HIV infection.',\n",
       " 'KIVEXA tablets should not be administered to adults or adolescents who weigh less than 40 kg because it is a fixed-dose tablet that cannot be dose reduced.',\n",
       " 'KIVEXA tablets can be taken with or without food.',\n",
       " 'KIVEXA tablets should not be prescribed for patients requiring dosage adjustments, such as those with creatinine clearance < 50 mL/min. Separate preparations of abacavir (ZIAGEN) or lamivudine (3TC) should be administered in cases where discontinuation or dose adjustment is indicated. In these cases the physician should refer to the individual product information for these medicinal products.',\n",
       " 'The recommended dose of KIVEXA tablets in adults and adolescents is one tablet once daily.',\n",
       " 'The pharmacokinetics of abacavir and lamivudine have not been studied in patients over 65 years of age. When treating elderly patients, consideration needs to be given to the greater frequency of decreased hepatic, renal and cardiac function, concomitant medicinal products or disease.',\n",
       " 'KIVEXA tablets are not recommended for treatment of children less than 12 years of age as the necessary dose adjustment cannot be made. Physicians should refer to the individual product information for lamivudine and abacavir.',\n",
       " 'Renal impairment Whilst no dosage adjustment of abacavir is necessary in patients with renal impairment, a dose reduction of lamivudine is required due to decreased clearance. Therefore, KIVEXA tablets are not recommended for use in patients with a creatinine clearance < 50 mL/min (see Section CLINICAL PHARMACOLOGY - Special populations ).',\n",
       " 'A dose reduction of abacavir may be required for patients with mild hepatic impairment (Child-Pugh grade A). As dose reduction is not possible with KIVEXA tablets, the separate preparations of abacavir and lamivudine should be used when this is judged to be necessary. KIVEXA is not recommended in patients with moderate and severe hepatic impairment (Child-Pugh grade B or C) (see Section CLINICAL PHARMACOLOGY - Special populations ).',\n",
       " 'Orange, film-coated, modified capsule shaped tablets, debossed with GS FC2 on one side.',\n",
       " 'Incompatibilities were either not assessed or not identified as part of the registration of this medicine.',\n",
       " 'In Australia, information on the shelf life can be found on the public summary of the ARTG. The expiry date can be found on the packaging.',\n",
       " 'Store below 30°C in a dry place.',\n",
       " 'KIVEXA tablets are supplied in opaque white, polyvinyl chloride ( PVC )/polyvinylidene chloride (PVdC) blister packs or in opaque white, PVC/PVdC child-resistant* blister packs. Each pack type contains 30 tablets.',\n",
       " '*complies with European Standard EN 14375:2003 Child-resistant Non-reclosable Packaging for Pharmaceutical Products - Requirements And Testing.',\n",
       " 'Not all blister types may be distributed in Australia.',\n",
       " 'In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.',\n",
       " 'Manufactured by: ViiV Healthcare Pty Ltd Level 4, 436 Johnston Street, Abbotsford, Victoria, 3067 Australia. Revised: April 2018',\n",
       " 'Ziagen coupons',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'ZIAGEN tablets and oral solution, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (HIV-1) infection.',\n",
       " 'Screen for the HLA-B*5701 allele prior to initiating therapy with ZIAGEN [see BOX WARNING , WARNINGS AND PRECAUTIONS ].',\n",
       " 'The recommended dosage of ZIAGEN for adults is 600 mg daily, administered orally as either 300 mg twice daily or 600 mg once daily, in combination with other antiretroviral agents.',\n",
       " 'The recommended dosage of ZIAGEN oral solution in HIV-1–infected pediatric patients aged 3 months and older is 8 mg per kg orally twice daily or 16 mg per kg orally once daily (up to a maximum of 600 mg daily) in combination with other antiretroviral agents.',\n",
       " 'ZIAGEN is also available as a scored tablet for HIV-1–infected pediatric patients weighing greater than or equal to 14 kg for whom a solid dosage form is appropriate. Before prescribing ZIAGEN tablets, children should be assessed for the ability to swallow tablets. If a child is unable to reliably swallow ZIAGEN tablets, the oral solution formulation should be prescribed. The recommended oral dosage of ZIAGEN tablets for HIV-1–infected pediatric patients is presented in Table 1.',\n",
       " 'Table 1. Dosing Recommendations for ZIAGEN Scored Tablets in Pediatric Patients',\n",
       " '',\n",
       " 'The recommended dose of ZIAGEN in patients with mild hepatic impairment (Child-Pugh Class A) is 200 mg twice daily. To enable dose reduction, ZIAGEN oral solution (10 mL twice daily) should be used for the treatment of these patients. The safety, efficacy, and pharmacokinetic properties of abacavir have not been established in patients with moderate to severe hepatic impairment; therefore, ZIAGEN is contraindicated in these patients.',\n",
       " 'ZIAGEN tablets contain 300 mg of abacavir as abacavir sulfate. The tablets are yellow, biconvex, scored, capsule-shaped, film-coated, and imprinted with “GX 623” on both sides.',\n",
       " 'ZIAGEN oral solution contains 20 mg per mL of abacavir as abacavir sulfate. The solution is a clear to opalescent, yellowish, strawberry-banana-flavored liquid, which may turn brown over time.',\n",
       " 'ZIAGEN tablets , containing abacavir sulfate equivalent to 300 mg abacavir are yellow, biconvex, scored, capsule-shaped, film-coated, and imprinted with “GX 623” on both sides. They are packaged as follows:',\n",
       " 'Bottles of 60 tablets ( NDC 49702-221-18).',\n",
       " 'Store at controlled room temperature of 20° to 25°C (68° to 77°F) (see USP).',\n",
       " 'ZIAGEN oral solution is a clear to opalescent, yellowish, strawberry-banana-flavored liquid, which may turn brown over time. Each mL of the solution contains abacavir sulfate equivalent to 20 mg of abacavir. It is packaged in plastic bottles as follows:',\n",
       " 'Bottles of 240 mL ( NDC 49702-222-48) with child-resistant closure. This product does not require reconstitution.',\n",
       " 'Store at controlled room temperature of 20° to 25°C (68° to 77°F) (see USP). DO NOT FREEZE. May be refrigerated.',\n",
       " 'Manufactured by: GlaxoSmithKline Research Triangle Park, NC 27709. Revised: Nov 2020',\n",
       " 'EPZICOM, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.',\n",
       " 'Screen for the HLA-B*5701 allele prior to initiating therapy with EPZICOM [see BOX WARNING , WARNINGS AND PRECAUTIONS ].',\n",
       " 'The recommended dosage of EPZICOM for adults is one tablet taken orally once daily, in combination with other antiretroviral agents, with or without food.',\n",
       " 'The recommended oral dose of EPZICOM for pediatric patients weighing at least 25 kg is one tablet daily in combination with other antiretroviral agents [see Clinical Studies ]. Before prescribing EPZICOM tablets, pediatric patients should be assessed for the ability to swallow tablets.',\n",
       " 'Because EPZICOM is a fixed-dose tablet and cannot be dose adjusted, EPZICOM is not recommended for:',\n",
       " 'Use of EPIVIR (lamivudine) oral solution or tablets and ZIAGEN (abacavir) oral solution may be considered.',\n",
       " 'EPZICOM tablets contain 600 mg of abacavir as abacavir sulfate and 300 mg of lamivudine. The tablets are modified capsule-shaped, orange, film-coated, and debossed with “GS FC2” on one side with no markings on the reverse side.',\n",
       " 'EPZICOM is available as tablets. Each tablet contains 600 mg of abacavir as abacavir sulfate and 300 mg of lamivudine. The tablets are orange, film-coated, modified capsule-shaped, and debossed with GS FC2 on one side with no markings on the reverse side. They are packaged as follows:',\n",
       " 'Bottles of 30 tablets ( NDC 49702-206-13).',\n",
       " 'Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) (see USP Controlled Room Temperature).',\n",
       " 'Manufactured for: ViiV Healthcare, Research Triangle Park, NC 27709. Revised: Dec 2021',\n",
       " 'TRIZIVIR is indicated in combination with other antiretrovirals or alone for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.',\n",
       " 'Screen for the HLA-B*5701 allele prior to initiating therapy with TRIZIVIR [see BOXED WARNING , WARNINGS AND PRECAUTIONS ].',\n",
       " 'The recommended dosage of TRIZIVIR is one tablet taken orally twice daily with or without food.',\n",
       " 'Because TRIZIVIR is a fixed-dose tablet and cannot be dose adjusted, TRIZIVIR is not recommended for:',\n",
       " 'TRIZIVIR tablets contain 300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine. The tablets are blue-green, capsule-shaped, film-coated, and imprinted with “GX LL1” on one side with no markings on the reverse side.',\n",
       " 'TRIZIVIR is available as tablets. Each tablet contains 300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine. The tablets are blue-green capsule-shaped, film-coated, and imprinted with GX LL1 on one side with no markings on the reverse side. They are packaged as follows:',\n",
       " 'Bottles of 60 tablets ( NDC 49702-217-18).',\n",
       " 'Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) (see USP Controlled Room Temperature ).',\n",
       " 'Manufactured for: ViiV Healthcare, Research Triangle Park, NC 27709. Revised: Feb 2021',\n",
       " 'TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 10 kg.',\n",
       " 'Screen for the HLA-B*5701 allele prior to initiating therapy with TRIUMEQ or TRIUMEQ PD [see BOX WARNING , WARNINGS AND PRECAUTIONS ].',\n",
       " 'Prior to or when initiating TRIUMEQ or TRIUMEQ PD, test patients for HBV infection [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Pregnancy testing is recommended before initiation of TRIUMEQ in adolescents and adults of childbearing potential [see WARNINGS AND PRECAUTIONS , Use In Specific Populations ].',\n",
       " 'TRIUMEQ is available in two dosage forms. Do not interchange TRIUMEQ tablets and TRIUMEQ PD tablets for oral suspension on a milligram-per-milligram basis due to differing pharmacokinetic profiles for the dolutegravir component [see WARNINGS AND PRECAUTIONS , CLINICAL PHARMACOLOGY ].',\n",
       " 'TRIUMEQ is a fixed-dose combination product containing 600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine. The recommended dosage regimen of TRIUMEQ in adults is one tablet once daily orally with or without food. Do not use TRIUMEQ PD in adults.',\n",
       " 'The dosage and dosage form recommended for pediatric patients varies by weight as shown in Table 1 below.',\n",
       " 'Table 1. Recommended Dosage of TRIUMEQ Tablets and TRIUMEQ PD Tablets for Oral Suspension in Pediatric Patients',\n",
       " '',\n",
       " 'Administer TRIUMEQ PD tablets for oral suspension with or without food. Instruct patients (or instruct caregivers) to fully disperse the tablets for oral suspension in 20 mL of drinking water in the supplied cup; swirl the suspension so that no lumps remain. After full dispersion, administer the oral suspension within 30 minutes of mixing [see INSTRUCTIONS FOR USE ]. Do not chew, cut, or crush the tablets.',\n",
       " 'Administer TRIUMEQ tablet with or without food. Do not chew, cut, or crush the tablet.',\n",
       " 'The dolutegravir dose in TRIUMEQ (50 mg) and TRIUMEQ PD (5 mg) is insufficient when coadministered with medications listed in Table 2 that may decrease dolutegravir concentrations; the following dolutegravir dosage regimen is recommended.',\n",
       " 'Table 2. Dosing Recommendations for TRIUMEQ and TRIUMEQ PD with Coadministered Medications',\n",
       " '',\n",
       " 'Because TRIUMEQ and TRIUMEQ PD are fixed-dose tablets and cannot be dose adjusted, TRIUMEQ and TRIUMEQ PD are not recommended in:',\n",
       " 'TRIUMEQ tablets are purple, biconvex, oval, and debossed with “572 Tri” on one side. Each film-coated tablet contains 600 mg of abacavir (as abacavir sulfate), 50 mg of dolutegravir (as dolutegravir sodium), and 300 mg of lamivudine [see DESCRIPTION ].',\n",
       " 'TRIUMEQ PD tablets for oral suspension are yellow, capsule-shaped, strawberry cream flavored, biconvex, film-coated tablets debossed with “SV WTU” on one side. Each film-coated tablet contains 60 mg of abacavir (as abacavir sulfate), 5 mg of dolutegravir (as dolutegravir sodium), and 30 mg of lamivudine [see DESCRIPTION ].',\n",
       " 'TRIUMEQ tablets are purple, oval, film-coated, biconvex tablets debossed with “572 Tri” on one side and contain 600 mg of abacavir (as abacavir sulfate), 50 mg of dolutegravir (as dolutegravir sodium), and 300 mg lamivudine.',\n",
       " 'Bottle of 30 tablets with desiccant and child-resistant closure. NDC 49702-231-13. Store and dispense in the original package, protect from moisture, and keep the bottle tightly closed. Do not remove desiccant.',\n",
       " 'Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F to 86°F). [See USP Controlled Room Temperature].',\n",
       " 'TRIUMEQ PD tablets for oral suspension , are yellow, capsule-shaped, strawberry cream flavored, film-coated, biconvex tablets debossed with “SV WTU” on one side and contain 60 mg of abacavir (as abacavir sulfate), 5 mg of dolutegravir (as dolutegravir sodium), and 30 mg lamivudine.',\n",
       " 'Bottle of 90 tablets ( NDC 49702-272-59) with desiccant and child-resistant closure. Each bottle is packaged as a kit ( NDC 49702-258-37) with one 40-mL dosing cup.',\n",
       " 'Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F to 86°F). [See USP Controlled Room Temperature]. Store and dispense in the original bottle, protect from moisture, and keep the bottle tightly closed. Do not remove desiccant.',\n",
       " 'Manufactured by: GlaxoSmithKline Research Triangle Park, NC 27709. Revised Mar 2022.',\n",
       " 'TYMLOS is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, TYMLOS reduces the risk of vertebral fractures and nonvertebral fractures [see Clinical Studies ].',\n",
       " 'Because of the unknown relevance of the rodent osteosarcoma findings to humans, cumulative use of TYMLOS and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patientâ€™s lifetime is not recommended [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Injection : 3120 mcg/1.56 mL (2000 mcg/mL) in a single-patient-use prefilled pen. The prefilled pen delivers 30 doses of TYMLOS, each containing 80 mcg of abaloparatide in 40 mcL of a sterile, clear, colorless solution.',\n",
       " 'TYMLOS injection is supplied as a pre-assembled single-patient-use disposable pen ( NDC 70539-001-01) packaged in a cardboard carton ( NDC 70539-001-02) with the Instructions for Use and Medication Guide . Each disposable pen embodies a glass cartridge that contains 3120 mcg of abaloparatide in 1.56 mL (2000 mcg/mL) of sterilized, clear, colorless fluid. Each pen provides a 30-day supply for once daily injection of 80 mcg abaloparatide in 40 mcL.',\n",
       " 'Sterile needles are not included.',\n",
       " 'Manufactured in Germany for: Radius Health, Inc. 22 Boston Wharf Road, 7th Floor Boston, MA 02210. Revised: Sep 2021',\n",
       " 'XEGLYZE is indicated for the topical treatment of head lice infestation in patients 6 months of age and older.',\n",
       " 'XEGLYZE should be used in the context of an overall lice management program:',\n",
       " 'Use a fine-tooth comb or special nit comb to remove dead lice and nits',\n",
       " 'For topical use only. XEGLYZE is not for oral, ophthalmic, or intravaginal use. Treatment with XEGLYZE involves a single application.',\n",
       " 'Shake well before use. Apply XEGLYZE to dry hair in an amount (up to the full content of one bottle) sufficient to thoroughly coat the hair and scalp. Massage XEGLYZE into the scalp and throughout the hair. Avoid contact with eyes. Leave on the hair and scalp for 10 minutes and then rinse off with warm water. Wash hands after application. Hair may be shampooed any time after the treatment.',\n",
       " 'Discard any unused product. Do not flush contents down sink or toilet.',\n",
       " 'Lotion, 0.74% [weight by weight], a viscous white to off-white oil in water emulsion, containing abametapir.',\n",
       " 'XEGLYZE is a white to off-white oil in water emulsion containing 0.74% [weight by weight] abametapir and supplied in a polyvinyl chloride (PVC) safety-coated single-use round amber glass bottle affixed with a polypropylene child resistant cap ( NDC # 43598-921-11) featuring a tri-foil inner liner. The container is filled to a nominal 200 g (approximately 7 oz. or 210 mL) of the lotion.',\n",
       " 'Store upright at room temperature, 20°C to 25°C (68°F to 77°F), with allowable excursions between 15°C and 30°C (59°F and 86°F).',\n",
       " 'Do not refrigerate or freeze.',\n",
       " 'Manufactured by Groupe Parima, Inc., for Dr. Reddy’s Laboratories, S.A. Elisabethenanlage 11, 4051 Basel, Switzerland. Revised: Jun 2020',\n",
       " 'Plenaxis™  is indicated for the palliative treatment of men with advanced\\r\\n  symptomatic prostate cancer, in whom LHRH agonist therapy is not appropriate\\r\\n  and who refuse surgical castration, and have one or more of the following: (1)\\r\\n  risk of neurological compromise due to metastases, (2) ureteral or bladder outlet obstruction due to local encroachment or metastatic disease, or (3) severe bone\\r\\n  pain from skeletal metastases persisting on narcotic analgesia.',\n",
       " \"For safety reasons, Plenaxis™  is approved with marketing restrictions. Only physicians who attest to the following qualifications and accept the following\\r\\n  responsibilities, and on that basis enroll in PRAECIS PHARMACEUTICALS INCORPORATED's\\r\\n  Plenaxis™  PLUS Program should prescribe Plenaxis™ . PRAECIS PHARMACEUTICALS\\r\\n  INCORPORATED and its agents will provide Plenaxis™  to physicians enrolled\\r\\n  in the Plenaxis™  PLUS Program.\",\n",
       " 'To enroll, physicians must attest that they are able and willing to:',\n",
       " 'To enroll in the Plenaxis™  Prescribing Program call 1-866-PLENAXIS (1-866-753-6294)\\r\\n  or visit www.plenaxisplus.com.',\n",
       " 'Dose: The recommended dose of Plenaxis™  is 100 mg administered\\r\\n  intramuscularly to the buttock on Day 1, 15, 29 (week 4) and every 4 weeks thereafter.\\r\\n  Treatment failure can be detected by measuring serum testosterone concentrations\\r\\n  just prior to Plenaxis™  administration, beginning on Day 29 and every\\r\\n  8 weeks thereafter.',\n",
       " 'Read the instructions completely before performing reconstitution.',\n",
       " 'The sterile powder for suspension is to be reconstituted in accordance with\\r\\n  the following directions:',\n",
       " 'Use aseptic technique throughout.',\n",
       " 'Prior to reconstitution, gently shake the vial of Plenaxis™  (abarelix\\r\\n  for injectable suspension). Hold the vial at an angle (45 degrees) and tap lightly\\r\\n  on table to break up any caking.',\n",
       " 'Withdraw 2.2 mL of 0.9% Sodium Chloride Inj., USP using the enclosed 18 G x\\r\\n  1 ½” needle and a 3 cc syringe. Discard the remaining diluent.',\n",
       " 'Picture 1',\n",
       " 'Keeping the vial upright , insert the needle all the way into the vial\\r\\n  and inject the diluent quickly .',\n",
       " 'Before withdrawing the needle, remove 2.2 mL of air. Shake immediately.',\n",
       " 'Picture 2',\n",
       " 'Shake for approximately 15 seconds. Allow the vial to stand for approximately\\r\\n  2 minutes. Tap the vial to reduce foaming and swirl the vial occasionally.',\n",
       " 'Again, shake for approximately 15 seconds. Allow the vial to stand for\\r\\n  approximately 2 minutes. Tap the vial to reduce foaming and swirl the\\r\\n  vial occasionally.',\n",
       " 'Picture 3',\n",
       " 'Do not reinject the air into the vial. Locate a second injection spot on the stopper, and then insert the 18 G needle. Invert the vial and draw up\\r\\n  some of the suspension into the syringe and without removing the needle from\\r\\n  the vial reinject it at any remaining solids in the vial. Repeat the process\\r\\n  until all solids are dispersed.',\n",
       " 'Swirl the vial before withdrawal and withdraw the entire contents (at least\\r\\n  2 mL) by positioning the needle at a 45 degree angle as shown in the picture.',\n",
       " 'Picture 4',\n",
       " 'Pull the plunger back to recover the residual suspension in the 18 G x1½”\\r\\n  needle.',\n",
       " 'Exchange the 18 G x 1 ½” needle with the enclosed 22 G x 1½”\\r\\n  Safety Glide™ injection needle.',\n",
       " 'Picture 5',\n",
       " 'Insert the needle at the desired injection site, pull the plunger back to check\\r\\n  for back-flow of blood. If blood flows into the syringe, do not inject at this\\r\\n  site. Select another injection site.',\n",
       " 'Deliver the entire reconstituted suspension intramuscularly immediately.',\n",
       " 'Picture 6',\n",
       " 'Observe the patient after injection for 30 minutes for any sign of an allergic-type\\r\\n  response.',\n",
       " 'Plenaxis™  does not contain a preservative and should be administered\\r\\n  within 1 hour following reconstitution.',\n",
       " 'Store at 25°C (77°F), excursions permitted to 15-30°C (59-86°F),\\r\\n  USP Controlled Room Temperature.',\n",
       " \"The physician must attest to meeting the qualifications and accepting the responsibilities\\r\\n  in the DOSAGE AND ADMINISTRATION section of this package insert by submitting\\r\\n  the Physician's Attestation form to PRAECIS PHARMACEUTICALS INCORPORATED to\\r\\n  be enrolled in the Plenaxis™  PLUS Program. PRAECIS PHARMACEUTICALS INCORPORATED\\r\\n  and its agents will only provide Plenaxis™  to physicians enrolled in the\\r\\n  Plenaxis™  Prescribing Program. Plenaxis™  vials are not to be resold\\r\\n  or redistributed.\",\n",
       " 'Plenaxis™  (abarelix for injectable suspension) is supplied as a single-dose,\\r\\n  preservativefree vial containing 113 mg of abarelix (anhydrous free base peptide)\\r\\n  as an abarelix CMC complex, a sterile powder (NDC 68158-149-01) which, when\\r\\n  reconstituted with 2.2 mL of 0.9% sodium chloride solution, yields a 2 mL delivered\\r\\n  dose of 100 mg (50 mg/mL). Each single use dispensing pack also contains: a\\r\\n  single-use 10 mL diluent vial of 0.9% Sodium Chloride Injection, USP, one 3\\r\\n  cc syringe with an 18 gauge 1½ inch needle and one 22 gauge 1½ inch Safety Glide™\\r\\n  injection needle.',\n",
       " 'Praecis Pharmaceuticals Incorporated, 830 Winter Street, Waltham, MA 02451-1420.\\r\\n  02-01',\n",
       " 'ORENCIA® is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis.',\n",
       " 'ORENCIA is indicated for the treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis.',\n",
       " 'ORENCIA is indicated for the treatment of adult patients with active psoriatic arthritis (PsA).',\n",
       " 'ORENCIA is indicated for the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele -mismatched unrelated- donor .',\n",
       " 'The concomitant use of ORENCIA with other potent immunosuppressants [e.g., biologic disease-modifying antirheumatic drugs (bDMARDS), Janus kinase (JAK) inhibitors] is not recommended.',\n",
       " 'ReoPro ® (abciximab) is indicated as an adjunct to percutaneous coronary intervention for the\\r\\nprevention of cardiac ischemic complications:',\n",
       " 'ReoPro ® use in patients not undergoing percutaneous coronary intervention has not been studied.',\n",
       " 'ReoPro ® is intended for use with acetylsalicylic acid and heparin and has been studied only in\\r\\nthat setting.',\n",
       " 'See WARNINGS AND PRECAUTIONS , Special Populations, Geriatrics',\n",
       " 'See WARNINGS AND PRECAUTIONS , Special Populations, Pediatrics',\n",
       " 'ABECMA is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody .',\n",
       " 'For autologous use only. For intravenous use only.',\n",
       " 'ABECMA is provided as a single dose for infusion containing a suspension of chimeric antigen receptor (CAR)-positive T cells in one or more infusion bags. The recommended dose range is 300 to 460 x 10 6 CAR-positive T cells.',\n",
       " 'See the accompanying Release for Infusion Certificate (RFI Certificate) for additional information pertaining to dose [see HOW SUPPLIED / Storage And Handling ].',\n",
       " 'ABECMA is for autologous use only. The patientâ€™s identity must match the patient identifiers on the ABECMA cassette (s) and infusion bag(s). Do not infuse ABECMA if the information on the patient-specific label(s) does not match the intended patient.',\n",
       " 'Confirm the availability of ABECMA prior to starting the lymphodepleting chemotherapy regimen.',\n",
       " 'Pretreatment',\n",
       " 'Administer the lymphodepleting chemotherapy regimen: cyclophosphamide 300 mg/m² intravenously (IV) and fludarabine 30 mg/m² IV for 3 days.',\n",
       " 'See the prescribing information of cyclophosphamide and fludarabine for information on dose adjustment in renal impairment.',\n",
       " 'Administer ABECMA 2 days after completion of lymphodepleting chemotherapy.',\n",
       " 'Delay the infusion of ABECMA up to 7 days if a patient has any of the following conditions:',\n",
       " 'Premedication',\n",
       " 'Administer acetaminophen (650 mg orally) and diphenhydramine (12.5 mg IV or 25 to 50 mg orally, or another H1-antihistamine) approximately 30 to 60 minutes before infusion of ABECMA.',\n",
       " 'Avoid prophylactic use of dexamethasone or other systemic corticosteroids, as the use may interfere with the activity of ABECMA.',\n",
       " 'Figure 1: ABECMA Bag Label(s)',\n",
       " '',\n",
       " 'ABECMA contains human blood cells that are genetically modified with replication-incompetent, self-inactivating lentiviral vector. Follow universal precautions and local biosafety guidelines for handling and disposal of ABECMA to avoid potential transmission of infectious diseases.',\n",
       " 'Identify CRS based on clinical presentation [see WARNINGS AND PRECAUTIONS ]. Evaluate for and treat other causes of fever, hypoxia , and hypotension.',\n",
       " 'If CRS is suspected, manage according to the recommendations in Table 1.',\n",
       " 'Patients who experience CRS should be closely monitored for cardiac and organ function until resolution of symptoms. Consider antiseizure prophylaxis with levetiracetam in patients who experience CRS.',\n",
       " 'Patients who experience Grade 2 or higher CRS (e.g., hypotension not responsive to fluids, or hypoxia requiring supplemental oxygenation ) should be monitored with continuous cardiac telemetry and pulse oximetry.',\n",
       " 'For severe or life-threatening CRS, consider intensive care unit level monitoring and supportive therapy.',\n",
       " 'For CRS refractory to first line interventions such as tocilizumab or tocilizumab and corticosteroids, consider alternate treatment options (i.e., higher corticosteroid dose, alternative anti-cytokine agents, anti-T cell therapies). Refractory CRS is characterized by fevers, end-organ toxicity (e.g., hypoxia, hypotension) not improving within 12 hours of first line interventions or development of hemophagocytic lymphohistiocytosis / macrophage activation syndrome (HLH/MAS).',\n",
       " 'If concurrent neurologic toxicity is suspected during CRS, administer:',\n",
       " 'Table 1: CRS Grading and Management Guidance',\n",
       " '',\n",
       " 'Monitor patients for signs and symptoms of neurologic toxicities (Table 2). Rule out other causes of neurologic signs or symptoms. Provide intensive care supportive therapy for severe or life-threatening neurologic toxicities. If neurologic toxicity is suspected, manage according to the recommendations in Table 2.',\n",
       " 'If concurrent CRS is suspected during the neurologic toxicity event, administer:',\n",
       " 'Table 2: Neurologic Toxicity Grading and Management Guidance',\n",
       " '',\n",
       " 'ABECMA is a cell suspension for intravenous infusion.',\n",
       " 'A single dose of ABECMA contains a cell suspension of 300 to 460 x 10 6 chimeric antigen receptor (CAR)-positive T cells in one or more infusion bags [see HOW SUPPLIED / Storage And Handling ].',\n",
       " 'ABECMA is supplied in one or more infusion bag(s) (see below) containing a frozen suspension of genetically modified autologous T cells in 5% DMSO.',\n",
       " 'Each infusion bag of ABECMA is individually packed in a metal cassette. ABECMA is stored in the vapor phase of liquid nitrogen and supplied in a liquid nitrogen dry vapor shipper. An RFI Certificate is affixed inside the shipper.',\n",
       " 'Match the identity of the patient with the patient identifiers on the cassette(s) and infusion bag(s) upon receipt.',\n",
       " 'Store ABECMA frozen in the vapor phase of liquid nitrogen (less than or equal to minus 130°C).',\n",
       " 'Thaw ABECMA prior to infusion [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'Manufactured by: Celgene Corporation, a Bristol-Myers Squibb Company, 556 Morris Avenue, Summit, NJ 07901. Marketed by: Celgene Corporation, a Bristol-Myers Squibb Company (Summit, NJ 07901), and bluebird bio, Inc. (Cambridge, MA 02142). Revised: Mar /2021',\n",
       " 'Abelcet coupons',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'ABELCET ® is indicated for the treatment of invasive fungal infections in patients who are refractory to\\r\\nor intolerant of conventional amphotericin B therapy. This is based on open-label treatment of patients\\r\\njudged by their physicians to be intolerant to or failing conventional amphotericin B therapy (See Description Of Clinical Studies ).',\n",
       " 'The recommended daily dosage for adults and children is 5 mg/kg given as a single infusion.\\r\\nABELCET ® should be administered by intravenous infusion at a rate of 2.5 mg/kg/h. If the infusion time\\r\\nexceeds 2 hours, mix the contents by shaking the infusion bag every 2 hours.',\n",
       " 'Renal toxicity of ABELCET ® , as measured by serum creatinine levels, has been shown to be dose\\r\\ndependent. Decisions about dose adjustments should be made only after taking into account the overall\\r\\nclinical condition of the patient.',\n",
       " 'Shake the vial gently until there is no evidence of any yellow\\r\\nsediment at the bottom. Withdraw the appropriate dose of ABELCET ® from the required number of\\r\\nvials into one or more sterile syringes using an 18-gauge needle. Remove the needle from each syringe\\r\\nfilled with ABELCET ® and replace with the 5-micron filter needle supplied with each vial. Each filter\\r\\nneedle may be used to filter the contents of up to four 100 mg vials. Insert the filter needle of the\\r\\nsyringe into an IV bag containing 5% Dextrose Injection USP, and empty the contents of the syringe into\\r\\nthe bag. The final infusion concentration should be 1 mg/mL. For pediatric patients and patients with\\r\\ncardiovascular disease the drug may be diluted with 5% Dextrose Injection to a final infusion\\r\\nconcentration of 2 mg/mL. Before infusion, shake the bag until the contents are thoroughly mixed. Do\\r\\nnot use the admixture after dilution with 5% Dextrose Injection if there is any evidence of foreign\\r\\nmatter. Vials are for single use. Unused material should be discarded. Aseptic technique must be\\r\\nstrictly observed throughout handling of ABELCET ® , since no bacteriostatic agent or preservative is\\r\\npresent.',\n",
       " 'DO NOT DILUTE WITH SALINE SOLUTIONS OR MIX WITH OTHER DRUGS OR\\r\\nELECTROLYTES as the compatibility of ABELCET ® with these materials has not been established.\\r\\nAn existing intravenous line should be flushed with 5% Dextrose Injection before infusion of\\r\\nABELCET ® , or a separate infusion line should be used. DO NOT USE AN IN-LINE FILTER.',\n",
       " 'The diluted ready-for-use admixture is stable for up to 48 hours at 2° to 8°C (36° to 46°F) and an\\r\\nadditional 6 hours at room temperature.',\n",
       " 'Single-use vials along with 5-micron filter needles are individually packaged.',\n",
       " '100 mg of ABELCET ® in 20 mL of suspension NDC 57665-101-41',\n",
       " 'Prior to admixture, ABELCET ® should be stored at 2° to 8°C (36° to 46°F) and protected from\\r\\nexposure to light. Do not freeze. ABELCET ® should be retained in the carton until time of use.',\n",
       " 'The admixed ABELCET ® and 5% Dextrose Injection may be stored for up to 48 hours at 2° to 8°C\\r\\n(36° to 46°F) and an additional 6 hours at room temperature. Do not freeze. Any unused material should\\r\\nbe discarded.',\n",
       " 'Manufactured by Exelead, Inc., Indianapolis, IN 46268. Revised: Dec 2017.',\n",
       " 'VERZENIO ® (abemaciclib) is indicated:',\n",
       " 'When used in combination with fulvestrant or an aromatase inhibitor, the recommended dose of VERZENIO is 150 mg taken orally twice\\r\\ndaily.',\n",
       " 'When used as monotherapy, the recommended dose of VERZENIO is 200 mg taken orally twice daily.',\n",
       " 'Continue treatment until disease progression or unacceptable toxicity. VERZENIO may be taken with or without food [see CLINICAL PHARMACOLOGY ].',\n",
       " 'Instruct patients to take their doses of VERZENIO at approximately the same times every day.',\n",
       " 'If the patient vomits or misses a dose of VERZENIO, instruct the patient to take the next dose at its scheduled time. Instruct patients to\\r\\nswallow VERZENIO tablets whole and not to chew, crush, or split tablets before swallowing. Instruct patients not to ingest VERZENIO\\r\\ntablets if broken, cracked, or otherwise not intact.',\n",
       " 'The recommended VERZENIO dose modifications for adverse reactions are provided in Tables 1-5. Discontinue VERZENIO for patients\\r\\nunable to tolerate 50 mg twice daily.',\n",
       " 'Table 1: VERZENIO Dose Modification for Adverse Reactions',\n",
       " 'Table 2: VERZENIO Dose Modification and Management — Hematologic Toxicities a',\n",
       " 'Table 3: VERZENIO Dose Modification and Management — Diarrhea',\n",
       " 'Table 4: VERZENIO Dose Modification and Management — Hepatotoxicity',\n",
       " 'Table 5: VERZENIO Dose Modification and Management for Other Toxicities a',\n",
       " 'Refer to the Full Prescribing Information for coadministered aromatase inhibitor or fulvestrant for dose modifications and other relevant\\r\\nsafety information.',\n",
       " 'Avoid concomitant use of the strong CYP3A inhibitor ketoconazole.',\n",
       " 'With concomitant use of strong CYP3A inhibitors other than ketoconazole, in patients with recommended starting doses of 200 mg twice\\r\\ndaily or 150 mg twice daily, reduce the VERZENIO dose to 100 mg twice daily. In patients who have had a dose reduction to 100 mg twice\\r\\ndaily due to adverse reactions, further reduce the VERZENIO dose to 50 mg twice daily. If a patient taking VERZENIO discontinues a\\r\\nCYP3A inhibitor, increase the VERZENIO dose (after 3-5 half-lives of the inhibitor) to the dose that was used before starting the strong\\r\\ninhibitor [see DRUG INTERACTIONS and CLINICAL PHARMACOLOGY ].',\n",
       " 'With concomitant use of moderate CYP3A inhibitors, monitor for adverse reactions and consider reducing the VERZENIO dose in 50 mg\\r\\ndecrements as demonstrated in Table 1, if necessary.',\n",
       " 'For patients with severe hepatic impairment (Child Pugh-C), reduce the VERZENIO dosing frequency to once daily [see Use In Specific Populations and CLINICAL PHARMACOLOGY ].',\n",
       " 'Refer to the Full Prescribing Information for coadministered aromatase inhibitor or fulvestrant for dose modification requirements for\\r\\nsevere hepatic impairment.',\n",
       " '50 mg tablets : oval beige tablet with “Lilly” debossed on one side and “50” on the other side.',\n",
       " '100 mg tablets : oval white to practically white tablet with “Lilly” debossed on one side and “100” on the other side.',\n",
       " '150 mg tablets : oval yellow tablet with “Lilly” debossed on one side and “150” on the other side.',\n",
       " '200 mg tablets : oval beige tablet with “Lilly” debossed on one side and “200” on the other side.',\n",
       " 'VERZENIO 50 mg tablets are oval beige tablet with “Lilly” debossed on one side and “50” on the other side.',\n",
       " 'VERZENIO 100 mg tablet are oval white to practically white tablet with “Lilly” debossed on one side and “100” on the other side.',\n",
       " 'VERZENIO 150 mg tablets are oval yellow tablet with “Lilly” debossed on one side and “150” on the other side.',\n",
       " 'VERZENIO 200 mg tablets are oval beige tablet with “Lilly” debossed on one side and “200” on the other side.',\n",
       " 'VERZENIO tablets are supplied in 7-day dose pack configurations as follows:',\n",
       " 'Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).',\n",
       " 'Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA. Revised: June 2019',\n",
       " 'Abilify coupons',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'ABILIFY Oral Tablets, Orally-Disintegrating Tablets, and\\r\\nOral Solution are indicated for the treatment of:',\n",
       " 'ABILIFY Injection is indicated for the treatment of:',\n",
       " 'ABILIFY MAINTENA (aripiprazole)\\r\\nis indicated for the treatment of schizophrenia [see Clinical Studies ].',\n",
       " 'ABILIFY MAINTENA is only to be administered by intramuscular injection by a healthcare professional. The recommended starting and\\r\\nmaintenance dose of ABILIFY MAINTENA is 400 mg monthly (no sooner than 26 days\\r\\nafter the previous injection).',\n",
       " 'For patients who have never taken aripiprazole, establish\\r\\ntolerability with oral aripiprazole prior to initiating treatment with ABILIFY\\r\\nMAINTENA. Due to the half-life of oral aripiprazole, it may take up to 2 weeks\\r\\nto fully assess tolerability.',\n",
       " 'After the first ABILIFY MAINTENA injection, administer\\r\\noral aripiprazole (10 mg to 20 mg) for 14 consecutive days to achieve\\r\\ntherapeutic aripiprazole concentrations during initiation of therapy. For\\r\\npatients already stable on another oral antipsychotic (and known to tolerate\\r\\naripiprazole), after the first ABILIFY MAINTENA injection, continue treatment\\r\\nwith the antipsychotic for 14 consecutive days to maintain therapeutic\\r\\nantipsychotic concentrations during initiation of therapy.',\n",
       " 'If there are adverse reactions with the 400 mg dosage,\\r\\nconsider reducing the dosage to 300 mg once monthly.',\n",
       " 'If the second or third doses are missed:',\n",
       " 'If the fourth or subsequent doses are missed:',\n",
       " 'Dosage adjustments are recommended in patients who are\\r\\nCYP2D6 poor metabolizers and in patients taking concomitant CYP3A4 inhibitors\\r\\nor CYP2D6 inhibitors for greater than 14 days (see Table 1). Dosage adjustments\\r\\nfor 200 mg and 160 mg are obtained only by using the 300 mg or 400 mg strength\\r\\nvials for intramuscular deltoid or gluteal injection.',\n",
       " 'If the CYP3A4 inhibitor or CYP2D6 inhibitor is withdrawn,\\r\\nthe ABILIFY MAINTENA dosage may need to be increased [see Dosage Overview for the Treatment of Schizophrenia above].',\n",
       " 'Avoid the concomitant use of CYP3A4 inducers with ABILIFY\\r\\nMAINTENA for greater than 14 days because the blood levels of aripiprazole are\\r\\ndecreased and may be below the effective levels.',\n",
       " 'Dosage adjustments are not recommended for patients with\\r\\nconcomitant use of CYP3A4 inhibitors, CYP2D6 inhibitors or CYP3A4 inducers for\\r\\nless than 14 days.',\n",
       " 'Table 1: Dose Adjustments of ABILIFY MAINTENA in\\r\\nPatients who are known CYP2D6 Poor Metabolizers and Patients Taking Concomitant\\r\\nCYP2D6 Inhibitors, 3A4 Inhibitors, and/or CYP3A4 Inducers for Greater than 14\\r\\ndays',\n",
       " 'ABILIFY MAINTENA comes in two\\r\\ntypes of kits. See instructions for reconstitution/injection/disposal\\r\\nprocedures for 1) Pre-filled Dual Chamber Syringe, and 2) Vials.',\n",
       " 'There are two aripiprazole\\r\\nformulations for intramuscular use with different dosages, dosing frequencies,\\r\\nand indications. ABILIFY MAINTENA is a long-acting aripiprazole formulation\\r\\nwith 4 week dosing intervals indicated for the treatment of schizophrenia. In contrast , aripiprazole injection (9.75 mg per vial) is a short-acting\\r\\nformulation indicated for agitation in patients with schizophrenia or mania . Do\\r\\nnot substitute these products. Refer to the prescribing information for\\r\\naripiprazole injection for more information about aripiprazole injection.',\n",
       " 'ABILIFY MAINTENA comes in two\\r\\ntypes of kits. See instructions for reconstitution/injection/disposal\\r\\nprocedures for 1) Pre-filled Dual Chamber Syringe available in 300 mg or 400 mg\\r\\nstrength syringes [see section below], and 2) Single-use\\r\\nvials available in 300 mg or 400 mg strength vials [see section below].',\n",
       " 'The 200 mg and 160 mg dosage\\r\\nadjustments are obtained only by using the 300 mg or 400 mg strength vials.',\n",
       " 'For deep intramuscular deltoid\\r\\nor gluteal injection by healthcare professionals only. Do not administer by any\\r\\nother route. Inject full syringe contents immediately following reconstitution.\\r\\nAdminister once monthly.',\n",
       " 'Lay out and confirm that\\r\\ncomponents listed below are provided in the kit:',\n",
       " 'Reconstitute at room temperature.',\n",
       " 'a) Push plunger rod slightly to engage threads. And then,\\r\\nrotate plunger rod until the rod stops rotating to release diluent. After\\r\\nplunger rod is at complete stop, middle stopper will be at the indicator line\\r\\n(See Figure 1).',\n",
       " 'Figure 1',\n",
       " 'b) Vertically shake the syringe\\r\\nvigorously for 20 seconds until drug is uniformly milky-white (See Figure 2).',\n",
       " 'Figure 2',\n",
       " 'c) Visually inspect the syringe\\r\\nfor particulate matter and discoloration prior to administration. The\\r\\nreconstituted ABILIFY MAINTENA suspension should appear to be a uniform,\\r\\nhomogeneous suspension that is opaque and milky-white in color.',\n",
       " 'Use appropriate aseptic\\r\\ntechniques throughout injection procedure. For deep intramuscular injection\\r\\nonly.',\n",
       " 'a) Twist and pull off Over-cap and Tip-cap (See Figure\\r\\n3).',\n",
       " 'Figure 3',\n",
       " 'b) Select appropriate needle\\r\\n(See Figure 4).',\n",
       " 'Figure 4',\n",
       " 'For deltoid administration :',\n",
       " 'For gluteal administration :',\n",
       " 'c) While holding the needle\\r\\ncap, ensure the needle is firmly seated on the safety device with a push. Twist\\r\\nclockwise until SNUGLY fitted (See Figure 5).',\n",
       " 'Figure 5',\n",
       " 'd) Then PULL needle-cap straight up (see Figure 6).',\n",
       " 'Figure 6',\n",
       " 'e) Hold syringe UPRIGHT and ADVANCE PLUNGER ROD SLOWLY\\r\\nTO EXPEL THE AIR. Expel air until suspension fills needle base. If\\r\\nitâ€™s not possible to advance plunger rod to expel the air, check that plunger\\r\\nrod is rotated to a complete stop (See Figure 7).',\n",
       " 'Figure 7',\n",
       " 'f) Inject slowly into the\\r\\ndeltoid or gluteal muscle. Do not massage the injection site.',\n",
       " 'a) Engage the needle safety\\r\\ndevice and safely discard all kit components (See Figure 8).',\n",
       " 'ABILIFY MAINTENA pre-filled\\r\\ndual chamber syringe is for single-use only.',\n",
       " 'Figure 8',\n",
       " 'b) Rotate sites of injections\\r\\nbetween the two deltoid or gluteal muscles.',\n",
       " 'b) ABILIFY MAINTENA should be\\r\\nsuspended using the Sterile Water for Injection as supplied in the kit.',\n",
       " 'c) The Sterile Water for\\r\\nInjection and ABILIFY MAINTENA vials are for single-use only.',\n",
       " 'd) Use appropriate aseptic techniques throughout reconstitution and reconstitute at room temperature.',\n",
       " 'e) Select the amount of Sterile\\r\\nWater for Injection needed for reconstitution (see Table 2).',\n",
       " 'Table 2: Amount of Sterile Water for Injection Needed\\r\\nfor Reconstitution',\n",
       " 'Important: There is more\\r\\nSterile Water for Injection in the vial than is needed to reconstitute ABILIFY\\r\\nMAINTENA (aripiprazole) for extended-release injectable suspension. The vial\\r\\nwill have excess Sterile Water for Injection; discard any unused portion.',\n",
       " 'a) Remove the cap of the vial\\r\\nof Sterile Water for Injection and remove the cap of the vial containing\\r\\nABILIFY MAINTENA lyophilized powder and wipe the tops with a sterile alcohol\\r\\nswab.',\n",
       " 'b) Using the syringe with\\r\\npre-attached hypodermic safety needle, withdraw the predetermined Sterile Water\\r\\nfor Injection volume from the vial of Sterile Water for Injection into the\\r\\nsyringe (see Figure 9). Residual Sterile Water for Injection will remain in the\\r\\nvial following withdrawal; discard any unused portion.',\n",
       " 'Figure 9',\n",
       " 'c) Slowly inject the Sterile\\r\\nWater for Injection into the vial containing the ABILIFY MAINTENA lyophilized\\r\\npowder (see Figure 10).',\n",
       " 'Figure 10',\n",
       " 'd) Withdraw air to equalize the\\r\\npressure in the vial by pulling back slightly on the plunger. Subsequently,\\r\\nremove the needle from the vial. Engage the needle safety device by using the\\r\\none-handed technique (see Figure 11). Gently press the sheath against a flat\\r\\nsurface until the needle is firmly engaged in the needle protection sheath.\\r\\nVisually confirm that the needle is fully engaged into the needle protection\\r\\nsheath, and discard.',\n",
       " 'Figure 11',\n",
       " 'e) Shake the vial vigorously\\r\\nfor 30 seconds until the reconstituted suspension appears uniform (see Figure\\r\\n12).',\n",
       " 'Figure 12',\n",
       " 'f) Visually inspect the\\r\\nreconstituted suspension for particulate matter and discoloration prior to\\r\\nadministration. The reconstituted ABILIFY MAINTENA is a uniform, homogeneous\\r\\nsuspension that is opaque and milky-white in color.',\n",
       " 'g) If the injection is not\\r\\nperformed immediately after reconstitution keep the vial at room temperature\\r\\nand shake the vial vigorously for at least 60 seconds to re-suspend prior to\\r\\ninjection.',\n",
       " 'h) Do not store the\\r\\nreconstituted suspension in a syringe.',\n",
       " 'a) Use appropriate aseptic\\r\\ntechniques throughout injection of the reconstituted ABILIFY MAINTENA suspension.',\n",
       " 'b) Remove the cover from the\\r\\nvial adapter package (see Figure 13). Do not remove the vial adapter from the\\r\\npackage.',\n",
       " 'Figure 13',\n",
       " 'c) Using the vial adapter\\r\\npackage to handle the vial adapter, attach the prepackaged luer lock syringe to\\r\\nthe vial adapter (see Figure 14).',\n",
       " 'Figure 14',\n",
       " 'd) Use the luer lock syringe to\\r\\nremove the vial adapter from the package and discard the vial adapter package\\r\\n(see Figure 15). Do not touch the spike tip of the adapter at any time.',\n",
       " 'Figure 15',\n",
       " 'Table 3: ABILIFY MAINTENA\\r\\nReconstituted Suspension Volume to Inject',\n",
       " 'f) Wipe the top of the vial of\\r\\nthe reconstituted ABILIFY MAINTENA suspension with a sterile alcohol swab.',\n",
       " \"g) Place and hold the vial of\\r\\nthe reconstituted ABILIFY MAINTENA suspension on a hard surface. Attach the\\r\\nadapter-syringe assembly to the vial by holding the outside of the adapter and\\r\\npushing the adapter's spike firmly through the rubber stopper, until the\\r\\nadapter snaps in place (see Figure 16).\",\n",
       " 'Figure 16',\n",
       " 'h) Slowly withdraw the\\r\\nrecommended volume from the vial into the luer lock syringe to allow for\\r\\ninjection (see Figure 17). A small amount of excess product will remain in the\\r\\nvial.',\n",
       " 'Figure 17',\n",
       " 'a) Detach the luer lock syringe\\r\\ncontaining the recommended volume of reconstituted ABILIFY MAINTENA suspension\\r\\nfrom the vial.',\n",
       " 'b) Select the appropriate\\r\\nhypodermic safety needle and attach the needle to the luer lock syringe\\r\\ncontaining the suspension for injection. While holding the needle cap, ensure\\r\\nthe needle is firmly seated on the safety device with a push. Twist clockwise\\r\\nuntil snugly fitted and then pull the needle cap straight away from the needle\\r\\n(see Figure 18).',\n",
       " 'For deltoid administration:',\n",
       " 'For gluteal administration:',\n",
       " 'Figure 18',\n",
       " '(c) Slowly inject the\\r\\nrecommended volume as a single intramuscular injection into the deltoid or\\r\\ngluteal muscle. Do not massage the injection site.',\n",
       " 'a) Engage the needle safety\\r\\ndevice as described in Section 2.6, Step (d) of Reconstitution of Lyophilized\\r\\nPowder in Vial and safely discard all kit components (see Figure 8). Dispose of\\r\\nthe vials, adapter, needles, and syringe appropriately after injection. The\\r\\nSterile Water for Injection and ABILIFY MAINTENA vials are for single-use only.',\n",
       " 'b) Rotate sites of injections\\r\\nbetween the two deltoid or gluteal muscles.',\n",
       " 'For extended-release injectable suspension: 300 mg and\\r\\n400 mg of lyophilized powder for reconstitution in:',\n",
       " 'The reconstituted\\r\\nextended-release injectable suspension is a uniform, homogeneous suspension\\r\\nthat is opaque and milky-white in color.',\n",
       " 'ABILIFY MAINTENA (aripiprazole)\\r\\npre-filled dual chamber syringe for extended-release injectable suspension in\\r\\nsingle-use syringes is available in 300 mg or 400 mg strength syringes. The\\r\\npre-filled dual chamber syringe consists of a front chamber that contains the\\r\\nlyophilized powder of aripiprazole monohydrate and a rear chamber that contains\\r\\nsterile water for injection.',\n",
       " 'The 300 mg kit includes ( 59148-045-80):',\n",
       " 'The 400 mg kit includes ( 59148-072-80):',\n",
       " 'Single-Use Vial:',\n",
       " 'ABILIFY MAINTENA (aripiprazole) extended-release\\r\\ninjectable suspension in single-use vials is available in 300 mg or 400 mg\\r\\nstrength vials.',\n",
       " 'The 300 mg kit includes ( 59148-018-71):',\n",
       " 'The 400 mg kit includes ( 59148-019-71):',\n",
       " 'Store below 30°C [86°F]. Do not freeze. Protect the\\r\\nsyringe from light by storing in the original package until time of use.',\n",
       " 'Store at 25°C (77°F), excursions permitted between 15°C\\r\\nand 30°C (59°F to 86°F) [see USP Controlled Room Temperature ].',\n",
       " 'Distributed and marketed by Otsuka America\\r\\nPharmaceutical, Inc., Rockville, MD 20850 USA Marketed by Lundbeck, Deerfield,\\r\\nIL 60015 USA ABILIFY MAINTENA is a trademark of Otsuka Pharmaceutical Company. Revised: Aug 2016',\n",
       " 'ABILIFY MYCITE, a drug-device combination product comprised of aripiprazole tablets embedded\\r\\nwith an Ingestible Event Marker (IEM) sensor intended to track drug ingestion, is indicated for the:',\n",
       " 'ZYTIGA is indicated in combination with prednisone for the treatment of patients with',\n",
       " 'The recommended dose of ZYTIGA is 1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily with prednisone 5 mg orally twice daily.',\n",
       " 'The recommended dose of ZYTIGA is 1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily with prednisone 5 mg administered orally once daily.',\n",
       " 'Patients receiving ZYTIGA should also receive a gonadotropin–releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.',\n",
       " 'ZYTIGA tablets must be taken as a single dose once daily on an empty stomach. Do not eat food 2 hours before and 1 hour after taking ZYTIGA. The tablets must be swallowed whole with water. Do not crush or chew tablets.',\n",
       " 'In patients with baseline moderate hepatic impairment (Child–Pugh Class B), reduce the recommended dose of ZYTIGA to 250 mg once daily. In patients with moderate hepatic impairment monitor ALT, AST, and bilirubin prior to the start of treatment, every week for the first month, every two weeks for the following two months of treatment and monthly thereafter. If elevations in ALT and/or AST greater than 5 x upper limit of normal (ULN) or total bilirubin greater than 3 × ULN occur in patients with baseline moderate hepatic impairment, discontinue ZYTIGA and do not re–treat patients with ZYTIGA [see Use In Specific Populations and CLINICAL PHARMACOLOGY ].',\n",
       " 'Do not use ZYTIGA in patients with baseline severe hepatic impairment (Child–Pugh Class C).',\n",
       " 'For patients who develop hepatotoxicity during treatment with ZYTIGA (ALT and/or AST greater than 5 × ULN or total bilirubin greater than 3 × ULN), interrupt treatment with ZYTIGA [see WARNINGS AND PRECAUTIONS ]. Treatment may be restarted at a reduced dose of 750 mg once daily following return of liver function tests to the patient’s baseline or to AST and ALT less than or equal to 2.5 × ULN and total bilirubin less than or equal to 1.5 × ULN. For patients who resume treatment, monitor serum transaminases and bilirubin at a minimum of every two weeks for three months and monthly thereafter.',\n",
       " 'If hepatotoxicity recurs at the dose of 750 mg once daily, re–treatment may be restarted at a reduced dose of 500 mg once daily following return of liver function tests to the patient’s baseline or to AST and ALT less than or equal to 2.5 × ULN and total bilirubin less than or equal to 1.5 × ULN.',\n",
       " 'If hepatotoxicity recurs at the reduced dose of 500 mg once daily, discontinue treatment with ZYTIGA.',\n",
       " 'Permanently discontinue ZYTIGA for patients who develop a concurrent elevation of ALT greater than 3 x ULN and total bilirubin greater than 2 × ULN in the absence of biliary obstruction or other causes responsible for the concurrent elevation [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Avoid concomitant strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital) during ZYTIGA treatment.',\n",
       " 'If a strong CYP3A4 inducer must be co–administered, increase the ZYTIGA dosing frequency to twice a day only during the co–administration period (e.g., from 1,000 mg once daily to 1,000 mg twice a day). Reduce the dose back to the previous dose and frequency, if the concomitant strong CYP3A4 inducer is discontinued [ DRUG INTERACTIONS and CLINICAL PHARMACOLOGY ].',\n",
       " 'Tablets (500 mg): purple, oval–shaped, film–coated tablets debossed with “AA” one side and “500” on the other side.',\n",
       " 'Tablets (250 mg): white to off–white, oval–shaped tablets debossed with “AA250” on one side.',\n",
       " 'ZYTIGA ® (abiraterone acetate) Tablets are available in the strengths and packages listed below:',\n",
       " 'Purple, oval–shaped tablets debossed with “AA” one side and “500” on the other side. NDC 57894–195–06 60 tablets available in high–density polyethylene bottles',\n",
       " 'White to off–white, oval–shaped tablets debossed with “AA250” on one side. NDC 57894–150–12 120 tablets available in high–density polyethylene bottles',\n",
       " 'Store at 20°C to 25°C (68°F to 77°F); excursions permitted in the range from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].',\n",
       " 'Keep out of reach of children.',\n",
       " 'Based on its mechanism of action, ZYTIGA may harm a developing fetus. Women who are pregnant or women who may be pregnant should not handle ZYTIGA 250 mg uncoated tablets or other ZYTIGA tablets if broken, crushed, or damaged without protection, e.g., gloves [see Use In Specific Populations ].',\n",
       " 'Manufactured by: Patheon France S.A.S., Bourgoin Jallieu, France. Revised: August 2021',\n",
       " 'Manufactured by: Patheon Inc., Mississauga, Canada. Revised: Aug 2021',\n",
       " 'YONSA is indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer.',\n",
       " 'The recommended dose of YONSA is 500 mg (four 125 mg tablets) administered orally once daily in combination with methylprednisolone 4 mg administered orally twice daily.',\n",
       " 'To avoid medication errors and overdose, be aware that YONSA (abiraterone acetate) tablets may have different dosing and food effects than other abiraterone acetate products. Patients receiving YONSA should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.',\n",
       " 'YONSA tablets can be taken with or without food [see CLINICAL PHARMACOLOGY ]. The tablets should be swallowed whole with water. Do not crush or chew tablets.',\n",
       " 'In patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the recommended dose of YONSA to 125 mg once daily. In patients with moderate hepatic impairment monitor ALT, AST, and bilirubin prior to the start of treatment, every week for the first month, every two weeks for the following two months of treatment and monthly thereafter. If elevations in ALT and/or AST greater than 5X upper limit of normal (ULN) or total bilirubin greater than 3X ULN occur in patients with baseline moderate hepatic impairment, discontinue YONSA and do not re-treat patients with abiraterone acetate [see Use In Specific Populations and CLINICAL PHARMACOLOGY ].',\n",
       " 'Do not use YONSA in patients with baseline severe hepatic impairment (Child-Pugh Class C).',\n",
       " 'For patients who develop hepatotoxicity during treatment with YONSA (ALT and/or AST greater than 5X ULN or total bilirubin greater than 3X ULN), interrupt treatment with YONSA [see WARNINGS AND PRECAUTIONS ]. Treatment may be restarted at a reduced dose of 375 mg once daily following return of liver function tests to the patient’s baseline or to AST and ALT less than or equal to 2.5X ULN and total bilirubin less than or equal to 1.5X ULN. For patients who resume treatment, monitor serum transaminases and bilirubin at a minimum of every two weeks for three months and monthly thereafter. If hepatotoxicity recurs at the dose of 375 mg once daily, re-treatment may be restarted at a reduced dose of 250 mg once daily following return of liver function tests to the patient’s baseline or to AST and ALT less than or equal to 2.5X ULN and total bilirubin less than or equal to 1.5X ULN.',\n",
       " 'If hepatotoxicity recurs at the reduced dose of 250 mg once daily, discontinue treatment with abiraterone acetate.',\n",
       " 'Permanently discontinue YONSA for patients who develop a concurrent elevation of ALT greater than 3 x ULN and total bilirubin greater than 2 x ULN in the absence of biliary obstruction or other causes responsible for the concurrent elevation [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Avoid concomitant strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital) during YONSA treatment.',\n",
       " 'If a strong CYP3A4 inducer must be co-administered, increase the YONSA dosing frequency to twice a day only during the co-administration period (e.g., from 500 mg once daily to 500 mg twice a day). Reduce the dose back to the previous dose and frequency, if the concomitant strong CYP3A4 inducer is discontinued [see DRUG INTERACTIONS and CLINICAL PHARMACOLOGY ].',\n",
       " 'YONSA (abiraterone acetate) tablets, 125 mg, are white to off-white, oval-shaped tablets debossed with “125 FP” on one side.',\n",
       " 'White to off-white, oval-shaped tablets debossed with “125 FP” on one side\\r\\n120 tablets available in high-density polyethylene bottles with child resistant closure NDC Number 47335-401-81',\n",
       " 'Store at 20°C to 25°C (68°F to 77°F); excursions permitted in the range from 15°C to 30°C (59°F to 86°F) [see USP controlled room temperature].',\n",
       " 'Women who are pregnant or women who may be pregnant should not handle YONSA without protection, e.g., gloves [see Use In Specific Populations ].',\n",
       " 'Distributed by Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512. Revised: May 2018',\n",
       " 'ABLAVAR is indicated for use as a contrast agent in\\r\\nmagnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease\\r\\n(AIOD) in adults with known or suspected peripheral vascular disease [see Clinical\\r\\nStudies ].',\n",
       " 'Administer ABLAVAR as an intravenous bolus injection,\\r\\nmanually or by power injection, at a dose of 0.12 mL/kg body weight (0.03\\r\\nmmol/kg) over a period of time up to 30 seconds followed by a 25-30 mL normal\\r\\nsaline flush. (See Table 1 for weight-adjusted dose volumes ).',\n",
       " 'TABLE 1: Weight-Adjusted Volumes for the 0.03 mmol/kg\\r\\nDose',\n",
       " 'Inspect the ABLAVAR vial visually for particulate matter\\r\\nand discoloration prior to administration. Do not use the solution if it is\\r\\ndiscolored or particulate matter is present.',\n",
       " 'ABLAVAR is intended for single use only and should be\\r\\nused immediately upon opening. Discard any unused portion of the ABLAVAR vial.',\n",
       " 'Do not mix intravenous medications or parenteral nutrition solutions with ABLAVAR. Do not administer any other medications in\\r\\nthe same intravenous line simultaneously with ABLAVAR.',\n",
       " 'ABLAVAR imaging is completed in two stages: the dynamic\\r\\nimaging stage and the steady-state imaging stage. Both stages are essential for\\r\\nadequate evaluation of the arterial system, and dynamic imaging always precedes\\r\\nsteady-state imaging. During interpretation of the steady-state images, ABLAVAR\\r\\nwithin the venous system may limit or confound the detection of arterial\\r\\nlesions.',\n",
       " 'To assess the initial distribution of ABLAVAR within the\\r\\narterial system, begin dynamic imaging immediately upon injection. Begin steady\\r\\nstate imaging after dynamic imaging has been completed, generally 5 to 7\\r\\nminutes following ABLAVAR administration. At this time point, ABLAVAR is generally\\r\\ndistributed throughout the blood. In clinical trials, steady-state imaging was\\r\\ncompleted within approximately one hour following ABLAVAR injection.',\n",
       " 'ABLAVAR is a sterile solution for intravenous injection\\r\\ncontaining 244 mg/mL (0.25 mmol/mL) gadofosveset trisodium [see HOW SUPPLIED / Storage\\r\\nand Handling ]',\n",
       " 'ABLAVAR Injection is a sterile, clear, colorless to pale\\r\\nyellow solution containing 244 mg/mL (0.25 mmol/mL) of gadofosveset trisodium\\r\\nin rubber-stoppered glass vials with an aluminum seal. ABLAVAR Injection is\\r\\nsupplied as follows:',\n",
       " 'NDC 11994-012-01 - 10 mL fills in 10 mL single use vials\\r\\npackages of 10 vials NDC 11994-012-02 - 15 mL fills in 20 mL single use vials\\r\\nin packages of 10 vials',\n",
       " 'Store ABLAVAR Injection up to 25°C (77°F: excursions\\r\\npermitted to 15 to 30°C [59 to 86°F]). Protect from light and freezing.',\n",
       " 'Distributed by : Lantheus Medical Imaging, Inc., 331\\r\\nTreble Cove Road, North Billerica, MA 01862, United States. Revised: Mar 2015',\n",
       " 'ABLYSINOL® is indicated to induce controlled cardiac\\r\\nseptal infarction to improve exercise capacity in adults with symptomatic\\r\\nhypertrophic obstructive cardiomyopathy who are not candidates for surgical\\r\\nmyectomy.',\n",
       " 'Use the minimum dose necessary to achieve the desired\\r\\nreduction in peak left ventricular outflow tract pressure gradient. Inject\\r\\nsmall volumes over 1 to 2 minutes percutaneously into septal arterial branches,\\r\\nguided by assessment of the gradient. In most situations, a dose of 1 mL to 2\\r\\nmL is sufficient. The maximum dose of ABLYSINOL that should be used in a single\\r\\nprocedure is 5 mL.',\n",
       " 'ABLYSINOL should only be administered under the\\r\\nsupervision of a qualified interventional cardiologist experienced in the percutaneous transluminal septal myocardial ablation procedure.',\n",
       " 'Inspect visually for particulate matter and discoloration\\r\\nprior to administration. ABLYSINOL should appear as a clear, colorless\\r\\nsolution.',\n",
       " 'Injection: 1 mL or 5 mL of ethyl alcohol ≥ 99% by\\r\\nvolume as a clear, colorless liquid in a singledose glass ampule.',\n",
       " 'ABLYSINOL (dehydrated alcohol) injection is a clear,\\r\\ncolorless liquid supplied in clear, glass, single-dose ampules. Each mL\\r\\ncontains ≥ 99% by volume ethyl alcohol.',\n",
       " '',\n",
       " 'Store at room temperature, between 20°C and 25°C (68°F\\r\\nand 77°F). Do not refrigerate or freeze. Highly flammable, store away from any\\r\\nheat source.',\n",
       " 'Manufactured for: Belcher Pharmaceuticals, LLC, Largo, FL\\r\\n33777 USA. Manufactured by: Sintetica SA, Via Penate 5, 6850 Mendrisio,\\r\\nSwitzerland. Revised: Jun 2018',\n",
       " 'DYSPORT is indicated for the treatment of adults with\\r\\ncervical dystonia.',\n",
       " 'DYSPORT is indicated for the temporary improvement in the\\r\\nappearance of moderate to severe glabellar lines associated with procerus and\\r\\ncorrugator muscle activity in adult patients less than 65 years of age.',\n",
       " 'DYSPORT is indicated for the treatment spasticity in\\r\\nadult patients.',\n",
       " 'DYSPORT is indicated for the treatment of lower limb\\r\\nspasticity in pediatric patients 2 years of age and older.',\n",
       " 'The potency Units of DYSPORT are specific to the\\r\\npreparation and assay method utilized. They are not interchangeable with other\\r\\npreparations of botulinum toxin products and, therefore, units of biological\\r\\nactivity of DYSPORT cannot be compared to or converted into units of any other\\r\\nbotulinum toxin products assessed with any other specific assay method [see DESCRIPTION ].',\n",
       " 'Reconstituted DYSPORT is intended for intramuscular\\r\\ninjection only.',\n",
       " 'Reconstitution instructions are specific for each of the\\r\\n300 Unit vial and the 500 Unit vial. These volumes yield concentrations\\r\\nspecific for the use for each indication (see Table 1).',\n",
       " 'Table 1: Dilution Instructions for DYSPORT Vials (500\\r\\nUnits and 300 Units)',\n",
       " 'After reconstitution, DYSPORT should be used for only one\\r\\ninjection session and for only one patient. Discard an unused portion. Once\\r\\nreconstituted, unused DYSPORT may be stored in the original container, in a\\r\\nrefrigerator at 2°C to 8°C (36°F to 46°F), protected from light for up to 24\\r\\nhours until time of use. It must be discarded if not used within 24 hours. Do\\r\\nnot freeze reconstituted DYSPORT. Discard the vial and needle in accordance\\r\\nwith local regulations.',\n",
       " 'The recommended initial dose of DYSPORT for the treatment\\r\\nof cervical dystonia is 500 Units given intramuscularly as a divided dose among\\r\\naffected muscles in patients with or without a history of prior treatment with\\r\\nbotulinum toxin. (A description of the average DYSPORT dose and percentage of\\r\\ntotal dose injected into specific muscles in the pivotal clinical trials can be\\r\\nfound in Table 12 of Section 14.1, Clinical Studies â€“ Cervical Dystonia.)\\r\\nLimiting the dose injected into the sternocleidomastoid muscle may reduce the\\r\\noccurrence of dysphagia . Clinical studies with DYSPORT in cervical dystonia\\r\\nsuggest that the peak effect occurs between two and four weeks after injection.\\r\\nSimultaneous EMGguided application of DYSPORT may be helpful in locating active\\r\\nmuscles.',\n",
       " \"Where dose modification is necessary for the treatment of\\r\\ncervical dystonia, uncontrolled open-label studies suggest that dose adjustment\\r\\ncan be made in 250 Unit steps according to the individual patient's response,\\r\\nwith re-treatment every 12 weeks or longer, as necessary, based on return of\\r\\nclinical symptoms. Uncontrolled open-label studies also suggest that the total\\r\\ndose administered in a single treatment should be between 250 Units and 1000\\r\\nUnits. Retreatment, if needed, should not occur in intervals of less than 12\\r\\nweeks. Doses above 1000 Units have not been systematically evaluated.\",\n",
       " 'The starting dose of 500 Units recommended for cervical\\r\\ndystonia is applicable to adults of all ages [see Use In Specific Populations ].',\n",
       " 'DYSPORT is supplied as a single-use vial. Only use\\r\\nsterile preservative-free 0.9% Sodium Chloride Injection, USP for reconstitution\\r\\nof DYSPORT. Each 500 Unit vial of DYSPORT is to be reconstituted with 1 mL of\\r\\npreservative-free 0.9% Sodium Chloride Injection USP to yield a solution of 50\\r\\nUnits per 0.1 mL or reconstituted with 2 mL of preservative-free 0.9% Sodium\\r\\nChloride Injection USP to yield a solution of 25 Units per 0.1 mL. Each 300 Unit\\r\\nvial of DYSPORT is to be reconstituted with 0.6 mL of preservative-free 0.9%\\r\\nSodium Chloride Injection USP to yield a solution equivalent to 50 Units per\\r\\n0.1 mL.',\n",
       " 'Using an appropriately sized sterile syringe, needle and aseptic technique, draw up 2 mL or 1 mL of sterile, preservative- free 0.9%\\r\\nSodium Chloride Injection USP for the 500 Unit vial or 0.6 mL of sterile,\\r\\npreservative-free 0.9% Sodium Chloride Injection USP for the 300 Unit vial.\\r\\nInsert the needle into the DYSPORT vial. The partial vacuum will begin to pull\\r\\nthe saline into the vial. Any remaining required saline should be expressed\\r\\ninto the vial manually. Do not use the vial if no vacuum is observed. Swirl\\r\\ngently to dissolve. Parenteral drug products should be inspected visually for\\r\\nparticulate matter and discoloration prior to administration. Reconstituted\\r\\nDYSPORT should be a clear, colorless solution, free of particulate matter,\\r\\notherwise it should not be injected.',\n",
       " 'Expel any air bubbles in the syringe barrel. Remove the\\r\\nneedle used to reconstitute the product and attach an appropriately sized new\\r\\nsterile needle.',\n",
       " 'Discard the vial and needle in accordance with local\\r\\nregulations.',\n",
       " 'The dose of DYSPORT for the treatment of glabellar lines\\r\\nis a total of 50 Units given intramuscularly in five equal aliquots of 10 Units\\r\\neach to achieve clinical effect (see Figure 1).',\n",
       " 'A total dose of 50 Units of DYSPORT, in five equal\\r\\naliquots, should be administered to achieve clinical effect.',\n",
       " 'The clinical effect of DYSPORT may last up to four\\r\\nmonths. Repeat dose clinical studies demonstrated continued efficacy with up to\\r\\nfour repeated administrations. It should be administered no more frequently\\r\\nthan every three months. When used for re-treatment, DYSPORT should be\\r\\nreconstituted and injected using the same techniques as the initial treatment.',\n",
       " 'DYSPORT is supplied as a single-use vial. Only use\\r\\nsterile preservative-free 0.9% Sodium Chloride Injection, USP for reconstitution\\r\\nof DYSPORT. Each 300 Unit vial of DYSPORT is to be reconstituted with 2.5 mL of\\r\\npreservative-free 0.9% Sodium Chloride Injection USP prior to injection. The\\r\\nconcentration of the resulting solution will be 10 Units per 0.08 mL (12 Units\\r\\nper 0.1 mL) to be delivered in five equally divided aliquots of 0.08 mL each.\\r\\nDYSPORT may also be reconstituted with 1.5 mL of preservative-free 0.9% Sodium\\r\\nChloride Injection USP for a solution of 10 Units per 0.05 mL (20 Units per 0.1\\r\\nmL) to be delivered in five equally divided aliquots of 0.05 mL each.',\n",
       " 'Using an appropriately sized sterile syringe, needle and\\r\\naseptic technique, draw up 2.5 mL or 1.5 mL of preservativefree 0.9% Sodium\\r\\nChloride Injection USP Insert the needle into the DYSPORT vial. The partial vacuum\\r\\nwill begin to pull the saline into the vial. Any remaining required saline\\r\\nshould be expressed into the vial manually. Do not use the vial if no vacuum is\\r\\nobserved. Swirl gently to dissolve. Parenteral drug products should be\\r\\ninspected visually for particulate matter and discoloration prior to\\r\\nadministration. Reconstituted DYSPORT should be a clear, colorless solution,\\r\\nfree of particulate matter otherwise it should not be injected.',\n",
       " 'Draw a single patient dose of DYSPORT into a sterile\\r\\nsyringe. Expel any air bubbles in the syringe barrel. Remove the needle used to\\r\\nreconstitute the product and attach a 30-gauge needle.',\n",
       " 'Discard the vial and needle in accordance with local\\r\\nregulations.',\n",
       " 'Glabellar facial lines arise from the activity of the lateral corrugator and vertical procerus muscles. These can be readily identified\\r\\nby palpating the tensed muscle mass while having the patient frown. The\\r\\ncorrugator depresses the skin creating a “furrowed” vertical line\\r\\nsurrounded by tensed muscle (i.e., frown lines). The location, size, and use of\\r\\nthe muscles vary markedly among individuals. Physicians administering DYSPORT\\r\\nmust understand the relevant neuromuscular and/or orbital anatomy of the area\\r\\ninvolved and any alterations to the anatomy due to prior surgical procedures.',\n",
       " 'Risk of ptosis can be mitigated by careful examination of\\r\\nthe upper lid for separation or weakness of the levator palpebrae muscle (true\\r\\nptosis), identification of lash ptosis, and evaluation of the range of lid\\r\\nexcursion while manually depressing the frontalis to assess compensation.',\n",
       " 'In order to reduce the complication of ptosis, the\\r\\nfollowing steps should be taken:',\n",
       " 'To inject DYSPORT, advance the needle through the skin\\r\\ninto the underlying muscle while applying finger pressure on the superior\\r\\nmedial orbital rim. Inject patients with a total of 50 Units in five equally\\r\\ndivided aliquots. Using a 30 gauge needle, inject 10 Units of DYSPORT into each\\r\\nof five sites, two in each corrugator muscle, and one in the procerus muscle (see\\r\\nFigure 1).',\n",
       " 'Figure 1',\n",
       " \"Dosing in initial and subsequent treatment sessions should\\r\\nbe tailored to the individual based on the size, number and location of muscles\\r\\ninvolved, severity of spasticity, the presence of local muscle weakness, the\\r\\npatient's response to previous treatment, and/or adverse event history with\\r\\nbotulinum toxins.\",\n",
       " 'No more than 1 mL should generally be administered at any\\r\\nsingle injection site. The maximum recommended total dose (upper and lower limb\\r\\ncombined) of DYSPORT for the treatment of spasticity in adults is 1500 Units.',\n",
       " 'Although actual location of the injection sites can be\\r\\ndetermined by palpation, the use of injection guiding technique e.g.,\\r\\nelectromyography, electrical stimulation is recommended to target the injection\\r\\nsites.',\n",
       " 'In the clinical trial that assessed the efficacy and\\r\\nsafety of DYSPORT for treatment of upper limb spasticity in adults [see Clinical\\r\\nStudies ], doses of 500 Units and 1000 Units were divided among selected\\r\\nmuscles at a given treatment session (see Table 2 and Figure 2).',\n",
       " 'Table 2: DYSPORT Dosing by Muscle for Upper Limb\\r\\nSpasticity in Adult Patients',\n",
       " 'Figure 2: Muscles for Injection for Upper Limb\\r\\nSpasticity in Adults',\n",
       " 'Repeat DYSPORT treatment should be administered when the\\r\\neffect of a previous injection has diminished, but no sooner than 12 weeks\\r\\nafter the previous injection. A majority of patients in clinical studies were\\r\\nretreated between 12- 16 weeks; however some patients had a longer duration of\\r\\nresponse, i.e. 20 weeks. The degree and pattern of muscle spasticity at the\\r\\ntime of re-injection may necessitate alterations in the dose of DYSPORT and\\r\\nmuscles to be injected. Clinical improvement may be expected one week after\\r\\nadministration of DYSPORT.',\n",
       " 'In the clinical trial that assessed the efficacy and\\r\\nsafety of DYSPORT for treatment of lower limb spasticity in adults [see Clinical\\r\\nStudies ], doses of 1000 Units and 1500 Units were divided among selected\\r\\nmuscles at a given treatment session (see Table 3 and Figure 3).',\n",
       " 'Table 3: DYSPORT Dosing by Muscle for Lower Limb\\r\\nSpasticity in Adults',\n",
       " 'Figure 3: Muscle for Injection for Lower Limb\\r\\nSpasticity in Adults',\n",
       " 'Repeat DYSPORT treatment should be administered when the\\r\\neffect of a previous injection has diminished, but no sooner than 12 weeks\\r\\nafter the previous injection. A majority of patients in clinical studies were\\r\\nretreated between 12- 16 weeks. The degree and pattern of muscle spasticity at\\r\\nthe time of re-injection may necessitate alterations in the dose of DYSPORT and\\r\\nmuscles to be injected.',\n",
       " 'DYSPORT is supplied as a single-use vial. Only use\\r\\nsterile preservative-free 0.9% Sodium Chloride Injection, USP for reconstitution\\r\\nof DYSPORT. The recommended concentration is 100 Units/mL or 200 Units/mL with\\r\\npreservative-free 0.9% Sodium Chloride Injection, USP) (see Table 1).',\n",
       " 'Using an appropriately sized sterile syringe, needle and\\r\\naseptic technique, draw up the required volume (see Table 1) of preservative-free\\r\\n0.9% Sodium Chloride Injection, USP.',\n",
       " 'Insert the needle into the DYSPORT vial. The partial\\r\\nvacuum will begin to pull the saline into the vial. No more than 2.5 mL of\\r\\nsaline should be introduced into the vial (see footnote in Table 1 ). Do not\\r\\nuse the vial if a vacuum is absent. Gently swirl to dissolve. Parenteral drug\\r\\nproducts should be inspected visually for particulate matter and discoloration prior\\r\\nto administration. Reconstituted DYSPORT should be a clear, colorless solution,\\r\\nfree of particulate matter; otherwise it should not be injected.',\n",
       " 'Expel any air bubbles in the syringe barrel. Remove the\\r\\nneedle used to reconstitute the product and attach an appropriately sized new\\r\\nsterile needle.',\n",
       " 'Discard the vial and needle in accordance with local\\r\\nregulations.',\n",
       " 'DYSPORT dosing for pediatric lower limb spasticity is\\r\\nbased on Units per kilogram of body weight. Table 4 describes the recommended\\r\\nUnits/kg dose of DYSPORT per muscle of the Gastrocnemius-Soleus Complex (GSC).\\r\\nThe recommended total DYSPORT dose per treatment session is 10 to 15 Units/kg\\r\\nfor unilateral lower limb injections or 20 to 30 Units/kg for bilateral lower\\r\\nlimb injections. However, the total dose of DYSPORT administered per treatment session\\r\\nmust not exceed 15 Units/kg for unilateral lower limb injections or 30 Units/kg\\r\\nfor bilateral lower limb injections or 1000 Units, whichever is lower. The\\r\\ntotal dose administered should be divided between the affected spastic muscles\\r\\nof the lower limb(s). When possible, the dose should be distributed across more\\r\\nthan 1 injection site in any single muscle (see Table 4). No more than 0.5 mL\\r\\nof DYSPORT should be administered in any single injection site.',\n",
       " \"Dosing in initial and sequential treatment sessions\\r\\nshould be tailored to the individual patient based on the size, number and\\r\\nlocation of muscles involved, severity of spasticity, the presence of local\\r\\nmuscle weakness, the patient's response to previous treatment, and/or adverse\\r\\nevent history with botulinum toxins.\",\n",
       " 'Table 4: DYSPORT Dosing by Muscle for Lower Limb\\r\\nSpasticity in Pediatric Patients',\n",
       " 'Figure 4: Muscles for Injection for Lower Limb\\r\\nSpasticityin Pediatric Patients',\n",
       " 'Although actual location of the injection sites can be\\r\\ndetermined by palpation, the use of injection guiding technique, e.g.\\r\\nelectromyography or electrical stimulation, is recommended to target the\\r\\ninjection sites.',\n",
       " 'Repeat DYSPORT treatment should be administered when the\\r\\neffect of a previous injection has diminished but no sooner than 12 weeks after\\r\\nthe previous injection. A majority of patients in the clinical studies were\\r\\nretreated between 16-22 weeks, however; some had a longer duration of response.\\r\\nThe degree and pattern of muscle spasticity and overall clinical benefit at the\\r\\ntime of re-injection may necessitate alterations in the dose of DYSPORT and\\r\\nmuscles to be injected.',\n",
       " 'The safety and effectiveness of DYSPORT injected into\\r\\nproximal muscles of the lower limb for the treatment of spasticity in pediatric\\r\\npatients has not been established.',\n",
       " 'The safety and effectiveness of DYSPORT in the treatment\\r\\nof lower limb spasticity in pediatric patients of less than 2 years of age has\\r\\nnot been evaluated.',\n",
       " 'The safety and effectiveness of DYSPORT in the treatment\\r\\nof upper limb spasticity in pediatric patients has not been demonstrated [see WARNINGS\\r\\nAND PRECAUTIONS and Use In Specific Populations ].',\n",
       " 'DYSPORT is supplied as single-use 300 Unit or 500 Unit\\r\\nvials. Only use sterile preservative-free 0.9% Sodium Chloride Injection, USP\\r\\nfor reconstitution of DYSPORT. Each 500 Unit vial of DYSPORT is to be\\r\\nreconstituted with 2.5 mL of preservative-free 0.9% Sodium Chloride Injection,\\r\\nUSP prior to injection. Each 300 Unit vial of DYSPORT is to be reconstituted\\r\\nwith 1.5 mL of preservative-free 0.9% Sodium Chloride Injection, USP prior to\\r\\ninjection. The concentration of the resulting solution will be 20 Units per 0.1\\r\\nmL. Further dilution with preservative-free 0.9% Sodium Chloride Injection,\\r\\nUSP, may be required to achieve the final volume for injection. No more than\\r\\n0.5 mL DYSPORT should be administered in any single injection site.',\n",
       " 'To calculate the total units of DYSPORT required for\\r\\ntreatment of one leg, select the dose of DYSPORT Units/kg/leg and the body\\r\\nweight (kg) of the patients (see Table 4). Using an appropriately sized sterile\\r\\nsyringe (e.g., 3 mL syringe), needle and aseptic technique, draw up 2.5 mL or\\r\\npreservative-free 0.9% Sodium Chloride Injection, USP. Insert the needle into\\r\\nthe DYSPORT 500 Unit vial. The partial vacuum will begin to pull the saline\\r\\ninto the vial. Any remaining required saline should be expressed into the vial\\r\\nmanually. Do not use the vial if no vacuum is observed. Swirl gently to\\r\\ndissolve. Parenteral drug products should be inspected visually for particle\\r\\nmatter and discoloration prior to administration. Reconstituted DYSPORT should\\r\\nbe a clear, colorless solution, free of particulate matter; otherwise it should\\r\\nnot be injected.',\n",
       " 'Draw the required patient dose of DYSPORT into a sterile\\r\\nsyringe and dilute with additional preservative-free 0.9% Sodium Chloride\\r\\nInjection, USP, if required, to achieve the final volume for injection. Expel\\r\\nany air bubbles in the syringe barrel. Remove the needle used to reconstitute\\r\\nthe product and attach an appropriately sized new sterile needle. Use\\r\\nimmediately after reconstitution in the syringe.',\n",
       " 'Discard the vial and needle in accordance with local\\r\\nregulations.',\n",
       " 'For injection: 300 Units or 500 Units of lyophilized\\r\\npowder in a single-dose vial for reconstitution with preservativefree 0.9%\\r\\nSodium Chloride Injection, USP.',\n",
       " 'DYSPORT® (abobotulinumtoxinA) for Injection is a sterile,\\r\\nlyophilized powder supplied in a single-dose, glass vial. Unopened vials of\\r\\nDYSPORT must be stored refrigerated between 2°C to 8°C (36°F to 46°F). Protect\\r\\nfrom light.',\n",
       " 'Do not use after the expiration date on the vial. All\\r\\nvials, including expired vials, or equipment used with DYSPORT should be\\r\\ndisposed of carefully as is done with all medical waste.',\n",
       " 'DYSPORT contains a unique hologram on the carton. If you\\r\\ndo not see the hologram, do not use the product. Instead contact 855-463-5127.',\n",
       " '500 Unit Vial',\n",
       " 'Each vial contains 500 Units of freeze-dried\\r\\nabobotulinumtoxinA.',\n",
       " 'Box containing 1 vial - NDC 15054-0500-1 Box containing 2 vials - NDC 15054-0500-2',\n",
       " '300 Unit Vial',\n",
       " 'Each vial contains 300 Units of freeze-dried\\r\\nabobotulinumtoxinA.',\n",
       " 'Box containing 1 vial - NDC 15054-0530-6',\n",
       " 'Each vial contains 300 Units of freeze-dried\\r\\nabobotulinumtoxinA.',\n",
       " 'Box containing 1 vial - NDC 0299-5962-30',\n",
       " 'Manufactured by: Ipsen Biopharm Ltd., Wrexham, LL13 9UF,\\r\\nUK, U.S. License No. 1787. Distributed by: Ipsen Biopharmaceuticals, Inc., Basking\\r\\nRidge, NJ 07920 And Galderma Laboratories, L.P. Fort Worth, TX 76177 USA. Revised:\\r\\nMar 2019',\n",
       " 'ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.',\n",
       " 'ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.',\n",
       " 'ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.',\n",
       " 'DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL FORMULATIONS. ABRAXANE has different dosage and administration instructions from other paclitaxel products.',\n",
       " 'Closely monitor the infusion site for extravasation or drug infiltration during administration. Limiting the infusion of ABRAXANE to 30 minutes may reduce the risk of infusion-related reactions [see ADVERSE REACTIONS ].',\n",
       " 'Consider premedication in patients who have had prior hypersensitivity reactions to ABRAXANE. Do not re-challenge patients who experience a severe hypersensitivity reaction to ABRAXANE [see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS ].',\n",
       " 'After failure of combination chemotherapy for metastatic breast cancer or relapse within 6 months of adjuvant chemotherapy, the recommended regimen for ABRAXANE is 260 mg/m² administered intravenously over 30 minutes every 3 weeks.',\n",
       " 'The recommended dose of ABRAXANE is 100 mg/m² administered as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of each 21-day cycle. Administer carboplatin on Day 1 of each 21-day cycle immediately after ABRAXANE [see Clinical Studies ].',\n",
       " 'The recommended dose of ABRAXANE is 125 mg/m² administered as an intravenous infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle. Administer gemcitabine immediately after ABRAXANE on Days 1, 8, and 15 of each 28-day cycle [see Clinical Studies ].',\n",
       " 'For patients with moderate or severe hepatic impairment, reduce the starting dose of ABRAXANE as shown in Table 1.',\n",
       " 'Table 1: Recommendations for Starting Dose in Patients with Moderate and Severe Hepatic Impairment',\n",
       " '',\n",
       " 'Patients who experience severe neutropenia (neutrophils less than 500 cells/mm³ for a week or longer) or severe sensory neuropathy during ABRAXANE therapy should have dosage reduced to 220 mg/m² for subsequent courses of ABRAXANE. For recurrence of severe neutropenia or severe sensory neuropathy, additional dose reduction should be made to 180 mg/m². For Grade 3 sensory neuropathy hold treatment until resolution to Grade 1 or 2, followed by a dose reduction for all subsequent courses of ABRAXANE [see CONTRAINDICATIONS , WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS ].',\n",
       " 'Table 2: Permanent Dose Reductions for Hematologic and Neurologic Adverse Reactions in NSCLC',\n",
       " '',\n",
       " 'Dose level reductions for patients with adenocarcinoma of the pancreas, as referenced in Tables 4 and 5, are provided in Table 3.',\n",
       " 'Table 3: Dose Level Reductions for Patients with Adenocarcinoma of the Pancreas',\n",
       " '',\n",
       " 'Recommended dose modifications for neutropenia and thrombocytopenia for patients with adenocarcinoma of the pancreas are provided in Table 4.',\n",
       " 'Table 4: Dose Recommendation and Modifications for Neutropenia and/or Thrombocytopenia at the Start of a Cycle orwithin a Cycle for Patients with Adenocarcinoma of the Pancreas',\n",
       " '',\n",
       " 'Recommended dose modifications for other adverse reactions in patients with adenocarcinoma of the pancreas are provided in Table 5.',\n",
       " 'Table 5: Dose Modifications for Other Adverse Reactions in Patients with Adenocarcinoma of the Pancreas',\n",
       " '',\n",
       " 'ABRAXANE is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 The use of gloves is recommended. If ABRAXANE (lyophilized cake or reconstituted suspension) contacts the skin, wash the skin immediately and thoroughly with soap and water. Following topical exposure to paclitaxel, events may include tingling, burning, and redness. If ABRAXANE contacts mucous membranes, the membranes should be flushed thoroughly with water.',\n",
       " 'ABRAXANE is supplied as a sterile lyophilized powder for reconstitution before use.',\n",
       " 'Read the entire preparation instructions prior to reconstitution.',\n",
       " '',\n",
       " '',\n",
       " 'Each mL of the reconstituted formulation will contain 5 mg/mL paclitaxel.',\n",
       " 'The reconstituted suspension should be milky and homogenous without visible particulates. If particulates or settling are visible, the vial should be gently inverted again to ensure complete resuspension prior to use. Discard the reconstituted suspension if precipitates are observed. Discard any unused portion.',\n",
       " 'Calculate the exact total dosing volume of 5 mg/mL suspension required for the patient and slowly withdraw the dosing volume of the reconstituted suspension from the vial(s) into a syringe: Dosing volume (mL)=Total dose (mg)/5 (mg/mL).',\n",
       " 'Inject the appropriate amount of reconstituted ABRAXANE into an empty, sterile intravenous bag [plasticized polyvinyl chloride (PVC) containers, PVC or non-PVC type intravenous bag]. The use of specialized DEHP-free solution containers or administration sets is not necessary to prepare or administer ABRAXANE infusions. The use of medical devices containing silicone oil as a lubricant (i.e., syringes and intravenous bags) to reconstitute and administer ABRAXANE may result in the formation of proteinaceous strands.',\n",
       " 'Visually inspect the reconstituted ABRAXANE suspension in the intravenous bag prior to administration. Discard the reconstituted suspension if proteinaceous strands, particulate matter, or discoloration are observed.',\n",
       " 'Unopened vials of ABRAXANE are stable until the date indicated on the package when stored between 20°C to 25°C (68°F to 77°F) in the original package. Neither freezing nor refrigeration adversely affects the stability of the product.',\n",
       " 'Reconstituted ABRAXANE in the vial should be used immediately, but may be refrigerated at 2°C to 8°C (36°F to 46°F) for a maximum of 24 hours if necessary. If not used immediately, each vial of reconstituted suspension should be replaced in the original carton to protect it from bright light. Discard any unused portion.',\n",
       " 'The suspension for infusion when prepared as recommended in an infusion bag should be used immediately, but may be refrigerated at 2°C to 8°C (36°F to 46°F) and protected from bright light for a maximum of 24 hours.',\n",
       " 'The total combined refrigerated storage time of reconstituted ABRAXANE in the vial and in the infusion bag is 24 hours. This may be followed by storage in the infusion bag at ambient temperature (approximately 25°C) and lighting conditions for a maximum of 4 hours.',\n",
       " 'Discard any unused portion.',\n",
       " 'For injectable suspension, for intravenous use: white to yellow, sterile lyophilized powder containing 100 mg of paclitaxel formulated as albumin-bound particles in single-dose vial for reconstitution.',\n",
       " 'ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) is a white to yellow, sterile lyophilized powder supplied as:',\n",
       " 'NDC : 68817-134-50 100 mg of paclitaxel in a single-dose vial, individually packaged in a carton.',\n",
       " 'Store the vials in original cartons at 20°C to 25°C (68°F to 77°F). Retain in the original package to protect from bright light.',\n",
       " 'Abraxane is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1',\n",
       " 'REFERENCES',\n",
       " '1. OSHA Hazardous Drugs. OSHA http://www.osha.gov/SLTC/hazardousdrugs/index.html',\n",
       " 'Manufactured for: Celgene Corporation Summit, NJ 07901. Revised: Aug 2020',\n",
       " 'Cold sore /fever blister treatment',\n",
       " 'adults and children 12 years or over:',\n",
       " 'children under 12 years :',\n",
       " 'Product : 50090-3476',\n",
       " 'NDC : 50090-3476-0 2 g in a TUBE',\n",
       " 'Distributed for Avanir Pharmaceuticals by\\r\\n  GlaxoSmithKline Consumer Healthcare, L.P.\\r\\nMoon Twp, PA 15108. Revised: Jun 2018',\n",
       " 'ABRILADA is indicated for\\r\\nreducing signs and symptoms, inducing major clinical response, inhibiting the\\r\\nprogression of structural damage, and improving physical function in adult\\r\\npatients with moderately to severely active\\r\\nrheumatoid arthritis. ABRILADA can be used alone or in combination with\\r\\nmethotrexate or other non-biologic disease-modifying anti-rheumatic drugs\\r\\n(DMARDs).',\n",
       " 'ABRILADA is indicated for\\r\\nreducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older. ABRILADA\\r\\ncan be used alone or in combination with methotrexate.',\n",
       " 'ABRILADA is indicated for\\r\\nreducing signs and symptoms, inhibiting the progression of structural damage,\\r\\nand improving physical function in adult patients with active psoriatic\\r\\narthritis. ABRILADA can be used alone or in combination with non-biologic\\r\\nDMARDs.',\n",
       " 'ABRILADA is indicated for\\r\\nreducing signs and symptoms in adult patients with active ankylosing spondylitis .',\n",
       " \"ABRILADA is indicated for\\r\\nreducing signs and symptoms and inducing and maintaining clinical remission in\\r\\nadult patients with moderately to severely active Crohn's disease who have had\\r\\nan inadequate response to conventional therapy. ABRILADA is indicated for\\r\\nreducing signs and symptoms and inducing clinical remission in these patients\\r\\nif they have also lost response to or are intolerant to infliximab products.\",\n",
       " 'ABRILADA is indicated for\\r\\ninducing and sustaining clinical remission in adult patients with moderately to\\r\\nseverely active ulcerative colitis who have had an inadequate response to\\r\\nimmunosuppressants such as corticosteroids, azathioprine or 6- mercaptopurine (6- MP ). The effectiveness of adalimumab products has not been established in\\r\\npatients who have lost response to or were intolerant to TNF blockers [see Clinical\\r\\nStudies ].',\n",
       " 'ABRILADA is indicated for the\\r\\ntreatment of adult patients with moderate to severe chronic plaque psoriasis\\r\\nwho are candidates for systemic therapy or phototherapy , and when other\\r\\nsystemic therapies are medically less appropriate. ABRILADA should only be\\r\\nadministered to patients who will be closely monitored and have regular\\r\\nfollow-up visits with a physician [see BOXED WARNING and WARNINGS AND PRECAUTIONS ].',\n",
       " 'CIBINQO is indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.',\n",
       " 'CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.',\n",
       " 'Perform the following tests and evaluations prior to CIBINQO initiation:',\n",
       " 'Complete any necessary immunizations, including herpes zoster vaccinations, in agreement with current immunization guidelines prior to CIBINQO initiation [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'The recommended dosage of CIBINQO is 100 mg orally once daily.',\n",
       " 'If an adequate response is not achieved with CIBINQO 100 mg orally daily after 12 weeks, consider increasing dosage to 200 mg orally once daily. Discontinue therapy if inadequate response is seen after dosage increase to 200 mg once daily.',\n",
       " 'CIBINQO can be used with or without topical corticosteroids.',\n",
       " 'If a dose is missed, administer the dose as soon as possible unless it is less than 12 hours before the next dose, in which case skip the missed dose. Thereafter, resume dosing at the regular scheduled time.',\n",
       " 'CIBINQO dosage recommendations for patients with renal impairment are provided in Table 1 [see Use In Specific Populations and CLINICAL PHARMACOLOGY ]. In subjects with mild and moderate renal impairment, if an adequate response is not achieved after 12 weeks, dose of CIBINQO can be doubled [see Recommended Dosage ].',\n",
       " 'Table 1. Dosage Recommendations in Patients with Renal Impairment',\n",
       " '',\n",
       " 'CIBINQO is not recommended for use in patients with severe hepatic impairment [see Use In Specific Populations and CLINICAL PHARMACOLOGY ].',\n",
       " 'In patients who are known or suspected to be CYP2C19 poor metabolizers, the recommended dosage of CIBINQO is 50 mg once daily [see Use In Specific Populations and CLINICAL PHARMACOLOGY ]. If an adequate response is not achieved with CIBINQO 50 mg orally daily after 12 weeks, consider increasing dosage to 100 mg orally once daily. Discontinue therapy if inadequate response is seen after dosage increase to 100 mg once daily.',\n",
       " 'In patients taking strong inhibitors of cytochrome P450 (CYP) 2C19 reduce the dosage to 50 mg once daily [see DRUG INTERACTIONS and CLINICAL PHARMACOLOGY ]. If an adequate response is not achieved with CIBINQO 50 mg orally daily after 12 weeks, consider increasing dosage to 100 mg orally once daily. Discontinue therapy if inadequate response is seen after dosage increase to 100 mg once daily.',\n",
       " 'If a patient develops a serious or opportunistic infection, discontinue CIBINQO and control the infection. The risks and benefits of treatment with CIBINQO should be carefully considered prior to reinitiating therapy with CIBINQO [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Recommendations for CIBINQO discontinuation for laboratory abnormalities are summarized in Table 2.',\n",
       " 'Table 2. Recommendations for CIBINQO Discontinuation for Hematologic Abnormalities',\n",
       " '',\n",
       " 'CBC evaluations are recommended at baseline, 4 weeks after treatment initiation and 4 weeks after dosing increase of CIBINQO. Laboratory evaluations may be extended for patients on chronic CIBINQO therapy who develop hematologic abnormalities [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Administer CIBINQO with or without food at approximately the same time each day.',\n",
       " 'Swallow CIBINQO tablets whole with water. Do not crush, split, or chew CIBINQO tablets.',\n",
       " 'CIBINQO is supplied as:',\n",
       " '',\n",
       " '',\n",
       " 'Store CIBINQO at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in original package. The container closure system is child resistant.',\n",
       " 'Distributed by: Pfizer Labs, Division of Pfizer Inc, New York, NY 10017. Revised: Jan 2022',\n",
       " 'HEMOSTASIS : GELFOAM Sterile Compressed Sponge, used\\r\\ndry or saturated with sterile sodium chloride solution, is indicated in\\r\\nsurgical procedures as a hemostatic device, when control of capillary , venous,\\r\\nand arteriolar bleeding by pressure, ligature , and other conventional\\r\\nprocedures is either ineffective or impractical. Although not necessary,\\r\\nGELFOAM can be used either with or without thrombin to obtain hemostasis.',\n",
       " 'Sterile technique should always be used to remove GELFOAM\\r\\nSterile Compressed Sponge from its packaging. Cut to the desired size, a piece\\r\\nof GELFOAM, either dry or saturated with sterile, isotonic sodium chloride\\r\\nsolution (sterile saline ), can be applied with pressure directly to the\\r\\nbleeding site.',\n",
       " 'When applied dry, a single piece of GELFOAM should be\\r\\nmanually applied to the bleeding site, and held in place with moderate pressure\\r\\nuntil hemostasis results.',\n",
       " 'When used with sterile saline, GELFOAM should be first\\r\\nimmersed in the solution and then withdrawn, squeezed between gloved fingers to\\r\\nexpel air bubbles, and then replaced in saline until needed. The GELFOAM sponge\\r\\nshould promptly return to its original size, with slight expansion in thickness\\r\\nand shape in the solution. If it does not, it should be removed again and\\r\\nkneaded vigorously until all air is expelled and it does expand to its original\\r\\nsize, with slight increases in thickness and shape when returned to the sterile\\r\\nsaline.',\n",
       " 'GELFOAM if used wet it may be blotted to dampness on\\r\\ngauze before application to the bleeding site. It should be held in place with\\r\\nmoderate pressure, using a pledget of cotton or small gauze sponge until\\r\\nhemostasis results. Removal of the pledget or gauze is made easier by wetting\\r\\nit with a few drops of sterile saline, to prevent pulling up the GELFOAM, which\\r\\nby then should enclose a firm clot.',\n",
       " 'Use of suction applied over the pledget of cotton or\\r\\ngauze to draw blood into the GELFOAM is unnecessary, as GELFOAM will draw up\\r\\nsufficient blood by capillary action. The first application of GELFOAM will\\r\\nusually control bleeding, but if not, additional applications may be made. For\\r\\nadditional applications, fresh pieces should be used and prepared as previously\\r\\ndescribed.',\n",
       " 'Use only the minimum amount of GELFOAM, cut to\\r\\nappropriate size, necessary to produce hemostasis. The GELFOAM may be left in\\r\\nplace at the bleeding site, when necessary. Since GELFOAM causes little more\\r\\ncellular reaction than does the blood clot , the wound may be closed over it.\\r\\nGELFOAM may be left in place when applied to mucosal surfaces until it\\r\\nliquefies.',\n",
       " 'For use with thrombin, consult the thrombin insert for\\r\\ncomplete prescribing information and proper sample preparation.',\n",
       " 'In oral and dental surgery, GELFOAM Dental Sponges are an\\r\\naid in providing hemostasis . GELFOAM may be used either dry or moistened,\\r\\ndepending upon conditions present at operation and preference of the surgeon .\\r\\nIsotonic saline is suitable for use with GELFOAM. Although not necessary,\\r\\nGELFOAM can be used either with or without thrombin to obtain hemostasis.',\n",
       " 'When used dry, GELFOAM Dental Sponges, cut to desired\\r\\nsize, are rolled between the fingers and lightly compressed to the approximate\\r\\ndiameter of the cavity or socket to be filled. Following insertion of the\\r\\nrolled pack, light finger pressure should be applied for one or two minutes.',\n",
       " 'When used moistened, GELFOAM, cut to desired size, is\\r\\nimmersed in the solution of sodium chloride. The piece is then removed from the\\r\\nsolution, squeezed thoroughly to remove air bubbles present in the meshes, and\\r\\nreplaced in the solution where it will swell to its original size. It is then\\r\\ntaken from the solution, blotted on sterile gauze to remove excess fluid, and\\r\\nplaced in the cavity or wound. For use with thrombin, consult the thrombin\\r\\ninsert for complete prescribing information and proper sample preparation.',\n",
       " 'GELFOAM Dental Sponges are available in Size 4 (2 x 2 cm)\\r\\nenvelopes of 2 sponges GTIN 00300090396053 (0009-0396-05)',\n",
       " 'GELFOAM Dental Sponges should be stored at 25°C (77°F);\\r\\nexcursions permitted to 15-30°C (59-86°F) [see USP Controlled Room\\r\\nTemperature ]. Once the package is opened, contents are subject to\\r\\ncontamination. It is recommended that GELFOAM be used as soon as the package is\\r\\nopened and unused contents discarded.',\n",
       " 'This product is prepackaged sterile and intended only for\\r\\nsingle use. Reuse can result in transmission of bloodborne pathogens (including HIV and hepatitis ), potentially endangering patients and health care providers.\\r\\nAdherence to the principles of aseptic technique when using this product is essential .',\n",
       " 'Federal law restricts this device to sale by or on the\\r\\norder of a dentist or physician.',\n",
       " '',\n",
       " 'Manufactured by: Pharmacia and Upjohn Company, 7000\\r\\nPortage Road, Kalamazoo, Michigan 49001, USA, 1-800-253-8600. Distributed by: Pharmacia & Upjohn\\r\\nCo., Division of Pfizer Inc., New York, NY 10017. Revised December 2014',\n",
       " 'Gelfoam coupons',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'GELFOAM Sterile Powder,\\r\\nsaturated with sterile sodium chloride solution, is indicated in surgical\\r\\nprocedures, including those involving cancellous bone bleeding, as a hemostatic\\r\\ndevice, when control of capillary , venous, and arteriolar bleeding by pressure, ligature , and other conventional procedures is either ineffective or\\r\\nimpractical. Although not necessary, GELFOAM can be used either with or without thrombin to obtain hemostasis .',\n",
       " 'GELFOAM Sterile Powder can be saturated with sterile,\\r\\nisotonic sodium chloride solution (sterile saline ) or a solution of thrombin 1 ,\\r\\nbefore use as an adjunct to hemostasis. The envelope of GELFOAM Sterile Powder\\r\\nshould be opened and the contents (1 gram ) poured carefully into a sterile\\r\\nbeaker, avoiding contamination. Using sterile technique, a puttylike paste is\\r\\nprepared by adding a total of approximately 3-4 mL of sterile saline or\\r\\nthrombin solution1 to the GELFOAM. If a mixture of less viscosity is desired,\\r\\n7-10 mL of sterile saline or thrombin solution may be utilized. Dispersion of\\r\\nthe powder can be avoided by initially compressing it with the gloved fingers\\r\\ninto the bottom of the beaker and then kneading it into the desired consistency.\\r\\nThe resulting doughy paste may be smeared or pressed against the bleeding\\r\\nsurface to control bleeding. When bleeding stops the excess should be removed.',\n",
       " 'Use only the minimum amount of GELFOAM, necessary to\\r\\nproduce hemostasis. The GELFOAM may be left in place at the bleeding site, when\\r\\nnecessary. Since GELFOAM causes little more cellular reaction than does the blood clot , the wound may be closed over it. GELFOAM may be left in place when\\r\\napplied to mucosal surfaces until it liquefies. For use with thrombin, consult\\r\\nthe thrombin insert for complete prescribing information and proper sample\\r\\npreparation.',\n",
       " 'Sterile technique should always be used to remove GELFOAM\\r\\nSterile Sponge from its packaging. Cut to the desired size, a piece of GELFOAM,\\r\\neither dry or saturated with sterile, isotonic sodium chloride solution\\r\\n(sterile saline ), can be applied with pressure directly to the bleeding site.\\r\\nWhen applied dry, a single piece of GELFOAM should be manually compressed\\r\\nbefore application to the bleeding site, and then held in place with moderate pressure\\r\\nuntil hemostasis results. When used with sterile saline, GELFOAM should be\\r\\nfirst immersed in the solution and then withdrawn, squeezed between gloved\\r\\nfingers to expel air bubbles, and then replaced in saline until needed. The GELFOAM\\r\\nsponge should promptly return to its original size and shape in the solution.\\r\\nIf it does not, it should be removed again and kneaded vigorously until all air\\r\\nis expelled and it does expand to its original size and shape when returned to\\r\\nthe sterile saline.',\n",
       " 'GELFOAM is used wet or blotted to dampness on gauze\\r\\nbefore application to the bleeding site. It should be held in place with\\r\\nmoderate pressure, using a pledget of cotton or small gauze sponge until\\r\\nhemostasis results. Removal of the pledget or gauze is made easier by wetting\\r\\nit with a few drops of sterile saline, to prevent pulling up the GELFOAM which\\r\\nby then should enclose a firm clot. Use of suction applied over the pledget of\\r\\ncotton or gauze to draw blood into the GELFOAM is unnecessary, as the GELFOAM\\r\\nwill draw up sufficient blood by capillary action. The first application of\\r\\nGELFOAM will usually control bleeding, but if not, additional applications may\\r\\nbe made using fresh pieces, prepared as described above.',\n",
       " 'Use only the minimum amount of GELFOAM, cut to\\r\\nappropriate size, necessary to produce hemostasis. The GELFOAM may be left in\\r\\nplace at the bleeding site, when necessary. Since GELFOAM causes little more\\r\\ncellular reaction than does the blood clot , the wound may be closed over it.\\r\\nGELFOAM may be left in place when applied to mucosal surfaces until it liquefies. For use with thrombin, consult the thrombin insert for complete prescribing\\r\\ninformation and proper sample preparation.',\n",
       " 'Nonconducive to undue\\r\\ninflammatory reaction and absorbable at a rate sufficiently slow to permit dural regeneration and healing of the arachnoid layer, GELFILM Sterile Film\\r\\nfavorably meets requisites for a dural substitute. Use in patients undergoing\\r\\ncraniotomies has been reported to prevent development of meningocerebral\\r\\nadhesions and thereby reduce risk of postoperative sequelae .',\n",
       " 'In repair of pleural defects in\\r\\nconnection with thoracotomies, thoracoplasties, and extrapleural procedures, implantation of GELFILM Sterile Film has been observed to be followed by\\r\\nminimal tissue reaction and closure of the defect by ingrowth of regenerating\\r\\npleural and fibrous tissue across the gradually resorbed GELFILM implant .',\n",
       " 'Various ocular surgical\\r\\nprocedures in which GELFILM Sterile Ophthalmic Film has been used include glaucoma filtration operations (i.e., iridencleisis and trephination),\\r\\nextraocular muscle surgery, and diathermy or sclera “buckling”\\r\\noperations for retinal detachment . Experimental studies in rabbits and clinical\\r\\ntrials in patients have shown a remarkable lack of cellular reaction to GELFILM\\r\\nimplanted subconjunctivally or used as a seton into the anterior chamber . Objective evidence that GELFILM implants aid in preventing formation of adhesionsbetween\\r\\ncontiguous ocular structures has been reported as follows: in iridencleisis in which\\r\\nGELFILM was employed as a seton, the resultant filtrating areas were large and\\r\\nthere was no postoperative rise in intraocular tension ; in extraocular muscle surgery\\r\\nand operations for retinal detachment, insertion of GELFILM implants between\\r\\ncontiguous tissue layers was found to enhance the ease of secondary operations.',\n",
       " 'Absorica coupons',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'ABSORICA and ABSORICA LD are indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, ABSORICA and ABSORICA LD are reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics.',\n",
       " 'If a second course of ABSORICA/ABSORICA LD therapy is needed, it is not recommended before a two-month waiting period because the patient’s acne may continue to improve following a 15 to 20-week course of therapy [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'ABSORICA is not substitutable with ABSORICA LD [see WARNINGS AND PRECAUTIONS ]. The recommended dosage',\n",
       " 'To decrease the risk of esophageal irritation, instruct patients to swallow the capsules with a full glass of liquid. During treatment, the dosage may be adjusted according to response of the disease and/or adverse reactions, some of which may be dose-related. Adult patients whose disease is very severe with scarring or is primarily manifested on the trunk may require dosage adjustments up to 2 mg/kg/day for ABSORICA (1.6 mg/kg/day for ABSORICA LD) in divided doses, as tolerated.',\n",
       " 'The safety and effectiveness of once daily dosing with ABSORICA/ABSORICA LD has not been established and is not recommended.',\n",
       " 'If a dose of ABSORICA/ABSORICA LD is missed, just skip that dose. Do not take two doses of ABSORICA/ ABSORICA LD at the same time.',\n",
       " 'Table 1: ABSORICA Daily Dosage by Body Weight 1',\n",
       " '',\n",
       " 'Table 2: ABSORICA LD Daily Dosage by Body Weight 1',\n",
       " '',\n",
       " 'A normal course of treatment is 15 to 20 weeks. If the total nodule count has been reduced by more than 70% prior to completing 15 to 20 weeks of treatment, may discontinue ABSORICA/ABSORICA LD.',\n",
       " 'After a period of 2 months or more off therapy, and if warranted by persistent or recurring severe nodular acne, may initiate a second course of ABSORICA/ABSORICA LD in patients who have completed skeletal growth. The use of another course of ABSORICA/ABSORICA LD therapy is not recommended before a two-month waiting period because the patient’s acne may continue to improve after a 15 to 20-week course of therapy. The optimal interval before retreatment has not been defined for patients who have not completed skeletal growth.',\n",
       " 'Long-term use of ABSORICA/ABSORICA LD, even in low dosages, has not been studied, and is not recommended. The effect of long-term use of ABSORICA/ABSORICA LD on bone loss is unknown [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'The following laboratory testing must be completed prior to ABSORICA/ABSORICA LD use:',\n",
       " 'ABSORICA and ABSORICA LD have different dosage regimens [see DOSAGE AND ADMINISTRATION ]. Although ABSORICA and ABSORICA LD have a 20 mg strength, these strengths have different bioavailability and are not substitutable.',\n",
       " 'ABSORICA is available in 10 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg capsules.',\n",
       " 'ABSORICA LD is available in 8 mg, 16 mg, 20 mg, 24 mg, 28 mg and 32 mg opaque-printed, hard-gelatin capsules.',\n",
       " 'ABSORICA and ABSORICA LD have different dosage regimens. Although ABSORICA and ABSORICA LD have a 20 mg strength, these strengths have different bioavailability and are not substitutable [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'ABSORICA (isotretinoin) Capsules (opaque) are supplied as follows:',\n",
       " 'ABSORICA LD (isotretinoin) Capsules (opaque-printed, hard-gelatin) are supplied as follows:',\n",
       " 'Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP controlled room temperature]. Protect from light.',\n",
       " 'REFERENCES',\n",
       " '1.Cinar SL, Kartal D, Aksoy H, et al. Long-term effect of systemic isotretinoin on female fertility. Cutan Ocul Toxicol. 2017;36(2):132-134.',\n",
       " 'Manufactured by: ABSORICA Galephar Pharmaceutical Research, Inc. Revised: Oct 2019',\n",
       " 'ABSORICA and ABSORICA LD are indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, ABSORICA and ABSORICA LD are reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics.',\n",
       " 'If a second course of ABSORICA/ABSORICA LD therapy is needed, it is not recommended before a two-month waiting period because the patientâ€™s acne may continue to improve following a 15 to 20-week course of therapy [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'ABSORICA is not substitutable with ABSORICA LD [see WARNINGS AND PRECAUTIONS ]. The recommended dosage of:',\n",
       " 'To decrease the risk of esophageal irritation, instruct patients to swallow the capsules with a full glass of liquid. During treatment, the dosage may be adjusted according to response of the disease and/or adverse reactions, some of which may be dose-related. Adult patients whose disease is very severe with scarring or is primarily manifested on the trunk may require dosage adjustments up to 2 mg/kg/day for ABSORICA (1.6 mg/kg/day for ABSORICA LD) in divided doses, as tolerated.',\n",
       " 'The safety and effectiveness of once daily dosing with ABSORICA/ABSORICA LD has not been established and is not recommended.',\n",
       " 'If a dose of ABSORICA/ABSORICA LD is missed, just skip that dose. Do not take two doses of ABSORICA/ ABSORICA LD at the same time.',\n",
       " 'Table 1: ABSORICA Daily Dosage by Body Weight 1',\n",
       " '',\n",
       " 'Table 2: ABSORICA LD Daily Dosage by Body Weight 1',\n",
       " '',\n",
       " 'A normal course of treatment is 15 to 20 weeks. If the total nodule count has been reduced by more than 70% prior to completing 15 to 20 weeks of treatment, may discontinue ABSORICA/ABSORICA LD.',\n",
       " 'After a period of 2 months or more off therapy, and if warranted by persistent or recurring severe nodular acne, may initiate a second course of ABSORICA/ABSORICA LD in patients who have completed skeletal growth. The use of another course of ABSORICA/ABSORICA LD therapy is not recommended before a two-month waiting period because the patientâ€™s acne may continue to improve after a 15 to 20-week course of therapy. The optimal interval before retreatment has not been defined for patients who have not completed skeletal growth.',\n",
       " 'Long-term use of ABSORICA/ABSORICA LD, even in low dosages, has not been studied, and is not recommended. The effect of long-term use of ABSORICA/ABSORICA LD on bone loss is unknown [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'The following laboratory testing must be completed prior to ABSORICA/ABSORICA LD use:',\n",
       " 'ABSORICA and ABSORICA LD have different dosage regimens [see DOSAGE AND ADMINISTRATION ]. Although ABSORICA and ABSORICA LD have a 20 mg strength, these strengths have different bioavailability and are not substitutable.',\n",
       " 'ABSORICA is available in 10 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg capsules.',\n",
       " 'ABSORICA LD is available in 8 mg, 16 mg, 20 mg, 24 mg, 28 mg and 32 mg opaque-printed, hard-gelatin capsules.',\n",
       " 'ABSORICA and ABSORICA LD have different dosage regimens. Although ABSORICA and ABSORICA LD have a 20 mg strength, these strengths have different bioavailability and are not substitutable [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'ABSORICA (isotretinoin) Capsules (opaque) are supplied as follows:',\n",
       " '10 mg: Dark yellow, capsule imprinted with black ink “G 240” on cap and “10” on the body, Box of 30 capsules (3 x 10 Prescription Packs): NDC 10631-115-31',\n",
       " '20 mg : Red, capsule imprinted with black ink “G 241” on cap and “20” on the body, Box of 30 capsules (3 x 10 Prescription Packs): NDC 10631-116-31',\n",
       " '25 mg : Green, capsule imprinted with white ink “G 342” on cap and “25” on the body, Box of 30 capsules (3 x 10 Prescription Packs): NDC 10631-133-31',\n",
       " '30 mg : Brown, capsule imprinted with white ink “G 242” on cap and “30” on the body, Box of 30 capsules (3 x 10 Prescription Packs): NDC 10631-117-31',\n",
       " '35 mg : Dark blue, capsule imprinted with white ink “G 343” on cap and “35” on the body, Box of 30 capsules (3 x 10 Prescription Packs): NDC 10631-134-31',\n",
       " '40 mg : Brown and red, capsule imprinted with white ink “G 325” on cap and “40” on the body, Box of 30 capsules (3 x 10 Prescription Packs): NDC 10631-118-31',\n",
       " 'ABSORICA LD (isotretinoin) Capsules (opaque-printed, hard-gelatin) are supplied as follows:',\n",
       " '8 mg : A size 3, light green, capsules banded with a colorless band. The cap is printed in white with “RL29” and the body is printed in white with “RL29”. Box of 30 capsules (3 x 10 Prescription Packs) NDC 10631-002-31',\n",
       " '16 mg : A size 2, dark blue, capsules banded with a colorless band. The cap is printed in white with “RL30” and the body is printed in white with “RL30”. Box of 30 capsules (3 x 10 Prescription Packs) NDC 10631-003-31',\n",
       " '20 mg : A size 1, dark pink, capsules banded with a colorless band. The cap is printed in black with “RL33”and the body is printed in black with “RL33”. Box of 30 capsules (3 x 10 Prescription Packs) NDC 10631-004-31',\n",
       " '24 mg : A size 1, yellow, capsules banded with a colorless band. The cap is printed in white with “RL31” and the body is printed in white with “RL31”. Box of 30 capsules (3 x 10 Prescription Packs) NDC 10631-005-31',\n",
       " '28 mg : A size 0, light blue, capsules banded with a colorless band. The cap is printed in black with “RL34” and the body is printed in black with “RL34”. Box of 30 capsules (3 x 10 Prescription Packs) NDC 10631-006-31',\n",
       " '32 mg : A size 0, caramel, capsules banded with a colorless band. The cap is printed in white with “RL32” and the body is printed in white with “RL32”. Box of 30 capsules (3 x 10 Prescription Packs): NDC 10631-007-31',\n",
       " 'Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP controlled room temperature ]. Protect from light.',\n",
       " 'REFERENCES',\n",
       " '1.Cinar SL, Kartal D, Aksoy H, et al. Long-term effect of systemic isotretinoin on female fertility. Cutan Ocul Toxicol. 2017;36(2):132-134.',\n",
       " 'Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512. Revised: Apr 2022',\n",
       " 'ABSTRAL (fentanyl) sublingual tablets are indicated for\\r\\nthe management of breakthrough pain in cancer patients 18 years of age and\\r\\nolder who are already receiving and who are tolerant to opioid therapy for\\r\\ntheir underlying persistent cancer pain. Patients considered opioid tolerant\\r\\nare those who are taking around-theclock medicine consisting of at least 60 mg\\r\\nof oral morphine daily, or at least 25 mcg of transdermal fentanyl/hour, or at\\r\\nleast 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone\\r\\ndaily or at least 25 mg oral oxymorphone daily, or an equianalgesic dose of\\r\\nanother opioid medication daily for a week or longer. Patients must remain on\\r\\naround-the-clock opioids when taking ABSTRAL.',\n",
       " 'ABSTRAL is contraindicated for patients who are not\\r\\nalready tolerant to opioids because life-threatening respiratory depression and\\r\\ndeath could result at any dose in patients not on a chronic regimen of opioids.\\r\\nFor this reason, ABSTRAL is contraindicated in the management of acute or\\r\\npostoperative pain, including headache/ migraine , dental pain , or use in the\\r\\nemergency room.',\n",
       " 'ABSTRAL is intended to be prescribed only by healthcare\\r\\nprofessionals who are knowledgeable of, and skilled in, the use of Schedule II\\r\\nopioids to treat cancer pain.',\n",
       " 'As a part of the TIRF REMS Access program, ABSTRAL may be\\r\\ndispensed only to outpatients enrolled in the program [see WARNINGS AND PRECAUTIONS ]. For inpatient administration of ABSTRAL (e.g., hospitals,\\r\\nhospices, and long-term care facilities that prescribe for inpatient use),\\r\\npatient and prescriber enrollment is not required.',\n",
       " 'CALQUENCE is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.',\n",
       " 'This indication is approved under accelerated approval based on overall response rate [see Clinical Studies ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.',\n",
       " 'CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).',\n",
       " 'For patients with MCL, CLL, or SLL, the recommended dosage of CALQUENCE is 100 mg taken orally approximately every 12 hours until disease progression or unacceptable toxicity.',\n",
       " 'For patients with previously untreated CLL or SLL, the recommended dosage of CALQUENCE is 100 mg taken orally approximately every 12 hours until disease progression or unacceptable toxicity. Start CALQUENCE at Cycle 1 (each cycle is 28 days). Start obinutuzumab at Cycle 2 for a total of 6 cycles and refer to the obinutuzumab prescribing information for recommended dosing. Administer CALQUENCE prior to obinutuzumab when given on the same day.',\n",
       " 'Advise patients to swallow tablet whole with water. Advise patients not to chew, crush, dissolve, or cut the tablets. CALQUENCE may be taken with or without food. If a dose of CALQUENCE is missed by more than 3 hours, it should be skipped and the next dose should be taken at its regularly scheduled time. Extra tablets of CALQUENCE should not be taken to make up for a missed dose.',\n",
       " 'These are described in Table 1 [see DRUG INTERACTIONS ].',\n",
       " 'Table 1: Recommended Dosage Modifications for Use with CYP3A Inhibitors or Inducers',\n",
       " '',\n",
       " 'Recommended dosage modifications of CALQUENCE for Grade 3 or greater adverse reactions are provided in Table 2.',\n",
       " 'Table 2: Recommended Dosage Modifications for Adverse Reactions',\n",
       " '',\n",
       " 'Adverse reactions graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE).',\n",
       " 'Refer to the obinutuzumab prescribing information for management of obinutuzumab toxicities.',\n",
       " 'Tablets :100 mg acalabrutinib, orange, oval, film-coated, biconvex, debossed with â€˜ACA 100â€™ on one side and plain on the other.',\n",
       " '',\n",
       " '',\n",
       " 'Store at 20°C-25°C (68°F-77°F); excursions permitted to 15°C-30°C (59°F-86°F) [see USP Controlled Room Temperature ].',\n",
       " 'Distributed by: AstraZeneca Pharmaceuticals LP Wilmington, DE 19850. Revised: Aug 2022',\n",
       " 'ACAM2000® is indicated for active immunization against smallpox disease for persons determined to be at high risk for smallpox\\r\\ninfection.',\n",
       " 'ACAM2000 must be administered only by vaccine providers\\r\\nwith training to safely and effectively administer the vaccine by the percutaneous route ( scarification ). ACAM2000 should not be injected by the intradermal , subcutaneous, intramuscular, or intravenous route.',\n",
       " 'ACAM2000 is reconstituted by addition of 0.3 mL of\\r\\ndiluent to the vial containing lyophilized vaccine. Note: this 0.3 mL of\\r\\ndiluent is not the entire content of the diluent vial. ACAM2000 should only\\r\\nbe reconstituted with 0.3 mL of the diluent provided. The vaccine vial should\\r\\nbe removed from cold storage and brought to room temperature before\\r\\nreconstitution. The flip cap seals of the vaccine and diluent vials are\\r\\nremoved, and each rubber stopper is wiped with an isopropyl alcohol swab and\\r\\nallowed to dry thoroughly. Using aseptic technique and a sterile 1 mL syringe\\r\\nfitted with a 25 gauge x 5/8” needle (provided), draw up 0.3 mL of diluent and\\r\\ntransfer the entire content of the syringe to the vaccine vial. Gently swirl to\\r\\nmix but try not to get product on the rubber stopper. The reconstituted vaccine\\r\\nshould be a clear to slightly hazy, colorless to straw-colored liquid free from\\r\\nextraneous matter. Reconstituted vaccine should be inspected visually for\\r\\nparticulate matter and discoloration prior to administration. If particulate\\r\\nmatter or discoloration is observed, the vaccine should not be used and the\\r\\nvial should be disposed safely. [See Preparation / Handling\\r\\nPrecautions and Instructions for Disposal ]',\n",
       " 'After reconstitution, ACAM2000 vaccine may be\\r\\nadministered within 6 to 8 hours if kept at room temperature (20-25°C,\\r\\n68-77°F). Unused, reconstituted ACAM2000 vaccine may be stored in a\\r\\nrefrigerator (2-8°C, 36-46°F) up to 30 days, after which it\\r\\nshould be discarded as a biohazardous material. [See Preparation / Handling\\r\\nPrecautions and Instructions for Disposal ] Exposure of reconstituted\\r\\nvaccine to room temperature during vaccination sessions should be minimized by\\r\\nplacing it in refrigerator or on ice between patient administrations.',\n",
       " 'Personnel preparing and administering the vaccine should\\r\\nwear surgical or protective gloves and avoid contact of vaccine with skin, eyes\\r\\nor mucous membranes.',\n",
       " 'The vaccine vial, its stopper, the diluent syringe, the\\r\\nvented needle used for reconstitution, the bifurcated needle used for\\r\\nadministration, and any gauze or cotton that came in contact with the vaccine\\r\\nshould be discarded in leak-proof, puncture-proof biohazard containers. These\\r\\ncontainers should then be disposed of appropriately.',\n",
       " 'All vaccine providers must receive education on the\\r\\nproper administration as required by the U.S. Food and Drug Administration. All\\r\\nvaccine providers also receive a Medication Guide to distribute to each\\r\\nvaccinee prior to administering the vaccine. In the event of an actual smallpox\\r\\nemergency, declared by the Secretary of the U.S. Department of Health and Human\\r\\nServices, vaccine providers may follow educational instructions they receive\\r\\nfrom the manufacturer, such as how to educate vaccinees without a Medication Guide.',\n",
       " 'The site of vaccination is the upper arm over the\\r\\ninsertion of the deltoid muscle.',\n",
       " 'No skin preparation should be performed unless the skin at the intended site of vaccination is obviously dirty, in which case an\\r\\nalcohol swab(s) may be used to clean the area. If alcohol is used, the skin\\r\\nmust be allowed to dry thoroughly to prevent inactivation of the live vaccine\\r\\nvirus by the alcohol.',\n",
       " 'Remove the vaccine vial cap. Remove bifurcated needle\\r\\nfrom individual wrapping. Submerge bifurcated end of needle in reconstituted\\r\\nvaccine solution. The needle will pick up a droplet of vaccine (0.0025 mL)\\r\\nwithin the fork of the bifurcation. Use aseptic technique, i.e., do not insert\\r\\nthe upper part of the needle that has been in contact with fingers into the\\r\\nvaccine vial, and never re-dip the needle into the vaccine vial if the needle\\r\\nhas touched skin.',\n",
       " \"Deposit the droplet of vaccine onto clean, dry skin of\\r\\nthe arm prepared for vaccination. The needle is held between thumb and first\\r\\nfinger perpendicular to the skin. The wrist of the hand holding the needle of\\r\\nthe vaccinator rests against the patient's arm. Rapidly make 15 jabs of the\\r\\nneedle perpendicular to the skin through the vaccine droplet to puncture the\\r\\nskin, within a diameter of about 5 mm. The jabs should be vigorous enough so\\r\\nthat a drop of blood appears at the vaccination site.\",\n",
       " 'Any excess droplets of vaccine and blood should be wiped\\r\\noff the skin using a dry gauze pad and discarded in a biohazard container.\\r\\nDiscard the needle in a biohazard sharps container. Close the vaccine vial by\\r\\nreinserting the rubber cap and return to a refrigerator or place on ice unless\\r\\nit will be used immediately to vaccinate another subject. [See Storage\\r\\nFollowing Reconstitution ]',\n",
       " 'Cover the vaccination site loosely with a gauze bandage,\\r\\nusing first aid adhesive tape to keep it in place. This bandage provides a\\r\\nbarrier to protect against spread of the vaccinia virus. If the vaccinee is\\r\\ninvolved in direct patient care, the gauze should be covered with a\\r\\nsemipermeable (semiocclusive) dressing as an additional barrier. A\\r\\nsemipermeable dressing is one that allows for the passage of air but does not\\r\\nallow for the passage of fluids.',\n",
       " 'Wash hands with soap and warm water or with alcohol-based\\r\\nhand rubs such as gels or foams after direct contact with the vaccination site,\\r\\nthe bandage or clothes, towels or sheets that might be contaminated with virus\\r\\nfrom the vaccination site. This is vital in order to remove any virus from your\\r\\nhands and prevent contact spread.',\n",
       " 'Put the contaminated bandages in a sealed plastic bag and\\r\\nthrow them away in the trash.',\n",
       " 'Wash separately clothing, towels, bedding or other items\\r\\nthat may have come in direct contact with the vaccination site or drainage from\\r\\nthe site, using hot water with detergent and/or bleach. Wash hands afterwards.',\n",
       " \"Don't use a bandage that blocks air from the vaccination\\r\\nsite. This may cause the skin at the vaccination site to soften and wear away.\\r\\nUse loose gauze secured with medical tape to cover the site.\",\n",
       " \"Don't put salves or ointments on the vaccination site.\",\n",
       " \"In an individual vaccinated for the first time (primary\\r\\nvaccination), the expected response to vaccination is the development of a\\r\\nmajor cutaneous reaction (characterized by a pustule ) at the site of\\r\\ninoculation. The lesion evolves gradually, with appearance of a papule at the\\r\\nsite of vaccination after 2-5 days. The papule becomes vesicular , then\\r\\npustular, and reaches its maximum size at 8-10 days after vaccination. The\\r\\npustule dries and forms a scab, which usually separates within 14-21 days,\\r\\nleaving a pitted scar. (See Figure 1) Formation of a major cutaneous reaction\\r\\nby day 6-8 is evidence of a successful 'take' and acquisition of protective immunity . An equivocal reaction is any reaction that is not a major reaction,\\r\\nand indicates a non-take (vaccination failure) due to impotent vaccine or\\r\\ninadequate vaccination technique.\",\n",
       " 'Successful vaccination in an individual previously\\r\\nexposed to vaccine is confirmed when a major cutaneous reaction [See Primary\\r\\nVaccinees and Figure 1] is observed 6 to 8 days post-vaccination. However\\r\\nany prior vaccination may modify (reduce) the cutaneous response upon\\r\\nrevaccination (Figure 2) such that the absence of a cutaneous response does not\\r\\nnecessarily indicate vaccination failure. Previously vaccinated individuals who\\r\\ndo not have a cutaneous response on revaccination do not require revaccination\\r\\nto try to elicit a cutaneous response.',\n",
       " 'Individuals who are not successfully vaccinated (i.e.,\\r\\nvaccination failures) after primary vaccination may be revaccinated again in an\\r\\nattempt to achieve a satisfactory take. The vaccination procedures should be\\r\\nchecked, and vaccination repeated with vaccine from another vial or vaccine\\r\\nlot, employing the same technique described above [See Vaccination\\r\\nInstructions ].',\n",
       " 'If a repeat vaccination is conducted using vaccine from\\r\\nanother vial or vaccine lot fails to produce a major reaction, healthcare\\r\\nproviders should consult the Centers for Disease Control and Prevention ( CDC )\\r\\nat (404) 639-3670 or their state or local health department before giving\\r\\nanother vaccination.',\n",
       " 'Figure 1: Progression of\\r\\nmajor cutaneous reaction after primary vaccination 1',\n",
       " 'Figure 2: Progression of major cutaneous reaction\\r\\nafter revaccination 1',\n",
       " 'Persons at continued high risk\\r\\nof exposure to smallpox (e.g., research laboratory workers handling variola virus) should receive repeat ACAM2000 vaccination every three years.',\n",
       " 'Additional information may be obtained from U.S.\\r\\nDepartment of Defense\\r\\n(http://www.dtic.mil/whs/directives/corres/html/620503.htm) and U.S. Centers\\r\\nfor Disease Control and Prevention (CDC) about smallpox vaccination\\r\\n(http://www.bt.cdc/gov/agent/smallpox/vaccination).',\n",
       " 'After reconstitution of the lyophilized preparation, each\\r\\nvial has approximately 100 doses of 0.0025 mL of vaccinia virus (live)\\r\\ncontaining 2.5-12.5x10 5 plaque forming units / dose.',\n",
       " 'ACAM2000, Smallpox (Vaccinia) Vaccine, Live, is supplied\\r\\nin multiple-dose 3 mL clear glass vials containing lyophilized powder\\r\\n(freeze-dried vaccine). After reconstitution with 0.3 mL of diluent, the vial\\r\\ncontains approximately 100 nominal doses of 0.0025 mL of vaccinia virus (live),\\r\\n1.0 - 5.0x108 PFU/mL or 2.5-12.5x105 PFU/dose.',\n",
       " 'Diluent for ACAM2000, 50% (v/v) Glycerin USP, 0.25% (v/v) Phenol USP in Water for Injection USP, is supplied in 3 mL clear glass vials\\r\\ncontaining 0.6 mL of diluent.',\n",
       " 'Bifurcated needles are supplied in boxes (5 x 5 x 1 in)\\r\\ncontaining 100 needles.',\n",
       " '1 mL tuberculin syringes with 25 gauge x 5/8” needles are\\r\\nsupplied for vaccine reconstitution.',\n",
       " 'ACAM2000 should be stored in a freezer with an average\\r\\ntemperature of -15°C to -25°C (+5°F to -13°F).',\n",
       " 'Prior to reconstitution, ACAM2000 vaccine retains a\\r\\npotency of 1.0x108 PFU or higher per dose for at least 18 months when stored at\\r\\nrefrigerated temperatures of +2-8°C (36-46°F).',\n",
       " 'During shipment, ACAM2000 should be maintained at a\\r\\ntemperature of -10°C or colder.',\n",
       " 'After reconstitution, ACAM2000 vaccine may be\\r\\nadministered during a 6 to 8 hour workday at room temperature (20-25°C,\\r\\n68-77°F). Reconstituted ACAM2000 vaccine may be stored in a refrigerator\\r\\n(2-8°C, 36-46°F) no longer than 30 days, after which it should be\\r\\ndiscarded [See Vaccination\\r\\nInstructions ]. Diluent for Smallpox Vaccine ,\\r\\n(Vero Cells) Lyophilized, ACAM2000 should be stored at room temperature (15-30°C,\\r\\n59-86°F). ACAM2000 contains live vaccinia virus that is transmissible,\\r\\nand should be handled as an infectious agent once vials are open. See [ Instructions\\r\\nfor Vaccine Preparation ] and [ Preparation / Handling Precautions\\r\\nand Instructions for Disposal ] for details on handling and disposal.',\n",
       " 'REFERENCES',\n",
       " '1 Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson,\\r\\n  DA. Smallpox vaccination: a review, part 1. background, vaccination technique,\\r\\n  normal vaccination and revaccination, and expected normal reactions. Clin\\r\\n  Infect Dis. 2003;37:241-250.',\n",
       " 'Sanofi Pasteur Biologics Co., 38 Sidney Street,\\r\\nCambridge, MA 02139. Revised: October 2009',\n",
       " 'Campral® is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment\\r\\ninitiation. Treatment with Campral should be part of a comprehensive management\\r\\nprogram that includes psychosocial support.',\n",
       " 'The efficacy of Campral in promoting abstinence has not\\r\\nbeen demonstrated in subjects who have not undergone detoxification and not\\r\\nachieved alcohol abstinence prior to beginning Campral treatment. The efficacy\\r\\nof Campral in promoting abstinence from alcohol in polysubstance abusers has\\r\\nnot been adequately assessed.',\n",
       " 'The recommended dose of Campral is two 333 mg tablets\\r\\n(each dose should total 666 mg) taken three Sections or subsections omitted\\r\\nfrom the full prescribing information are not listed. times daily. A lower dose\\r\\nmay be effective in some patients.',\n",
       " 'Although dosing may be done without regard to meals,\\r\\ndosing with meals was employed during clinical trials and is suggested in those\\r\\npatients who regularly eat three meals daily.',\n",
       " 'Treatment with Campral should be initiated as soon as\\r\\npossible after the period of alcohol withdrawal, when the patient has achieved\\r\\nabstinence, and should be maintained if the patient relapses. Campral should be\\r\\nused as part of a comprehensive psychosocial treatment program.',\n",
       " 'For patients with moderate renal impairment (creatinine\\r\\nclearance of 30-50 mL/min), a starting dose of one 333 mg tablet taken three\\r\\ntimes daily is recommended. Campral is contraindicated in patients with severe\\r\\nrenal impairment (creatinine clearance of  ≤ 30 mL/min). [see CONTRAINDICATIONS , WARNINGS AND PRECAUTIONS , Use in Specific Populations , and CLINICAL\\r\\nPHARMACOLOGY ]',\n",
       " 'Campral 333 mg tablets are enteric-coated , white, round,\\r\\nbiconvex tablets, identified with “333” debossed on one side.',\n",
       " 'NDC :68151-4760-0 in a PACKAGE of 1 TABLET, DELAYED\\r\\nRELEASES',\n",
       " 'Store at 25°C (77°F); excursions permitted to 15° to 30°C\\r\\n(59° to 86°F).',\n",
       " 'Manufactured by: Merck Santé s.a.s. Subsidiary of Merck\\r\\nKGaA, Darmstadt, Germany 37, rue Saint- Romain 69008 LYON FRANCE. Manufactured\\r\\nfor: Forest Pharmaceuticals, Inc. Subsidiary of Forest Laboratories, Inc. St.\\r\\nLouis, MO, 63045. Revised: Aug 2014',\n",
       " 'ACANYA® Gel is indicated for the topical treatment of acne vulgaris in patients 12 years or older.',\n",
       " 'Before applying ACANYA Gel, wash your face gently with a mild soap, rinse with warm water, and pat your skin dry. Apply a pea-sized amount of ACANYA Gel to the face once daily. Avoid the eyes, mouth, mucous membranes, or areas of broken skin.',\n",
       " 'Use of ACANYA Gel beyond 12 weeks has not been evaluated.',\n",
       " 'Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating, or abrasive agents.',\n",
       " 'ACANYA Gel is not for oral, ophthalmic, or intravaginal use.',\n",
       " 'Gel, 1.2%/2.5%',\n",
       " 'Each gram of ACANYA Gel contains 10 mg (1%) clindamycin as phosphate, and 25 mg (2.5%) benzoyl peroxide in a white to off-white, opaque, smooth gel.',\n",
       " 'ACANYA Gel, 1.2%/2.5% is a white to off-white smooth gel is supplied as:',\n",
       " 'NDC 13548-132-50 50 g pump',\n",
       " 'Distributed by: Bausch Health US, LLC Bridgewater, NJ 08807 USA. Manufactured by: Bausch Health Companies Inc. Laval, Quebec H7L 4A8, Canada. Â\\xa0Revised: Feb 2020',\n",
       " 'Precose coupons',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'PRECOSE is indicated as an adjunct to diet and exercise to\\r\\nimprove glycemic control in adults with type 2 diabetes mellitus .',\n",
       " 'There is no fixed dosage regimen for the management of diabetes mellitus with PRECOSE or any other pharmacologic agent. Dosage of\\r\\nPRECOSE must be individualized on the basis of both effectiveness and tolerance\\r\\nwhile not exceeding the maximum recommended dose of 100 mg t.i.d. PRECOSE\\r\\nshould be taken three times daily at the start (with the first bite) of each\\r\\nmain meal.',\n",
       " 'PRECOSE should be started at a low dose, with gradual dose\\r\\nescalation as described below, both to reduce gastrointestinal side effects and\\r\\nto permit identification of the minimum dose required for adequate glycemic\\r\\ncontrol of the patient. If the prescribed diet is not observed, the intestinal\\r\\nside effects may be intensified. If strongly distressing symptoms develop in\\r\\nspite of adherence to the diabetic diet prescribed, the doctor must be\\r\\nconsulted and the dose temporarily or permanently reduced.',\n",
       " 'During treatment initiation and dose titration (see below),\\r\\none-hour postprandial plasma glucose may be used to determine the therapeutic response to PRECOSE and identify the minimum effective dose for the patient.\\r\\nThereafter, glycosylated hemoglobin should be measured at intervals of\\r\\napproximately three months. The therapeutic goal should be to decrease both\\r\\npostprandial plasma glucose and glycosylated hemoglobin levels to normal or\\r\\nnear normal by using the lowest effective dose of PRECOSE, either as\\r\\nmonotherapy or in combination with sulfonylureas, insulin or metformin.',\n",
       " 'The recommended starting dosage of PRECOSE is 25 mg given\\r\\norally three times daily at the start (with the first bite) of each main meal.\\r\\nHowever, some patients may benefit from more gradual dose titration to minimize\\r\\ngastrointestinal side effects. This may be achieved by initiating treatment at\\r\\n25 mg once per day and subsequently increasing the frequency of administration\\r\\nto achieve 25 mg t.i.d.',\n",
       " 'Once a 25 mg t.i.d. dosage regimen is reached, dosage of\\r\\nPRECOSE should be adjusted at 4–8 week intervals based on one-hour postprandial\\r\\nglucose or glycosylated hemoglobin levels, and on tolerance. The dosage can be\\r\\nincreased from 25 mg t.i.d. to 50 mg t.i.d. Some patients may benefit from\\r\\nfurther increasing the dosage to 100 mg t.i.d. The maintenance dose ranges from\\r\\n50 mg t.i.d. to 100 mg t.i.d. However, since patients with low body weight may\\r\\nbe at increased risk for elevated serum transaminases, only patients with body\\r\\nweight  >  60 kg should be considered for dose titration above 50 mg t.i.d.\\r\\n(see PRECAUTIONS ). If no further reduction in postprandial glucose or\\r\\nglycosylated hemoglobin levels is observed with titration to 100 mg t.i.d.,\\r\\nconsideration should be given to lowering the dose. Once an effective and\\r\\ntolerated dosage is established, it should be maintained.',\n",
       " 'The maximum recommended dose for patients  ≤  60 kg is\\r\\n50 mg t.i.d. The maximum recommended dose for patients  >  60 kg is 100 mg\\r\\nt.i.d.',\n",
       " 'Sulfonylurea agents or insulin may cause hypoglycemia .\\r\\nPRECOSE given in combination with a sulfonylurea or insulin will cause a\\r\\nfurther lowering of blood glucose and may increase the potential for\\r\\nhypoglycemia. If hypoglycemia occurs, appropriate adjustments in the dosage of\\r\\nthese agents should be made.',\n",
       " 'PRECOSE is available as 25 mg, 50 mg or 100 mg round, unscored\\r\\ntablets. Each tablet strength is white to yellow-tinged in color. The 25 mg\\r\\ntablet is coded with the word “PRECOSE” on one side and “25” on the other side.\\r\\nThe 50 mg tablet is coded with the word “PRECOSE” and “50” on the same side.\\r\\nThe 100 mg tablet is coded with the word “PRECOSE” and “100” on the same side.\\r\\nPRECOSE is available in bottles of 100 and 50 mg strength in unit dose packages\\r\\nof 100.',\n",
       " '',\n",
       " 'Do not store above 25°C (77°F).\\r\\nProtect from moisture. For bottles, keep container tightly closed.',\n",
       " 'Bayer HealthCare Pharmaceuticals Inc. Wayne, NJ 07470. Made\\r\\nin Germany. 11/11',\n",
       " 'ACCOLATE is indicated for the prophylaxis and chronic\\r\\ntreatment of asthma in adults and children 5 years of age and older.',\n",
       " 'Because food can reduce the bioavailability of\\r\\nzafirlukast, ACCOLATE should be taken at least 1 hour before or 2 hours after\\r\\nmeals.',\n",
       " 'The recommended dose of ACCOLATE in adults and children\\r\\n12 years and older is 20 mg twice daily.',\n",
       " 'The recommended dose of ACCOLATE in children 5 through 11\\r\\nyears of age is 10 mg twice daily.',\n",
       " 'Based on cross-study comparisons, the clearance of\\r\\nzafirlukast is reduced in elderly patients (65 years of age and older), such\\r\\nthat Cmax and AUC are approximately twice those of younger adults. In clinical trials,\\r\\na dose of 20 mg twice daily was not associated with an increase in the overall\\r\\nincidence of adverse events or withdrawals because of adverse events in elderly\\r\\npatients.',\n",
       " 'ACCOLATE is contraindicated in patients with hepatic\\r\\nimpairment including hepatic cirrhosis (see CONTRAINDICATIONS ). The\\r\\nclearance of zafirlukast is reduced in patients with stable alcoholic cirrhosis\\r\\nsuch that the Cmax and AUC are approximately 50 - 60% greater than those of\\r\\nnormal adults. ACCOLATE has not been evaluated in patients with hepatitis or in\\r\\nlong-term studies of patients with cirrhosis.',\n",
       " 'Dosage adjustment is not required for patients with renal\\r\\nimpairment.',\n",
       " 'ACCOLATE 10 mg Tablets, ( NDC 0310-0401) white,\\r\\nunflavored, round, biconvex, film-coated, minitablets identified with “ACCOLATE\\r\\n10” debossed on one side are supplied in opaque HDPE bottles of 60 tablets.',\n",
       " 'ACCOLATE 20 mg Tablets, ( NDC 0310-0402) white,\\r\\nround, biconvex, coated tablets identified with “ACCOLATE 20” debossed on one\\r\\nside are supplied in opaque HDPE bottles of 60 tablets.',\n",
       " 'Store at controlled room temperature, 20-25°C (68-77°F) [see USP ]. Protect from light and moisture. Dispense in the original air-tight\\r\\ncontainer.',\n",
       " 'Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington,\\r\\nDE 19850. Revised: Nov 2013',\n",
       " 'Accretropin™ ( somatropin ) is indicated for:',\n",
       " 'The dose regimen for Accretropin™ [(somatropin) for injection] should be individualized for each patient. Therapy should not be continued if epiphyseal fusion has occurred. Response to growth hormone therapy tends to decrease with time. However, failure to increase growth rate, particularly during the first year of therapy, should prompt close assessment of compliance and evaluation of other causes of growth failure such as hypothyroidism , under- nutrition and advanced bone age.',\n",
       " 'Growth hormone deficiency - The recommended weekly dose is 0.18 \\r\\n  mg/kg body weight to 0.3 mg/kg (0.90 IU/kg) body weight. The dose should be \\r\\n  divided into equal daily doses given 6 or 7 times per week subcutaneously.',\n",
       " 'Turner Syndrome - The recommended weekly dose is 0.36 mg/kg of \\r\\n  body weight. The dose should be divided into equal daily doses given 6 or 7 \\r\\n  times per week subcutaneously.',\n",
       " 'Accretropin™ (somatropin injection)  should not be injected intravenously.',\n",
       " 'Administration - the vial should be swirled with a GENTLE rotary motion. DO NOT SHAKE. The solution should be inspected for clarity. It should be clear. If the solution is cloudy or contains particles, the contents MUST NOT be injected.',\n",
       " 'Vials of Accretropin™ (somatropin injection)  Injection should be stored in the refrigerator [2° \\r\\n  to 8°C (36° to 46°F)]. Avoid freezing and shaking. Expiration dates \\r\\n  are stated on the vial and carton labels. Do not use after expiration date. \\r\\n  Once opened, Accretropin™ (somatropin injection)  may be stored up to 14 days when refrigerated [2° \\r\\n  to 8°C (36° to 46°F)]. Discard 14 days after first use. Protect \\r\\n  from light.',\n",
       " '',\n",
       " 'REFERENCES',\n",
       " 'Janssen YJ, Frolich M, Roelfsema F. The absorption profile and availability of a physiological subcutaneously administered dose of recombinant human growth hormone (GH) in adults with GH deficiency. Br J Clin Pharmacol 1999 Mar;47(3):273-8.',\n",
       " 'Zeisel HJ, Lutz A, von Petrykowski W. Immunogenicity of a mammalian cell-derived recombinant human growth hormone preparation during long-term treatment. Horm Res 1992;37 Suppl 2:47-55.',\n",
       " 'Manufactured by: Cangene Corporation, Winnipeg, Canada R3T 5Y3. \\r\\n  March 2007. FDA Rev date: 1/23/2008',\n",
       " 'ACCRUFER is indicated for the treatment of iron deficiency in adults.',\n",
       " 'The recommended dosage of ACCRUFER is 30 mg twice daily, taken 1 hour before or 2 hours after a meal. Do not open, break, or chew ACCRUFER capsules.',\n",
       " 'Treatment duration will depend on the severity of iron deficiency but generally at least 12 weeks of treatment is required. The treatment should be continued as long as necessary until ferritin levels are within the normal range.',\n",
       " 'ACCRUFER contains 30 mg iron, as ferric maltol, in red capsules printed with “30”.',\n",
       " 'ACCRUFER (ferric maltol) 30 mg iron capsules are supplied as 60 capsules in HDPE bottles with a child-proof polypropylene push-lock.',\n",
       " '1 Bottle of 60-count 30 mg ferric iron capsules ( NDC 73059-001-60).',\n",
       " 'Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP controlled room temperature ].',\n",
       " 'Distributed by : Shield Therapeutics Inc, 9020 Capital of Texas Highway North, Austin, TX, 78759. Revised: Feb 2022',\n",
       " 'AccuNeb (albuterol sulfate inhalation solution)  is indicated for the relief of bronchospasm in patients 2 to 12 years\\r\\n  of age with asthma (reversible obstructive airway disease).',\n",
       " 'The usual starting dosage for patients 2 to 12 years of age is 1.25 mg or 0.63\\r\\n  mg of AccuNeb (albuterol sulfate inhalation solution)  administered 3 or 4 times daily, as needed, by nebulization. More\\r\\n  frequent administration is not recommended.',\n",
       " 'To administer 1.25 mg or 0.63 mg of albuterol, use the entire contents of one\\r\\n  unit-dose vial (3 mL of 1.25 mg or 0.63 mg inhalation solution) by nebulization.\\r\\n  Adjust nebulizer flow rate to deliver AccuNeb (albuterol sulfate inhalation solution)  over 5 to 15 minutes.',\n",
       " 'The use of AccuNeb (albuterol sulfate inhalation solution)  can be continued as medically indicated to control recurring\\r\\n  bouts of bronchospasm. During this time most patients gain optimum benefit from\\r\\n  regular use of the inhalation solution.',\n",
       " 'Patients 6 to 12 years of age with more severe asthma (baseline FEV 1 less than 60% predicted), weight  > 40 kg, or patients 11 to 12 years of age\\r\\n  may achieve a better initial response with the 1.25 mg dose.',\n",
       " 'AccuNeb (albuterol sulfate inhalation solution)  has not been studied in the setting of acute attacks of bronchospasm.\\r\\n  A 2.5 mg dose of albuterol provided by a higher concentration product (2.5 mg\\r\\n  albuterol per 3 mL) may be more appropriate for treating acute exacerbations,\\r\\n  particularly in children 6 years old and above.',\n",
       " 'If a previously effective dosage regimen fails to provide the usual relief,\\r\\n  medical advice should be sought immediately, as this is often a sign of seriously\\r\\n  worsening asthma which would require reassessment of therapy.',\n",
       " 'The drug compatibility (physical and chemical), clinical efficacy and safety\\r\\n  of AccuNeb (albuterol sulfate inhalation solution)  solution, when mixed with other drugs in a nebulizer have not been\\r\\n  established.',\n",
       " 'The safety and efficacy of AccuNeb (albuterol sulfate inhalation solution)  have been established in clinical trials\\r\\n  when administered using the Pari LC Plus™ nebulizer and Pari PRONEB™\\r\\n  compressor. The safety and efficacy of AccuNeb (albuterol sulfate inhalation solution)  when administered with other\\r\\n  nebulizer systems have not been established.',\n",
       " 'AccuNeb (albuterol sulfate inhalation solution)  should be administered via jet nebulizer connected to an air compressor\\r\\n  with adequate air flow, equipped with a mouthpiece or suitable face mask.',\n",
       " 'AccuNeb (albuterol sulfate) Inhalation Solution is supplied as a 3 mL, clear,\\r\\n  colorless, sterile, preservative-free, aqueous solution in two different strengths,\\r\\n  0.63 mg and 1.25 mg, of albuterol (equivalent to 0.75 mg of albuterol sulfate\\r\\n  or 1.5 mg of albuterol sulfate per 3 mL) in unit-dose low-density polyethylene\\r\\n  (LDPE) vials. Each unit-dose LDPE vial is protected in a foil pouch, and each\\r\\n  foil pouch contains 5 unit-dose LDPE vials. Each strength of AccuNeb (albuterol sulfate inhalation solution)  (albuterol\\r\\n  sulfate) Inhalation Solution is available in a shelf carton containing multiple\\r\\n  foil pouches.',\n",
       " 'AccuNeb® (albuterol sulfate) Inhalation Solution, 0.63 mg (potency\\r\\n  expressed as albuterol) contains 0.75 mg albuterol sulfate per 3 mL in unit-dose\\r\\n  vials and is available in the following packaging configuration.',\n",
       " 'NDC 49502-692-03 5 foil pouches, each containing 5 vials,\\r\\n  total 25 vials per carton',\n",
       " 'AccuNeb® (albuterol sulfate) Inhalation Solution, 1.25 mg (potency\\r\\n  expressed as albuterol) contains 1.50 mg albuterol sulfate per 3 mL in unit-dose\\r\\n  vials and is available in the following packaging configuration.',\n",
       " 'NDC 49502-693-03 5 foil pouches, each containing 5 vials,\\r\\n  total 25 vials per carton',\n",
       " 'Store between 2°C and 25°C (36°F - 77°F). Protect from light\\r\\n  and excessive heat.',\n",
       " 'Store unit-dose vials in protective foil pouch at all times. Once removed from\\r\\n  the foil pouch, use vial(s) within one week. Discard the vial if the solution\\r\\n  is not colorless.',\n",
       " 'Keep out of the reach of children.',\n",
       " 'DEY®, Napa, CA 94558.\\xa0 JAN 07',\n",
       " 'ACCUPRIL is indicated for the treatment of hypertension , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with ACCUPRIL.',\n",
       " 'Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).',\n",
       " 'Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke , but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.',\n",
       " 'Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia ), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.',\n",
       " 'Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina , heart failure , or diabetic kidney disease). These considerations may guide selection of therapy.',\n",
       " 'ACCUPRIL may be used alone or in combination with thiazide diuretics .',\n",
       " 'ACCUPRIL is indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics and/or digitalis.',\n",
       " 'In using ACCUPRIL, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis , particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that ACCUPRIL does not have a similar risk (see WARNINGS ).',\n",
       " 'Angioedema in black patients: Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks.',\n",
       " 'ACCURETIC is indicated for the treatment of hypertension ,\\r\\nto lower blood pressure. Lowering blood pressure reduces the risk of fatal and\\r\\nnonfatal cardiovascular events, primarily strokes and myocardial infarctions.\\r\\nThese benefits have been seen in controlled trials of antihypertensive drugs\\r\\nfrom a wide variety of pharmacologic classes including the class to which this\\r\\ndrug principally belongs. There are no controlled trials demonstrating risk\\r\\nreduction with ACCURETIC.',\n",
       " \"Control of high blood pressure should be part of\\r\\ncomprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation,\\r\\nexercise, and limited sodium intake. Many patients will require more than one\\r\\ndrug to achieve blood pressure goals. For specific advice on goals and\\r\\nmanagement, see published guidelines, such as those of the National High Blood\\r\\nPressure Education Program's Joint National Committee on Prevention, Detection,\\r\\nEvaluation, and Treatment of High Blood Pressure (JNC).\",\n",
       " 'Numerous antihypertensive drugs, from a variety of pharmacologic\\r\\nclasses and with different mechanisms of action, have been shown in randomized\\r\\ncontrolled trials to reduce cardiovascular morbidity and mortality, and it can\\r\\nbe concluded that it is blood pressure reduction, and not some other\\r\\npharmacologic property of the drugs, that is largely responsible for those\\r\\nbenefits. The largest and most consistent cardiovascular outcome benefit has\\r\\nbeen a reduction in the risk of stroke , but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.',\n",
       " 'Elevated systolic or diastolic pressure causes increased\\r\\ncardiovascular risk, and the absolute risk increase per mmHg is greater at\\r\\nhigher blood pressures, so that even modest reductions of severe hypertension\\r\\ncan provide substantial benefit. Relative risk reduction from blood pressure\\r\\nreduction is similar across populations with varying absolute risk, so the\\r\\nabsolute benefit is greater in patients who are at higher risk independent of\\r\\ntheir hypertension (for example, patients with diabetes or hyperlipidemia ), and\\r\\nsuch patients would be expected to benefit from more aggressive treatment to a\\r\\nlower blood pressure goal.',\n",
       " 'Some antihypertensive drugs have smaller blood pressure\\r\\neffects (as monotherapy) in black patients, and many antihypertensive drugs\\r\\nhave additional approved indications and effects (e.g., on angina , heart\\r\\nfailure, or diabetic kidney disease). These considerations may guide selection\\r\\nof therapy.',\n",
       " 'This fixed combination is not indicated for the initial\\r\\ntherapy of hypertension (see DOSAGE AND ADMINISTRATION ).',\n",
       " 'In using ACCURETIC, consideration should be given to the\\r\\nfact that another angiotensinconverting enzyme inhibitor, captopril, has caused agranulocytosis , particularly in patients with renal impairment or\\r\\ncollagen-vascular disease. Available data are insufficient to show that\\r\\nquinapril does not have a similar risk (see WARNINGS : Neutropenia/Agranulocytosis ).',\n",
       " 'Black patients receiving ACE inhibitor monotherapy have\\r\\nbeen reported to have a higher incidence of angioedema compared to non-blacks.\\r\\nIt should also be noted that in controlled clinical trials, ACE inhibitors have\\r\\nan effect on blood pressure that is less in black patients than in non-blacks.',\n",
       " 'Accutane (isotretinoin)  is indicated for the treatment of severe recalcitrant nodular acne. \\r\\n  Nodules are inflammatory lesions with a diameter of 5 mm or greater. The nodules \\r\\n  may become suppurative or hemorrhagic. “Severe,” by definition, 2 means “many” as opposed to “few or several” nodules. \\r\\n  Because of significant adverse effects associated with its use, Accutane (isotretinoin)  should \\r\\n  be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. In addition, Accutane (isotretinoin)  is indicated \\r\\n  only for those female patients who are not pregnant, because Accutane (isotretinoin)  can cause \\r\\n  severe birth defects (see Boxed CONTRAINDICATIONS AND \\r\\n  WARNINGS ).',\n",
       " 'A single course of therapy for 15 to 20 weeks has been shown to result in complete \\r\\n  and prolonged remission of disease in many patients. 1,3,4 If a second \\r\\n  course of therapy is needed, it should not be initiated until at least 8 weeks \\r\\n  after completion of the first course, because experience has shown that patients \\r\\n  may continue to improve while off Accutane (isotretinoin) . The optimal interval before retreatment \\r\\n  has not been defined for patients who have not completed skeletal growth (see WARNINGS : Skeletal: Bone Mineral Density, Hyperostosis, \\r\\n  and Premature Epiphyseal Closure ).',\n",
       " 'ACCUZYME (papain and urea)  is indicated for debridement of necrotic tissue and liquefication of slough in acute and chronic lesions such as pressure ulcers, varicose and diabetic ulcers, burns, postoperative wounds, pilonidal cyst wounds, carbuncles and miscellaneous traumatic or infected wounds.',\n",
       " 'Cleanse the wound with ALLCLENZ® Wound Cleanser or saline . Avoid cleansing with hydrogen peroxide solution as it may inactivate the papain. Apply ACCUZYME (papain and urea)  directly to the wound, cover with appropriate dressing, secure into place. Daily or twice daily applications are preferred. Irrigate the wound at each redressing to remove any accumulation of liquefied necrotic material. NOTE: Papain may also be inactivated by the salts of heavy metals such as lead, silver and mercury. Contact with medications containing these metals should be avoided.',\n",
       " '30g tube, 6g tube. Store in a cool place 8°-15°C (46°-59°F). Do not refrigerate. ACCUZYME (papain and urea) Ointment is a registered trademark of Healthpoint, Ltd. ALLCLENZ Wound Cleanser is a registered trademark of Healthpoint, Ltd.',\n",
       " 'Sectral coupons',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Sectral is indicated for the management of hypertension in adults. It may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.',\n",
       " 'Sectral is indicated in the management of ventricular premature beats; it reduces the total number of premature beats, as well as the number of paired and multiform ventricular ectopic beats, and R-on-T beats.',\n",
       " 'The initial dosage of Sectral in uncomplicated mild-to-moderate hypertension is 400 mg. This can be given as a single daily dose, but in occasional patients twice daily dosing may be required for adequate 24-hour blood-pressure control. An optimal response is usually achieved with dosages of 400 to 800 mg per day, although some patients have been maintained on as little as 200 mg per day. Patients with more severe hypertension or who have demonstrated inadequate control may respond to a total of 1200 mg daily (administered b.i.d.), or to the addition of a second antihypertensive agent. Beta-1 selectivity diminishes as dosage is increased.',\n",
       " 'The usual initial dose of Sectral is 400 mg daily given as 200 mg b.i.d. Dosage should be increased gradually until an optimal clinical response is obtained, generally at 600 to 1200 mg per day. If treatment is to be discontinued, the dosage should be reduced gradually over a period of about two weeks.',\n",
       " 'Older patients have an approximately 2-fold increase in bioavailability and may require lower maintenance doses. Doses above 800 mg/day should be avoided in the elderly.',\n",
       " 'Sectral ® (acebutolol HCl) is available in the following dosage strengths:',\n",
       " '200 mg , opaque purple and orange capsule marked “ RP 700” and “Sectral 200”',\n",
       " 'NDC 67857-700-01, in bottles of 100 capsules.',\n",
       " '400 mg , opaque brown and orange capsule marked “RP 701” and “Sectral 400”',\n",
       " 'NDC 67857-701-01, in bottles of 100 capsules.',\n",
       " 'Keep tightly closed',\n",
       " 'Store at controlled room temperature 20° to 25°C (68° to 77°F)',\n",
       " 'Protect from light',\n",
       " 'Dispense in a light-resistant, tight container',\n",
       " 'Us e carton to protect contents from light',\n",
       " 'Distributed by: Promius Pharma, LLC, Bridgewater, NJ 08807. Manufactured by: PATHEON, Puerto Rico, Inc., Manatí, Puerto Rico 00674, USA. Revised: April 2008',\n",
       " 'The majority of side effects observed have been reversible and of a minor nature and include gastrointestinal disorders ( dyspepsia , abdominal pain, nausea), rash, ruber, urticaria , symptoms of enuresis , headache, dizziness, and drowsiness. To report suspected adverse reactions, call 1-800-FDA-1088.',\n",
       " 'There has been no drug interactions reported, but close monitoring of patients on combination with lithium and digoxin, oral antidiabetic agents, anticoagulants, diuretics, and other analgesics.',\n",
       " 'ACEON is indicated for the treatment of patients with essential hypertension . ACEON may be used alone or given with other classes of antihypertensives, especially thiazide diuretics .',\n",
       " 'ACEON is indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction . ACEON can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid -lowering therapy.',\n",
       " 'Acetaminophen Suppositories coupons',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Pain reliever/fever reducer',\n",
       " 'temporarily',\n",
       " 'NDC 0713-0165-01',\n",
       " 'G&W Laboratories, Inc. Revised: Jan 2012',\n",
       " 'ACETADOTE is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (RSI).',\n",
       " 'The following recommendations are related to acute acetaminophen ingestion. For recommendations related to repeated supratherapeutic exposure see Recommendations For Repeated Supratherapeutic Acetaminophen Ingestion .',\n",
       " 'ACETADOTE is an antidote for acetaminophen overdose. The critical ingestion-treatment interval for maximal protection against severe hepatic injury is between 0 – 8 hours. Efficacy diminishes progressively after 8 hours and treatment initiation between 15 and 24 hours post-ingestion of acetaminophen yields limited efficacy. However, it does not appear to worsen the condition of patients and it should not be withheld, since the reported time of ingestion may not be correct.',\n",
       " 'If the timing of the acute acetaminophen ingestion is known and the results of the acetaminophen assay are available within 8 hours:',\n",
       " 'The nomogram may underestimate the hepatotoxicity risk in patients with chronic alcoholism, malnutrition, or CYP2E1 enzyme inducing drugs (e.g., isoniazid), and consideration should be given to treating these patients even if the acetaminophen concentrations are in the nontoxic range.',\n",
       " 'For patients whose acetaminophen concentrations are at or above the “possible” toxicity line (dotted line in nomogram):',\n",
       " 'For patients with an acute overdose from an extended-release acetaminophen, if the acetaminophen concentration at 4 hours post ingestion is below the possible toxicity line then obtain a second sample for acetaminophen concentration 8 to 10 hours after the acute ingestion. If the second value is at or above the “possible” toxicity line (dotted line in nomogram):',\n",
       " 'For patients whose values are below the “possible” toxicity line, but time of ingestion was unknown or sample was obtained less than 4 hours after ingestion:',\n",
       " 'For patients whose values are below the “possible” toxicity line and time of ingestion is known and the sample was obtained more than 4 hours after ingestion, do not administer ACETADOTE because there is minimal risk of hepatotoxicity.',\n",
       " 'Figure 1:Rumack-Matthew Nomogram for Estimating Potential for Hepatoxicity for Acetaminophen Posioning – Plasma or Serum Acetaminophen Concentration versus Time (hours) Post-acetaminophen Ingestion',\n",
       " '',\n",
       " '(Adapted from Rumack and Matthew, Pediatrics 1975; 55: 871-876)',\n",
       " 'Determine need for continued treatment with ACETADOTE after the loading dose. Choose ONE of the following based on the acetaminophen concentration:',\n",
       " 'The acetaminophen concentration is above the possible toxicity line according to the nomogram (see Figure 1):',\n",
       " 'The acetaminophen concentration could not be obtained:',\n",
       " 'For patients whose acetaminophen concentration is below the “possible” toxicity line (see Figure 1) and time of ingestion is known and the sample was obtained more than 4 hours after ingestion:',\n",
       " 'The acetaminophen concentration was in the non-toxic range, but time of ingestion was unknown or less than 4 hours:',\n",
       " 'In cases of suspected massive overdose, or with concomitant ingestion of other substances, or in patients with preexisting liver disease; the absorption and/or the half-life of acetaminophen may be prolonged. In such cases, consideration should be given to the need for continued treatment with ACETADOTE beyond a total of three separate doses over a 21-hour infusion period.',\n",
       " 'Acetaminophen levels and ALT/AST and INR should be checked after the last maintenance dose. If acetaminophen levels are still detectable, or if the ALT/AST are still increasing or the INR remains elevated; dosing should be continued and the treating physician should contact a US regional poison center at 1-800-222-1222, alternatively, a “special health professional assistance line for acetaminophen overdose” at 1-800-525-6115 for assistance with dosing recommendations, or 1-877-484-2700 for additional information.',\n",
       " 'Because ACETADOTE is hyperosmolar (2600 mOsmol/L), ACETADOTE must be diluted in sterile water for injection, 0.45% sodium chloride injection (1/2 normal saline), or 5% dextrose in water prior to intravenous administration [see WARNINGS AND PRECAUTIONS ]. Dilution in these three solutions results in different osmolarity of the solution for intravenous administration (see Table 1 for examples of different osmolarity of the solution depending on the type of solution and the ACETADOTE concentration).',\n",
       " 'Visually inspect for particular matter and discoloration prior to administration. The color of the diluted solution ranges from colorless to a slight pink or purple once the stopper is punctured (the color change does not affect the quality of the product). The diluted solution can be stored for 24 hours at room temperature. Discard unused portion. If a vial was previously opened, do not use for intravenous administration.',\n",
       " 'Table 1. Examples of ACETADOTE Concentration and Osmolarity in Three Solutions',\n",
       " '',\n",
       " 'ACETADOTE is for intravenous administration only.',\n",
       " 'The total recommended dosage of ACETADOTE is 300 mg/kg given intravenously as 3 separate, sequential doses (i.e., 3-bag method to administer the loading, second, and third doses). The total recommended infusion time for 3 doses is 21 hours. For the recommended weight-based dosage and weightbased dilution in patients who weigh:',\n",
       " 'Table 2. Recommended ACETADOTE Dosage and Dilution for Patients 5 kg to 20 kg',\n",
       " '',\n",
       " 'Table 3. Recommended ACETADOTE Dosage and Dilution for Patients 21 kg to 40 kg',\n",
       " '',\n",
       " 'Table 4. Recommended ACETADOTE Dosage and Dilution for Patients 41 kg or Greater',\n",
       " '',\n",
       " 'Repeated supratherapeutic acetaminophen ingestion (RSI) is an ingestion of acetaminophen at dosages higher than those recommended for extended periods of time. The risk of hepatotoxicity and the recommendations for treatment of acute acetaminophen ingestion (i.e., the Rumack-Matthew nomogram) do not apply to patients with RSI. Therefore, obtain the following information to guide ACETADOTE treatment for RSI:',\n",
       " 'For specific ACETADOTE dosage and administration information in patients with RSI, consider contacting your regional poison center at 1-800-222- 1222, or alternatively, a special health professional assistance line for acetaminophen overdose at 1-800-525-6115.',\n",
       " '200 mg/mL (6 grams of acetylcysteine in 30 mL) in a single-dose vial.',\n",
       " 'ACETADOTE (acetylcysteine) injection is available as a 20% solution (200 mg/mL) in 30 mL single-dose glass vials. Each single dose vial contains 6 g/30mL (200 mg/mL) of ACETADOTE injection. ACETADOTE is sterile and can be used for intravenous administration. It is available as follows:',\n",
       " 'Do not use previously opened vials for intravenous administration.',\n",
       " 'Note: The color of ACETADOTE may turn from essentially colorless to a slight pink or purple once the stopper is punctured. The color change does not affect the quality of the product.',\n",
       " 'The stopper in the ACETADOTE vial is formulated with a synthetic base-polymer and does not contain Natural Rubber Latex, Dry Natural Rubber, or blends of Natural Rubber.',\n",
       " 'Store unopened vials at controlled room temperature, 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]',\n",
       " 'Manufactured for: Cumberland Pharmaceuticals Inc. Nashville, TN 37203. Revised: Oct 2021.',\n",
       " 'Purpose',\n",
       " 'Pain reliever/fever reducer',\n",
       " 'Keep Out of Reach of Children',\n",
       " 'This package is intended for institutional use only. Keep\\r\\nthis and all drugs out of the reach of children.',\n",
       " 'Uses',\n",
       " 'For Hospital and Government Use Only',\n",
       " 'Temporarily relieves minor aches and pains due to: the common cold , headache, backache, minor pain of arthritis , toothache , premenstrual and menstrual cramps , and temporarily reduces fever.',\n",
       " 'TYLENOL® with Codeine ( acetaminophen and codeine phosphate ) tablets are \\r\\n  indicated for the relief of mild to moderately severe pain .',\n",
       " 'Dosage should be adjusted according to severity of pain and response of the \\r\\n  patient.',\n",
       " 'The usual adult dosage is:',\n",
       " '',\n",
       " 'Doses may be repeated up to every 4 hours.',\n",
       " 'The prescriber must determine the number of tablets per dose, and the maximum \\r\\n  number of tablets per 24 hours, based upon the above dosage guidance. This information \\r\\n  should be conveyed in the prescription .',\n",
       " 'It should be kept in mind, however, that tolerance to codeine can develop with \\r\\n  continued use and that the incidence of untoward effects is dose related. Adult \\r\\n  doses of codeine higher than 60 mg fail to give commensurate relief of pain \\r\\n  but merely prolong analgesia and are associated with an appreciably increased \\r\\n  incidence of undesirable side effects. Equivalently high doses in children would \\r\\n  have similar effects.',\n",
       " 'TYLENOL® with Codeine (acetaminophen and codeine phosphate) \\r\\n  tablets are white, round, flat-faced, beveled edged tablet imprinted “McNEIL” \\r\\n  on one side and “TYLENOL CODEINE” and either “3” or \\r\\n  “4” on the other side and are supplied as follows: No. 3 - NDC 0045-0513-60 bottles of 100, NDC 0045-0513-80 bottles of 1000, No. 4 \\r\\n  - NDC 0045-0515-60 bottles of 100, NDC 0045-0515-70 bottles of \\r\\n  500.',\n",
       " 'Store TYLENOL® with Codeine (acetaminophen and codeine)  tablets at 20° to 25°C (68° to \\r\\n  77°F). (See USP Controlled Room Temperature.) Dispense in tight, light-resistant \\r\\n  container as defined in the official compendium.',\n",
       " 'Manufactured by: JOLLC, Gurabo, Puerto Rico 00778. Distributed \\r\\n  by: Omp Division, Ortho- Mcneil Pharmaceutical, Inc. Raritan, New Jersey 08869. \\r\\n  Revised January 2008.',\n",
       " 'Acetaminophen Suppositories coupons',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Pain reliever/fever reducer',\n",
       " 'temporarily',\n",
       " 'NDC 0713-0165-01',\n",
       " 'G&W Laboratories, Inc. Revised: Jan 2012',\n",
       " 'Trezix Capsules coupons',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'TREZIX™ (acetaminophen, caffeine, and dihydrocodeine bitartrate) capsules are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.',\n",
       " 'Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS ], reserve TREZIX™ for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]',\n",
       " 'Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see WARNINGS ].',\n",
       " \"Initiate the dosing regimen for each patient individually, taking into account the patient's severity of pain, patient response, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse [see WARNINGS ].\",\n",
       " 'Monitor patients closely for respiratory depression , especially within the first 24-72 hours of initiating therapy and following dosage increases with TREZIX™ and adjust the dosage accordingly [see WARNINGS ].',\n",
       " 'The usual adult dosage is two (2) TREZIX™ ( acetaminophen , caffeine , and dihydrocodeine bitartrate) capsules orally every four (4) hours, as needed. No more than five (5) doses, or ten (10) capsules should be taken in a 24-hour period.',\n",
       " 'There is inter-patient variability in the potency of opioid drugs and opioid formulations. Therefore, a conservative approach is advised when determining the total daily dosage of TREZIX™. It is safer to underestimate a patient’s 24-hour TREZIX™ dosage than to overestimate the 24-hour TREZIX™ dosage and manage an adverse reaction due to overdose.',\n",
       " 'Individually titrate TREZIX™ to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving TREZIX™ to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse [see WARNINGS ]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.',\n",
       " 'If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the TREZIX™ dosage. If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.',\n",
       " 'When a patient who has been taking TREZIX™ regularly and may be physically dependent no longer requires therapy with TREZIX™, taper the dose gradually, by 25% to 50% every 2 to 4 days, while monitoring carefully for signs and symptoms of withdrawal. If the patient develops these signs or symptoms, raise the dose to the previous level and taper more slowly, either by increasing the interval between decreases, decreasing the amount of change in dose, or both. Do not abruptly discontinue TREZIX™ in a physically-dependent patient [see WARNINGS , Drug Abuse And Dependence ].',\n",
       " 'TREZIX ™ capsules, containing acetaminophen 320.5 mg, caffeine 30 mg and dihydrocodeine bitartrate 16 mg, are supplied in bottles of 100 capsules ( NDC #66992-840-10).',\n",
       " 'Capsules are imprinted “TREZIX” on the red cap in white ink.',\n",
       " 'Store at 20°C to 25°C (68°F to 77°F). [see USP Controlled Room Temperature].',\n",
       " 'Dispense in a tight, light-resistant container with a child-resistant closure. Protect from moisture.',\n",
       " 'Manufactured for: WraSer Pharmaceuticals, Ridgeland, MS 39157. Revised: Jul 2017',\n",
       " 'For relief of tension and vascular headaches*.',\n",
       " '*Based on a review of this drug (isometheptene mucate) by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the other indication as \"possibly\" effective in the treatment of migraine headache. Final classification of the less-than-effective indication requires further investigation.',\n",
       " 'FOR RELIEF OF MIGRAINE HEADACHE: The usual adult dosage is two capsules \\r\\n  at once, followed by one capsule every hour until relieved, up to 5 capsules \\r\\n  within a twelve hour period.',\n",
       " 'FOR RELIEF OF TENSION HEADACHE: The usual adult dosage is one or two \\r\\n  capsules every four hours up to 8 capsules a day.',\n",
       " 'Red capsules imprinted with the word MIDRIN (acetaminophen, isometheptene and dichloralphenazone)  in pink letters. Bottles of 100 \\r\\n  capsules, NDC 14508-304-08. Store at controlled room temperature 15°-30°C (59°-86° \\r\\n  F) in a dry place.',\n",
       " 'Manufactured and distributed by: CARACO PHARMACEUTICAL LABORATORIES, \\r\\n  LTD. DETROIT, MI 48202 Under license from: Sun Pharmaceutical Industries. FDA \\r\\n  Rev date: n/a',\n",
       " 'Ofirmev coupons',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'Est. Regular Price',\n",
       " 'with free coupon',\n",
       " 'OFIRMEV ® ( acetaminophen ) injection is indicated for',\n",
       " 'OFIRMEV may be given as a single or repeated dose for the treatment of acute pain or fever. No dose adjustment is required when converting between oral acetaminophen and OFIRMEV dosing in adults and adolescents who weigh 50 kg and above. Calculated maximum daily dose of acetaminophen is based on all routes of administration (i.e., intravenous, oral, and rectal ) and all products containing acetaminophen. Exceeding the maximum mg/kg daily dose of acetaminophen as described in Tables 1-3 may result in hepatic injury, including the risk of liver failure and death. To avoid the risk of overdose, ensure that the total amount of acetaminophen from all routes and from all sources does not exceed the maximum recommended dose.',\n",
       " 'Adults and adolescents weighing 50 kg and over: the recommended dosage of OFIRMEV is 1000 mg every 6 hours or 650 mg every 4 hours, with a maximum single dose of OFIRMEV of 1000 mg, a minimum dosing interval of 4 hours, and a maximum daily dose of acetaminophen of 4000 mg per day (includes all routes of administration and all acetaminophen-containing products including combination products).',\n",
       " 'Adults and adolescents weighing under 50 kg: the recommended dosage of OFIRMEV is 15 mg/kg every 6 hours or 12.5 mg/kg every 4 hours, with a maximum single dose of OFIRMEV of 15 mg/kg, a minimum dosing interval of 4 hours, and a maximum daily dose of acetaminophen of 75 mg/kg per day (includes all routes of administration and all acetaminophen-containing products including combination products).',\n",
       " 'Table 1. Dosing for Adults and Adolescents',\n",
       " 'Children 2 to 12 years of age: the recommended dosage of OFIRMEV is 15 mg/kg every 6 hours or\\r\\n12.5 mg/kg every 4 hours, with a maximum single dose of OFIRMEV of 15 mg/kg, a minimum dosing interval of 4 hours, and a maximum daily dose of acetaminophen of 75 mg/kg per\\r\\nday.',\n",
       " 'Table 2. Dosing for Children',\n",
       " 'Neonates, including premature neonates born at ≥ 32 weeks gestational age, up to 28 days chronological age: the recommended dosage of OFIRMEV is 12.5 mg/kg every 6 hours, to a maximum daily dose of acetaminophen of 50 mg/kg per day, with a minimum dosing interval of 6 hours.',\n",
       " 'Infants 29 days to 2 years of age: the recommended dosage of OFIRMEV is 15 mg/kg every 6 hours, to a maximum daily dose of acetaminophen of 60 mg/kg per day, with a minimum dosing interval of 6 hours.',\n",
       " 'Table 3. Dosing for Treatment of Fever in Neonates and Infants',\n",
       " 'For adult and adolescent patients weighing ≥ 50 kg requiring 1000 mg doses of OFIRMEV, administer the dose by inserting a vented intravenous set through the septum of the 100 mL vial or a non-vented intravenous set through the administration spike port of the 100 mL bag. OFIRMEV may be administered without further dilution. DO NOT USE if particulate matter or discoloration is observed. Administer the contents of the vial intravenously over 15-minutes. Use aseptic technique when preparing OFIRMEV for intravenous infusion. Do not add other medications to the OFIRMEV vial or infusion device.',\n",
       " 'For doses less than 1000 mg, the appropriate dose must be withdrawn from the container and placed into a separate container prior to administration. Using aseptic technique, withdraw the appropriate dose (650 mg or weight-based) from an intact sealed OFIRMEV container and place the measured dose in a separate empty, sterile container (e.g., glass bottle, plastic intravenous container, or syringe) for intravenous infusion to avoid the inadvertent delivery and administration of the total volume of the commercially available container. The entire 100 mL container of OFIRMEV is not intended for use in patients weighing less than 50 kg. OFIRMEV is supplied in a single-dose container and the unused portion must be discarded.',\n",
       " 'Place small volume pediatric doses up to 60 mL in volume in a syringe and administer over 15 minutes using a syringe pump.',\n",
       " 'Monitor the end of the infusion in order to prevent the possibility of an air embolism , especially in cases where the OFIRMEV infusion is the primary infusion.',\n",
       " 'Once the container seal has been penetrated, or the contents transferred to another container, administer the dose of OFIRMEV within 6 hours.',\n",
       " 'For bags, refrain from applying excessive pressure causing distortion to the bag, such as wringing or twisting, since such handling could result in breakage of the bag.',\n",
       " 'Do not add other medications to the OFIRMEV solution. Diazepam and chlorpromazine hydrochloride are physically incompatible with OFIRMEV, therefore do not administer simultaneously.',\n",
       " 'OFIRMEV is a sterile, clear, colorless, non pyrogenic, preservative free, isotonic formulation of acetaminophen intended for intravenous infusion. Each 100 mL glass vial or 100 mL bag contains 1000 mg acetaminophen (10 mg/mL).',\n",
       " 'NDC 43825-102-01 - OFIRMEV (acetaminophen) Injection is supplied in a 100 mL glass vial containing 1000 mg acetaminophen (10 mg/mL) in cartons of 24 vials.',\n",
       " 'NDC 43825-102-03 - OFIRMEV (acetaminophen) Injection is supplied in a 100 mL bag containing 1000 mg acetaminophen (10 mg/mL) in cartons of 24 bags.',\n",
       " 'Do not remove unit from overwrap until ready for use.',\n",
       " 'To open, tear outer wrap at the notch and remove solution bag. After removing the outer wrap, check the container for minute leaks by squeezing the solution bag firmly. If leaks are found, discard the solution because the sterility may be impaired. A small amount of moisture may be present inside the outer wrap.',\n",
       " 'OFIRMEV should be stored at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].',\n",
       " 'For single-dose only. The product should be used within 6 hours after opening. Do not refrigerate or freeze.',\n",
       " 'Manufactured for: Mallinckrodt Hospital Products Inc. Hazelwood, MO 63042 USA. Revised: Jan 2017.',\n",
       " 'For adjunctive treatment of: edema due to congestive heart failure ; drug-induced edema; centrencephalic epilepsies ( petit mal , unlocalized seizures); chronic simple (open-angle) glaucoma , secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure .',\n",
       " 'Preparation and Storage of Parenteral Solution: Each 500 mg vial containing \\r\\n  sterile acetazolamide sodium should be reconstituted with at least 5 mL of Sterile \\r\\n  Water for Injection prior to use. Reconstituted solutions retain their physical \\r\\n  and chemical properties for 3 days under refrigeration at 2° - 8° C \\r\\n  (36° - 46° F), or 12 hours at room temperature 15° - 30° C (59° - \\r\\n  86° F). Contains no preservative. The direct intravenous route of administration \\r\\n  is preferred. Intramuscular administration is not recommended.',\n",
       " 'Glaucoma: Acetazolamide should be used as an adjunct to the usual therapy. \\r\\n  The dosage employed in the treatment of chronic simple (open-angle) glaucoma ranges from 250 mg to 1 g of acetazolamide per 24 hours, usually in divided \\r\\n  doses for amounts over 250 mg. It has usually been found that a dosage in excess \\r\\n  of 1 g per 24 hours does not produce an increased effect. In all cases, the \\r\\n  dosage should be adjusted with careful individual attention both to symptomatology \\r\\n  and ocular tension . Continuous supervision by a physician is advisable.',\n",
       " 'In treatment of secondary glaucoma and in the preoperative treatment of some \\r\\n  cases of acute congestive (closed-angle) glaucoma , the preferred dosage \\r\\n  is 250 mg every four hours, although some cases have responded to 250 mg twice \\r\\n  daily on short-term therapy. In some acute cases, it may be more satisfactory \\r\\n  to administer an initial dose of 500 mg followed by 125 or 250 mg every four \\r\\n  hours depending on the individual case. Intravenous therapy may be used for \\r\\n  rapid relief of ocular tension in acute cases. A complementary effect has been \\r\\n  noted when acetazolamide has been used in conjunction with miotics or mydriatics \\r\\n  as the case demanded.',\n",
       " 'Epilepsy: It is not clearly known whether the beneficial effects observed \\r\\n  in epilepsy are due to direct inhibition of carbonic anhydrase in the central \\r\\n  nervous system or whether they are due to the slight degree of acidosis produced \\r\\n  by the divided dosage. The best results to date have been seen in petit mal \\r\\n  in children. Good results, however, have been seen in patients, both children \\r\\n  and adult, in other types of seizures such as grand mal , mixed seizure patterns, \\r\\n  myoclonic jerk patterns, etc. The suggested total daily dose is 8 to 30 mg per \\r\\n  kg in divided doses. Although some patients respond to a low dose, the optimum \\r\\n  range appears to be from 375 to 1000 mg daily. However, some investigators feel \\r\\n  that daily doses in excess of 1 g do not produce any better results than a 1 \\r\\n  g dose. When acetazolamide is given in combination with other anticonvulsants, \\r\\n  it is suggested that the starting dose should be 250 mg once daily in addition \\r\\n  to the existing medications. This can be increased to levels as indicated above.',\n",
       " 'The change from other medications to acetazolamide should be gradual and in \\r\\n  accordance with usual practice in epilepsy therapy.',\n",
       " 'Congestive Heart Failure: For diuresis in congestive heart failure, \\r\\n  the starting dose is usually 250 to 375 mg once daily in the morning (5 mg per \\r\\n  kg). If, after an initial response, the patient fails to continue to lose edema \\r\\n  fluid, do not increase the dose but allow for kidney recovery by skipping medication \\r\\n  for a day.',\n",
       " 'Acetazolamide yields best diuretic results when given on alternate days, or for two days alternating with a day of rest. Failures in therapy may be due to overdosage or too frequent dosage. The use of acetazolamide does not eliminate the need for other therapy such as digitalis, bed rest, and salt restriction.',\n",
       " 'Drug-Induced Edema: Recommended dosage is 250 to 375 mg of acetazolamide \\r\\n  once a day for one or two days, alternating with a day of rest.',\n",
       " 'Note: The dosage recommendations for glaucoma and epilepsy differ considerably \\r\\n  from those for congestive heart failure, since the first two conditions are \\r\\n  not dependent upon carbonic anhydrase inhibition in the kidney which requires \\r\\n  intermittent dosage if it is to recover from inhibitory effect of the therapeutic \\r\\n  agent.',\n",
       " 'Parenteral drug products should be inspected visually for particulate matter \\r\\n  and discoloration prior to administration, whenever solution and container permit.',\n",
       " 'Intravenous Acetazolamide for Injection USP (lyophilized) powder.',\n",
       " 'NDC 55390-460-01 500 mg Vial',\n",
       " 'Store drug product at controlled room temperature 15°-30°C (59°-86°F). Reconstituted solution should be stored in refrigerator at 2°- 8°C (36° \\r\\n  - 46°F). Use within 12 hours of reconstitution. Contains no preservative. Discard unused \\r\\n  portion.',\n",
       " 'Manufactured by: Ben Venue Laboratories, Inc. 270 Northfield Road Bedford, \\r\\n  Ohio 44146 Manufactured for: Bedford Laboratories™ 270 Northfield Road Bedford, Ohio \\r\\n  44146 December 2002 FDA rev date: 3/1/2005',\n",
       " 'Acetazolamide Tablets coupons',\n",
       " ...]"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "indication"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "9cdc79ef",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "11736"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(indication)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "bdadb770",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Sodium retention, Fluid retention, Congestive heart failure in susceptible \\r\\n  patients, Potassium loss, Hypokalemic alkalosis , Hypertension',\n",
       " 'Muscle weakness, Steroid myopathy , Loss of muscle mass, Severe arthralgia , \\r\\n  Vertebral compression fractures, Aseptic necrosis of femoral and humeral heads, Pathologic fracture of long bones, Osteoporosis',\n",
       " 'Peptic ulcer with possible perforation and hemorrhage , Pancreatitis , Abdominal distention , and Ulcerative esophagitis',\n",
       " 'Impaired wound healing, Thin fragile skin, Petechiae and ecchymoses, Facial erythema , Increased sweating , May suppress reactions to skin tests',\n",
       " 'Increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually \\r\\n  after treatment, Convulsions, Vertigo , Headache',\n",
       " 'Development of Cushingoid state, Suppression of growth in children, Secondary \\r\\n  adrenocortical and pituitary unresponsiveness, particularly in times of stress , \\r\\n  as in trauma , surgery or illness, Menstrual irregularities, Decreased carbohydrate tolerance, Manifestations of latent diabetes mellitus , Increased requirements \\r\\n  for insulin or oral hypoglycemic agents in diabetics',\n",
       " 'Posterior subcapsular cataracts, Increased intraocular pressure , Glaucoma , Exophthalmos',\n",
       " 'Negative nitrogen balance due to protein catabolism',\n",
       " 'The following additional adverse reactions are related to parenteral corticosteroid therapy : Hyperpigmentation or hypopigmentation, Subcutaneous and cutaneous atrophy , \\r\\n  Sterile abscess , Anaphylactic reaction with or without circulatory collapse, cardiac arrest , bronchospasm, Urticaria , Nausea and vomiting, Cardiac arrhythmias; hypotension or hypertension',\n",
       " 'The pharmacokinetic interactions listed below are potentially clinically important. \\r\\n  Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and \\r\\n  methylprednisolone; therefore, it is possible that adverse events associated \\r\\n  with the individual use of either drug may be more apt to occur. Convulsions \\r\\n  have been reported with concurrent use of methylprednisolone and cyclosporin.',\n",
       " 'As KIVEXA tablets contain abacavir and lamivudine, any interactions that have been identified with these agents individually may occur with KIVEXA tablets. Clinical studies have shown that there are no clinically significant interactions between abacavir and lamivudine. Abacavir and lamivudine are not significantly metabolised by cytochrome P 450 enzymes (such as CYP 3A4, CYP 2C9 or CYP 2D6) nor do they inhibit or induce this enzyme system. Therefore, there is little potential for interactions with antiretroviral protease inhibitors, non-nucleosides and other medicinal products metabolised by major P 450 enzymes.',\n",
       " 'The likelihood of metabolic interactions with lamivudine is low due to limited metabolism and plasma protein binding, and almost complete renal clearance. Lamivudine is predominantly eliminated by active organic cationic secretion. The possibility of interactions with other medicinal products administered concurrently should be considered, particularly when the main route of elimination is renal.',\n",
       " 'In vitro , abacavir demonstrates no or weak inhibition of the drug transporters organic anion transporter 1B1 (OATP1B1), OATP1B3, breast cancer resistance protein (BCRP) or P- glycoprotein (Pgp) and minimal inhibition of organic cation transporter 1 (OCT1), OCT2 and multidrug and toxin extrusion protein 2-K (MATE2-K). Abacavir is therefore not expected to affect the plasma concentrations of drugs that are substrates of these drug transporters.',\n",
       " 'Abacavir is an inhibitor of MATE1 in vitro , however abacavir has low potential to affect the plasma concentrations of MATE1 substrates at therapeutic drug exposures (up to 600 mg).',\n",
       " 'In vitro , abacavir is not a substrate of OATP1B1, OATP1B3, OCT1, OCT2, OAT1, MATE1, MATE2-K, Multidrug resistance-associated protein 2 (MRP2) or MRP4, therefore drugs that modulate these transporters are not expected to affect abacavir plasma concentrations.',\n",
       " 'Although abacavir is a substrate of BCRP and Pgp in vitro , clinical studies demonstrate no clinically significant changes in abacavir pharmacokinetics when co-administered with lopinavir/ritonavir (Pgp and BCRP inhibitors).',\n",
       " 'The metabolism of abacavir is altered by concomitant ethanol resulting in an increase in AUC of abacavir of about 41%. Given the safety profile of abacavir, these findings are not considered clinically significant. Abacavir has no effect on the metabolism of ethanol.',\n",
       " 'In a pharmacokinetic study, co-administration of 600 mg abacavir twice daily with methadone showed a 35% reduction in abacavir Cmax and a one hour delay in tmax, but AUC was unchanged. The changes in abacavir pharmacokinetics are not considered clinically relevant. In this study, abacavir increased the mean methadone systemic clearance by 22%. This change is not considered clinically relevant for the majority of patients, however occasionally methadone dose re-titration may be required.',\n",
       " 'Retinoid compounds such as isotretinoin, are eliminated via alcohol dehydrogenase. Interaction with abacavir is possible but has not been studied.',\n",
       " 'In vitro , lamivudine demonstrates no or weak inhibition of the drug transporters OATP1B1, OATP1B3, BCRP or Pgp, MATE1, MATE2-K or OCT3. Lamivudine is therefore not expected to affect the plasma concentrations of drugs that are substrates of these drug transporters.',\n",
       " 'Lamivudine is an inhibitor of OCT1 and OCT2 in vitro with IC50 values of 17 and 33 uM, respectively, however lamivudine has low potential to affect the plasma concentrations of OCT1 and OCT2 substrates at therapeutic drug exposures (up to 300 mg).',\n",
       " 'Lamivudine is a substrate of MATE1, MATE2-K and OCT2 in vitro . Trimethoprim (an inhibitor of these drug transporters) has been shown to increase lamivudine plasma concentrations, however this interaction is not considered clinically significant as no dose adjustment of lamivudine is needed.',\n",
       " 'Lamivudine is a substrate of the hepatic uptake transporter OCT1. As hepatic elimination plays a minor role in the clearance of lamivudine, drug interactions due to inhibition of OCT1 are unlikely to be of clinical significance.',\n",
       " 'Lamivudine is a substrate of Pgp and BCRP, however due to its high bioavailability it is unlikely that these transporters play a significant role in the absorption of lamivudine. Therefore co-administration of drugs that are inhibitors of these efflux transporters is unlikely to affect the disposition and elimination of lamivudine.',\n",
       " 'Coadministration of sorbitol solution (3.2 g, 10.2 g, 13.4 g) with a single 300 mg dose of lamivudine oral solution resulted in dose-dependent decreases of 14% (9 - 20%), 32% (28 - 37%), and 36% (32 - 41%) in lamivudine exposure (AUC∞) and 28% (20 - 34%), 52% (47 - 57%), and 55% (50 - 59%) in the Cmax of lamivudine in adults. When possible, avoid chronic coadministration of sorbitol-containing medicines with lamivudine. Consider more frequent monitoring of HIV-1 viral load when chronic coadministration cannot be avoided.',\n",
       " 'Administration of trimethoprim/sulphamethoxazole 160 mg/800 mg (co-trimoxazole) causes a 40% increase in lamivudine exposure because of the trimethoprim component. However, unless the patient has renal impairment, no dosage adjustment of lamivudine is necessary (see Section Dose And Method Of Administration ). Lamivudine has no effect on the pharmacokinetics of trimethoprim or sulphamethoxazole. Administration of lamivudine in patients with renal impairment should be assessed carefully. The effect of co-administration of lamivudine with higher doses of co-trimoxazole used for the treatment of Pneumocystis carinii pneumonia and toxoplasmosis has not been studied.',\n",
       " 'Lamivudine may inhibit the intracellular phosphorylation of emtricitabine when the two medicinal products are used concurrently. Additionally, the mechanism of viral resistance for both lamivudine and emtricitabine is mediated via mutation of the same viral reverse transcriptase gene (M184V) and therefore the therapeutic efficacy of these drugs in combination therapy may be limited. Lamivudine is not recommended for use in combination with emtricitabine or emtricitabine-containing fixed-dose combinations.',\n",
       " \"There have been no studies to investigate the effect of abacavir or lamivudine, on driving performance or the ability to operate machinery. Further, a detrimental effect on such activities cannot be predicted from the pharmacology of these medicinal products. The clinical status of the patient and the adverse event profile of KIVEXA tablets should be borne in mind when considering the patient's ability to drive or operate machinery.\",\n",
       " 'Included as part of the \"PRECAUTIONS\" Section',\n",
       " 'Serious and sometimes fatal hypersensitivity reactions have occurred with ZIAGEN (abacavir). These hypersensitivity reactions have included multi-organ failure and anaphylaxis and typically occurred within the first 6 weeks of treatment with ZIAGEN (median time to onset was 9 days); although abacavir hypersensitivity reactions have occurred any time during treatment [see ADVERSE REACTIONS ]. Patients who carry the HLA-B*5701 allele are at a higher risk of abacavir hypersensitivity reactions; although, patients who do not carry the HLA-B*5701 allele have developed hypersensitivity reactions. Hypersensitivity to abacavir was reported in approximately 206 (8%) of 2,670 patients in 9 clinical trials with abacavir-containing products where HLA-B*5701 screening was not performed. The incidence of suspected abacavir hypersensitivity reactions in clinical trials was 1% when subjects carrying the HLA-B*5701 allele were excluded. In any patient treated with abacavir, the clinical diagnosis of hypersensitivity reaction must remain the basis of clinical decision making.',\n",
       " 'Due to the potential for severe, serious, and possibly fatal hypersensitivity reactions with ZIAGEN:',\n",
       " 'Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues, including ZIAGEN. A majority of these cases have been in women. Female sex and obesity may be risk factors for the development of lactic acidosis and severe hepatomegaly with steatosis in patients treated with antiretroviral nucleoside analogues. Treatment with ZIAGEN should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity, which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations.',\n",
       " 'Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including ZIAGEN. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jirovecii pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.',\n",
       " 'Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable and can occur many months after initiation of treatment.',\n",
       " 'Several prospective, observational, epidemiological studies have reported an association with the use of abacavir and the risk of myocardial infarction (MI). Meta-analyses of randomized, controlled, clinical trials have observed no excess risk of MI in abacavir-treated subjects as compared with control subjects. To date, there is no established biological mechanism to explain a potential increase in risk. In totality, the available data from the observational studies and from controlled clinical trials show inconsistency; therefore, evidence for a causal relationship between abacavir treatment and the risk of MI is inconclusive.',\n",
       " 'As a precaution, the underlying risk of coronary heart disease should be considered when prescribing antiretroviral therapies, including abacavir, and action taken to minimize all modifiable risk factors (e.g., hypertension, hyperlipidemia, diabetes mellitus, smoking).',\n",
       " 'Advise the patient to read the FDA-approved patient labeling ( PATIENT INFORMATION ).',\n",
       " 'Inform patients:',\n",
       " 'dvise patients that lactic acidosis and severe hepatomegaly with steatosis have been reported with use of nucleoside analogues and other antiretrovirals. Advise patients to stop taking ZIAGEN if they develop clinical symptoms suggestive of lactic acidosis or pronounced hepatotoxicity [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Advise patients to inform their healthcare provider immediately of any signs and symptoms of infection as inflammation from previous infection may occur soon after combination antiretroviral therapy, including when ZIAGEN is started [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ZIAGEN during pregnancy [see Use In Specific Populations ].',\n",
       " 'Instruct women with HIV-1 infection not to breastfeed because HIV-1 can be passed to the baby in the breast milk [see Use In Specific Populations ].',\n",
       " 'Instruct patients that if they miss a dose of ZIAGEN, to take it as soon as they remember. Advise patients not to double their next dose or take more than the prescribed dose [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'Instruct patients to read the Medication Guide before starting ZIAGEN and to re-read it each time the prescription is renewed. Instruct patients to inform their physician or pharmacist if they develop any unusual symptom, or if any known symptom persists or worsens.',\n",
       " 'COMBIVIR, EPIVIR, TRIUMEQ, and ZIAGEN are trademarks owned by or licensed to the ViiV Healthcare group of companies.',\n",
       " 'The other brands listed are owned by or licensed to their respective owner and are not owned by or licensed to the ViiV Healthcare group of companies. The makers of these brands are not affiliated with and do not endorse the ViiV Healthcare group of companies or its products.',\n",
       " 'Abacavir was administered orally at 3 dosage levels to separate groups of mice and rats in 2-year carcinogenicity studies. Results showed an increase in the incidence of malignant and non-malignant tumors. Malignant tumors occurred in the preputial gland of males and the clitoral gland of females of both species, and in the liver of female rats. In addition, non-malignant tumors also occurred in the liver and thyroid gland of female rats. These observations were made at systemic exposures in the range of 6 to 32 times the human exposure at the recommended dose of 600 mg.',\n",
       " 'Abacavir induced chromosomal aberrations both in the presence and absence of metabolic activation in an in vitro cytogenetic study in human lymphocytes. Abacavir was mutagenic in the absence of metabolic activation, although it was not mutagenic in the presence of metabolic activation in an L5178Y mouse lymphoma assay. Abacavir was clastogenic in males and not clastogenic in females in an in vivo mouse bone marrow micronucleus assay.',\n",
       " 'Abacavir was not mutagenic in bacterial mutagenicity assays in the presence and absence of metabolic activation.',\n",
       " 'Abacavir did not affect male or female fertility in rats at a dose associated with exposures (AUC) approximately 3.3 times (male) or 4.1 times (female) those in humans at the clinically recommended dose.',\n",
       " 'There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ZIAGEN during pregnancy. Healthcare Providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263.',\n",
       " 'Available data from the APR show no difference in the overall risk of birth defects for abacavir compared with the background rate for birth defects of 2.7% in the Metropolitan Atlanta Congenital Defects Program (MACDP) reference population (see Data ). The APR uses the MACDP as the U.S. reference population for birth defects in the general population. The MACDP evaluates women and infants from a limited geographic area and does not include outcomes for births that occurred at less than 20 weeks’ gestation. The rate of miscarriage is not reported in the APR. The estimated background rate of miscarriage in clinically recognized pregnancies in the U.S. general population is 15% to 20%. The background risk for major birth defects and miscarriage for the indicated population is unknown.',\n",
       " 'In animal reproduction studies, oral administration of abacavir to pregnant rats during organogenesis resulted in fetal malformations and other embryonic and fetal toxicities at exposures 35 times the human exposure (AUC) at the recommended clinical daily dose. However, no adverse developmental effects were observed following oral administration of abacavir to pregnant rabbits during organogenesis, at exposures approximately 9 times the human exposure (AUC) at the recommended clinical dose (see Data ).',\n",
       " 'Human Data',\n",
       " 'Based on prospective reports to the APR of exposures to abacavir during pregnancy resulting in live births (including over 1,300 exposed in the first trimester and over 1,300 exposed in second/third trimester), there was no difference between the overall risk of birth defects for abacavir compared with the background birth defect rate of 2.7% in the U.S. reference population of the MACDP. The prevalence of defects in live births was 3.2% (95% CI: 2.3% to 4.3%) following first trimester exposure to abacavir-containing regimens and 2.9% (95% CI: 2.1% to 4.0%) following second/third trimester exposure to abacavir-containing regimens.',\n",
       " 'Abacavir has been shown to cross the placenta and concentrations in neonatal plasma at birth were essentially equal to those in maternal plasma at delivery [see CLINICAL PHARMACOLOGY ].',\n",
       " 'Animal Data',\n",
       " 'Abacavir was administered orally to pregnant rats (at 100, 300, and 1,000 mg per kg per day) and rabbits (at 125, 350, or 700 mg per kg per day) during organogenesis (on Gestation Days 6 through 17 and 6 through 20, respectively). Fetal malformations (increased incidences of fetal anasarca and skeletal malformations) or developmental toxicity (decreased fetal body weight and crown-rump length) were observed in rats at doses up to 1,000 mg per kg per day, resulting in exposures approximately 35 times the human exposure (AUC) at the recommended daily dose. No developmental effects were observed in rats at 100 mg per kg per day, resulting in exposures (AUC) 3.5 times the human exposure at the recommended daily dose. In a fertility and early embryo-fetal development study conducted in rats (at 60, 160, or 500 mg per kg per day), embryonic and fetal toxicities (increased resorptions, decreased fetal body weights) or toxicities to the offspring (increased incidence of stillbirth and lower body weights) occurred at doses up to 500 mg per kg per day. No developmental effects were observed in rats at 60 mg per kg per day, resulting in exposures (AUC) approximately 4 times the human exposure at the recommended daily dose. Studies in pregnant rats showed that abacavir is transferred to the fetus through the placenta. In pregnant rabbits, no developmental toxicities and no increases in fetal malformations occurred at up to the highest dose evaluated, resulting in exposures (AUC) approximately 9 times the human exposure at the recommended dose.',\n",
       " 'The Centers for Disease Control and Prevention recommends that HIV-1–infected mothers in the United States not breastfeed their infants to avoid risking postnatal transmission of HIV-1 infection. Abacavir is present in human milk. There is no information on the effects of abacavir on the breastfed infant or the effects of the drug on milk production. Because of the potential for (1) HIV-1 transmission (in HIV-negative infants), (2) developing viral resistance (in HIV-positive infants), and (3) adverse reactions in a breastfed infant, instruct mothers not to breastfeed if they are receiving ZIAGEN.',\n",
       " 'The safety and effectiveness of ZIAGEN have been established in pediatric patients aged 3 months and older. Use of ZIAGEN is supported by pharmacokinetic trials and evidence from adequate and well-controlled trials of ZIAGEN in adults and pediatric subjects [see DOSAGE AND ADMINISTRATION , ADVERSE REACTIONS , CLINICAL PHARMACOLOGY , Clinical Studies ].',\n",
       " 'Clinical trials of ZIAGEN did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, caution should be exercised in the administration of ZIAGEN in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.',\n",
       " 'A dose reduction is required for patients with mild hepatic impairment (Child-Pugh Class A) [see DOSAGE AND ADMINISTRATION ]. The safety, efficacy, and pharmacokinetic properties of abacavir have not been established in patients with moderate or severe hepatic impairment; therefore, ZIAGEN is contraindicated in these patients [see CONTRAINDICATIONS , CLINICAL PHARMACOLOGY ].',\n",
       " 'In a trial of 11 HIV-1-infected subjects receiving methadone-maintenance therapy with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased [see CLINICAL PHARMACOLOGY ]. This alteration will not result in a methadone dose modification in the majority of patients; however, an increased methadone dose may be required in a small number of patients.',\n",
       " 'Coadministration of single doses of lamivudine and sorbitol resulted in a sorbitol dose-dependent reduction in lamivudine exposures. When possible, avoid use of sorbitol-containing medicines with lamivudine-containing medicines [see CLINICAL PHARMACOLOGY ].',\n",
       " 'Coadministration with fixed-dose abacavir/dolutegravir/lamivudine resulted in increased riociguat exposure, which may increase the risk of riociguat adverse reactions [see CLINICAL PHARMACOLOGY ]. The riociguat dose may need to be reduced. See full prescribing information for ADEMPAS (riociguat).',\n",
       " 'In a trial of 11 HIV-1-infected subjects receiving methadone-maintenance therapy with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased [see CLINICAL PHARMACOLOGY ]. This alteration will not result in a methadone dose modification in the majority of patients; however, an increased methadone dose may be required in a small number of patients.',\n",
       " 'Coadministration with fixed-dose abacavir/dolutegravir/lamivudine resulted in increased riociguat exposure, which may increase the risk of riociguat adverse reactions [see CLINICAL PHARMACOLOGY ]. The riociguat dose may need to be reduced. See full prescribing information for ADEMPAS (riociguat).',\n",
       " 'Coadministration of single doses of lamivudine and sorbitol resulted in a sorbitol dose-dependent reduction in lamivudine exposures. When possible, avoid use of sorbitol-containing medicines with lamivudine-containing medicines [see CLINICAL PHARMACOLOGY ].',\n",
       " 'Concomitant use of zidovudine with the following drugs should be avoided since an antagonistic relationship has been demonstrated in vitro:',\n",
       " 'Coadministration with the following drugs may increase the hematologic toxicity of zidovudine:',\n",
       " 'In vitro , dolutegravir inhibited the renal organic cation transporters (OCT)2 (IC 50 = 1.93 microM) and multidrug and toxin extrusion transporter (MATE)1 (IC 50 = 6.34 microM). In vivo , dolutegravir inhibits tubular secretion of creatinine by inhibiting OCT2 and potentially MATE1. Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see CONTRAINDICATIONS , Established And Other Potentially Significant Drug Interactions ].',\n",
       " 'In vitro , dolutegravir inhibited the basolateral renal transporters, organic anion transporter (OAT) 1 (IC 50 = 2.12 microM) and OAT3 (IC 50 = 1.97 microM). However, in vivo , dolutegravir did not alter the plasma concentrations of tenofovir or para- amino hippurate, substrates of OAT1 and OAT3.',\n",
       " 'In vitro , dolutegravir did not inhibit (IC 50 >50 microM) the following: cytochrome P450 (CYP)1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A, uridine diphosphate (UDP)-glucuronosyl transferase (UGT)1A1, UGT2B7, P- glycoprotein (P-gp), breast cancer resistance protein (BCRP), bile salt export pump (BSEP), organic anion transporter polypeptide (OATP)1B1, OATP1B3, OCT1, or multidrug resistance protein (MRP)2, or MRP4. In vitro , dolutegravir did not induce CYP1A2, CYP2B6, CYP3A4. Based on these data and the results of drug interaction trials, dolutegravir is not expected to affect the pharmacokinetics of drugs that are substrates of these enzymes or transporters.',\n",
       " 'In drug interaction trials, dolutegravir did not have a clinically relevant effect on the pharmacokinetics of the following drugs: daclatasvir, tenofovir, methadone , midazolam, rilpivirine, and oral contraceptives containing norgestimate and ethinyl estradiol. Using crossstudy comparisons to historical pharmacokinetic data for each interacting drug, dolutegravir did not appear to affect the pharmacokinetics of the following drugs: atazanavir, darunavir, efavirenz, etravirine, fosamprenavir, lopinavir, ritonavir, and boceprevir.',\n",
       " 'Dolutegravir is metabolized by UGT1A1 with some contribution from CYP3A. Dolutegravir is also a substrate of UGT1A3, UGT1A9, BCRP, and P-gp in vitro . Drugs that induce those enzymes and transporters may decrease dolutegravir plasma concentrations and reduce the therapeutic effect of dolutegravir.',\n",
       " 'Coadministration of dolutegravir and other drugs that inhibit these enzymes may increase dolutegravir plasma concentrations.',\n",
       " 'Etravirine significantly reduced plasma concentrations of dolutegravir, but the effect of etravirine was mitigated by coadministration of lopinavir/ritonavir or darunavir/ritonavir and is expected to be mitigated by atazanavir/ritonavir (Table 6) [see Established And Other Potentially Significant Drug Interactions , CLINICAL PHARMACOLOGY ].',\n",
       " 'In vitro , dolutegravir was not a substrate of OATP1B1 or OATP1B3. Darunavir/ritonavir, lopinavir/ritonavir, rilpivirine, tenofovir, boceprevir, daclatasvir, prednisone, rifabutin, and omeprazole had no clinically significant effect on the pharmacokinetics of dolutegravir.',\n",
       " 'There were no drug-drug interaction trials conducted with the abacavir, dolutegravir, and lamivudine fixed-dose combination tablets.',\n",
       " 'Information regarding potential drug interactions with the individual components of TRIUMEQ and TRIUMEQ PD are provided below. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse events or loss of efficacy. [see CONTRAINDICATIONS , CLINICAL PHARMACOLOGY ]',\n",
       " 'Table 6. Established and Other Potentially Significant Drug Interactions for Dolutegravir: Alterations in Dose May Be Recommended Based on Drug Interaction Trials or Predicted Interactions',\n",
       " '',\n",
       " 'Abacavir',\n",
       " 'In a trial of 11 HIV-1–infected subjects receiving methadone- maintenance therapy with 600 mg of abacavir twice daily (twice the currently recommended dose), oral methadone clearance increased [see CLINICAL PHARMACOLOGY ]. This alteration will not result in a methadone dose modification in the majority of patients; however, an increased methadone dose may be required in a small number of patients.',\n",
       " 'Lamivudine',\n",
       " 'Coadministration of single doses of lamivudine and sorbitol resulted in a sorbitol dose-dependent reduction in lamivudine exposures. When possible, avoid use of sorbitolcontaining medicines with lamivudine-containing medicines [see CLINICAL PHARMACOLOGY ].',\n",
       " 'Abacavir',\n",
       " 'Coadministration with TRIUMEQ resulted in increased riociguat exposure, which may increase the risk of riociguat adverse reactions [see CLINICAL PHARMACOLOGY ]. The riociguat dose may need to be reduced. See full prescribing information for ADEMPAS (riociguat).',\n",
       " 'Included as part of the PRECAUTIONS section.',\n",
       " 'Abaloparatide caused a dose-dependent increase in the incidence of osteosarcoma in male and female rats after subcutaneous administration at exposures 4 to 28 times the human exposure at the clinical dose of 80 mcg [see Nonclinical Toxicology ]. It is unknown whether TYMLOS will cause osteosarcoma in humans.',\n",
       " \"The use of TYMLOS is not recommended in patients at increased risk of osteosarcoma including those with Paget's disease of bone or unexplained elevations of alkaline phosphatase, open epiphyses, bone metastases or skeletal malignancies, hereditary disorders predisposing to osteosarcoma, or prior external beam or implant radiation therapy involving the skeleton .\",\n",
       " 'Cumulative use of TYMLOS and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patientâ€™s lifetime is not recommended.',\n",
       " 'Orthostatic hypotension may occur with TYMLOS, typically within 4 hours of injection. Associated symptoms may include dizziness, palpitations, tachycardia or nausea, and may resolve by having the patient lie down. For the first several doses, TYMLOS should be administered where the patient can sit or lie down if necessary [see ADVERSE REACTIONS ].',\n",
       " 'TYMLOS may cause hypercalcemia. TYMLOS is not recommended in patients with preexisting hypercalcemia or in patients who have an underlying hypercalcemic disorder, such as primary hyperparathyroidism , because of the possibility of exacerbating hypercalcemia [see ADVERSE REACTIONS ].',\n",
       " 'TYMLOS may cause hypercalciuria. It is unknown whether TYMLOS may exacerbate urolithiasis in patients with active or a history of urolithiasis. If active urolithiasis or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered [see ADVERSE REACTIONS ].',\n",
       " 'Advise the patient to read the FDA-approved patient labeling ( Medication Guide and Instructions for Use ).',\n",
       " 'Advise patients that the active ingredient in TYMLOS, abaloparatide, caused a dose-dependent increase in the incidence of osteosarcoma in male and female rats and that it is unknown whether TYMLOS will cause osteosarcoma in humans [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Instruct patients to promptly report signs and symptoms of possible osteosarcoma such as persistent localized pain or occurrence of a new soft tissue mass that is tender to palpation.',\n",
       " 'Advise patients that TYMLOS may cause hypercalcemia and discuss the symptoms of hypercalcemia (e.g., nausea, vomiting, constipation, lethargy, muscle weakness) [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Instruct patients to promptly report signs and symptoms of hypercalcemia.',\n",
       " 'Advise patients to sit or lie down if they feel lightheaded or have palpitations after the injection until their symptoms resolve. If these symptoms persist or worsen, advise patients to consult their healthcare provider before continuing treatment [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'Advise patients to seek immediate medical attention if they experience signs or symptoms of a hypersensitivity reaction including anaphylaxis , dyspnea or urticaria [see CONTRAINDICATIONS and ADVERSE REACTIONS ].',\n",
       " 'Instruct patients and caregivers who administer TYMLOS on how to properly use the TYMLOS pen and to follow sharps disposal recommendations [see DOSAGE AND ADMINISTRATION ]. Advise patients not to share their TYMLOS pen or needles with other patients and not to transfer the contents of the pen to a syringe.',\n",
       " 'Advise patients that each TYMLOS pen can be used for up to 30 days, and after the 30-day use period, to discard the TYMLOS pen, even if it still contains unused solution [see HOW SUPPLIED / Storage And Handling ].',\n",
       " 'In a 2-year carcinogenicity study, abaloparatide was administered once daily to male and female Fischer rats by subcutaneous injection at doses of 10, 25, and 50 mcg/kg. These doses resulted in systemic exposures to abaloparatide that were 4, 16, and 28 times, respectively, the systemic exposure observed in humans following the recommended subcutaneous dose of 80 mcg (based on AUC comparisons). Neoplastic changes related to treatment with abaloparatide consisted of marked dose-dependent increases in osteosarcoma and osteoblastoma incidence in all male and female dose groups. The incidence of osteosarcoma was 0-2% in untreated controls and reached 87% and 62% in male and female high-dose groups, respectively. The bone neoplasms were accompanied by marked increases in bone mass.',\n",
       " 'The relevance of the rat findings to humans is uncertain. The use of TYMLOS is not recommended in patients at increased risk of osteosarcoma [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Abaloparatide was not genotoxic or mutagenic in a standard battery of tests including the Ames test for bacterial mutagenesis , the chromosome aberration test using human peripheral lymphocytes, and the mouse micronucleus test.',\n",
       " 'TYMLOS is not indicated for use in females of reproductive potential. There are no human data with TYMLOS use in pregnant women to inform any drug associated risks. Animal reproduction studies with abaloparatide have not been conducted.',\n",
       " 'TYMLOS is not indicated for use in females of reproductive potential. There is no information on the presence of abaloparatide in human milk, the effects on the breastfed infant, or the effects on milk production.',\n",
       " 'Safety and effectiveness of TYMLOS have not been established in pediatric patients. TYMLOS is not recommended for use in pediatric patients with open epiphyses or hereditary disorders predisposing to osteosarcoma because of an increased baseline risk of osteosarcoma [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Of the total number of patients in the postmenopausal osteoporosis clinical studies of TYMLOS, 82% were age 65 years and over, and 19% were age 75 years and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.',\n",
       " 'No dosage adjustment is required for patients with mild, moderate, or severe renal impairment. A study of a single dose of TYMLOS 80 mcg given subcutaneously was conducted in subjects with normal renal function or mild, moderate, or severe renal impairment. The maximal concentration (Cmax) and area under the concentration-time curve (AUC) of abaloparatide increased 1.4-and 2.1-fold, respectively, in subjects with severe renal impairment, compared to subjects with normal renal function. Patients with severe renal impairment may have increased abaloparatide exposure that may increase the risk of adverse reactions; therefore, monitor for adverse reactions [see CLINICAL PHARMACOLOGY ].',\n",
       " 'Included as part of the \"PRECAUTIONS\" Section',\n",
       " 'XEGLYZE contains benzyl alcohol. Systemic exposure to benzyl alcohol has been associated with serious and fatal adverse reactions including “gasping syndrome” in neonates and low birth weight infants. The “gasping syndrome” is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. The minimum amount of benzyl alcohol at which toxicity may occur is not known. Premature and low-birth weight infants may be more likely to develop toxicity [see Use In Specific Populations ].',\n",
       " 'The safety and effectiveness of XEGLYZE have not been established in pediatric patients below the age of 6 months. Use is not recommended in pediatric patients under 6 months of age because of the potential for increased systemic absorption.',\n",
       " 'In order to prevent accidental ingestion in pediatric patients, XEGLYZE should only be administered under direct supervision of an adult.',\n",
       " 'Ingestion of benzyl alcohol in large quantities may result in gastrointestinal (nausea, vomiting, diarrhea) and central nervous system (headache, ataxia, convulsions, coma) adverse reactions. Serious adverse reactions may include respiratory depression and death. If accidentally swallowed, advise the patient or the caregiver to call their Poison Control Center at 1-800-2221222.',\n",
       " 'Advise the patient or caregiver to read the FDA-approved patient labeling ( PATIENT INFORMATION and Instructions for Use ).',\n",
       " 'Inform the patient and caregiver of the following instructions:',\n",
       " 'Long-term studies in animals have not been conducted to evaluate the carcinogenic potential of XEGLYZE or abametapir.',\n",
       " 'Abametapir was not mutagenic or clastogenic based on the results of two in vitro genotoxicity tests (Ames test and human lymphocyte chromosomal aberration assay) and one in vivo genotoxicity test (rat micronucleus assay).',\n",
       " 'No effects on fertility have been observed in rats following repeated oral doses of up to 75 mg/kg/day abametapir (50 times the MRHD based on Cmax comparisons).',\n",
       " 'There are no available data on XEGLYZE use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In embryofetal development studies conducted with oral administration of abametapir during organogenesis, no evidence of fetal harm or malformations, independent of maternal toxicity were observed in pregnant rats and rabbits at doses that produced exposures up to 50 times and equivalent to the maximum recommended human dose (MRHD) in rats and rabbits, respectively. The highest dose evaluated in rabbits was limited due to maternal toxicity associated with the vehicle used in the study (see Data ).',\n",
       " 'The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.',\n",
       " 'Animal Data',\n",
       " 'Systemic embryofetal development studies were performed in rats and rabbits. Oral doses of 10, 25 and 75 mg/kg/day abametapir were administered during the period of organogenesis (gestational days 6 – 17) to pregnant rats. In the presence of maternal toxicity, embryofetal toxicity (lower fetal body weights and delayed ossification) was noted at 75 mg/kg/day. No treatment related effects on malformations were noted at 75 mg/kg/day (50 times the MRHD based on Cmax comparisons).',\n",
       " 'Oral doses of 4, 16 and 40 mg/kg/day abametapir were administered during the period of organogenesis (gestational days 6 – 19) to pregnant rabbits. No treatment related effects on embryofetal toxicity or malformations were noted at 40 mg/kg/day (~1 time the MRHD based on Cmax comparisons). Maternal toxicity related to the vehicle limited the maximum dose in pregnant rabbits.',\n",
       " 'In a perinatal and postnatal development study in rats, oral doses of 10, 25 and 75 mg/kg/day were administered from the beginning of organogenesis (gestational day 6) through the end of lactation (lactation day 20). In the presence of maternal toxicity, embryofetal lethality, and decreased fetal body weight gain were noted at 75 mg/kg/day. No treatment related effects on postnatal development were noted at 75 mg/kg/day (47 times the MRHD based on Cmax comparisons).',\n",
       " 'No data are available regarding the presence of abametapir in human milk or the effects of abametapir on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for XEGLYZE and any potential adverse effects on the breastfed child from XEGLYZE or from the underlying maternal condition.',\n",
       " 'The safety and effectiveness of XEGLYZE have been established in pediatric patients 6 months of age and older [see CLINICAL PHARMACOLOGY and Clinical Studies ].',\n",
       " 'The safety and effectiveness of XEGLYZE have not been established in pediatric patients below the age of 6 months. XEGLYZE is not recommended in pediatric patients under 6 months of age because of the potential for increased systemic absorption due to a high ratio of skin surface to body mass and the potential for an immature skin barrier.',\n",
       " 'XEGLYZE contains benzyl alcohol. Benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants. The “gasping syndrome” (characterized by central nervous system depression, metabolic acidosis, gasping respirations, and high levels of benzyl alcohol and its metabolites found in the blood and urine) has been associated with intravenously administered benzyl alcohol dosages >99 mg/kg/day in neonates and low birthweight infants. Additional symptoms may include gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse.',\n",
       " 'The minimum amount of benzyl alcohol at which toxicity may occur is not known. Premature and low-birthweight infants, as well as patients receiving high dosages, may be more likely to develop toxicity [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Because of the risk of accidental ingestion, XEGLYZE should be administered to pediatric patients only under direct adult supervision [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Clinical studies of XEGLYZE did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger subjects.',\n",
       " 'In the\\r\\n  clinical trial of patients with advanced, symptomatic prostate cancer, 3 of\\r\\n  81 (3.7%) patients experienced an immediate-onset systemic allergic reaction \\r\\n  within minutes of receiving Plenaxis™ . The allergic reactions were urticaria \\r\\n  (Day 15), urticaria and pruritis (Day 29), and hypotension and syncope (Day\\r\\n  141). Patients should be monitored for at least 30 minutes after each injection\\r\\n  of Plenaxis™ . In the event of an allergic reaction associated with hypotension\\r\\n  and/or syncope, appropriate supportive measures such as leg elevation, oxygen,\\r\\n  IV fluids, antihistamines, corticosteroids, and epinephrine (alone or in combination)\\r\\n  should be employed. From all the prostate cancer clinical trials with Plenaxis™\\r\\n  (mostly in men without advanced, symptomatic disease), immediate-onset systemic\\r\\n  allergic reactions (occurring within 30 minutes of dosing), were observed in\\r\\n  1.1% (15/1397) of patients dosed with Plenaxis™ . In 14/15 patients who\\r\\n  experienced an allergic reaction, each developed symptoms within 8 minutes of\\r\\n  injection. The cumulative risk of such a reaction increased with duration of\\r\\n  treatment. The cumulative rates (and 95% confidence intervals) on Days 56, 141,\\r\\n  365 and 676 were 0.51%, (0.13%, 0.88%) 0.80% (0.30%, 1.29%), 1.24% (0.43%, 2.04%)\\r\\n  and 2.91% (0.87, 4.95%), respectively. Seven patients experienced hypotension\\r\\n  or syncope as part of their allergic reaction, representing 0.5% of all patients.\\r\\n  The cumulative rates (and 95% confidence intervals) for these types of reactions\\r\\n  on Days 56, 141, 365, and 617 after the initial dose were 0.22% (0.0%, 0.46%),\\r\\n  0.32% (0.0%, 0.64%), 0.61% (0.0%, 1.24%) and 1.67% (0.07, 3.28%), respectively.',\n",
       " 'A decrease in overall effectiveness with increased duration of treatment, as\\r\\n  measured by failure to maintain suppression of serum testosterone below 50 ng/dL,\\r\\n  was noted (see CLINICAL PHARMACOLOGY , Pharmacodynamics ). Treatment\\r\\n  failure can be detected by measuring serum total testosterone concentrations\\r\\n  just prior to administration on Day 29 after the initial dose and every 8 weeks\\r\\n  thereafter.',\n",
       " 'Because Plenaxis™  may prolong the QT interval (see CLINICAL PHARMACOLOGY , Pharmacodynamics ), physicians should carefully consider whether the risks\\r\\n  of Plenaxis™  outweigh the benefits in patients with baseline QTc values\\r\\n   > 450 msec (e.g. congenital QT prolongation) and in patients taking Class\\r\\n  IA (e.g. quinidine, procainamide) or Class III (e.g. amiodarone, sotalol) antiarrhythmic\\r\\n  medications.',\n",
       " 'The following clinically significant adverse reactions are described elsewhere in the labeling:',\n",
       " 'Because clinical trials are conducted under widely varying and controlled conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not predict the rates observed in a broader patient population in clinical practice.',\n",
       " 'The data from placebo-controlled studies described herein reflect exposure to ORENCIA administered intravenously in patients with active RA (1955 patients with ORENCIA, 989 with placebo) (Studies I through VI) [see Clinical Studies ]. The studies had either a double-blind, placebo-controlled period of 6 months (258 patients with ORENCIA, 133 with placebo) or 1 year (1697 patients with ORENCIA, 856 with placebo). A subset of these patients received concomitant biologic DMARD therapy, such as a TNF antagonist (204 patients with ORENCIA, 134 with placebo). The concomitant use of ORENCIA with a TNF antagonist is not recommended [see INDICATIONS AND USAGE ]. The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: methotrexate, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, TNF antagonist, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.',\n",
       " 'The most serious adverse reactions were serious infections and malignancies. The most commonly reported adverse events (occurring in ≥10% of patients treated with ORENCIA) were headache, upper respiratory tract infection, nasopharyngitis, and nausea.',\n",
       " 'The adverse reactions most frequently resulting in clinical intervention (interruption or discontinuation of ORENCIA) were due to infection. The most frequently reported infections resulting in dose interruption were upper respiratory tract infection (1%), bronchitis (0.7%), and herpes zoster (0.7%). The most frequent infections resulting in discontinuation were pneumonia (0.2%), localized infection (0.2%), and bronchitis (0.1%).',\n",
       " 'Adverse reactions occurring in 3% or more of patients and at least 1% more frequently in ORENCIA-treated patients (intravenous) during placebo-controlled RA studies are summarized in Table 3.',\n",
       " 'Table 3: Most Common Adverse Reactions* During Placebo-Controlled RA Studies of Intravenous ORENCIA',\n",
       " '',\n",
       " 'In the placebo-controlled trials in patients with RA, infections were reported in 54% of intravenous ORENCIA-treated patients and 48% of placebo-treated patients. The most commonly reported infections (reported in 5%-13% of patients) were upper respiratory tract infection, nasopharyngitis, sinusitis , urinary tract infection , influenza , and bronchitis. Other infections reported in fewer than 5% of patients at a higher frequency (>0.5%) with ORENCIA compared to placebo, were rhinitis , herpes simplex, and pneumonia [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Serious infections were reported in 3% of patients treated with ORENCIA and 1.9% of patients treated with placebo. The most common (0.2%-0.5%) serious infections reported with ORENCIA were pneumonia, cellulitis , urinary tract infection, bronchitis, diverticulitis , and acute pyelonephritis [see WARNINGS AND PRECAUTIONS ].',\n",
       " \"In the placebo-controlled portions of the clinical trials (1955 patients treated for RA with ORENCIA for a median of 12 months), the overall frequencies of malignancies were similar in the ORENCIA-and placebo-treated patients (1.3% and 1.1%, respectively). However, more cases of lung cancer were observed in ORENCIA-treated patients (4 cases, 0.2%) than placebo-treated patients (0 cases, 0%). In the cumulative intravenous ORENCIA clinical trials in patients with RA (placebo-controlled and uncontrolled, open-label) a total of 8 cases of lung cancer (0.21 cases per 100 patient-years) and 4 lymphomas (0.10 cases per 100 patient-years) were observed in 2688 patients (3827 patient-years). The rate observed for lymphoma is approximately 3.5-fold higher than expected in an age-and gender-matched general population based on the National Cancer Institute 's Surveillance, Epidemiology, and End Results Database. Patients with RA, particularly those with highly active disease, are at a higher risk for the development of lymphoma. Other malignancies included skin, breast, bile duct , bladder , cervical , endometrial, lymphoma, melanoma , myelodysplastic syndrome , ovarian , prostate , renal, thyroid , and uterine cancers [see WARNINGS AND PRECAUTIONS ]. The potential role of ORENCIA in the development of malignancies in humans is unknown.\",\n",
       " 'Acute infusion-related events (adverse reactions occurring within 1 hour of the start of the infusion) in Studies III, IV, and V [see Clinical Studies ] were more common in the ORENCIA-treated patients than the placebo patients (9% for ORENCIA, 6% for placebo). The most frequently reported events (1%-2%) were dizziness, headache, and hypertension .',\n",
       " 'Acute infusion-related events that were reported in >0.1% and ≤1% of patients treated with ORENCIA included cardiopulmonary symptoms, such as hypotension , increased blood pressure, and dyspnea ; other symptoms included nausea, flushing, urticaria , cough, hypersensitivity, pruritus , rash, and wheezing. Most of these reactions were mild (68%) to moderate (28%). Fewer than 1% of ORENCIA-treated patients discontinued due to an acute infusion-related event. In controlled trials, 6 ORENCIA-treated patients compared to 2 placebo-treated patients discontinued study treatment due to acute infusion-related events.',\n",
       " 'In clinical trials of 2688 adult RA patients treated with intravenous ORENCIA, there were two cases (<0.1%) of anaphylaxis . Other reactions potentially associated with drug hypersensitivity, such as hypotension, urticaria, and dyspnea, each occurred in less than 0.9% of ORENCIA-treated patients and generally occurred within 24 hours of ORENCIA infusion. Appropriate medical support measures for the treatment of hypersensitivity reactions should be available for immediate use in the event of a reaction [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'In Study V [see Clinical Studies ], there were 37 and 17 patients with chronic obstructive pulmonary disease (COPD) who were treated for RA with ORENCIA and placebo, respectively. The COPD patients treated with ORENCIA for RA developed adverse events more frequently than those treated with placebo (97% vs 88%, respectively). Respiratory disorders occurred more frequently in ORENCIA-treated patients compared to placebo-treated patients (43% vs 24%, respectively) including COPD exacerbation, cough, rhonchi, and dyspnea. A greater percentage of ORENCIA-treated patients developed a serious adverse event compared to placebo-treated patients (27% vs 6%), including COPD exacerbation [3 of 37 patients (8%)] and pneumonia [1 of 37 patients (3%)] [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Study VI was an active-controlled clinical trial in methotrexate-naive patients [see Clinical Studies ]. The safety experience in these patients was consistent with the patients in Studies I-V.',\n",
       " 'The data described below are derived from Study SC-1. Study SC-1 was a randomized, double-blind, double-dummy, non-inferiority study that compared the safety of ORENCIA administered subcutaneously or intravenously in 1457 patients with RA, who received background methotrexate, and experienced an inadequate response to methotrexate ( MTX -IR) [see Clinical Studies ]. The adverse reaction profile in patients treated with subcutaneous ORENCIA was similar to the adverse reaction profile in patients treated with intravenous ORENCIA and consistent with intravenous ORENCIA administered in Studies I-VI.',\n",
       " 'The overall frequency of injection site reactions in Study SC-1 was 2.6% (19/736) and 2.5% (18/721) for the subcutaneous ORENCIA group and the subcutaneous placebo group (given intravenous ORENCIA), respectively [see Clinical Studies ]. All these injection site reactions (including hematoma , pruritus, and erythema ) were mild (83%) to moderate (17%) in severity, and none necessitated drug discontinuation.',\n",
       " 'The safety of ORENCIA was evaluated in 594 patients with PsA (341 patients on ORENCIA and 253 patients on placebo), in two randomized, double-blind, placebo-controlled trials [see Clinical Studies ]. Of the 341 patients who received ORENCIA, 128 patients received intravenous ORENCIA (PsA-I) and 213 patients received subcutaneous ORENCIA (PsA-II). The safety profile was comparable between ORENCIA given intravenously in Study PsA-I and ORENCIA given subcutaneously in Study PsA-II and also consistent with the safety profile of ORENCIA in patients with RA [see WARNINGS AND PRECAUTIONS , ADVERSE REACTIONS ].',\n",
       " 'In general, the adverse events in pediatric patients with polyarticular JIA (pJIA) treated with intravenous ORENCIA were similar in frequency and type to those seen in adult patients with RA treated with intravenous ORENCIA [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS ].',\n",
       " 'Study JIA-1 was a three-part study including an open-label extension that assessed the safety of intravenous ORENCIA in 190 pediatric patients, 6 to 17 years of age, with pJIA. Overall frequency of adverse events in the 4-month, lead-in, open-label period of the study was 70%; infections occurred at a frequency of 36% [see Clinical Studies ]. The most common infections were upper respiratory tract infection and nasopharyngitis. The infections resolved without sequelae , and the types of infections were consistent with those commonly seen in outpatient pediatric populations. Other events that occurred at a prevalence of at least 5% were headache, nausea, diarrhea, cough, pyrexia, and abdominal pain.',\n",
       " 'A total of 6 serious adverse events [ acute lymphocytic leukemia , ovarian cyst , varicella infection, disease flare (2), and joint wear] were reported during the initial 4 months of treatment with intravenous ORENCIA.',\n",
       " 'Of the 190 pediatric patients with pJIA treated with intravenous ORENCIA in clinical trials, there was one case of a hypersensitivity reaction (0.5%). During Periods A, B, and C, acute infusion-related reactions occurred at a frequency of 4%, 2%, and 3%, respectively, and were consistent with the types of events reported in adults.',\n",
       " 'Upon continued treatment in the open-label extension period, the types of adverse events were similar in frequency and type to those seen in adult patients, except for a single patient diagnosed with multiple sclerosis while on open-label treatment.',\n",
       " 'Study JIA-2 was an open-label study with a 4-month short-term period and a long-term extension period that assessed the safety of subcutaneous ORENCIA in 205 pediatric patients, 2 to 17 years of age with pJIA. The adverse reaction profile in patients with pJIA treated with ORENCIA administered subcutaneously in Study JIA-2 were consistent with the adverse reaction profile in patients with pJIA treated with intravenous Study JIA-1.',\n",
       " 'There were no reported cases of hypersensitivity reactions. Local injection-site reactions occurred at a frequency of 4.4%.',\n",
       " 'The data described herein were from one clinical study of ORENCIA ( GVHD -1) for aGVHD prophylaxis in patients 6 years and older with hematologic malignancies who were undergoing unrelated HSCT wherein all patients were receiving calcineurin inhibitor and methotrexate as the standard of care for aGVHD prophylaxis [see Clinical Studies ]. Two cohorts were studied at 10 mg/kg (maximum dose of 1,000 mg) as an intravenous infusion over 60 minutes on the day before transplantation (Day -1), followed by administration on Days 5, 14, and 28 after transplantation:',\n",
       " 'Of the 116 patients who received ORENCIA, 27 (23%) were 6 to less than 17 years of age [see Use In Specific Populations ].',\n",
       " 'The safety information from the date of first dose of ORENCIA up to Day 225 post-transplantation from this study is presented below. The incidence of adverse reactions was determined based on pooled data of ORENCIA-treated patients from the 2 study cohorts (n=116).',\n",
       " 'Serious adverse reactions reported in > 5% of patients who received ORENCIA in combination with a calcineurin inhibitor and methotrexate included pyrexia (20%), pneumonia (8%), acute kidney injury (7%), diarrhea (6%), hypoxia (5%), and nausea (5%).',\n",
       " 'Permanent discontinuation of ORENCIA due to an adverse reaction occurred in two patients (1.7%) due to one case each of pneumonia and allergic reaction.',\n",
       " 'The most common (≥10%) adverse reactions in the ORENCIA treated patients were anemia , hypertension, CMV reactivation/CMV infection, pyrexia, pneumonia, epistaxis , CD4 lymphocytes decreased, hypermagnesemia , and acute kidney injury.',\n",
       " 'Table 4 summarizes the frequency of adverse reactions reported in the study of ORENCIA in GVHD-1.',\n",
       " 'Table 4: Adverse Reactions (≥10%) in Patients with aGVHD Who Received ORENCIA with a Difference Between Arms of >2% Compared to Placebo in GVHD-1',\n",
       " '',\n",
       " 'Clinically relevant adverse reactions in <10% of patients who received ORENCIA in combination with calcineurin inhibitor and methotrexate in Study GVHD-1 included EBV reactivation.',\n",
       " 'As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other abatacept products may be misleading.',\n",
       " 'Antibodies directed against the entire abatacept molecule or to the CTLA-4 portion of abatacept were assessed by ELISA assays in RA patients for up to 2 years following repeated treatment with intravenous ORENCIA. Thirty-four of 1993 (2%) patients developed binding antibodies to the entire abatacept molecule or to the CTLA-4 portion of abatacept. Because trough levels of abatacept can interfere with assay results, a subset analysis was performed. In the subset analysis, 9 of 154 (6%) patients that had discontinued intravenous ORENCIA treatment for over 56 days developed antibodies. Samples with confirmed binding activity to CTLA-4 were assessed for the presence of neutralizing antibodies in a cell-based luciferase reporter assay. Six of 9 (67%) evaluable patients were shown to possess neutralizing antibodies. However, the development of neutralizing antibodies may be underreported due to lack of assay sensitivity.',\n",
       " 'No correlation of anti-abatacept antibody development to clinical response or adverse events was observed.',\n",
       " 'Study SC-1 compared the immunogenicity to abatacept following subcutaneous or intravenous ORENCIA administration. The overall immunogenicity frequency to abatacept was 1% (8/725) and 2% (16/710) for the subcutaneous and intravenous groups, respectively. The rate is consistent with previous experience, and there was no correlation of immunogenicity with effects on pharmacokinetics, safety, or efficacy.',\n",
       " 'Study SC-2 was conducted to determine the effect of subcutaneous monotherapy use of ORENCIA on immunogenicity (without an intravenous loading dose) in 100 RA patients, who had not previously received ORENCIA or other CTLA4Ig. Patients in this study received either subcutaneous ORENCIA plus methotrexate (n=51) or subcutaneous ORENCIA monotherapy (n=49). No patients in either group developed anti-abatacept antibodies after 4 months of treatment. The safety observed in this study was consistent with that observed in the other subcutaneous studies.',\n",
       " 'Study SC-3 was conducted to investigate the immunogenicity in adult RA patients after treatment, withdrawal (three months), and restart of ORENCIA subcutaneous treatment (patients were treated concomitantly with methotrexate). One hundred sixty-seven patients were enrolled in the first 3-month treatment period and responders (n=120) were randomized to either subcutaneous ORENCIA or placebo for the second 3-month period (withdrawal period). Patients from this period then received open-label ORENCIA treatment in the final 3-month period of the study (period 3). At the end of the withdrawal period, 0/38 (0%) patients who continued to receive subcutaneous ORENCIA developed anti-abatacept antibodies compared to 7/73 (10%) of patients who had subcutaneous ORENCIA withdrawn during this period. Half of the patients who received subcutaneous placebo during the withdrawal period received a single intravenous infusion of ORENCIA at the start of period 3 and half received intravenous placebo. At the end of period 3, when all patients again received subcutaneous ORENCIA, the immunogenicity rates were 1/38 (3%) in the group who received subcutaneous ORENCIA throughout, and 2/73 (3%) in the group that had received placebo during the withdrawal period. Upon reinitiating therapy, there were no injection reactions and no differences in response to therapy in patients who were withdrawn from subcutaneous therapy for up to 3 months compared to those who remained on subcutaneous therapy (these results occurred in those who received or did not receive an intravenous loading dose). The safety observed in this study was consistent with that observed in the other studies.',\n",
       " 'Antibodies directed against the entire abatacept molecule or to the CTLA-4 portion of abatacept were assessed by ELISA assays in patients with pJIA following repeated treatment with intravenous ORENCIA throughout the open-label period. For patients who were withdrawn from therapy for up to 6 months during the double-blind period, the rate of antibody formation to the CTLA-4 portion of the molecule was 41% (22/54), while for those who remained on therapy the rate was 13% (7/54). Twenty of these patients had samples that could be tested for antibodies with neutralizing activity; of these, 8 (40%) patients were shown to possess neutralizing antibodies.',\n",
       " 'The presence of antibodies was generally transient, and titers were low. The presence of antibodies was not associated with adverse events, changes in efficacy, or an effect on serum concentrations of abatacept. For patients who were withdrawn from ORENCIA during the double-blind period for up to 6 months, no serious acute infusion-related events were observed upon re-initiation of ORENCIA therapy.',\n",
       " 'ORENCIA Immunogenicity was assessed in patients undergoing HSCT. Overall, immunogenicity incidence and associated antibody titers were low from the 4-dose intravenous ORENCIA regimen used in this study. Of the 114 immunogenicity evaluable subjects in the ORENCIA groups, none were positive during the ORENCIA treatment period (Day -1 to Day 28 following transplant). During the off-treatment period (Day 29 and up to Day 180 following transplant); 6 of 91 immunogenicity evaluable subjects (6.6%) were positive for CTLA4 and possibly Ig ; 4 of the 6 positive subjects were found to have at least one positive sample with neutralization activity. In this study, immunogenicity positive subjects only had ADA positive samples on Day 180 (off-treatment period) and thus due to the timing of the response, the impact on PK, safety, or efficacy could not be determined.',\n",
       " 'Adverse reactions have been reported during the postapproval use of ORENCIA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to ORENCIA. Based on the postmarketing experience with ORENCIA, the following adverse reactions have been identified:',\n",
       " 'During postmarketing experience with intravenous ORENCIA, systemic infusion reactions were similar to that seen in the clinical trial experience with intravenous ORENCIA with the exception of one case of fatal anaphylaxis [see WARNINGS AND PRECAUTIONS ]. Postmarketing reports of systemic injection reactions (e.g., pruritus, throat tightness, dyspnea) have occurred following the use of subcutaneous ORENCIA.',\n",
       " 'Bleeding was classified as major or minor by the criteria of the Thrombolysis in Myocardial Infarction (TIMI) study group. Major bleeding events were defined as either an intracranial hemorrhage or decrease in hemoglobin greater than 5 g/dL. Minor bleeding events included\\r\\nspontaneous gross hematuria or hematemesis or observed blood loss with a hemoglobin\\r\\ndecreasing more than 3 g/dL or with a decrease in hemoglobin of at least 4 g/dL with no\\r\\nobserved blood loss.',\n",
       " 'In the EPIC trial, in which a non-weight-adjusted, standard heparin dose regimen was used, the\\r\\nmost common complication during ReoPro ® (abciximab) therapy was bleeding during the first\\r\\n36 hours. The incidences of major bleeding, minor bleeding and transfusion of blood products\\r\\nwere approximately doubled. Approximately 70% of ReoPro ® -treated patients with major\\r\\nbleeding had bleeding at the arterial access site in the groin . ReoPro ® -treated patients also had a\\r\\nhigher incidence of major bleeding events from gastrointestinal, genitourinary, retroperitoneal,\\r\\nand other sites.',\n",
       " 'In a subsequent clinical trial, EPILOG, using the heparin and ReoPro ® dosing, sheath removal\\r\\nand arterial access site guidelines described under WARNINGS AND PRECAUTIONS , the\\r\\nincidence of major bleeding in patients treated with ReoPro ® and low-dose, weight-adjusted\\r\\nheparin (1.8%) was not significantly different from patients receiving placebo (3.1%) and there\\r\\nwas no significant increase in the incidence of intracranial hemorrhage. The reduction in\\r\\nbleeding observed in the EPILOG trial was achieved without loss of efficacy.',\n",
       " 'The rates of major bleeding, minor bleeding and bleeding events requiring transfusions in the\\r\\nEPIC, CAPTURE and EPILOG trials are shown in Table 1.',\n",
       " 'Table 1: Non-CABG Bleeding in the EPIC, EPILOG and CAPTURE Trials Number of Patients with Bleeds (%)',\n",
       " 'Although data are limited, ReoPro ® treatment was not associated with excess major bleeding in\\r\\npatients who underwent CABG surgery. Some patients with prolonged bleeding times received\\r\\nplatelet transfusions to correct the bleeding time prior to surgery. (see WARNINGS AND PRECAUTIONS , Restoration of Platelet Function ).',\n",
       " 'The total incidence of intracranial hemorrhage and non- hemorrhagic stroke across all three trials\\r\\nwas similar, 7/2225 (0.31%) for placebo patients and 10/3112 (0.32%) for ReoPro ® -treated\\r\\npatients. The incidence of intracranial hemorrhage was 0.13% in placebo patients and 0.19% in\\r\\nReoPro ® patients.',\n",
       " 'Pulmonary hemorrhage with fatal outcome following administration of ReoPro ® has been\\r\\nreported. In many cases, patients received at least two co-suspect or concomitant medications\\r\\nsuch as heparin or aspirin. Although the outcomes of most cases were not provided,\\r\\napproximately 2/3 had fatal outcomes. Based on exposure data, the reporting rate for pulmonary\\r\\nhemorrhage is less than 1 case report per 10,000 patients (see WARNINGS AND PRECAUTIONS , Pulmonary Hemorrhage ).',\n",
       " 'In the clinical trials, patients treated with ReoPro ® were more likely than patients treated with\\r\\nplacebo to experience decreases in platelet counts. The overall rates of thrombocytopenia\\r\\n(platelet counts < 100,000 cells/μL) in the EPIC, EPILOG and CAPTURE trials were 0.5% for\\r\\nplacebo-treated patients and 2.9% for patients receiving ReoPro ® bolus plus infusion. The\\r\\nincidence of thrombocytopenia was lowest in the EPILOG trial (placebo: 1.5%; ReoPro ® and\\r\\nstandard-dose, weight-adjusted heparin: 2.6%; ReoPro ® and low-dose, weight-adjusted heparin:\\r\\n2.5%). The lowest rates of platelet transfusions in ReoPro ® -treated patients were also observed in\\r\\nthe EPILOG trial, (placebo: 1.1%; ReoPro ® and standard-dose, weight-adjusted heparin: 1.6%;\\r\\nReoPro ® and low-dose, weight-adjusted heparin: 0.9%).',\n",
       " 'In a readministration registry study of patients receiving a second or subsequent exposure to\\r\\nReoPro ® (see WARNINGS AND PRECAUTIONS , Re-administration ) the incidence of any\\r\\ndegree of thrombocytopenia was 5%, with an incidence of profound thrombocytopenia of 2%\\r\\n(<20,000 cell/μL). Factors associated with an increased risk of thrombocytopenia were a history\\r\\nof thrombocytopenia on previous ReoPro ® exposure, readministration within 30 days, and a\\r\\npositive HACA assay prior to the readministration.',\n",
       " 'Among 14 patients who had thrombocytopenia associated with a prior exposure to ReoPro ® , 7\\r\\n(50%) had recurrent thrombocytopenia. In 130 patients with a readministration interval of 30\\r\\ndays or less, 25 (19%) developed thrombocytopenia. Severe thrombocytopenia occurred in 19 of\\r\\nthese patients. Among the 71 patients who had a positive HACA assay at baseline, 11 (15%)\\r\\ndeveloped thrombocytopenia, 7 of which were severe.',\n",
       " 'Human antichimeric antibody (HACA) may appear in response to the administration of ReoPro ® .\\r\\nIn the EPIC, EPILOG, and CAPTURE trials, positive responses occurred in approximately 5.8%\\r\\nof the ReoPro ® -treated patients. There was no excess of hypersensitivity or allergic reactions\\r\\nrelated to ReoPro ® treatment compared with placebo treatment. See also WARNINGS AND PRECAUTIONS , Hypersensitivity Reactions.',\n",
       " 'In a study of readministration of ReoPro ® to patients (See PRECAUTIONS : Readministration ) the\\r\\noverall rate of HACA positivity prior to the readministration was 6% and increased postreadministration\\r\\nto 27%. Among the 36 subjects receiving a fourth or greater ReoPro ® exposure,\\r\\nHACA positive assays were observed post-readministration in 16 subjects (44%). There were no\\r\\nreports of serious allergic reactions or anaphylaxis. HACA positive status was associated with an\\r\\nincreased risk of thrombocytopenia (see WARNINGS AND PRECAUTIONS ,\\r\\nThrombocytopenia ).',\n",
       " 'The data reflect the percentage of patients whose test results were considered positive for\\r\\nantibodies to ReoPro ® using an ELISA assay, and are highly dependent on the sensitivity and\\r\\nspecificity of the assay. Additionally, the observed incidence of antibody positivity in an assay\\r\\nmay be influenced by several factors including sample handling, timing of sample collection,\\r\\nconcomitant medications, and underlying disease. For these reasons, comparison of the incidence\\r\\nof antibodies to ReoPro ® with the incidence of antibodies to other products may be misleading.',\n",
       " 'Because clinical trials are conducted under very specific conditions the adverse reaction\\r\\nrates observed in the clinical trials may not reflect the rates observed in practice and\\r\\nshould not be compared to the rates in the clinical trials of another drug. Adverse drug\\r\\nreaction information from clinical trials is useful for identifying drug-related adverse\\r\\nevents and for approximating rates.',\n",
       " 'Table 2 below shows adverse drug reactions other than bleeding, intracranial hemorrhage and\\r\\nthrombocytopenia from the combined EPIC, EPILOG and CAPTURE trials which occurred in\\r\\n≥1% of patients in either the ReoPro ® or placebo treatment arms.',\n",
       " 'Table 2: Adverse Drug Reactions Among Treated Patients in the EPIC, EPILOG and CAPTURE Trials',\n",
       " 'General disorders and administration site conditions: Injection site reaction',\n",
       " 'Immune system disorders: Allergic reactions',\n",
       " 'Cases of anaphylaxis, sometimes fatal, have been very rarely observed and reported following\\r\\nmarketing of ReoPro ® . Gastrointestinal hemorrhage has also been very rarely reported following\\r\\nmarketing of ReoPro ® . Cases of fatal bleeding have been rarely reported following marketing of\\r\\nReoPro ® (see WARNINGS AND PRECAUTIONS , Bleeding Events ).',\n",
       " 'Included as part of the PRECAUTIONS section.',\n",
       " 'CRS, including fatal or life-threatening reactions, occurred following treatment with ABECMA. CRS occurred in 85% (108/127) of patients receiving ABECMA. Grade 3 or higher CRS (Lee grading system 1 ) occurred in 9% (12/127) of patients, with Grade 5 CRS reported in one (0.8%) patient. The median time-to-onset of CRS, any grade, was 1 day (range: 1 to 23 days), and the median duration of CRS was 7 days (range: 1 to 63 days) in all patients, including the patient who died. The most common manifestations of CRS included pyrexia (98%), hypotension (41%), tachycardia (35%), chills (31%), hypoxia (20%), fatigue (12%), and headache (10%). Grade 3 or higher events that may be associated with CRS include hypotension, hypoxia, hyperbilirubinemia, hypofibrinogenemia, ARDS, atrial fibrillation, hepatocellular injury, metabolic acidosis, pulmonary edema, multiple organ dysfunction syndrome and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) [see ADVERSE REACTIONS ].',\n",
       " 'Identify CRS based on clinical presentation. Evaluate for and treat other causes of fever, hypoxia, and hypotension. CRS has been reported to be associated with findings of HLH/MAS, and the physiology of the syndromes may overlap. HLH/MAS is a potentially life-threatening condition. In patients with progressive symptoms of CRS or refractory CRS despite treatment, evaluate for evidence of HLH/MAS. Please see Section 5.3; Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome.',\n",
       " 'Overall rate of CRS was 79%, and rate of Grade 2 CRS was 23% in patients treated in the 300 x 10 6 CAR-positive T cells dose cohort (dose ranging from 277 to 339 x 10 6 CAR-positive T cells). For patients treated in the 450 x 10 6 CAR-positive T cells dose cohort (dose range 447 to 518 x 10 6 CAR-positive T cells), the overall rate of CRS was 96%, and rate of Grade 2 CRS was 40%. Rate of Grade 3 or higher CRS was similar across the dose range. The median duration of CRS for the 450 x 10 6 CAR-positive T cells dose cohort was 7 days (range 1 to 63 days), and was 6 days (range 2 to 28 days) for the 300 x 10 6 CAR-positive T cells dose cohort. In the 450 x 10 6 CAR-positive T cells dose cohort, 68% (36/53) of patients received tocilizumab and 23% (12/53) received at least 1 dose of corticosteroids for treatment of CRS. This was higher than the tocilizumab use of 44% (31/70) and corticosteroid use of 10% (7/70) at the 300 x 10 6 CAR-positive T cells dose cohort.',\n",
       " 'Sixty-eight of 127 (54%) patients received tocilizumab; 35% (45/127) received a single dose, while 18% (23/127) received more than 1 dose of tocilizumab. Overall, across the dose levels, 15% (19/127) of patients received at least 1 dose of corticosteroids for treatment of CRS. All patients that received corticosteroids for CRS also received tocilizumab.',\n",
       " 'Ensure that a minimum of 2 doses of tocilizumab are available prior to infusion of ABECMA.',\n",
       " 'Monitor patients at least daily for 7 days following ABECMA infusion at the REMS-certified healthcare facility for signs and symptoms of CRS. Monitor patients for signs or symptoms of CRS for at least 4 weeks after infusion. At the first sign of CRS, institute treatment with supportive care, tocilizumab and/or corticosteroids as indicated [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time [see PATIENT INFORMATION ].',\n",
       " 'Neurologic toxicities, which may be severe or life-threatening, occurred following treatment with ABECMA, including concurrently with CRS, after CRS resolution, or in the absence of CRS.',\n",
       " 'CAR T cell-associated neurotoxicity, occurred in 28% (36/127) of patients receiving ABECMA, including Grade 3 in 4% (5/127) of patients. One patient had ongoing Grade 2 neurotoxicity at the time of death. Two patients had ongoing Grade 1 tremor at the time of data cutoff. The median time to onset of neurotoxicity was 2 days (range: 1 to 42 days). CAR T cell-associated neurotoxicity resolved in 33 of 36 (92%); For patients who experienced neurotoxicity including three patients with ongoing neurotoxicity, the median duration of CAR T cell-associated neurotoxicity was 6 days (range: 1 to 578 days). Neurotoxicity resolved in 33 patients and median time to resolution was 5 days (range 1 to 61 days). Thirty-four patients with neurotoxicity had CRS. The onset of neurotoxicity during CRS was observed in 29 patients, before the onset of CRS in three patients, and after the CRS event in two patients.',\n",
       " 'The rate of Grade 3 neurotoxicity was 8% in 450 x 10 6 CAR-positive T cells dose cohort and 1.4% in the 300 x 10 6 CAR-positive T cells dose cohort. The most frequent (greater than or equal to 5%) manifestations of CAR T cell-associated neurotoxicity include encephalopathy (20%), tremor (9%), aphasia (7%), and delirium (6%).',\n",
       " 'Grade 4 neurotoxicity and cerebral edema have been associated with ABECMA in a patient in another study in multiple myeloma. Grade 3 myelitis and Grade 3 parkinsonism have occurred after treatment with ABECMA in another study in multiple myeloma.',\n",
       " 'Monitor patients at least daily for 7 days following ABECMA infusion at the REMS-certified healthcare facility for signs and symptoms of neurologic toxicities. Rule out other causes of neurologic symptoms. Monitor patients for signs or symptoms of neurologic toxicities for at least 4 weeks after infusion and treat promptly. Neurologic toxicity should be managed with supportive care and/or corticosteroids as needed [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'Counsel patients to seek immediate medical attention should signs or symptoms of neurologic toxicity occur at any time [see PATIENT INFORMATION ].',\n",
       " 'HLH/MAS occurred in 4% (5/127) of patients receiving ABECMA. One patient treated in the 300 x10 6 CAR-positive T cells dose cohort developed fatal multi-organ HLH/MAS with CRS. In another patient with fatal bronchopulmonary aspergillosis, HLH/MAS was contributory to the fatal outcome. Three cases of Grade 2 HLH/MAS resolved.',\n",
       " 'The rate of HLH/MAS was 8% in the 450 x10 6 CAR-positive T cells dose cohort and 1% in the 300 x10 6 CAR-positive T cells dose cohort. All events of HLH/MAS had onset within 10 days of receiving ABECMA, with a median onset of 7 days (range: 4 to 9 days) and occurred in the setting of ongoing or worsening CRS. Two patients with HLH/MAS had overlapping neurotoxicity.',\n",
       " 'The manifestations of HLH/MAS include hypotension, hypoxia, multiple organ dysfunction, renal dysfunction and cytopenia.',\n",
       " 'HLH/MAS is a potentially life-threatening condition with a high mortality rate if not recognized early and treated. Treatment of HLH/MAS should be administered per institutional standards.',\n",
       " 'Because of the risk of CRS and neurologic toxicities, ABECMA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the ABECMA REMS [see BOXED WARNING and WARNINGS AND PRECAUTIONS ].',\n",
       " 'The required components of the ABECMA REMS are:',\n",
       " 'Allergic reactions may occur with the infusion of ABECMA. Serious hypersensitivity reactions, including anaphylaxis, may be due to dimethyl sulfoxide (DMSO) in ABECMA.',\n",
       " 'ABECMA should not be administered to patients with active infections or inflammatory disorders. Severe, life-threatening, or fatal infections occurred in patients after ABECMA infusion. Infections (all grades) occurred in 70% of patients. Grade 3 or 4 infections occurred in 23% of patients. Grade 3 or 4 infections with an unspecified pathogen occurred in 15%, viral infections in 9%, bacterial infections in 3.9%, and fungal infections in 0.8% of patients. Overall, four patients had Grade 5 infections (3%); two patients (1.6%) had Grade 5 events of pneumonia, 1 patient (0.8%) had Grade 5 bronchopulmonary aspergillosis, and 1 patient (0.8%) had cytomegalovirus (CMV) pneumonia associated with Pneumocystis jirovecii. Monitor patients for signs and symptoms of infection before and after ABECMA infusion and treat appropriately. Administer prophylactic, pre-emptive, and/or therapeutic antimicrobials according to standard institutional guidelines.',\n",
       " 'Febrile neutropenia (was observed in 16% (20/127) of patients after ABECMA infusion and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids, and other supportive care as medically indicated.13',\n",
       " 'Cytomegalovirus (CMV) infection resulting in pneumonia and death has occurred following ABECMA administration. Monitor and treat for CMV reactivation in accordance with clinical guidelines.',\n",
       " 'Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against plasma cells.',\n",
       " 'Perform screening for CMV, HBV, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) in accordance with clinical guidelines before collection of cells for manufacturing.',\n",
       " 'Consider antiviral therapy to prevent viral reactivation per local institutional guidelines/clinical practice.',\n",
       " 'Patients may exhibit prolonged cytopenias following lymphodepleting chemotherapy and ABECMA infusion. In the KarMMa study, 41% of patients (52/127) experienced prolonged Grade 3 or 4 neutropenia and 49% (62/127) experienced prolonged Grade 3 or 4 thrombocytopenia that had not resolved by Month 1 following ABECMA infusion. Rate of prolonged neutropenia was 49% in the 450 x 10 6 CAR-positive T cells dose cohort and 34% in the 300 x 10 6 CAR-positive T cells dose cohort. In 83% (43/52) of patients who recovered from Grade 3 or 4 neutropenia after Month 1, the median time to recovery from ABECMA infusion was 1.9 months. In 65% (40/62) of patients who recovered from Grade 3 or 4 thrombocytopenia, the median time to recovery was 2.1 months. Median time to cytopenia recovery was similar across the 300 and 450 x 10 6 CAR-positive T cells dose cohort.',\n",
       " 'Three patients underwent stem cell therapy (2 patients with autologous and 1 with allogeneic cells) for hematopoietic reconstitution due to prolonged cytopenia. Two of the three patients died from complications of prolonged cytopenia, which occurred in the setting of ongoing or prior severe CRS or HLH/MAS. Cause of death included lower gastrointestinal bleeding in the setting of prolonged thrombocytopenia in one patient and bronchopulmonary aspergillosis in the setting of prolonged neutropenia in another patient. The third patient recovered from neutropenia after autologous stem cell therapy.',\n",
       " 'Monitor blood counts prior to and after ABECMA infusion. Manage cytopenia with myeloid growth factor and blood product transfusion support according to local institutional guidelines.',\n",
       " 'Plasma cell aplasia and hypogammaglobulinemia can occur in patients receiving treatment with ABECMA. Hypogammaglobulinemia was reported as an adverse event in 21% (27/127) of patients; laboratory IgG levels fell below 500 mg/dL after infusion in 25% (32/127) of patients treated with ABECMA.',\n",
       " 'Hypogammaglobulinemia either as an adverse reaction or laboratory IgG level below 500 mg/dL after infusion occurred in 41% (52/127) of patients treated with ABECMA. Sixty-one percent of patients received intravenous immunoglobulin (IVIG) post-ABECMA for serum IgG <400 mg/dL.',\n",
       " 'Monitor immunoglobulin levels after treatment with ABECMA and administer IVIG for IgG <400 mg/dL. Manage per local institutional guidelines, including infection precautions and antibiotic or antiviral prophylaxis.',\n",
       " 'The safety of immunization with live viral vaccines during or following ABECMA treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during ABECMA treatment, and until immune recovery following treatment with ABECMA.',\n",
       " 'Patients treated with ABECMA may develop secondary malignancies. Monitor life-long for secondary malignancies. In the event that a secondary malignancy occurs, contact Bristol-Myers Squibb at 1-888-805-4555 for reporting and to obtain instructions on collection of patient samples for testing of secondarymalignancy of T cell origin.',\n",
       " 'Due to the potential for neurologic events, including altered mental status or seizures, patients receiving ABECMA are at risk for altered or decreased consciousness or coordination in the 8 weeks following ABECMA infusion. Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery, during this initial period.',\n",
       " 'Advise the patient to read the FDA-approved patient labeling ( Medication Guide ).',\n",
       " 'Ensure that patients understand the risk of manufacturing failure (1.5%, [2/135 in the clinical study]). In case of a manufacturing failure, a second manufacturing of ABECMA may be attempted. In addition, while the patient awaits the product, additional anticancer treatment (not the lymphodepletion) may be necessary and may increase the risk of adverse events during the pre-infusion period, which could delay or prevent the administration of ABECMA.',\n",
       " 'Advise patients to seek immediate attention for any of the following:',\n",
       " 'Advise patients for the need to:',\n",
       " 'Genotoxicity assays and carcinogenicity studies in rodents were not performed for ABECMA',\n",
       " 'In vitro expansion studies with CAR-positive T cells (ABECMA) from 5 patients and 2 healthy donor drug product lots showed no evidence for transformation and/or immortalization of T cells. A genomic insertion site analysis of the lentiviral vector was performed on ABECMA samples from twenty (20) individual patient donors. There was no evidence for preferential integration near genes of concern or preferential outgrowth of cells harboring integration sites of concern.',\n",
       " 'No studies on the effects of ABECMA on fertility have been conducted.',\n",
       " 'There are no available data with ABECMA use in pregnant women. No animal reproductive and developmental toxicity studies have been conducted with ABECMA to assess whether it can cause fetal harm when administered to a pregnant woman.',\n",
       " 'It is not known if ABECMA has the potential to be transferred to the fetus. Based on the mechanism of action, if the transduced cells cross the placenta, they may cause fetal toxicity, including plasma cell aplasia or hypogammaglobulinemia. Therefore, ABECMA is not recommended for women who are pregnant, and pregnancy after ABECMA infusion should be discussed with the treating physician. Assess immunoglobulin levels in newborns of mothers treated with ABECMA.',\n",
       " 'The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. The estimated background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.',\n",
       " \"There is no information regarding the presence of ABECMA in human milk, the effect on the breastfed infant, and the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ABECMA and any potential adverse effects on the breastfed infant from ABECMA or from the underlying maternal condition.\",\n",
       " 'Pregnancy status of sexually-active females with reproductive potential should be verified via pregnancy testing prior to starting treatment with ABECMA.',\n",
       " 'See the prescribing information for fludarabine and cyclophosphamide for information on the need for effective contraception in patients who receive the lymphodepleting chemotherapy.',\n",
       " 'There are insufficient exposure data to provide a recommendation concerning duration of contraception following treatment with ABECMA.',\n",
       " 'There are no data on the effect of ABECMA on fertility.',\n",
       " 'The safety and efficacy of ABECMA in patients under 18 years of age have not been established.',\n",
       " 'In the clinical trial of ABECMA, 45 (35%) of the 127 patients in the KarMMa study were 65 years of age or older and 4/127 (3%) patients were 75 years of age or older. All five cases of Grade 3 neurotoxicity occurred in patients ≥65 years of age (66 to 74 years). No clinically important differences in effectiveness of ABECMA were observed between these patients and patients younger than 65 years of age.',\n",
       " 'REFERENCES',\n",
       " '1.Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine releasesyndrome. Blood 2014; 124(2): 188-95. Errata in Blood: 2015;126(8):1048. and 2016;128(11):1533.',\n",
       " 'No formal clinical studies of drug interactions have been conducted with ABELCET ® . However, when\\r\\nadministered concomitantly, the following drugs are known to interact with amphotericin B; therefore,\\r\\nthe following drugs may interact with ABELCET ® :',\n",
       " 'Concurrent use of antineoplastic agents and amphotericin B may enhance the\\r\\npotential for renal toxicity, bronchospasm, and hypotension. Antineoplastic agents should be given\\r\\nconcomitantly with ABELCET ® with great caution.',\n",
       " 'Concurrent use of corticosteroids and corticotropin (ACTH)\\r\\nwith amphotericin B may potentiate hypokalemia which could predispose the patient to cardiac\\r\\ndysfunction. If used concomitantly with ABELCET ® , serum electrolytes and cardiac function should be\\r\\nclosely monitored.',\n",
       " 'Data from a prospective study of prophylactic ABELCET ® in 22 patients undergoing\\r\\nbone marrow transplantation suggested that concurrent initiation of cyclosporin A and ABELCET ® within several days of bone marrow ablation may be associated with increased nephrotoxicity.',\n",
       " 'Concurrent use of amphotericin B may induce hypokalemia and may potentiate\\r\\ndigitalis toxicity. When administered concomitantly with ABELCET ® , serum potassium levels should\\r\\nbe closely monitored.',\n",
       " 'Concurrent use of flucytosine with amphotericin B-containing preparations may increase\\r\\nthe toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.\\r\\nFlucytosine should be given concomitantly with ABELCET ® with caution.',\n",
       " 'Antagonism between amphotericin B and imidazole derivatives such as miconazole and ketoconazole, which inhibit\\r\\nergosterol synthesis, has been reported in both in vitro and in vivo animal studies. The clinical\\r\\nsignificance of these findings has not been determined.',\n",
       " 'Acute pulmonary toxicity has been reported in patients receiving intravenous\\r\\namphotericin B and leukocyte transfusions. Leukocyte transfusions and ABELCET ® should not be\\r\\ngiven concurrently.',\n",
       " 'Concurrent use of amphotericin B and agents such as aminoglcosides and\\r\\npentamidine may enhance the potential for drug-induced renal toxicity. Aminoglycosides and\\r\\npentamidine should be used concomitantly with ABELCET ® only with great caution. Intensive\\r\\nmonitoring of renal function is recommended in patients requiring any combination of nephrotoxic medications.',\n",
       " 'Amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine) due to hypokalemia. When administered concomitantly with\\r\\nABELCET ® , serum potassium levels should be closely monitored.',\n",
       " 'Increased myelotoxicity and nephrotoxicity were observed in dogs when either\\r\\nABELCET ® (at doses 0.16 or 0.5 times the recommended human dose) or amphotericin B\\r\\ndesoxycholate (at 0.5 times the recommended human dose) were administered concomitantly with\\r\\nzidovudine for 30 days. If zidovudine is used concomitantly with ABELCET ® , renal and hematologic\\r\\nfunction should be closely monitored.',\n",
       " 'Strong and moderate CYP3A4 inhibitors increased the exposure of abemaciclib plus its active metabolites to a clinically meaningful extent\\r\\nand may lead to increased toxicity.',\n",
       " 'Ketoconazole',\n",
       " 'Avoid concomitant use of ketoconazole. Ketoconazole is predicted to increase the AUC of abemaciclib by up to 16-fold [see CLINICAL PHARMACOLOGY ].',\n",
       " 'Other Strong CYP3A Inhibitors',\n",
       " 'In patients with recommended starting doses of 200 mg twice daily or 150 mg twice daily, reduce the VERZENIO dose to 100 mg twice\\r\\ndaily with concomitant use of strong CYP3A inhibitors other than ketoconazole. In patients who have had a dose reduction to 100 mg twice\\r\\ndaily due to adverse reactions, further reduce the VERZENIO dose to 50 mg twice daily with concomitant use of strong CYP3A inhibitors.\\r\\nIf a patient taking VERZENIO discontinues a strong CYP3A inhibitor, increase the VERZENIO dose (after 3-5 half-lives of the inhibitor)\\r\\nto the dose that was used before starting the inhibitor. Patients should avoid grapefruit products [see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY ].',\n",
       " 'Moderate CYP3A Inhibitors',\n",
       " 'With concomitant use of moderate CYP3A inhibitors, monitor for adverse reactions and consider reducing the VERZENIO dose in 50 mg\\r\\ndecrements as demonstrated in Table 1, if necessary.',\n",
       " 'Coadministration of strong or moderate CYP3A inducers decreased the plasma concentrations of abemaciclib plus its active metabolites and\\r\\nmay lead to reduced activity. Avoid concomitant use of strong or moderate CYP3A inducers and consider alternative agents [see CLINICAL PHARMACOLOGY ].',\n",
       " 'Because clinical trials are conducted under widely\\r\\nvarying conditions, adverse reaction rates observed in the clinical trials of a\\r\\ndrug cannot be directly compared to rates in the clinical trials of another\\r\\ndrug and may not reflect the rates observed in practice.',\n",
       " 'The following adverse reactions are discussed in more\\r\\ndetail in other sections of the labeling:',\n",
       " 'The most common adverse reactions in adult patients in\\r\\nclinical trials (≥10%) were nausea, vomiting, constipation, headache,\\r\\ndizziness, akathisia , anxiety, insomnia, and restlessness.',\n",
       " 'The most common adverse reactions in the pediatric\\r\\nclinical trials (≥10%) were somnolence , headache, vomiting,\\r\\nextrapyramidal disorder, fatigue, increased appetite, insomnia, nausea,\\r\\nnasopharyngitis, and weight increased.',\n",
       " \"ABILIFY has been evaluated for safety in 13,543 adult\\r\\npatients who participated in multiple-dose, clinical trials in schizophrenia , bipolar disorder , major depressive disorder, Dementia of the Alzheimer's type, Parkinson's disease , and alcoholism , and who had approximately 7619\\r\\npatient-years of exposure to oral ABILIFY and 749 patients with exposure to\\r\\nABILIFY injection. A total of 3390 patients were treated with oral ABILIFY for\\r\\nat least 180 days and 1933 patients treated with oral ABILIFY had at least 1\\r\\nyear of exposure.\",\n",
       " \"ABILIFY has been evaluated for safety in 1,686 patients\\r\\n(6 to 18 years) who participated in multiple-dose, clinical trials in\\r\\nschizophrenia, bipolar mania , autistic disorder, or Tourette's disorder and who\\r\\nhad approximately 1,342 patient-years of exposure to oral ABILIFY. A total of\\r\\n959 pediatric patients were treated with oral ABILIFY for at least 180 days and\\r\\n556 pediatric patients treated with oral ABILIFY had at least 1 year of\\r\\nexposure.\",\n",
       " 'The conditions and duration of treatment with ABILIFY\\r\\n(monotherapy and adjunctive therapy with antidepressants or mood stabilizers)\\r\\nincluded (in overlapping categories) double-blind, comparative and\\r\\nnoncomparative open-label studies, inpatient and outpatient studies, fixed- and\\r\\nflexible-dose studies, and short- and longer-term exposure.',\n",
       " 'The following findings are based on a pool of five\\r\\nplacebo-controlled trials (four 4-week and one 6-week) in which oral ABILIFY\\r\\nwas administered in doses ranging from 2 to 30 mg/day.',\n",
       " 'The only commonly observed adverse reaction associated\\r\\nwith the use of ABILIFY in patients with schizophrenia (incidence of 5% or\\r\\ngreater and ABILIFY incidence at least twice that for placebo) was akathisia (ABILIFY\\r\\n8%; placebo 4%).',\n",
       " 'The following findings are based on a pool of 3-week,\\r\\nplacebo-controlled, bipolar mania trials in which oral ABILIFY was administered\\r\\nat doses of 15 or 30 mg/day.',\n",
       " 'Commonly observed adverse reactions associated with the\\r\\nuse of ABILIFY in patients with bipolar mania (incidence of 5% or greater and\\r\\nABILIFY incidence at least twice that for placebo) are shown in Table 16.',\n",
       " 'Table 16: Commonly Observed Adverse Reactions in\\r\\nShort-Term, Placebo-Controlled Trials of Adult Patients with Bipolar Mania\\r\\nTreated with Oral ABILIFY Monotherapy',\n",
       " 'Table 17 enumerates the pooled incidence, rounded to the\\r\\nnearest percent, of adverse reactions that occurred during acute therapy (up to\\r\\n6 weeks in schizophrenia and up to 3 weeks in bipolar mania), including only\\r\\nthose reactions that occurred in 2% or more of patients treated with ABILIFY\\r\\n(doses ≥2 mg/day) and for which the incidence in patients treated with\\r\\nABILIFY was greater than the incidence in patients treated with placebo in the\\r\\ncombined dataset.',\n",
       " 'Table 17: Adverse Reactions in Short-Term,\\r\\nPlacebo-Controlled Trials in Adult Patients Treated with Oral ABILIFY',\n",
       " 'An examination of population subgroups did not reveal any\\r\\nclear evidence of differential adverse reaction incidence on the basis of age,\\r\\ngender, or race.',\n",
       " 'The following findings are based on a placebo-controlled\\r\\ntrial of adult patients with bipolar disorder in which ABILIFY was administered\\r\\nat doses of 15 or 30 mg/day as adjunctive therapy with lithium or valproate.',\n",
       " 'In a study of patients who were already tolerating either\\r\\nlithium or valproate as monotherapy, discontinuation rates due to adverse\\r\\nreactions were 12% for patients treated with adjunctive ABILIFY compared to 6%\\r\\nfor patients treated with adjunctive placebo. The most common adverse drug\\r\\nreactions associated with discontinuation in the adjunctive ABILIFY-treated\\r\\ncompared to placebo-treated patients were akathisia (5% and 1%, respectively)\\r\\nand tremor (2% and 1%, respectively).',\n",
       " 'The commonly observed adverse reactions associated with\\r\\nadjunctive ABILIFY and lithium or valproate in patients with bipolar mania\\r\\n(incidence of 5% or greater and incidence at least twice that for adjunctive\\r\\nplacebo) were: akathisia, insomnia, and extrapyramidal disorder.',\n",
       " 'Table 18 enumerates the incidence, rounded to the nearest\\r\\npercent, of adverse reactions that occurred during acute treatment (up to 6\\r\\nweeks), including only those reactions that occurred in 2% or more of patients\\r\\ntreated with adjunctive ABILIFY (doses of 15 or 30 mg/day) and lithium or\\r\\nvalproate and for which the incidence in patients treated with this combination\\r\\nwas greater than the incidence in patients treated with placebo plus lithium or\\r\\nvalproate.',\n",
       " 'Table 18: Adverse Reactions in a Short-Term,\\r\\nPlacebo-Controlled Trial of Adjunctive Therapy in Patients with Bipolar\\r\\nDisorder',\n",
       " 'The following findings are based on one 6-week,\\r\\nplacebo-controlled trial in which oral ABILIFY was administered in doses\\r\\nranging from 2 to 30 mg/day.',\n",
       " 'The incidence of discontinuation due to adverse reactions\\r\\nbetween ABILIFY-treated and placebo-treated pediatric patients (13 to 17 years)\\r\\nwas 5% and 2%, respectively.',\n",
       " 'Commonly observed adverse reactions associated with the\\r\\nuse of ABILIFY in adolescent patients with schizophrenia (incidence of 5% or\\r\\ngreater and ABILIFY incidence at least twice that for placebo) were\\r\\nextrapyramidal disorder, somnolence, and tremor.',\n",
       " 'The following findings are based on one 4-week,\\r\\nplacebo-controlled trial in which oral ABILIFY was administered in doses of 10\\r\\nor 30 mg/day.',\n",
       " 'The incidence of discontinuation due to adverse reactions\\r\\nbetween ABILIFY-treated and placebo-treated pediatric patients (10 to 17 years)\\r\\nwas 7% and 2%, respectively.',\n",
       " 'Commonly observed adverse reactions associated with the\\r\\nuse of ABILIFY in pediatric patients with bipolar mania (incidence of 5% or\\r\\ngreater and ABILIFY incidence at least twice that for placebo) are shown in\\r\\nTable 19.',\n",
       " 'Table 19: Commonly Observed Adverse Reactions in\\r\\nShort-Term, Placebo-Controlled Trials of Pediatric Patients (10 to 17 years) with\\r\\nBipolar Mania Treated with Oral ABILIFY',\n",
       " 'The following findings are based on two 8-week,\\r\\nplacebo-controlled trials in which oral ABILIFY was administered in doses of 2\\r\\nto 15 mg/day.',\n",
       " 'The incidence of discontinuation due to adverse reactions\\r\\nbetween ABILIFY-treated and placebo-treated pediatric patients (6 to 17 years)\\r\\nwas 10% and 8%, respectively.',\n",
       " 'Commonly observed adverse reactions associated with the\\r\\nuse of ABILIFY in pediatric patients with autistic disorder (incidence of 5% or\\r\\ngreater and ABILIFY incidence at least twice that for placebo) are shown in\\r\\nTable 20.',\n",
       " 'Table 20: Commonly Observed Adverse Reactions in\\r\\nShort-Term, Placebo-Controlled Trials of Pediatric Patients (6 to 17 years)\\r\\nwith Autistic Disorder Treated with Oral ABILIFY',\n",
       " 'The following findings are based on one 8-week and one\\r\\n10-week, placebo-controlled trials in which oral ABILIFY was administered in\\r\\ndoses of 2 to 20 mg/day.',\n",
       " 'The incidence of discontinuation due to adverse reactions\\r\\nbetween ABILIFY-treated and placebo-treated pediatric patients (6 to 18 years)\\r\\nwas 7% and 1%, respectively.',\n",
       " \"Commonly observed adverse reactions associated with the\\r\\nuse of ABILIFY in pediatric patients with Tourette's disorder (incidence of 5% or\\r\\ngreater and ABILIFY incidence at least twice that for placebo) are shown in\\r\\nTable 21.\",\n",
       " \"Table 21: Commonly Observed Adverse Reactions in\\r\\nShort-Term, Placebo-Controlled Trials of Pediatric Patients (6 to 18 years)\\r\\nwith Tourette's Disorder Treated with Oral ABILIFY\",\n",
       " \"Table 22 enumerates the pooled incidence, rounded to the\\r\\nnearest percent, of adverse reactions that occurred during acute therapy (up to\\r\\n6 weeks in schizophrenia, up to 4 weeks in bipolar mania, up to 8 weeks in\\r\\nautistic disorder, and up to 10 weeks in Tourette's disorder), including only\\r\\nthose reactions that occurred in 2% or more of pediatric patients treated with\\r\\nABILIFY (doses ≥2 mg/day) and for which the incidence in patients treated\\r\\nwith ABILIFY was greater than the incidence in patients treated with placebo.\",\n",
       " 'Table 22: Adverse Reactions in Short-Term,\\r\\nPlacebo-Controlled Trials of Pediatric Patients (6 to 18 years) Treated with\\r\\nOral ABILIFY',\n",
       " 'The following findings are based on a pool of two\\r\\nplacebo-controlled trials of patients with major depressive disorder in which\\r\\nABILIFY was administered at doses of 2 mg to 20 mg as adjunctive treatment to\\r\\ncontinued antidepressant therapy.',\n",
       " 'The incidence of discontinuation due to adverse reactions\\r\\nwas 6% for adjunctive ABILIFY-treated patients and 2% for adjunctive\\r\\nplacebo-treated patients.',\n",
       " 'The commonly observed adverse reactions associated with\\r\\nthe use of adjunctive ABILIFY in patients with major depressive disorder\\r\\n(incidence of 5% or greater and ABILIFY incidence at least twice that for\\r\\nplacebo) were: akathisia, restlessness, insomnia, constipation, fatigue, and\\r\\nblurred vision.',\n",
       " 'Table 23 enumerates the pooled incidence, rounded to the\\r\\nnearest percent, of adverse reactions that occurred during acute therapy (up to\\r\\n6 weeks), including only those adverse reactions that occurred in 2% or more of\\r\\npatients treated with adjunctive ABILIFY (doses ≥2 mg/day) and for which\\r\\nthe incidence in patients treated with adjunctive ABILIFY was greater than the\\r\\nincidence in patients treated with adjunctive placebo in the combined dataset.',\n",
       " 'Table 23: Adverse Reactions in Short-Term,\\r\\nPlacebo-Controlled Adjunctive Trials in Patients with Major Depressive Disorder',\n",
       " 'The following findings are based on a pool of three\\r\\nplacebo-controlled trials of patients with agitation associated with\\r\\nschizophrenia or bipolar mania in which ABILIFY injection was administered at\\r\\ndoses of 5.25 mg to 15 mg.',\n",
       " 'There was one commonly observed adverse reaction (nausea)\\r\\nassociated with the use of ABILIFY injection in patients with agitation\\r\\nassociated with schizophrenia and bipolar mania (incidence of 5% or greater and\\r\\nABILIFY incidence at least twice that for placebo).',\n",
       " 'Table 24 enumerates the pooled incidence, rounded to the\\r\\nnearest percent, of adverse reactions that occurred during acute therapy\\r\\n(24-hour), including only those adverse reactions that occurred in 2% or more\\r\\nof patients treated with ABILIFY injection (doses ≥5.25 mg/day) and for\\r\\nwhich the incidence in patients treated with ABILIFY injection was greater than\\r\\nthe incidence in patients treated with placebo in the combined dataset.',\n",
       " 'Table 24: Adverse Reactions in Short-Term,\\r\\nPlacebo-Controlled Trials in Patients Treated with ABILIFY Injection',\n",
       " 'Dose response relationships for the incidence of\\r\\ntreatment-emergent adverse events were evaluated from four trials in adult\\r\\npatients with schizophrenia comparing various fixed doses (2, 5, 10, 15, 20,\\r\\nand 30 mg/day) of oral ABILIFY to placebo. This analysis, stratified by study,\\r\\nindicated that the only adverse reaction to have a possible dose response\\r\\nrelationship, and then most prominent only with 30 mg, was somnolence\\r\\n[including sedation]; (incidences were placebo, 7.1%; 10 mg, 8.5%; 15 mg, 8.7%;\\r\\n20 mg, 7.5%; 30 mg, 12.6%).',\n",
       " 'In the study of pediatric patients (13 to 17 years of\\r\\nage) with schizophrenia, three common adverse reactions appeared to have a\\r\\npossible dose response relationship: extrapyramidal disorder (incidences were\\r\\nplacebo, 5.0%; 10 mg, 13.0%; 30 mg, 21.6%); somnolence (incidences were\\r\\nplacebo, 6.0%; 10 mg, 11.0%; 30 mg, 21.6%); and tremor (incidences were\\r\\nplacebo, 2.0%; 10 mg, 2.0%; 30 mg, 11.8%).',\n",
       " 'In the study of pediatric patients (10 to 17 years of\\r\\nage) with bipolar mania, four common adverse reactions had a possible dose\\r\\nresponse relationship at 4 weeks; extrapyramidal disorder (incidences were\\r\\nplacebo, 3.1%; 10 mg, 12.2%; 30 mg, 27.3%); somnolence (incidences were\\r\\nplacebo, 3.1%; 10 mg, 19.4%; 30 mg, 26.3%); akathisia (incidences were placebo,\\r\\n2.1%; 10 mg, 8.2%; 30 mg, 11.1%); and salivary hypersecretion (incidences were\\r\\nplacebo, 0%; 10 mg, 3.1%; 30 mg, 8.1%).',\n",
       " 'In a study of pediatric patients (6 to 17 years of age)\\r\\nwith autistic disorder, one common adverse reaction had a possible dose\\r\\nresponse relationship: fatigue (incidences were placebo, 0%; 5 mg, 3.8%; 10 mg,\\r\\n22.0%; 15 mg, 18.5%).',\n",
       " \"In a study of pediatric patients (7 to 17 years of age)\\r\\nwith Tourette's disorder, no common adverse reaction(s) had a dose response\\r\\nrelationship.\",\n",
       " 'In short-term, placebo-controlled trials in schizophrenia\\r\\nin adults, the incidence of reported EPS -related events, excluding events\\r\\nrelated to akathisia, for ABILIFY-treated patients was 13% vs. 12% for placebo;\\r\\nand the incidence of akathisia-related events for ABILIFY-treated patients was\\r\\n8% vs. 4% for placebo. In the short-term, placebo-controlled trial of\\r\\nschizophrenia in pediatric patients (13 to 17 years), the incidence of reported\\r\\nEPS-related events, excluding events related to akathisia, for ABILIFY-treated\\r\\npatients was 25% vs. 7% for placebo; and the incidence of akathisia-related\\r\\nevents for ABILIFY-treated patients was 9% vs. 6% for placebo.',\n",
       " 'Objectively collected data from those trials was\\r\\ncollected on the Simpson Angus Rating Scale (for EPS), the Barnes Akathisia\\r\\nScale (for akathisia), and the Assessments of Involuntary Movement Scales (for\\r\\ndyskinesias). In the adult schizophrenia trials, the objectively collected data\\r\\ndid not show a difference between ABILIFY and placebo, with the exception of\\r\\nthe Barnes Akathisia Scale (ABILIFY, 0.08; placebo, -0.05). In the pediatric\\r\\n(13 to 17 years) schizophrenia trial, the objectively collected data did not\\r\\nshow a difference between ABILIFY and placebo, with the exception of the\\r\\nSimpson Angus Rating Scale (ABILIFY, 0.24; placebo, -0.29).',\n",
       " 'Similarly, in a long-term (26-week), placebo-controlled\\r\\ntrial of schizophrenia in adults, objectively collected data on the Simpson\\r\\nAngus Rating Scale (for EPS), the Barnes Akathisia Scale (for akathisia), and\\r\\nthe Assessments of Involuntary Movement Scales (for dyskinesias) did not show a\\r\\ndifference between ABILIFY and placebo.',\n",
       " 'In the short-term, placebo-controlled trials in bipolar\\r\\nmania in adults, the incidence of reported EPS-related events, excluding events\\r\\nrelated to akathisia, for monotherapy ABILIFY-treated patients was 16% vs. 8%\\r\\nfor placebo and the incidence of akathisia-related events for monotherapy\\r\\nABILIFY-treated patients was 13% vs. 4% for placebo. In the 6-week,\\r\\nplacebo-controlled trial in bipolar mania for adjunctive therapy with lithium\\r\\nor valproate, the incidence of reported EPS-related events, excluding events\\r\\nrelated to akathisia for adjunctive ABILIFY-treated patients was 15% vs. 8% for\\r\\nadjunctive placebo and the incidence of akathisia-related events for adjunctive\\r\\nABILIFY-treated patients was 19% vs. 5% for adjunctive placebo. In the\\r\\nshort-term, placebo-controlled trial in bipolar mania in pediatric (10 to 17\\r\\nyears) patients, the incidence of reported EPS-related events, excluding events\\r\\nrelated to akathisia, for ABILIFY-treated patients was 26% vs. 5% for placebo\\r\\nand the incidence of akathisia-related events for ABILIFY-treated patients was\\r\\n10% vs. 2% for placebo.',\n",
       " 'In the adult bipolar mania trials with monotherapy\\r\\nABILIFY, the Simpson Angus Rating Scale and the Barnes Akathisia Scale showed a\\r\\nsignificant difference between ABILIFY and placebo (ABILIFY, 0.50; placebo,\\r\\n-0.01 and ABILIFY, 0.21; placebo, -0.05). Changes in the Assessments of\\r\\nInvoluntary Movement Scales were similar for the ABILIFY and placebo groups. In\\r\\nthe bipolar mania trials with ABILIFY as adjunctive therapy with either lithium\\r\\nor valproate, the Simpson Angus Rating Scale and the Barnes Akathisia Scale\\r\\nshowed a significant difference between adjunctive ABILIFY and adjunctive\\r\\nplacebo (ABILIFY, 0.73; placebo, 0.07 and ABILIFY, 0.30; placebo, 0.11).\\r\\nChanges in the Assessments of Involuntary Movement Scales were similar for\\r\\nadjunctive ABILIFY and adjunctive placebo. In the pediatric (10 to 17 years),\\r\\nshort-term, bipolar mania trial, the Simpson Angus Rating Scale showed a\\r\\nsignificant difference between ABILIFY and placebo (ABILIFY, 0.90; placebo,\\r\\n-0.05). Changes in the Barnes Akathisia Scale and the Assessments of\\r\\nInvoluntary Movement Scales were similar for the ABILIFY and placebo groups.',\n",
       " 'In the short-term, placebo-controlled trials in major\\r\\ndepressive disorder, the incidence of reported EPS-related events, excluding\\r\\nevents related to akathisia, for adjunctive ABILIFY-treated patients was 8% vs.\\r\\n5% for adjunctive placebo-treated patients; and the incidence of\\r\\nakathisia-related events for adjunctive ABILIFY-treated patients was 25% vs. 4%\\r\\nfor adjunctive placebo-treated patients.',\n",
       " 'In the major depressive disorder trials, the Simpson\\r\\nAngus Rating Scale and the Barnes Akathisia Scale showed a significant\\r\\ndifference between adjunctive ABILIFY and adjunctive placebo (ABILIFY, 0.31;\\r\\nplacebo, 0.03 and ABILIFY, 0.22; placebo, 0.02). Changes in the Assessments of\\r\\nInvoluntary Movement Scales were similar for the adjunctive ABILIFY and\\r\\nadjunctive placebo groups.',\n",
       " 'In the short-term, placebo-controlled trials in autistic\\r\\ndisorder in pediatric patients (6 to 17 years), the incidence of reported\\r\\nEPS-related events, excluding events related to akathisia, for ABILIFY-treated\\r\\npatients was 18% vs. 2% for placebo and the incidence of akathisia-related\\r\\nevents for ABILIFY-treated patients was 3% vs. 9% for placebo.',\n",
       " 'In the pediatric (6 to 17 years) short-term autistic\\r\\ndisorder trials, the Simpson Angus Rating Scale showed a significant difference\\r\\nbetween ABILIFY and placebo (ABILIFY, 0.1; placebo, -0.4). Changes in the\\r\\nBarnes Akathisia Scale and the Assessments of Involuntary Movement Scales were\\r\\nsimilar for the ABILIFY and placebo groups.',\n",
       " \"In the short-term, placebo-controlled trials in\\r\\nTourette's disorder in pediatric patients (6 to 18 years), the incidence of\\r\\nreported EPS-related events, excluding events related to akathisia, for\\r\\nABILIFY-treated patients was 7% vs. 6% for placebo and the incidence of akathisia-related\\r\\nevents for ABILIFY-treated patients was 4% vs. 6% for placebo.\",\n",
       " \"In the pediatric (6 to 18 years) short-term Tourette's\\r\\ndisorder trials, changes in the Simpson Angus Rating Scale, Barnes Akathisia\\r\\nScale and Assessments of Involuntary Movement Scale were not clinically\\r\\nmeaningfully different for ABILIFY and placebo.\",\n",
       " 'In the placebo-controlled trials in patients with\\r\\nagitation associated with schizophrenia or bipolar mania, the incidence of\\r\\nreported EPS-related events excluding events related to akathisia for\\r\\nABILIFY-treated patients was 2% vs. 2% for placebo and the incidence of\\r\\nakathisia-related events for ABILIFY-treated patients was 2% vs. 0% for\\r\\nplacebo. Objectively collected data on the Simpson Angus Rating Scale (for EPS)\\r\\nand the Barnes Akathisia Scale (for akathisia) for all treatment groups did not\\r\\nshow a difference between ABILIFY and placebo.',\n",
       " 'Symptoms of dystonia , prolonged abnormal contractions of\\r\\nmuscle groups, may occur in susceptible individuals during the first few days\\r\\nof treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes\\r\\nprogressing to tightness of the throat, swallowing difficulty, difficulty\\r\\nbreathing, and/or protrusion of the tongue. While these symptoms can occur at\\r\\nlow doses, they occur more frequently and with greater severity with high\\r\\npotency and at higher doses of first generation antipsychotic drugs. An\\r\\nelevated risk of acute dystonia is observed in males and younger age groups.',\n",
       " 'The adverse reactions reported in a 26-week, double-blind\\r\\ntrial comparing oral ABILIFY and placebo in patients with schizophrenia were\\r\\ngenerally consistent with those reported in the short-term, placebo-controlled\\r\\ntrials, except for a higher incidence of tremor [8% (12/153) for ABILIFY vs. 2%\\r\\n(3/153) for placebo]. In this study, the majority of the cases of tremor were\\r\\nof mild intensity (8/12 mild and 4/12 moderate), occurred early in therapy\\r\\n(9/12 ≤49 days), and were of limited duration (7/12 ≤10 days).\\r\\nTremor infrequently led to discontinuation (<1%) of ABILIFY. In addition, in\\r\\na long-term (52 week), active-controlled study, the incidence of tremor was 5%\\r\\n(40/859) for ABILIFY. A similar profile was observed in a long-term monotherapy\\r\\nstudy and a long-term adjunctive study with lithium and valproate in bipolar\\r\\ndisorder.',\n",
       " 'The following listing does not include reactions: 1)\\r\\nalready listed in previous tables or elsewhere in labeling, 2) for which a drug\\r\\ncause was remote, 3) which were so general as to be uninformative, 4) which\\r\\nwere not considered to have significant clinical implications, or 5) which\\r\\noccurred at a rate equal to or less than placebo.',\n",
       " 'Reactions are categorized by body system according to the\\r\\nfollowing definitions: frequent adverse reactions are those occurring in\\r\\nat least 1/100 patients; infrequent adverse reactions are those\\r\\noccurring in 1/100 to 1/1000 patients; rare reactions are those\\r\\noccurring in fewer than 1/1000 patients:',\n",
       " 'Blood And Lymphatic System Disorders: rare - thrombocytopenia',\n",
       " 'Cardiac Disorders: infrequent - bradycardia , palpitations , rare - atrial flutter , cardiorespiratory arrest, atrioventricular block, atrial fibrillation , angina pectoris , myocardial ischemia , myocardial infarction , cardiopulmonary failure',\n",
       " 'Eye Disorders: infrequent - photophobia ; rare - diplopia',\n",
       " 'Gastrointestinal Disorders: infrequent - gastroesophageal reflux disease',\n",
       " 'General Disorders and Administration Site Conditions: frequent - asthenia ; infrequent - peripheral edema, chest pain; rare - face edema',\n",
       " 'Hepatobiliary Disorders: rare - hepatitis , jaundice',\n",
       " 'Immune System Disorders : rare - hypersensitivity',\n",
       " 'Injury, Poisoning, and Procedural Complications: infrequent - fall; rare - heat stroke',\n",
       " 'Investigations: frequent - weight decreased, infrequent - hepatic enzyme increased, blood glucose increased, blood lactate dehydrogenase increased, gamma glutamyl transferase increased; rare -\\r\\nblood prolactin increased, blood urea increased, blood creatinine increased,\\r\\nblood bilirubin increased, electrocardiogram QT prolonged, glycosylated hemoglobin increased',\n",
       " 'Metabolism and Nutrition Disorders: frequent - anorexia ; rare - hypokalemia , hyponatremia , hypoglycemia',\n",
       " 'Musculoskeletal and Connective Tissue Disorders: infrequent - muscular weakness, muscle tightness; rare - rhabdomyolysis , mobility decreased',\n",
       " 'Nervous System Disorders: infrequent - parkinsonism ,\\r\\nmemory impairment, cogwheel rigidity, hypokinesia, bradykinesia ; rare - akinesia , myoclonus , coordination abnormal, speech disorder , Grand Mal convulsion ; <1/10,000 patients -choreoathetosis',\n",
       " 'Psychiatric Disorders: infrequent - aggression, loss of libido , delirium ; rare - libido increased, anorgasmia , tic , homicidal\\r\\nideation, catatonia, sleep walking',\n",
       " 'Renal and Urinary Disorders: rare - urinary\\r\\nretention, nocturia',\n",
       " 'Reproductive System and Breast Disorders: infrequent - erectile dysfunction ; rare - gynaecomastia, menstruation irregular, amenorrhea , breast pain , priapism',\n",
       " 'Respiratory, Thoracic, and Mediastinal Disorders: infrequent - nasal congestion , dyspnea',\n",
       " 'Skin and Subcutaneous Tissue Disorders: infrequent -\\r\\nrash, hyperhidrosis , pruritus , photosensitivity reaction, alopecia ; rare - urticaria',\n",
       " 'Vascular Disorders: infrequent - hypotension , hypertension',\n",
       " 'Most adverse events observed in the pooled database of\\r\\n1,686 pediatric patients, aged 6 to 18 years, were also observed in the adult\\r\\npopulation. Additional adverse reactions observed in the pediatric population\\r\\nare listed below.',\n",
       " 'Eye Disorders infrequent - oculogyric crisis',\n",
       " 'Gastrointestinal Disorders: infrequent -tongue\\r\\ndry, tongue spasm',\n",
       " 'Investigations: frequent - blood insulin increased',\n",
       " 'Nervous System Disorders: infrequent - sleep\\r\\ntalking',\n",
       " 'Renal and Urinary Disorders frequent - enuresis',\n",
       " 'Skin and Subcutaneous Tissue Disorders: infrequent - hirsutism',\n",
       " 'Most adverse reactions observed in the pooled database of\\r\\n749 adult patients treated with ABILIFY injection, were also observed in the adult\\r\\npopulation treated with oral ABILIFY. Additional adverse reactions observed in\\r\\nthe ABILIFY injection population are listed below.',\n",
       " 'General Disorders and Administration Site Conditions: ≥1/100\\r\\npatients - injection site reaction; ≥1/1000 patients and <1/100\\r\\npatients - venipuncture site bruise',\n",
       " 'The following adverse reactions have been identified\\r\\nduring post-approval use of ABILIFY. Because these reactions are reported\\r\\nvoluntarily from a population of uncertain size, it is not always possible to\\r\\nestablish a causal relationship to drug exposure: occurrences of allergic\\r\\nreaction (anaphylactic reaction, angioedema , laryngospasm, pruritus/urticaria,\\r\\nor oropharyngeal spasm), pathological gambling, hiccups and blood glucose fluctuation.',\n",
       " 'Drugs Having Clinically Important Interactions With ABILIFY\\r\\nMAINTENA',\n",
       " 'Table 8: Clinically Important Drug Interactions with\\r\\nABILIFY MAINTENA',\n",
       " 'Based on pharmacokinetic\\r\\nstudies with oral aripiprazole, no dosage adjustment of ABILIFY MAINTENA is\\r\\nrequired when administered concomitantly with famotidine, valproate, lithium ,\\r\\nlorazepam [see CLINICAL PHARMACOLOGY ].',\n",
       " 'In addition, no dosage\\r\\nadjustment is necessary for substrates of CYP2D6 (e.g., dextromethorphan , fluoxetine , paroxetine, or venlafaxine), CYP2C9 (e.g., warfarin), CYP2C19\\r\\n(e.g., omeprazole, warfarin), or CYP3A4 (e.g., dextromethorphan) when\\r\\nco-administered with ABILIFY MAINTENA. Additionally, no dosage adjustment is\\r\\nnecessary for valproate, lithium, lamotrigine, lorazepam, or sertraline when\\r\\nco-administered with ABILIFY MAINTENA. [see CLINICAL PHARMACOLOGY ].',\n",
       " 'The following adverse reactions are discussed in more detail in other sections of the labeling:',\n",
       " 'Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed\\r\\nin the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug\\r\\nand may not reflect the rates observed in practice.',\n",
       " 'The safety of ABILIFY MYCITE for the treatment of adults with schizophrenia, treatment of adults with\\r\\nmanic and mixed episodes associated with bipolar I disorder, and adjunctive treatment of adults with\\r\\nmajor depressive disorder (MDD) has been established and is based on trials of aripiprazole including\\r\\n13,543 adult patients who participated in multiple-dose, clinical trials in schizophrenia, bipolar\\r\\ndisorder, major depressive disorder, and other disorders, and who had approximately 7619 patientyears\\r\\nof exposure to oral aripiprazole. A total of 3390 patients were treated with oral aripiprazole for\\r\\nat least 180 days and 1933 patients treated with oral aripiprazole had at least 1 year of exposure.',\n",
       " 'The conditions and duration of treatment with aripiprazole (monotherapy and adjunctive therapy with\\r\\nantidepressants or mood stabilizers) included (in overlapping categories) double-blind, comparative and\\r\\nnoncomparative open-label studies, inpatient and outpatient studies, fixed- and flexible-dose studies, and\\r\\nshort- and longer-term exposure.',\n",
       " 'The most common adverse reactions of aripiprazole in adult patients in clinical trials (≥10%) were\\r\\nnausea, vomiting, constipation, headache, dizziness, akathisia, anxiety, insomnia, and restlessness.',\n",
       " 'The following findings are based on a pool of five placebo-controlled trials (four 4 week and one\\r\\n6 week) in which oral aripiprazole was administered in doses ranging from 2 to 30 mg/day.',\n",
       " 'The commonly observed adverse reaction associated with the use of aripiprazole tablets in patients with\\r\\nschizophrenia (incidence of 5% or greater and aripiprazole tablets incidence at least twice that for\\r\\nplacebo) was akathisia (aripiprazole tablets 8%; placebo 4%).',\n",
       " 'The following findings are based on a pool of 3 week, placebo-controlled, bipolar mania trials in\\r\\nwhich oral aripiprazole was administered at doses of 15 or 30 mg/day.',\n",
       " 'Commonly observed adverse reactions associated with the use of aripiprazole tablets in patients with\\r\\nbipolar mania (incidence of 5% or greater and aripiprazole tablets incidence at least twice that for\\r\\nplacebo) are shown in Table 9.',\n",
       " 'Table 9: Commonly Observed Adverse Reactions in\\r\\n  Short-Term, Placebo-Controlled Trials of Adult Patients\\r\\n  with Bipolar Mania Treated with Oral Aripiprazole\\r\\n  Monotherapy',\n",
       " 'Table 10 enumerates the pooled incidence, rounded to the nearest percent, of adverse reactions that\\r\\noccurred during acute therapy (up to 6 weeks in schizophrenia and up to 3 weeks in bipolar mania),\\r\\nincluding only those reactions that occurred in 2% or more of patients treated with aripiprazole tablets\\r\\n(doses ≥2 mg/day) and for which the incidence in patients treated with aripiprazole tablets was greater\\r\\nthan the incidence in patients treated with placebo in the combined dataset.',\n",
       " 'Table 10: Adverse Reactions in Short-Term, Placebo-\\r\\n  Controlled Trials in Adult Patients Treated with Oral\\r\\n  Aripiprazole',\n",
       " 'An examination of population subgroups did not reveal any clear evidence of differential adverse\\r\\nreaction incidence on the basis of age, gender, or race.',\n",
       " 'The following findings are based on a placebo-controlled trial of adult patients with bipolar disorder in\\r\\nwhich aripiprazole tablets was administered at doses of 15 or 30 mg/day as adjunctive therapy with\\r\\nlithium or valproate.',\n",
       " 'In a study of patients who were already tolerating either lithium or valproate as monotherapy,\\r\\ndiscontinuation rates due to adverse reactions were 12% for patients treated with adjunctive aripiprazole\\r\\ntablets compared to 6% for patients treated with adjunctive placebo. The most common adverse drug\\r\\nreactions associated with discontinuation in the adjunctive aripiprazole-treated compared to placebotreated\\r\\npatients were akathisia (5% and 1%, respectively) and tremor (2% and 1%, respectively).',\n",
       " 'The commonly observed adverse reactions associated with adjunctive aripiprazole tablets and lithium or\\r\\nvalproate in patients with bipolar mania (incidence of 5% or greater and incidence at least twice that for\\r\\nadjunctive placebo) were: akathisia, insomnia, and extrapyramidal disorder.',\n",
       " 'Table 11 enumerates the incidence, rounded to the nearest percent, of adverse reactions that occurred\\r\\nduring acute treatment (up to 6 weeks), including only those reactions that occurred in 2% or more of\\r\\npatients treated with adjunctive aripiprazole tablets (doses of 15 or 30 mg/day) and lithium or valproate\\r\\nand for which the incidence in patients treated with this combination was greater than the incidence in\\r\\npatients treated with placebo plus lithium or valproate.',\n",
       " 'Table 11: Adverse Reactions in a Short-Term, Placebo-\\r\\n  Controlled Trial of Adjunctive Therapy in Patients with\\r\\n  Bipolar Disorder',\n",
       " 'The following findings are based on a pool of two placebo-controlled trials of patients with major\\r\\ndepressive disorder in which aripiprazole tablets were administered at doses of 2 mg to 20 mg as\\r\\nadjunctive treatment to continued antidepressant therapy.',\n",
       " 'The incidence of discontinuation due to adverse reactions was 6% for adjunctive aripiprazole-treated\\r\\npatients and 2% for adjunctive placebo-treated patients.',\n",
       " 'The commonly observed adverse reactions associated with the use of adjunctive aripiprazole tablets in\\r\\npatients with major depressive disorder (incidence of 5% or greater and aripiprazole tablets incidence\\r\\nat least twice that for placebo) were: akathisia, restlessness, insomnia, constipation, fatigue, and blurred\\r\\nvision.',\n",
       " 'Table 12 enumerates the pooled incidence, rounded to the nearest percent, of adverse reactions that\\r\\noccurred during acute therapy (up to 6 weeks), including only those adverse reactions that occurred in\\r\\n2% or more of patients treated with adjunctive aripiprazole tablets (doses ≥2 mg/day) and for which the\\r\\nincidence in patients treated with adjunctive aripiprazole tablets was greater than the incidence in\\r\\npatients treated with adjunctive placebo in the combined dataset.',\n",
       " 'Table 12: Adverse Reactions in Short-Term, Placebo-\\r\\n  Controlled Adjunctive Trials in Patients with Major\\r\\n  Depressive Disorder',\n",
       " 'Dose response relationships for the incidence of treatment-emergent adverse events were evaluated\\r\\nfrom four trials in adult patients with schizophrenia comparing various fixed doses (2, 5, 10, 15, 20, and\\r\\n30 mg/day) of oral aripiprazole to placebo. This analysis, stratified by study, indicated that the only\\r\\nadverse reaction to have a possible dose response relationship, and then most prominent only with\\r\\n30 mg, was somnolence [including sedation]; (incidences were placebo, 7.1%; 10 mg, 8.5%; 15 mg,\\r\\n8.7%; 20 mg, 7.5%; 30 mg, 12.6%).',\n",
       " 'In short-term, placebo-controlled trials in schizophrenia in adults, the incidence of reported EPS-related\\r\\nevents, excluding events related to akathisia, for aripiprazole-treated patients was 13% vs. 12% for\\r\\nplacebo; and the incidence of akathisia-related events for aripiprazole-treated patients was 8% vs. 4%\\r\\nfor placebo.',\n",
       " 'Objectively collected data from those trials was collected on the Simpson Angus Rating Scale (for\\r\\nEPS), the Barnes Akathisia Scale (for akathisia), and the Assessments of Involuntary Movement Scales\\r\\n(for dyskinesias). In the adult schizophrenia trials, the objectively collected data did not show a\\r\\ndifference between aripiprazole tablets and placebo, with the exception of the Barnes Akathisia Scale\\r\\n(aripiprazole tablets, 0.08; placebo, –0.05).',\n",
       " 'Similarly, in a long-term (26 week), placebo-controlled trial of schizophrenia in adults, objectively\\r\\ncollected data on the Simpson Angus Rating Scale (for EPS), the Barnes Akathisia Scale (for akathisia),\\r\\nand the Assessments of Involuntary Movement Scales (for dyskinesias) did not show a difference\\r\\nbetween aripiprazole tablets and placebo.',\n",
       " 'In the short-term, placebo-controlled trials in bipolar mania in adults, the incidence of reported EPSrelated\\r\\nevents, excluding events related to akathisia, for monotherapy aripiprazole-treated patients was\\r\\n16% vs. 8% for placebo and the incidence of akathisia-related events for monotherapy aripiprazoletreated\\r\\npatients was 13% vs. 4% for placebo. In the 6 week, placebo-controlled trial in bipolar mania\\r\\nfor adjunctive therapy with lithium or valproate, the incidence of reported EPS-related events,\\r\\nexcluding events related to akathisia for adjunctive aripiprazole-treated patients was 15% vs. 8% for\\r\\nadjunctive placebo and the incidence of akathisia-related events for adjunctive aripiprazole-treated\\r\\npatients was 19% vs. 5% for adjunctive placebo.',\n",
       " 'In the adult bipolar mania trials with monotherapy aripiprazole tablets, the Simpson Angus Rating Scale\\r\\nand the Barnes Akathisia Scale showed a significant difference between aripiprazole tablets and\\r\\nplacebo (aripiprazole tablets, 0.50; placebo, –0.01 and aripiprazole tablets, 0.21; placebo, –0.05).\\r\\nChanges in the Assessments of Involuntary Movement Scales were similar for the aripiprazole tablets\\r\\nand placebo groups. In the bipolar mania trials with aripiprazole tablets as adjunctive therapy with either\\r\\nlithium or valproate, the Simpson Angus Rating Scale and the Barnes Akathisia Scale showed a\\r\\nsignificant difference between adjunctive aripiprazole tablets and adjunctive placebo (aripiprazole\\r\\ntablets, 0.73; placebo, 0.07 and aripiprazole tablets, 0.30; placebo, 0.11). Changes in the Assessments of\\r\\nInvoluntary Movement Scales were similar for adjunctive aripiprazole tablets and adjunctive placebo.',\n",
       " 'In the short-term, placebo-controlled trials in major depressive disorder, the incidence of reported\\r\\nEPS-related events, excluding events related to akathisia, for adjunctive aripiprazole-treated patients\\r\\nwas 8% vs. 5% for adjunctive placebo-treated patients; and the incidence of akathisia-related events for\\r\\nadjunctive aripiprazole-treated patients was 25% vs. 4% for adjunctive placebo-treated patients.',\n",
       " 'In the major depressive disorder trials, the Simpson Angus Rating Scale and the Barnes Akathisia Scale\\r\\nshowed a significant difference between adjunctive aripiprazole tablets and adjunctive placebo\\r\\n(aripiprazole tablets, 0.31; placebo, 0.03 and aripiprazole tablets, 0.22; placebo, 0.02). Changes in the\\r\\nAssessments of Involuntary Movement Scales were similar for the adjunctive aripiprazole tablets and\\r\\nadjunctive placebo groups.',\n",
       " 'Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible\\r\\nindividuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck\\r\\nmuscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing,\\r\\nand/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more\\r\\nfrequently and with greater severity with high potency and at higher doses of first generation\\r\\nantipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.',\n",
       " 'Symptoms of skin irritation localized at the site of the MYCITE Patch may occur in some patients. In\\r\\nclinical studies, sixty-one patients (12.4%) experienced skin rashes localized at the site of patch\\r\\nplacement.',\n",
       " 'The adverse reactions reported in a 26 week, double-blind trial comparing oral aripiprazole and\\r\\nplacebo in patients with schizophrenia were generally consistent with those reported in the short-term,\\r\\nplacebo-controlled trials, except for a higher incidence of tremor [8% (12/153) for aripiprazole tablets\\r\\nvs. 2% (3/153) for placebo]. In this study, the majority of the cases of tremor were of mild intensity\\r\\n(8/12 mild and 4/12 moderate), occurred early in therapy (9/12 ≤49 days), and were of limited duration\\r\\n(7/12 ≤10 days). Tremor led to discontinuation (<1%) of aripiprazole tablets. In addition, in a long-term\\r\\n(52 week), active-controlled study, the incidence of tremor was 5% (40/859) for aripiprazole tablets. A\\r\\nsimilar profile was observed in a long-term monotherapy study and a long-term adjunctive study with\\r\\nlithium and valproate in bipolar disorder.',\n",
       " 'Other adverse reactions associated with aripiprazole are presented below. The listing does not include\\r\\nreactions: 1) already listed in previous tables or elsewhere in labeling, 2) for which a drug cause was\\r\\nremote, 3) which were so general as to be uninformative, 4) which were not considered to have\\r\\nsignificant clinical implications, or 5) which occurred at a rate equal to or less than placebo.',\n",
       " 'Reactions are categorized by body system according to the following definitions: frequent adverse\\r\\nreactions are those occurring in at least 1/100 patients; infrequent adverse reactions are those occurring\\r\\nin 1/100 to 1/1000 patients; rare reactions are those occurring in fewer than 1/1000 patients:',\n",
       " 'The following adverse reactions have been identified during post-approval use of aripiprazole.\\r\\nBecause these reactions are reported voluntarily from a population of uncertain size, it is not always\\r\\npossible to reliably estimate their frequency or establish a causal relationship to drug exposure:\\r\\noccurrences of allergic reaction (anaphylactic reaction, angioedema, laryngospasm, pruritus/urticaria,\\r\\nor oropharyngeal spasm), pathological gambling, hiccups and blood glucose fluctuation.',\n",
       " 'Based on in vitro data, ZYTIGA is a substrate of CYP3A4.',\n",
       " 'In a dedicated drug interaction trial, co–administration of rifampin, a strong CYP3A4 inducer, decreased exposure of abiraterone by 55%. Avoid concomitant strong CYP3A4 inducers during ZYTIGA treatment. If a strong CYP3A4 inducer must be co–administered, increase the ZYTIGA dosing frequency [see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY ].',\n",
       " 'In a dedicated drug interaction trial, co–administration of ketoconazole, a strong inhibitor of CYP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone [see CLINICAL PHARMACOLOGY ].',\n",
       " 'ZYTIGA is an inhibitor of the hepatic drug–metabolizing enzymes CYP2D6 and CYP2C8. In a CYP2D6 drug–drug interaction trial, the Cmax and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8–and 2.9–fold, respectively, when dextromethorphan was given with abiraterone acetate 1,000 mg daily and prednisone 5 mg twice daily. Avoid co–administration of abiraterone acetate with substrates of CYP2D6 with a narrow therapeutic index (e.g., thioridazine). If alternative treatments cannot be used, consider a dose reduction of the concomitant CYP2D6 substrate drug [see CLINICAL PHARMACOLOGY ].',\n",
       " 'In a CYP2C8 drug–drug interaction trial in healthy subjects, the AUC of pioglitazone (CYP2C8 substrate) was increased by 46% when pioglitazone was given together with a single dose of 1,000 mg abiraterone acetate. Therefore, patients should be monitored closely for signs of toxicity related to a CYP2C8 substrate with a narrow therapeutic index if used concomitantly with ZYTIGA [see CLINICAL PHARMACOLOGY and WARNINGS AND PRECAUTIONS ].',\n",
       " 'Based on in vitro data, YONSA is a substrate of CYP3A4.',\n",
       " 'In a dedicated drug interaction trial, co-administration of rifampin, a strong CYP3A4 inducer, decreased exposure of abiraterone by 55%. Avoid concomitant strong CYP3A4 inducers during YONSA treatment. If a strong CYP3A4 inducer must be co-administered, increase the YONSA dosing frequency [see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY ].',\n",
       " 'In a dedicated drug interaction trial, co-administration of ketoconazole, a strong inhibitor of CYP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone [see CLINICAL PHARMACOLOGY ].',\n",
       " 'Abiraterone is an inhibitor of the hepatic drug-metabolizing enzymes CYP2D6 and CYP2C8. In a CYP2D6 drug-drug interaction trial, the Cmax and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8and\\r\\n2.9-fold, respectively, when dextromethorphan was given with an abiraterone acetate dose equivalent to YONSA 500 mg daily and a different corticosteroid twice daily. Avoid coadministration of abiraterone acetate with substrates of CYP2D6 with a narrow therapeutic index (e.g., thioridazine). If alternative treatments cannot be used, exercise caution and consider a dose reduction of the concomitant CYP2D6 substrate drug [see CLINICAL PHARMACOLOGY ].',\n",
       " 'In a CYP2C8 drug-drug interaction trial in healthy subjects, the AUC of pioglitazone (CYP2C8 substrate) was increased by 46% when pioglitazone was given together with an abiraterone acetate single dose equivalent to YONSA 500 mg. Therefore, patients should be monitored closely for signs of toxicity related to a CYP2C8 substrate with a narrow therapeutic index if used concomitantly with abiraterone acetate [see CLINICAL PHARMACOLOGY ].',\n",
       " 'Following injection, ABLAVAR binds to blood albumin and\\r\\nhas the potential to alter the binding of other drugs that also bind to\\r\\nalbumin. No drug interaction reactions were observed in clinical trials. Consider\\r\\nthe possibility of ABLAVAR interaction with concomitantly administered\\r\\nmedications that bind to albumin. An interaction may enhance or decrease the\\r\\nactivity of the concomitant medication [see CLINICAL PHARMACOLOGY ].',\n",
       " 'In a clinical trial of 10 patients receiving a stable\\r\\ndose of warfarin, a single dose of ABLAVAR (0.05 mmol/kg) did not alter the anticoagulant activity of warfarin as measured by the International Normalized Ratio (INR).',\n",
       " 'Included as part of  the PRECAUTIONS section.',\n",
       " 'Transient heart block is common at the time of dehydrated\\r\\nalcohol, such as ABLYSINOL, injection into a septal artery. Prior to the\\r\\ninjection, a temporary pacing wire is routinely inserted into the apex of the right ventricle , usually via the femoral vein , to treat transient heart block. The\\r\\npacing lead can be removed if no episode of high-degree atrioventricular block\\r\\noccurs, usually after several hours of observation following percutaneous\\r\\ntransluminal septal myocardial ablation.',\n",
       " 'Approximately 10% of complete heart block events become\\r\\npermanent and require placement of a permanent pacemaker following percutaneous\\r\\ntransluminal septal myocardial ablation. Risk factors for permanent pacemaker\\r\\ndependency after septal ablation include a baseline PQ interval > 160 ms,\\r\\nbaseline minimum heart rate < 50 bpm, baseline left ventricular outflow\\r\\ngradient > 70 mmHg, maximum QRS during the first 48 hours > 155 ms, 3rd degree\\r\\natrio-ventricular block occurring during the procedure, and no clinical\\r\\nrecovery between 12-48 hours after the procedure.',\n",
       " 'Injection of dehydrated alcohol is intended to create a\\r\\ncontrolled myocardial infarction for therapeutic purposes. However, excessive\\r\\nmyocardial necrosis and subsequent heart failure have been reported. Factors\\r\\nincreasing the risk of excessive tissue necrosis include higher volume of alcohol\\r\\nused and a higher number of septal branches injected to reduce the left\\r\\nventricular outflow tract gradient.',\n",
       " 'Ventricular tachycardia and ventricular fibrillation requiring electrocardioversion occurred at a frequency of approximately 1%.\\r\\nPerform continuous electrocardiographic monitoring for 48 hours after the\\r\\nprocedure.',\n",
       " 'Ethanol (of alcohol beverages) was added to Group 1\\r\\nInternational Agency for Research on Cancer (IARC) Carcinogenicity Ratings\\r\\n(IARC monographs). Substances in this group are either carcinogenic to humans,\\r\\nor there is sufficient evidence of carcinogenicity in experimental animals and\\r\\nstrong evidence in exposed humans that the substance acts through a relevant mechanism\\r\\nof carcinogenicity. Alcohol consumption has been associated with various\\r\\ncancers, including liver, esophageal , breast, prostate , and colorectal cancer .\\r\\nSince ABLYSINOL is not expected to reach the systemic circulation following\\r\\nadministration into a septal artery during percutaneous transluminal septal\\r\\nmyocardial ablation, the recommended clinical use of the drug product is not\\r\\nexpected to have carcinogenic risk in patients.',\n",
       " 'Literature reports suggest that ethanol is not mutagenic\\r\\nin the in vitro bacterial reverse mutation (Ames) assay or in vitro chromosomal\\r\\naberration assays. Ethanol is metabolized to acetaldehyde, which is a known mutagen .',\n",
       " 'There are no data from either animal or human studies\\r\\nregarding potential for the impairment of fertility.',\n",
       " 'The concentrations of alcohol in blood after PTSMA were\\r\\nnot measured, but ABLYSINOL is not expected to increase significantly the\\r\\nsystemic concentrations of endogenous alcohol following administration into a\\r\\nseptal artery during percutaneous transluminal septal myocardial ablation.\\r\\nMaternal use is not expected to result in fetal exposure to the drug.',\n",
       " 'ABLYSINOL for percutaneous transluminal septal myocardial\\r\\nablation has not been evaluated in pregnant women and is not recommended during\\r\\npregnancy. When possible, the percutaneous transluminal septal myocardial\\r\\nablation procedure should be postponed in women until the postpartum period.',\n",
       " 'Animal reproduction studies have shown an adverse effect on the fetus and chronic fetal alcohol exposure is known to cause developmental\\r\\ndefects in human. The developmental effects of acute ethanol exposure, such as\\r\\nfrom percutaneous transluminal septal myocardial ablation, have not been\\r\\nstudied in pregnant or lactating women.',\n",
       " 'ABLYSINOL is not expected to increase significantly the\\r\\nsystemic concentrations of endogenous alcohol following administration into a\\r\\nseptal artery during percutaneous transluminal septal myocardial ablation and\\r\\nbreastfeeding is not expected to result in exposure of the child to the drug.',\n",
       " 'Safety and effectiveness in pediatric patients have not\\r\\nbeen established.',\n",
       " 'A comparison of the outcomes in patients with\\r\\nhypertrophic obstructive cardiomyopathy in patients < 60 years old and in\\r\\npatients ≥ 60 years old showed similar improvement in exercise capacity\\r\\nafter ablation. The rate of heart blocks and dysrhythmia increased with age.\\r\\nPermanent pacemaker dependency increased to 34% in patients > 60 years old.',\n",
       " 'Included as part of  the PRECAUTIONS section.',\n",
       " 'The potency Units of DYSPORT are specific to the\\r\\npreparation and assay method utilized. They are not interchangeable with other\\r\\npreparations of botulinum toxin products and, therefore, units of biological\\r\\nactivity of DYSPORT cannot be compared to or converted into units of any other\\r\\nbotulinum toxin products assessed with any other specific assay method [see DESCRIPTION ].',\n",
       " 'Post-marketing safety data from DYSPORT and other\\r\\napproved botulinum toxins suggest that botulinum toxin effects may, in some\\r\\ncases, be observed beyond the site of local injection. The symptoms are\\r\\nconsistent with the mechanism of action of botulinum toxin and may include asthenia , generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia,\\r\\ndysphonia, dysarthria , urinary incontinence and breathing difficulties. These\\r\\nsymptoms have been reported hours to weeks after injection. Swallowing and\\r\\nbreathing difficulties can be life-threatening and there have been reports of\\r\\ndeath related to spread of toxin effects. The risk of symptoms is probably\\r\\ngreatest in children treated for spasticity but symptoms can also occur in\\r\\nadults treated for spasticity and other conditions, particularly in those\\r\\npatients who have underlying conditions that would predispose them to these\\r\\nsymptoms. In unapproved uses, including upper limb spasticity in children and\\r\\napproved indications, symptoms consistent with spread of toxin effect have been\\r\\nreported at doses comparable to or lower than the maximum recommended total\\r\\ndose. [see Use In Specific Populations ].',\n",
       " 'Serious hypersensitivity reactions have been reported\\r\\nwith DYSPORT. Hypersensitivity reactions include anaphylaxis, serum sickness, urticaria , soft tissue edema, and dyspnea. If such a serious hypersensitivity\\r\\nreaction occurs, discontinue further injection of DYSPORT and institute\\r\\nappropriate medical therapy immediately.',\n",
       " 'Treatment with DYSPORT and other botulinum toxin products\\r\\ncan result in swallowing or breathing difficulties. Patients with pre-existing\\r\\nswallowing or breathing difficulties may be more susceptible to these\\r\\ncomplications. In most cases, this is a consequence of weakening of muscles in\\r\\nthe area of injection that are involved in breathing or swallowing. When\\r\\ndistant effects occur, additional respiratory muscles may be involved [see Spread of Toxin Effect ].',\n",
       " 'Deaths as a complication of severe dysphagia have been reported\\r\\nafter treatment with botulinum toxin. Dysphagia may persist for several weeks,\\r\\nand require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when\\r\\ntreating patients in whom swallowing or respiratory function is already\\r\\ncompromised.',\n",
       " 'Treatment of cervical dystonia with botulinum toxins may\\r\\nweaken neck muscles that serve as accessory muscles of ventilation . This may\\r\\nresult in a critical loss of breathing capacity in patients with respiratory\\r\\ndisorders who may have become dependent upon these accessory muscles. There\\r\\nhave been post-marketing reports of serious breathing difficulties, including respiratory failure .',\n",
       " 'Patients treated with botulinum toxin may require immediate\\r\\nmedical attention should they develop problems with swallowing, speech or\\r\\nrespiratory disorders. These reactions can occur within hours to weeks after\\r\\ninjection with botulinum toxin [see Spread of Toxin Effect , ADVERSE\\r\\nREACTIONS , CLINICAL PHARMACOLOGY ].',\n",
       " 'Caution should be exercised when administering DYSPORT to\\r\\npatients with surgical alterations to the facial anatomy, excessive weakness or\\r\\natrophy in the target muscle(s), marked facial asymmetry, inflammation at the\\r\\ninjection site(s), ptosis, excessive dermatochalasis, deep dermal scarring,\\r\\nthick sebaceous skin [see DOSAGE AND ADMINISTRATION ] or the inability to\\r\\nsubstantially lessen glabellar lines by physically spreading them apart [see Clinical\\r\\nStudies ].',\n",
       " 'Do not exceed the recommended dosage and frequency of\\r\\nadministration of DYSPORT. In clinical trials, subjects who received a higher\\r\\ndose of DYSPORT had an increased incidence of eyelid ptosis.',\n",
       " 'Dry eye has been reported with the use of DYSPORT in the\\r\\ntreatment of glabellar lines [see ADVERSE REACTIONS ]. Reduced tear\\r\\nproduction, reduced blinking, and corneal disorders, may occur with use of\\r\\nbotulinum toxins, including DYSPORT.',\n",
       " 'If symptoms of dry eye (e.g., eye irritation,\\r\\nphotophobia, or visual changes) persist, consider referring patient to an opththalmologist\\r\\n[see Spread of Toxin Effect ].',\n",
       " 'Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis or neuromuscular junction disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly\\r\\nclosely when given botulinum toxin. Patients with neuromuscular disorders may\\r\\nbe at increased risk of clinically significant effects including severe\\r\\ndysphagia and respiratory compromise from typical doses of DYSPORT [see ADVERSE\\r\\nREACTIONS ].',\n",
       " 'This product contains albumin, a derivative of human\\r\\nblood. Based on effective donor screening and product manufacturing processes,\\r\\nit carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease ( vCJD ). There is a theoretical risk for\\r\\ntransmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually\\r\\nexists, the risk of transmission would also be considered extremely remote. No\\r\\ncases of transmission of viral diseases, CJD, or vCJD have ever been identified\\r\\nfor licensed albumin or albumin contained in other licensed products.',\n",
       " 'The possibility of an immune reaction when injected\\r\\nintradermally is unknown. The safety of DYSPORT for the treatment of hyperhidrosis has not been established. DYSPORT is approved only for\\r\\nintramuscular injection.',\n",
       " 'Advise the patient to read the FDA-approved patient\\r\\nlabelling ( Medication Guide ).',\n",
       " 'Advise patients to inform their doctor or pharmacist if\\r\\nthey develop any unusual symptoms (including difficulty with swallowing,\\r\\nspeaking or breathing), or if any known symptom persists or worsens.',\n",
       " 'Inform patients that DYSPORT injection may cause eye\\r\\ndryness. Advise patients to report symptoms of eye dryness (e.g., eye pain, eye\\r\\nirritation, photosensitivity , or changes in vision) to their doctor.',\n",
       " 'Inform patients that if loss of strength, muscle\\r\\nweakness, blurred vision or drooping eyelids occur, they should avoid driving a\\r\\ncar or engaging in other potentially hazardous activities.',\n",
       " 'Studies to evaluate the carcinogenic potential of DYSPORT\\r\\nhave not been conducted.',\n",
       " 'Genotoxicity studies have not been conducted for DYSPORT.',\n",
       " 'In a fertility and early embryonic development study in\\r\\nrats in which either males (2.9, 7.2, 14.5 or 29 Units/kg) or females (7.4,\\r\\n19.7, 39.4 or 78.8 Units/kg) received weekly intramuscular injections prior to\\r\\nand after mating, doserelated increases in pre- implantation loss and reduced\\r\\nnumbers of corpora lutea were noted in treated females. Failure to mate was\\r\\nobserved in males that received the high dose. The no-effect dose for effects\\r\\non fertility was 7.4 Units/kg in females and 14.5 Units/kg in males\\r\\n(approximately one-half and equal to, respectively, the maximum recommended human\\r\\ndose of 1000 Units on a body weight basis).',\n",
       " 'There are no adequate and well-controlled clinical\\r\\nstudies with DYSPORT in pregnant women.',\n",
       " 'DYSPORT should only be used during pregnancy if the\\r\\npotential benefit justifies the potential risk to the fetus.',\n",
       " 'DYSPORT produced embryo-fetal toxicity in relation to\\r\\nmaternal toxicity when given to pregnant rats and rabbits at doses lower than\\r\\nor similar to the maximum recommended human dose (MRHD) of 1000 Units on a body\\r\\nweight (Units/kg) basis (see Data ).',\n",
       " 'In the U.S. general population, the estimated background\\r\\nrisk of major birth defects and miscarriage in clinically recognized\\r\\npregnancies is 2-4% and 15-20%, respectively. The background risk of major\\r\\nbirth defects and miscarriage for the indicated population is unknown.',\n",
       " 'In a study in which pregnant rats received daily\\r\\nintramuscular injections of DYSPORT (2.2, 6.6, or 22 Units/kg on gestation days\\r\\n6 through 17 or intermittently 44 Units/kg on gestation days 6 and 12 only)\\r\\nduring organogenesis, increased early embryonic death was observed with both\\r\\nschedules at the highest tested doses (22 and 44 Units/kg), which were\\r\\nassociated with maternal toxicity. The no-effect dose for embryo-fetal\\r\\ndevelopmental toxicity was 2.2 Units/kg (less than maximum recommended human\\r\\n[MRHD] on a body weight basis).',\n",
       " 'In a study in which pregnant rabbits received daily\\r\\nintramuscular injections of DYSPORT® (0.3, 3.3 or 6.7 Units/kg) on gestation\\r\\ndays 6 through 19 or intermittently (13.3 Units/kg on gestation days 6 and 13\\r\\nonly) during organogenesis, no embryofetal data were available at the highest\\r\\ndose administered daily (6.7 Units/kg) because of premature death in all does\\r\\nat that dose. At the lower daily doses or with intermittent dosing, no adverse\\r\\ndevelopmental effects were observed. All dosed for which data were available\\r\\nare less than the MRHD on a body weight basis.',\n",
       " 'In a study in which pregnant rats received 6 weekly\\r\\nintramuscular injections of DYSPORT (4.4, 11.1, 22.2, or 44 Units/kg) beginning\\r\\non day 6 of gestation and continuing through parturition to weaning, an\\r\\nincrease in stillbirths was observed at the highest dose tested, which was\\r\\nmaternally toxic. The no-effect dose for pre- and post-natal development\\r\\ntoxicity was 22.2 Units/kg (similar to the MRHD).',\n",
       " 'There are no data on the presence of DYSPORT in human or\\r\\nanimal milk, the effects on the breastfed infant, or the effects on milk\\r\\nproduction.',\n",
       " \"The development and health benefits of breastfeeding\\r\\nshould be considered along with the mother's clinical need for DYSPORT and any\\r\\npotential adverse effects on the breastfed infant from DYSPORT or from the\\r\\nunderlying maternal condition.\",\n",
       " 'In rats, DYSPORT produced adverse effects on mating\\r\\nbehavior and fertility [see Carcinogenesis, Mutagenesis, Impairment Of Fertility ].',\n",
       " 'Safety and effectiveness in pediatric patients have not\\r\\nbeen established [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'DYSPORT is not recommended for use in pediatric patients\\r\\nless than 18 years of age.',\n",
       " 'Safety and effectiveness in pediatric patients have not\\r\\nbeen established [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'The safety and effectiveness of DYSPORT injected into proximal muscles of the lower limb for the treatment of spasticity in pediatric\\r\\npatients has not been established [see WARNINGS AND PRECAUTIONS and ADVERSE\\r\\nREACTIONS ].',\n",
       " 'Safety and effectiveness in pediatric patients with lower\\r\\nlimb spasticity below 2 years of age have not been evaluated [see WARNINGS\\r\\nAND PRECAUTIONS ].',\n",
       " 'Juvenile Animal Data',\n",
       " 'In a study in which juvenile rats received a single\\r\\nintramuscular injection of DYSPORT (1, 3 or 10 Units/animal) on postnatal day\\r\\n21, decreased growth and bone length (injected and contralateral limbs),\\r\\ndelayed sexual maturation, and decreased fertility were observed at the highest\\r\\ndose tested, which was associated with excessive toxicity during the first week\\r\\nafter dosing.',\n",
       " 'In a study in which juvenile rats received weekly\\r\\nintramuscular injections of DYSPORT (0.1, 0.3, or 1.0 Units/animal) from\\r\\npostnatal day 21 to 13 weeks of age, decreases in bone mineral content in the\\r\\ninjected limb, associated with atrophy of injected and adjacent muscles, were\\r\\nobserved at the highest dose tested. No adverse effects were observed on\\r\\nneurobehavioral development. However, dose levels were not adjusted for growth\\r\\nof the pups. On a body weight basis, the doses at the end of the dosing period\\r\\nwere approximately 15% of those at initiation of dosing. Therefore, the effects\\r\\nof DYSPORT throughout postnatal development were not adequately evaluated.',\n",
       " 'There were insufficient numbers of patients aged 65 years\\r\\nand over in the clinical studies to determine whether they respond differently\\r\\nthan younger patients. In general, elderly patients should be observed to\\r\\nevaluate their tolerability of DYSPORT, due to the greater frequency of\\r\\nconcomitant disease and other drug therapy [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'Of the total number of subjects in the placebo-controlled\\r\\nclinical studies of DYSPORT, 8 (1%) were 65 years and over. Efficacy was not\\r\\nobserved in subjects aged 65 years and over [see Clinical Studies ]. For\\r\\nthe entire safety database of geriatric subjects, although there was no\\r\\nincrease in the incidence of eyelid ptosis, geriatric subjects did have an\\r\\nincrease in the number of ocular adverse reactions compared to younger subjects\\r\\n(11% vs. 5%) [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'Upper Limb Spasticity',\n",
       " 'Of the total number of subjects in placebo-controlled\\r\\nclinical studies of DYSPORT, 30 percent were aged 65 years and over, while 8\\r\\npercent were aged 75 years and over. No overall differences in safety or\\r\\neffectiveness were observed between these subjects and younger subjects. Other\\r\\nreported clinical experience has not identified differences in responses\\r\\nbetween the elderly and younger patients, but greater sensitivity of some older\\r\\nindividuals can not be ruled out.',\n",
       " 'Lower Limb Spasticity',\n",
       " 'Of the total number of subjects in placebo controlled\\r\\nclinical studies of DYSPORT, 18% (n=115) were 65 and over, while 3% (n=20) were\\r\\n75 and over. Subjects aged 65 years and over who were treated with DYSPORT\\r\\nreported a greater percentage of adverse reactions as compared to younger\\r\\nsubjects (46% versus 39%). Fall and asthenia were observed with greater\\r\\nfrequency in older subjects, as compared to those younger (10% versus 6% and 4%\\r\\nversus 2%, respectively).',\n",
       " 'Exploratory analyses in trials for glabellar lines in\\r\\nAfrican-American subjects with Fitzpatrick skin types IV, V, or VI and in\\r\\nHispanic subjects suggested that response rates at Day 30 were comparable to\\r\\nand no worse than the overall population.',\n",
       " 'Included as part of the PRECAUTIONS section.',\n",
       " 'Severe myelosuppression (primarily neutropenia) is dose-dependent and a dose-limiting toxicity of ABRAXANE. In clinical studies, Grade 3-4 neutropenia occurred in 34% of patients with metastatic breast cancer (MBC), 47% of patients with non-small cell lung cancer (NSCLC), and 38% of patients with pancreatic cancer.',\n",
       " 'Monitor for severe neutropenia and thrombocytopenia by performing complete blood cell counts frequently, including prior to dosing on Day 1 (for MBC) and Days 1, 8, and 15 (for NSCLC and for pancreatic cancer). Do not administer ABRAXANE to patients with baseline absolute neutrophil counts (ANC) of less than 1,500 cells/mm³ [see CONTRAINDICATIONS ].',\n",
       " 'In the case of severe neutropenia (<500 cells/mm³ for seven days or more) during a course of ABRAXANE therapy, reduce the dose of ABRAXANE in subsequent courses in patients with either MBC or NSCLC.',\n",
       " 'In patients with MBC, resume treatment with every-3-week cycles of ABRAXANE after ANC recovers to a level >1,500 cells/mm³ and platelets recover to a level >100,000 cells/mm³. In patients with NSCLC, resume treatment if recommended at permanently reduced doses for both weekly ABRAXANE and every-3-week carboplatin after ANC recovers to at least 1500 cells/mm³ and platelet count of at least 100,000 cells/mm³ on Day 1 or to an ANC of at least 500 cells/mm³ and platelet count of at least 50,000 cells/mm³ on Days 8 or 15 of the cycle [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'In patients with adenocarcinoma of the pancreas, withhold ABRAXANE and gemcitabine if the ANC is less than 500 cells/mm³ or platelets are less than 50,000 cells/mm³ and delay initiation of the next cycle if the ANC is less than 1500 cells/mm³ or platelet count is less than 100,000 cells/mm³ on Day 1 of the cycle. Resume treatment with appropriate dose reduction if recommended [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'Sensory neuropathy is dose-and schedule-dependent [see ADVERSE REACTIONS ]. If ≥ Grade 3 sensory neuropathy develops, withhold ABRAXANE treatment until resolution to Grade 1 or 2 for metastatic breast cancer or until resolution to ≤ Grade 1 for NSCLC and pancreatic cancer followed by a dose reduction for all subsequent courses of ABRAXANE [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'Sepsis occurred in 5% of patients with or without neutropenia who received ABRAXANE in combination with gemcitabine. Biliary obstruction or presence of biliary stent were risk factors for severe or fatal sepsis.',\n",
       " 'If a patient becomes febrile (regardless of ANC) initiate treatment with broad spectrum antibiotics. For febrile neutropenia, interrupt',\n",
       " 'ABRAXANE and gemcitabine until fever resolves and ANC ≥ 1500, then resume treatment at reduced dose levels [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'Pneumonitis, including some cases that were fatal, occurred in 4% of patients receiving ABRAXANE in combination with gemcitabine.',\n",
       " 'Monitor patients for signs and symptoms of pneumonitis and interrupt ABRAXANE and gemcitabine during evaluation of suspected pneumonitis. After ruling out infectious etiology and upon making a diagnosis of pneumonitis, permanently discontinue treatment with ABRAXANE and gemcitabine.',\n",
       " 'Severe and sometimes fatal hypersensitivity reactions, including anaphylactic reactions, have been reported. Do not rechallenge patients who experience a severe hypersensitivity reaction to ABRAXANE with this drug [see CONTRAINDICATIONS ].',\n",
       " 'Cross-hypersensitivity between ABRAXANE and other taxane products has been reported and may include severe reactions such as anaphylaxis. Closely monitor patients with a previous history of hypersensitivity to other taxanes during initiation of ABRAXANE therapy.',\n",
       " 'The exposure and toxicity of paclitaxel can be increased in patients with hepatic impairment. Closely monito patients with hepatic impairment for severe myelosuppression.',\n",
       " 'ABRAXANE is not recommended in patients who have total bilirubin >5 x ULN or AST >10 x ULN. In addition, ABRAXANE is not recommended in patients with metastatic adenocarcinoma of the pancreas who have moderate to severe hepatic impairment (total bilirubin >1.5 x ULN and AST ≤10 x ULN). Reduce the starting dose for patients with moderate or severe hepatic impairment [see DOSAGE AND ADMINISTRATION , Use In Specific Populations , CLINICAL PHARMACOLOGY ].',\n",
       " 'ABRAXANE contains albumin (human), a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries a remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob Disease (CJD) also is considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for albumin.',\n",
       " 'Based on mechanism of action and findings in animals, ABRAXANE can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of paclitaxel formulated as albumin-bound particles to rats during pregnancy at doses lower than the maximum recommended human dose, based on body surface area, caused embryo-fetal toxicities, including intrauterine mortality, increased resorptions, reduced numbers of live fetuses, and malformations.',\n",
       " 'Advise females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception and avoid becoming pregnant during treatment with ABRAXANE and for at least six months after the last dose of ABRAXANE [see Use In Specific Populations , CLINICAL PHARMACOLOGY ].',\n",
       " 'Based on findings from genetic toxicity and animal reproduction studies, advise male patients with female partners of reproductive potential to use effective contraception and avoid fathering a child during treatment with ABRAXANE and for at least three months after the last dose of ABRAXANE [see Use In Specific Populations , Nonclinical Toxicology ].',\n",
       " 'Advise the patient to read the approved patient labeling ( PATIENT INFORMATION ).',\n",
       " 'The carcinogenic potential of ABRAXANE has not been studied.',\n",
       " 'Paclitaxel was clastogenic in vitro (chromosome aberrations in human lymphocytes) and in vivo (micronucleus test in mice). Paclitaxel was not mutagenic in the Ames test or the CHO/HGPRT gene mutation assay.',\n",
       " 'Administration of paclitaxel formulated as albumin-bound particles to male rats at 42 mg/m² on a weekly basis (approximately 16% of the daily maximum recommended human exposure on a body surface area basis) for 11 weeks prior to mating with untreated female rats resulted in significantly reduced fertility accompanied by decreased pregnancy rates and increased loss of embryos in mated females. A dose of 42 mg/m² also reduced male reproductive organ weights, mating performance, and sperm production.',\n",
       " 'Testicular atrophy/degeneration was observed in single-dose toxicology studies in animals administered paclitaxel formulated as albumin-bound particles at doses lower than the recommended human dose; doses were 54 mg/m² in rodents and 175 mg/m² in dogs. Similar testicular degeneration was seen in monkeys administered three weekly doses of 108 mg/m² paclitaxel formulated as albumin bound particles.',\n",
       " 'Administration of paclitaxel prior to and during mating produced impairment of fertility in male and female rats. Paclitaxel caused reduced fertility and reproductive indices, and increased embryo-fetal toxicity.',\n",
       " 'Based on its mechanism of action and findings in animals, ABRAXANE can cause fetal harm when administered to a pregnant woman [see CLINICAL PHARMACOLOGY ]. There are no available human data on ABRAXANE use in pregnant women to inform the drug-associated risk.',\n",
       " 'In animal reproduction studies, administration of paclitaxel formulated as albumin-bound particles to pregnant rats during the period of organogenesis resulted in embryo-fetal toxicity at doses approximately 2% of the daily maximum recommended human dose on a mg/m² basis (see Data ). Advise females of reproductive potential of the potential risk to a fetus.',\n",
       " 'The background rate of major birth defects and miscarriage is unknown for the indicated population. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.',\n",
       " 'Animal Data',\n",
       " 'In embryo-fetal development studies, intravenous administration of paclitaxel formulated as albumin-bound particles to rats during pregnancy, on gestation days 7 to 17 at doses of 6 mg/m² (approximately 2% of the daily maximum recommended human dose on a mg/m² basis) caused embryo-fetal toxicities, as indicated by intrauterine mortality, increased resorptions (up to 5-fold), reduced numbers of litters and live fetuses, reduction in fetal body weight, and increase in fetal anomalies. Fetal anomalies included soft tissue and skeletal malformations, such as eye bulge, folded retina, microphthalmia, and dilation of brain ventricles.',\n",
       " 'There are no data on the presence of paclitaxel in human milk, or its effect on the breastfed child or on milk production. In animal studies, paclitaxel and/or its metabolites were excreted into the milk of lactating rats (see Data ). Because of the potential for serious adverse reactions in a breastfed child from ABRAXANE, advise lactating women not to breastfeed during treatment with ABRAXANE and for two weeks after the last dose.',\n",
       " 'Animal Data',\n",
       " 'Following intravenous administration of radiolabeled paclitaxel to rats on days 9 to 10 postpartum, concentrations of radioactivity in milk were higher than in plasma and declined in parallel with the plasma concentrations.',\n",
       " 'Based on animal studies and mechanism of action, ABRAXANE can cause fetal harm when administered to a pregnant woman [see Use In Specific Populations ].',\n",
       " 'Verify the pregnancy status of females of reproductive potential prior to starting treatment with ABRAXANE.',\n",
       " 'Females',\n",
       " 'Advise females of reproductive potential to use effective contraception and avoid becoming pregnant during treatment with ABRAXANE and for at least six months after the last dose of ABRAXANE.',\n",
       " 'Males',\n",
       " 'Based on findings in genetic toxicity and animal reproduction studies, advise males with female partners of reproductive potential to use effective contraception and avoid fathering a child during treatment with ABRAXANE and for at least three months after the last dose of ABRAXANE [see Use In Specific Populations and Nonclinical Toxicology ].',\n",
       " 'Females And Males',\n",
       " 'Based on findings in animals, ABRAXANE may impair fertility in females and males of reproductive potential [see Nonclinical Toxicology ].',\n",
       " 'Safety and effectiveness in pediatric patients have not been established. Pharmacokinetics, safety, and antitumor activity of ABRAXANE were assessed in an open-label, dose escalation, dose expansion study (NCT01962103) in 96 pediatric patients aged 1.4 to < 17 years with recurrent or refractory pediatric solid tumors. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. No new safety signals were observed in pediatric patients across these studies.',\n",
       " 'Paclitaxel protein-bound exposures normalized by dose were higher in 96 pediatric patients (aged 1.4 to < 17 years) as compared to those in adults.',\n",
       " 'Of the 229 patients in the randomized study who received ABRAXANE for the treatment of metastatic breast cancer, 13% were at least 65 years of age and < 2% were 75 years or older. This study of ABRAXANE did not include a sufficient number of patients with metastatic breast cancer who were 65 years and older to determine whether they respond differently from younger patients.',\n",
       " 'A subsequent pooled analysis was conducted in 981 patients receiving ABRAXANE monotherapy for metastatic breast cancer, of which 15% were 65 years of age or older and 2% were 75 years of age or older. A higher incidence of epistaxis, diarrhea, dehydration, fatigue, and peripheral edema was found in patients 65 years of age or older.',\n",
       " 'Of the 514 patients in the randomized study who received ABRAXANE and carboplatin for the first-line treatment of non-small cell lung cancer, 31% were 65 years or older and 3.5% were 75 years or older. Myelosuppression, peripheral neuropathy, and arthralgia were more frequent in patients 65 years or older compared to patients younger than 65 years old. No overall difference in effectiveness, as measured by response rates, was observed between patients 65 years or older compared to patients younger than 65 years old.',\n",
       " 'Of the 431 patients in the randomized study who received ABRAXANE and gemcitabine for the first-line treatment of pancreatic adenocarcinoma, 41% were 65 years or older and 10% were 75 years or older. No overall differences in effectiveness were observed between patients who were 65 years of age or older and younger patients. Diarrhea, decreased appetite, dehydration, and epistaxis were more frequent in patients 65 years or older compared with patients younger than 65 years old. Clinical studies of ABRAXANE did not include sufficient number of patients with pancreatic cancer who were 75 years and older to determine whether they respond differently from younger patients.',\n",
       " 'No adjustment of the starting ABRAXANE dose is required for patients with mild to moderate renal impairment (estimated creatinine clearance 30 to <90 mL/min) [see CLINICAL PHARMACOLOGY ]. There are insufficient data to permit dosage recommendations in patients with severe renal impairment or end stage renal disease (estimated creatinine clearance <30 mL/min).',\n",
       " 'No adjustment of the starting ABRAXANE dose is required for patients with mild hepatic impairment (total bilirubin > ULN and ≤ 1.5 x ULN and aspartate aminotransferase [AST] ≤ 10 x ULN). Reduce ABRAXANE starting dose in patients with moderate to severe hepatic impairment [see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY ]. ABRAXANE is not recommended for use in patients with total bilirubin > 5 x ULN or AST > 10 x ULN [see DOSAGE AND ADMINISTRATION , WARNINGS AND PRECAUTIONS , and CLINICAL PHARMACOLOGY ]. ABRAXANE is not recommended for use in patients with metastatic adenocarcinoma of the pancreas who have moderate to severe hepatic impairment [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'For external use only',\n",
       " 'Do not use',\n",
       " 'When using this product',\n",
       " 'Stop use and ask a doctor if',\n",
       " 'Keep out of reach of children.',\n",
       " 'If swallowed, get medical help or contact a poison control center right away.',\n",
       " 'See WARNINGS above.',\n",
       " 'The most serious adverse reactions described elsewhere in\\r\\nthe labeling include the following:',\n",
       " 'Because clinical trials are conducted under widely\\r\\nvarying conditions, adverse reaction rates observed in the clinical trials of a\\r\\ndrug cannot be directly compared to rates in the clinical trials of another\\r\\ndrug and may not reflect the rates observed in practice.',\n",
       " 'The most common adverse reaction with adalimumab was\\r\\ninjection site reactions. In placebo-controlled trials, 20% of patients treated\\r\\nwith adalimumab developed injection site reactions ( erythema and/or itching, hemorrhage , pain or swelling), compared to 14% of patients receiving placebo.\\r\\nMost injection site reactions were described as mild and generally did not\\r\\nnecessitate drug discontinuation.',\n",
       " 'The proportion of patients who discontinued treatment due\\r\\nto adverse reactions during the double-blind, placebo-controlled portion of\\r\\nstudies in patients with RA (i.e., Studies RA-I, RA-II, RA-III and RA-IV) was\\r\\n7% for patients taking adalimumab and 4% for placebo-treated patients. The most\\r\\ncommon adverse reactions leading to discontinuation of adalimumab in these RA\\r\\nstudies were clinical flare reaction (0.7%), rash (0.3%) and pneumonia (0.3%).',\n",
       " 'In the controlled portions of the 39 global adalimumab\\r\\nclinical trials in adult patients with RA, PsA, AS, CD, UC, Ps, and other\\r\\nindications, the rate of serious infections was 4.3 per 100 patient-years in\\r\\n7973 adalimumab-treated patients versus a rate of 2.9 per 100 patient-years in\\r\\n4848 control-treated patients. Serious infections observed included pneumonia, septic arthritis , prosthetic and post-surgical infections, erysipelas, cellulitis , diverticulitis , and pyelonephritis [see WARNINGS\\r\\nAND PRECAUTIONS ].',\n",
       " 'In 52 global controlled and uncontrolled clinical trials\\r\\nin RA, PsA, AS, CD, UC, Ps, and other indications that included 24,605\\r\\nadalimumab-treated patients, the rate of reported active tuberculosis was 0.20\\r\\nper 100 patient-years and the rate of positive PPD conversion was 0.09 per 100\\r\\npatient-years. In a subgroup of 10,113 U.S. and Canadian adalimumab-treated\\r\\npatients, the rate of reported active TB was 0.05 per 100 patient-years and the\\r\\nrate of positive PPD conversion was 0.07 per 100 patient-years. These trials\\r\\nincluded reports of miliary, lymphatic , peritoneal , and pulmonary TB. Most of\\r\\nthe TB cases occurred within the first eight months after initiation of therapy\\r\\nand may reflect recrudescence of latent disease. In these global clinical\\r\\ntrials, cases of serious opportunistic infections have been reported at an\\r\\noverall rate of 0.05 per 100 patient-years. Some cases of serious opportunistic\\r\\ninfections and TB have been fatal [see WARNINGS\\r\\nAND PRECAUTIONS ].',\n",
       " 'In the rheumatoid arthritis controlled trials, 12% of\\r\\npatients treated with adalimumab and 7% of placebo-treated patients that had\\r\\nnegative baseline ANA titers developed positive titers at Week 24. Two patients\\r\\nout of 3046 treated with adalimumab developed clinical signs suggestive of\\r\\nnew-onset lupus -like syndrome. The patients improved following discontinuation\\r\\nof therapy. No patients developed lupus nephritis or central nervous system symptoms. The impact of long-term treatment with adalimumab products on the development\\r\\nof autoimmune diseases is unknown.',\n",
       " 'There have been reports of severe hepatic reactions\\r\\nincluding acute liver failure in patients receiving TNF-blockers. In controlled\\r\\nPhase 3 trials of adalimumab (40 mg SC every other week) in patients with RA,\\r\\nPsA, and AS with control period duration ranging from 4 to 104 weeks, ALT\\r\\nelevations ≥3 x ULN occurred in 3.5% of adalimumab-treated patients and\\r\\n1.5% of control-treated patients. Since many of these patients in these trials\\r\\nwere also taking medications that cause liver enzyme elevations (e.g., NSAIDS,\\r\\nMTX), the relationship between adalimumab and the liver enzyme elevations is\\r\\nnot clear. In a controlled Phase 3 trial of adalimumab in patients with\\r\\npolyarticular JIA who were 4 to 17 years, ALT elevations ≥3 x ULN\\r\\noccurred in 4.4% of adalimumab-treated patients and 1.5% of control-treated patients\\r\\n(ALT more common than AST); liver enzyme test elevations were more frequent\\r\\namong those treated with the combination of adalimumab and MTX than those\\r\\ntreated with adalimumab alone. In general, these elevations did not lead to\\r\\ndiscontinuation of adalimumab treatment.',\n",
       " 'In controlled Phase 3 trials of adalimumab (initial doses\\r\\nof 160 mg and 80 mg, or 80 mg and 40 mg on Days 1 and 15, respectively,\\r\\nfollowed by 40 mg every other week) in adult patients with CD with a control\\r\\nperiod duration ranging from 4 to 52 weeks, ALT elevations ≥3 x ULN\\r\\noccurred in 0.9% of adalimumab-treated patients and 0.9% of control-treated\\r\\npatients. In controlled Phase 3 trials of adalimumab (initial doses of 160 mg\\r\\nand 80 mg on Days 1 and 15 respectively, followed by 40 mg every other week) in\\r\\npatients with UC with control period duration ranging from 1 to 52 weeks, ALT\\r\\nelevations ≥3 x ULN occurred in 1.5% of adalimumab-treated patients and\\r\\n1.0% of control-treated patients. In controlled Phase 3 trials of adalimumab\\r\\n(initial dose of 80 mg then 40 mg every other week) in patients with Ps with\\r\\ncontrol period duration ranging from 12 to 24 weeks, ALT elevations ≥3 x\\r\\nULN occurred in 1.8% of adalimumab-treated patients and 1.8% of control-treated\\r\\npatients.',\n",
       " 'As with all therapeutic proteins, there is potential for\\r\\nimmunogenicity. The detection of antibody formation is highly dependent on the\\r\\nsensitivity and specificity of the assay. Additionally, the observed incidence\\r\\nof antibody (including neutralizing antibody) positivity in an assay may be\\r\\ninfluenced by several factors, including assay methodology, sample handling,\\r\\ntiming of sample collection, concomitant medications, and underlying disease.\\r\\nFor these reasons, comparison of the incidence of antibodies in the studies described\\r\\nbelow with the incidence of antibodies in other studies or to other adalimumab\\r\\nproducts may be misleading.',\n",
       " 'Patients in Studies RA-I, RA-II, and RA-III were tested\\r\\nat multiple time points for antibodies to adalimumab during the 6-to 12-month\\r\\nperiod. Approximately 5% (58 of 1062) of adult RA patients receiving adalimumab\\r\\ndeveloped low- titer antibodies to adalimumab at least once during treatment,\\r\\nwhich were neutralizing in vitro. Patients treated with concomitant\\r\\nmethotrexate (MTX) had a lower rate of antibody development than patients on\\r\\nadalimumab monotherapy (1% versus 12%). No apparent correlation of antibody\\r\\ndevelopment to adverse reactions was observed. With monotherapy, patients\\r\\nreceiving every other week dosing may develop antibodies more frequently than\\r\\nthose receiving weekly dosing. In patients receiving the recommended dosage of\\r\\n40 mg every other week as monotherapy, the ACR 20 response was lower among\\r\\nantibody-positive patients than among antibody-negative patients. The long-term\\r\\nimmunogenicity of adalimumab is unknown.',\n",
       " 'In patients with polyarticular JIA who were 4 to 17 years\\r\\nof age, adalimumab antibodies were identified in 16% of adalimumab-treated\\r\\npatients. In patients receiving concomitant MTX, the incidence was 6% compared\\r\\nto 26% with adalimumab monotherapy.',\n",
       " 'In patients with AS, the rate of development of\\r\\nantibodies to adalimumab in adalimumab-treated patients was comparable to\\r\\npatients with RA.',\n",
       " 'In patients with PsA, the rate of antibody development in\\r\\npatients receiving adalimumab monotherapy was comparable to patients with RA;\\r\\nhowever, in patients receiving concomitant MTX the rate was 7% compared to 1%\\r\\nin RA.',\n",
       " 'In adult patients with CD, the rate of antibody\\r\\ndevelopment was 3%.',\n",
       " 'In patients with moderately to severely active UC, the rate\\r\\nof antibody development in patients receiving adalimumab was 5%. However, due\\r\\nto the limitation of the assay conditions, antibodies to adalimumab could be\\r\\ndetected only when serum adalimumab levels were <2 mcg/mL. Among the\\r\\npatients whose serum adalimumab levels were <2 mcg/mL (approximately 25% of\\r\\ntotal patients studied), the immunogenicity rate was 20.7%.',\n",
       " 'In patients with Ps, the rate of antibody development\\r\\nwith adalimumab monotherapy was 8%. However, due to the limitation of the assay\\r\\nconditions, antibodies to adalimumab could be detected only when serum\\r\\nadalimumab levels were <2 mcg/mL. Among the patients whose serum adalimumab\\r\\nlevels were <2 mcg/mL (approximately 40% of total patients studied), the\\r\\nimmunogenicity rate was 20.7%. In Ps patients who were on adalimumab\\r\\nmonotherapy and subsequently withdrawn from the treatment, the rate of\\r\\nantibodies to adalimumab after retreatment was similar to the rate observed\\r\\nprior to withdrawal.',\n",
       " 'The data described below reflect exposure to adalimumab\\r\\nin 2468 patients, including 2073 exposed for 6 months, 1497 exposed for greater\\r\\nthan one year and 1380 in adequate and well-controlled studies (Studies RA-I,\\r\\nRA-II, RA-III, and RA-IV). Adalimumab was studied primarily in\\r\\nplacebo-controlled trials and in long-term follow up studies for up to 36\\r\\nmonths duration. The population had a mean age of 54 years, 77% were female,\\r\\n91% were Caucasian and had moderately to severely active rheumatoid arthritis.\\r\\nMost patients received 40 mg adalimumab every other week.',\n",
       " 'Table 1 summarizes reactions reported at a rate of at\\r\\nleast 5% in patients treated with adalimumab 40 mg every other week compared to\\r\\nplacebo and with an incidence higher than placebo. In Study RA-III, the types\\r\\nand frequencies of adverse reactions in the second year open-label extension were similar to those observed in the one-year double-blind portion.',\n",
       " 'Table 1: Adverse Reactions Reported by ≥5% of\\r\\nPatients Treated with Adalimumab During Placebo-Controlled Period of Pooled RA\\r\\nStudies (Studies RA-I, RA-II, RA-III, and RA-IV)',\n",
       " 'Other infrequent serious\\r\\nadverse reactions that do not appear in the Warnings and Precautions or Adverse\\r\\nReaction sections that occurred at an incidence of less than 5% in\\r\\nadalimumab-treated patients in RA studies were:',\n",
       " 'In general, the adverse\\r\\nreactions in the adalimumab-treated patients in the polyarticular juvenile\\r\\nidiopathic arthritis (JIA) trial (Study JIA-I) were similar in frequency and\\r\\ntype to those seen in adult patients [see WARNINGS AND PRECAUTIONS , ADVERSE\\r\\nREACTIONS ]. Important findings and differences from adults are discussed in\\r\\nthe following paragraphs.',\n",
       " 'In Study JIA-I, adalimumab was\\r\\nstudied in 171 patients who were 4 to 17 years of age, with polyarticular JIA.\\r\\nSevere adverse reactions reported in the study included neutropenia,\\r\\nstreptococcal pharyngitis, increased aminotransferases, herpes zoster,\\r\\nmyositis, metrorrhagia, and appendicitis. Serious infections were observed in\\r\\n4% of patients within approximately 2 years of initiation of treatment with\\r\\nadalimumab and included cases of herpes simplex, pneumonia, urinary tract\\r\\ninfection, pharyngitis, and herpes zoster.',\n",
       " 'In Study JIA-I, 45% of patients\\r\\nexperienced an infection while receiving adalimumab with or without concomitant\\r\\nMTX in the first 16 weeks of treatment. The types of infections reported in\\r\\nadalimumab-treated patients were generally similar to those commonly seen in\\r\\npolyarticular JIA patients who are not treated with TNF blockers. Upon\\r\\ninitiation of treatment, the most common adverse reactions occurring in this\\r\\npatient population treated with adalimumab were injection site pain and\\r\\ninjection site reaction (19% and 16%, respectively). A less commonly reported\\r\\nadverse event in patients receiving adalimumab was granuloma annulare which did\\r\\nnot lead to discontinuation of adalimumab treatment.',\n",
       " 'In the first 48 weeks of\\r\\ntreatment in Study JIA-I, non-serious hypersensitivity reactions were seen in\\r\\napproximately 6% of patients and included primarily localized allergic\\r\\nhypersensitivity reactions and allergic rash.',\n",
       " 'In Study JIA-I, 10% of patients\\r\\ntreated with adalimumab who had negative baseline anti-dsDNA antibodies\\r\\ndeveloped positive titers after 48 weeks of treatment. No patient developed\\r\\nclinical signs of autoimmunity during the clinical trial.',\n",
       " 'Approximately 15% of patients\\r\\ntreated with adalimumab developed mild-to-moderate elevations of creatine\\r\\nphosphokinase (CPK) in Study JIA-I. Elevations exceeding 5 times the upper\\r\\nlimit of normal were observed in several patients. CPK levels decreased or\\r\\nreturned to normal in all patients. Most patients were able to continue\\r\\nadalimumab without interruption.',\n",
       " 'Adalimumab has been studied in\\r\\n395 patients with psoriatic arthritis (PsA) in two placebo-controlled trials\\r\\nand in an open label study and in 393 patients with ankylosing spondylitis (AS)\\r\\nin two placebo-controlled studies. The safety profile for patients with PsA and\\r\\nAS treated with adalimumab 40 mg every other week was similar to the safety\\r\\nprofile seen in patients with RA, adalimumab Studies RA-I through IV.',\n",
       " \"Adalimumab has been studied in\\r\\n1478 adult patients with Crohn's disease (CD) in four placebo-controlled and\\r\\ntwo open-label extension studies. The safety profile for adult patients with CD\\r\\ntreated with adalimumab was similar to the safety profile seen in patients with\\r\\nRA.\",\n",
       " 'Adalimumab has been studied in\\r\\n1010 patients with ulcerative colitis (UC) in two placebo-controlled studies\\r\\nand one open-label extension study. The safety profile for patients with UC\\r\\ntreated with adalimumab was similar to the safety profile seen in patients with\\r\\nRA.',\n",
       " 'Adalimumab has been studied in\\r\\n1696 subjects with plaque psoriasis (Ps) in placebo-controlled and open-label\\r\\nextension studies. The safety profile for subjects with Ps treated with\\r\\nadalimumab was similar to the safety profile seen in subjects with RA with the\\r\\nfollowing exceptions. In the placebo-controlled portions of the clinical trials\\r\\nin Ps subjects, adalimumab-treated subjects had a higher incidence of\\r\\narthralgia when compared to controls (3% vs. 1%).',\n",
       " 'The following adverse reactions\\r\\nhave been identified during post-approval use of adalimumab products. Because\\r\\nthese reactions are reported voluntarily from a population of uncertain size,\\r\\nit is not always possible to reliably estimate their frequency or establish a\\r\\ncausal relationship to adalimumab products exposure.',\n",
       " 'Table 4 includes drugs with clinically significant drug interactions affecting CIBINQO.',\n",
       " 'Table 4. Clinically Significant Drug Interactions Affecting CIBINQO',\n",
       " '',\n",
       " 'Table 5 includes clinically significant drug interactions affecting other drugs.',\n",
       " 'Table 5. Clinically Significant Interactions Affecting Other Drugs',\n",
       " '',\n",
       " 'There have been reports of fever associated with the use\\r\\nof GELFOAM, without demonstrable infection. GELFOAM Sterile Compressed Sponge\\r\\nmay form a nidus of infection and abscess formation 1 , and has been\\r\\nreported to potentiate bacterial growth. Giant-cell granuloma has been reported\\r\\nat the implantation site of absorbable gelatin product in the brain 2 ,\\r\\nand compression of the brain and spinal cord resulting from an accumulation of\\r\\nsterile fluid 3 has been reported following use of absorbable gelatin\\r\\nsponge in closed space.',\n",
       " 'Foreign body reactions, “encapsulation” of\\r\\nfluid and hematoma have also been reported. When GELFOAM was used in laminectomy operations, multiple neurologic events were reported, including but\\r\\nnot limited to cauda equina syndrome , spinal stenosis , meningitis , arachnoiditis ,\\r\\nheadaches, paresthesias, pain, bladder and bowel dysfunction, and impotence .',\n",
       " 'Excessive fibrosis and prolonged fixation of a tendon have been reported when absorbable gelatin products were used in severed tendon\\r\\nrepair.',\n",
       " 'Toxic shock syndrome has been reported in association\\r\\nwith the use of GELFOAM in nasal surgery.',\n",
       " 'Fever, failure of absorption, and hearing loss have been\\r\\nreported in association with the use of GELFOAM during tympanoplasty .',\n",
       " 'GELFOAM is not recommended for use other than as an\\r\\nadjunct for hemostasis . While some adverse medical events following the\\r\\nunapproved use of GELFOAM have been reported (see ADVERSE REACTIONS ),\\r\\nother hazards associated with such use may not have been reported.',\n",
       " 'When GELFOAM has been used during intravascular\\r\\ncatheterization for the purpose of producing vessel occlusion , the following\\r\\nadverse events have been reported; fever, duodenal and pancreatic infarct , embolization of lower extremity vessels, pulmonary embolization, splenic\\r\\nabscess, necrosis of specific anatomic areas, asterixis, and death. These\\r\\nadverse medical events have been associated with the use of GELFOAM for repair of dural defects encountered during laminectomy and craniotomy operations: fever, infection,\\r\\nleg paresthesias, neck and back pain , bladder and bowel incontinence , cauda equina syndrome, neurogenic bladder, impotence, and paresis .',\n",
       " 'No information provided.',\n",
       " 'REFERENCES',\n",
       " '1. Lindstrom PA: Complications from the use of absorbable\\r\\nhemostatic sponges. AMA Arch Surg 1956; 73:133-141.',\n",
       " '2. Knowlson GTG: Gelfoam granuloma in the brain. J Neuro\\r\\nNeurosurg Psychiatry 1974; 37:971-973.',\n",
       " '3. Herndon JH, Grillo HC, Riseborough EJ, et al:\\r\\n  Compression of the brain and spinal cord following use of GELFOAM. Arch Surg 1972;\\r\\n  104:107.',\n",
       " 'This product should not be resterilized by heat, because\\r\\nheating may change absorption time. Ethylene oxide is not recommended for\\r\\nresterilization because it may be trapped in the interstices of the foam.\\r\\nAlthough not reported for GELFOAM Dental Sponges, the gas is toxic to tissue\\r\\nand in trace amounts may cause burns or irritation.',\n",
       " \"Although the safety and efficacy of the combined use of\\r\\nGELFOAM with other agents such as topical thrombin has not been evaluated in\\r\\ncontrolled clinical trials, if in the physician's judgment concurrent use of\\r\\nother agents is medically advisable, the product literature for that agent\\r\\nshould be consulted for complete prescribing information.\",\n",
       " 'GELFOAM is supplied as a sterile product and cannot be\\r\\nresterilized. Unused, opened envelopes of GELFOAM should be discarded. WARNING:\\r\\nTo prevent contamination, employ aseptic procedure in opening envelope and\\r\\nwithdrawing GELFOAM. If the envelope is torn or punctured, the contained\\r\\nGELFOAM should not be used.',\n",
       " 'There have been reports of fever associated with the use\\r\\nof GELFOAM, without demonstrable infection. GELFOAM may serve as a nidus for\\r\\ninfection and abscess formation 1 , and has been reported to\\r\\npotentiate bacterial growth. Giant-cell granuloma has been reported at the implantation site of absorbable gelatin product in the brain 2 , as\\r\\nhas compression of the brain and spinal cord resulting from the accumulation of\\r\\nsterile fluid. 3',\n",
       " 'Foreign body reactions, “encapsulation” of fluid and hematoma have also been reported.',\n",
       " 'When GELFOAM was used in laminectomy operations, multiple\\r\\nneurologic events were reported, including but not limited to cauda equina syndrome, spinal stenosis , meningitis , arachnoiditis , headaches, paresthesias,\\r\\npain, bladder and bowel dysfunction, and impotence .',\n",
       " 'Excessive fibrosis and prolonged fixation of a tendon have been reported when absorbable gelatin products were used in severed tendon\\r\\nrepair.',\n",
       " 'Toxic shock syndrome has been reported in association\\r\\nwith the use of GELFOAM in nasal surgery.',\n",
       " 'Fever, failure of absorption, and hearing loss have been\\r\\nreported in association with the use of GELFOAM during tympanoplasty .',\n",
       " 'GELFOAM is not recommended for use other than as an\\r\\nadjunct for hemostasis . While some adverse medical events following the\\r\\nunapproved use of GELFOAM have been reported to Pharmacia & Upjohn Company\\r\\n(see ADVERSE REACTIONS above), other hazards associated with such use may not\\r\\nhave been reported.',\n",
       " 'When GELFOAM has been used during intravascular\\r\\ncatheterization for the purpose of producing vessel occlusion , the following\\r\\nadverse events have been reported; fever, duodenal and pancreatic infarct , embolization of lower extremity vessels, pulmonary embolization, splenic\\r\\nabscess, necrosis of specific anatomic areas, asterixis, and death.',\n",
       " 'These adverse medical events have been associated with\\r\\nthe use of GELFOAM for repair of dural defects encountered during laminectomy\\r\\nand craniotomy operations: fever, infection, leg paresthesias, neck and back\\r\\npain, bladder and bowel incontinence , cauda equina syndrome , neurogenic bladder, impotence, and paresis .',\n",
       " 'In a clinical study, 108 patients received GELFOAM\\r\\nSterile Powder on the cut surface of the sternum during cardiopulmonary bypass surgery, while 107 patients received no treatment on the cut surface of the\\r\\nbone. Table 1 is a summary of medical events reported by at least 1.0% of\\r\\npatients in a treatment group. The most frequently reported events were atrial fibrillation , perioperative event, and wound infection. Events occurring in\\r\\nless than 1.0% of the patients were as follows: anaphylaxis , cardiogenic shock , delirium tremens , infection at the vascular catheter site, unevaluable\\r\\nreaction, sepsis , angina pectoris , atrial arrhythmia , nodal arrhythmia, arteriosclerosis , cardiac insufficiency , cardiac tamponade , cardiomyopathy , deep vein thrombosis , mitral valve disorder, endocarditis , ventricular extrasystoles, heart arrest, hypotension ,\\r\\nmesenteric occlusion, superventricular tachycardia , thrombophlebitis , thrombosis , gastrointestinal disorder, gastrointestinal bleeding, increased serum creatinine,\\r\\ndehydration, anemia , thrombocytopenia , abnormal healing, hypovolemia , hypoxia ,\\r\\nmetabolic acidosis , cerebral infarction , visual hallucinations, stupor, aspiration pneumonia , chest congestion , pleural effusion , pulmonary infiltration, retinal\\r\\nartery occlusion, anuria, UG disorder, abnormal kidney function and menorrhagia .',\n",
       " 'Table 1: Summary of Medical Events for GELFOAM Sterile\\r\\nPowder when used as a Bone Hemostatic Agent During Cardiopulmonary Bypass\\r\\nSurgery',\n",
       " 'In general, the following adverse events have been\\r\\nreported with the use of absorbable porcine gelatin-based hemostatic agents:',\n",
       " 'No information provided.',\n",
       " 'There have been reports of fever associated with the use\\r\\nof GELFOAM, without demonstrable infection. GELFOAM Sterile Sponge may serve as\\r\\na nidus of infection and abscess formation 1 , and has been reported\\r\\nto potentiate bacterial growth. Giantcell granuloma has been reported at the implantation site of absorbable gelatin product in the brain, 2 as\\r\\nhas compression of the brain and spinal cord resulting from the accumulation of\\r\\nsterile fluid. 3',\n",
       " 'Foreign body reactions, encapsulation of fluid and hematoma have also been reported.',\n",
       " 'When GELFOAM was used in laminectomy operations, multiple\\r\\nneurologic events were reported, including but not limited to cauda equina syndrome, spinal stenosis , meningitis , arachnoiditis , headaches, paresthesias,\\r\\npain, bladder and bowel dysfunction, and impotence .',\n",
       " 'Excessive fibrosis and prolonged fixation of a tendon have been reported when absorbable gelatin products were used in severed tendon\\r\\nrepair.',\n",
       " 'Toxic shock syndrome has been reported in association\\r\\nwith the use of GELFOAM in nasal surgery.',\n",
       " 'Fever, failure of absorption, and hearing loss have been\\r\\nreported in association with the use of GELFOAM during tympanoplasty .',\n",
       " 'GELFOAM is not recommended for use other than as an\\r\\nadjunct for hemostasis .',\n",
       " 'While some adverse medical events following the\\r\\nunapproved use of GELFOAM have been reported to Pharmacia & Upjohn Company\\r\\n(see ADVERSE REACTIONS above), other hazards associated with such use may not\\r\\nhave been reported.',\n",
       " 'When GELFOAM has been used during intravascular catheterization\\r\\nfor the purpose of producing vessel occlusion , the following adverse events\\r\\nhave been reported; fever, duodenal and pancreatic infarct , embolization of\\r\\nlower extremity vessels, pulmonary embolization, splenic abscess, necrosis of\\r\\nspecific anatomic areas, asterixis, and death.',\n",
       " 'The following adverse medical events have been associated\\r\\nwith the use of GELFOAM for repair of dural defects encountered during\\r\\nlaminectomy and craniotomy operations: fever, infection, leg paresthesias, neck\\r\\nand back pain , bladder and bowel incontinence , cauda equine syndrome, neurogenic bladder, impotence, and paresis .',\n",
       " 'No information provided.',\n",
       " 'REFERENCES',\n",
       " '1. Lindstrom PA: Complications from the use of absorbable\\r\\nhemostatic sponges. AMA Arch Surg. 1956; 73(1):133-141.',\n",
       " '2. Knowlson GTG. Gelfoam granuloma in the brain. J Neurol\\r\\nNeurosurg Psychiatry 1974; 37:971-973.',\n",
       " '3. Herndon JH, Grillo HC, Riseborough EJ, et al:\\r\\n  Compression of the brain and spinal cord following use of GELFOAM. Arch Surg. 1972;104:107.',\n",
       " 'No information provided.',\n",
       " 'No information provided.',\n",
       " 'ABSORICA/ABSORICA LD is closely related to vitamin A. Therefore, the use of both vitamin A and ABSORICA/ABSORICA LD at the same time may lead to vitamin A related adverse reactions. Patients treated with ABSORICA/ABSORICA LD should be advised against taking supplements containing Vitamin A to avoid additive toxic effects.',\n",
       " 'Concomitant treatment with ABSORICA/ABSORICA LD and tetracyclines should be avoided because isotretinoin use has been associated with a number of cases of intracranial hypertension (pseudotumor cerebri), some of which involved concomitant use of tetracyclines [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Phenytoin is known to cause osteomalacia. No formal clinical trials have been conducted to assess if there is an interactive effect on bone loss between phenytoin and isotretinoin. Therefore, caution should be exercised when using these drugs together.',\n",
       " 'Systemic corticosteroids are known to cause osteoporosis. No formal clinical trials have been conducted to assess if there is an interactive effect on bone loss with concomitant use of systemic corticosteroids and isotretinoin. Therefore, caution should be exercised when using these drugs together.',\n",
       " 'In a trial of 31 premenopausal female patients with severe recalcitrant nodular acne receiving norethindrone and ethinyl estradiol as an oral contraceptive agent, isotretinoin capsules within the recommended dosage, did not induce clinically relevant changes in the pharmacokinetics of ethinyl estradiol and norethindrone and in the serum levels of progesterone, follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Although this study did not show any clinically significant interaction between isotretinoin and norethindrone, it is not known if there is an interaction between isotretinoin with other progestins.',\n",
       " 'ABSORICA/ABSORICA LD is closely related to vitamin A. Therefore, the use of both vitamin A and ABSORICA/ABSORICA LD at the same time may lead to vitamin A related adverse reactions. Patients treated with ABSORICA/ABSORICA LD should be advised against taking supplements containing Vitamin A to avoid additive toxic effects.',\n",
       " 'Concomitant treatment with ABSORICA/ABSORICA LD and tetracyclines should be avoided because isotretinoin use has been associated with a number of cases of intracranial hypertension (pseudotumor cerebri), some of which involved concomitant use of tetracyclines [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Phenytoin is known to cause osteomalacia. No formal clinical trials have been conducted to assess if there is an interactive effect on bone loss between phenytoin and isotretinoin. Therefore, caution should be exercised when using these drugs together.',\n",
       " 'Systemic corticosteroids are known to cause osteoporosis. No formal clinical trials have been conducted to assess if there is an interactive effect on bone loss with concomitant use of systemic corticosteroids and isotretinoin. Therefore, caution should be exercised when using these drugs together.',\n",
       " 'In a trial of 31 premenopausal female patients with severe recalcitrant nodular acne receiving norethindrone and ethinyl estradiol as an oral contraceptive agent, isotretinoin capsules within the recommended dosage, did not induce clinically relevant changes in the pharmacokinetics of ethinyl estradiol and norethindrone and in the serum levels of progesterone, follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Although this study did not show any clinically significant interaction between isotretinoin and norethindrone, it is not known if there is an interaction between isotretinoin with other progestins.',\n",
       " 'Because clinical trials are conducted under widely\\r\\nvarying conditions, adverse event rates observed in the clinical trials of a\\r\\ndrug cannot be directly compared to rates in the clinical trials of another\\r\\ndrug and may not reflect the rates observed in practice.',\n",
       " 'The safety of ABSTRAL has been evaluated in 311 opioid -tolerant cancer patients with breakthrough pain. Two hundred and seventy\\r\\n(270) of these patients were treated in multiple-dose studies. The duration of\\r\\ntherapy for patients in multiple-dose studies ranged from 1-405 days with an\\r\\naverage duration of 131 days and with 44 patients treated for at least 12\\r\\nmonths.',\n",
       " 'The most commonly observed adverse reactions with ABSTRAL\\r\\ninclude typical opioid adverse reactions, such as nausea, constipation, somnolence and headache. Expect opioid side effects and manage them\\r\\naccordingly.',\n",
       " 'The clinical trials of ABSTRAL were designed to evaluate\\r\\nsafety and efficacy in treating patients with cancer and breakthrough pain; all\\r\\npatients were taking concomitant opioids, such as sustained-release morphine ,\\r\\nsustained-release oxycodone or transdermal fentanyl, for their persistent pain.',\n",
       " 'The adverse reaction data presented in Table 2 reflect\\r\\nthe actual percentage of patients experiencing reactions among patients who\\r\\nreceived ABSTRAL for breakthrough pain along with concomitant opioid use for\\r\\npersistent pain. There has been no attempt to correct for concomitant use of\\r\\nother opioids, duration of ABSTRAL therapy or cancer-related symptoms.',\n",
       " 'Table 2 lists adverse reactions with an overall frequency\\r\\nof 5% or greater within the total population that occurred during titration by\\r\\nmaximum dose received. The ability to assign ABSTRAL a dose-response\\r\\nrelationship to these adverse reactions is limited by the titration schemes\\r\\nused in these studies.',\n",
       " 'Table2: Adverse Reactions Which Occurred During\\r\\nTitration at a Frequency of  ≥ 5%',\n",
       " 'Table 3 lists, by successful\\r\\ndose, adverse reactions with an overall frequency of  ≥ 5% within the total\\r\\npopulation that occurred after a successful dose had been determined.',\n",
       " 'Table3: Adverse Reactions\\r\\nWhich Occurred During Maintenance Therapy at a Frequency of  ≥  5%',\n",
       " 'The frequencies listed below\\r\\nrepresent adverse reactions that occurred in  ≥ 1% of patients from two clinical trials who experienced\\r\\nthat reaction while receiving ABSTRAL. Reactions are classified by system organ\\r\\nclass.',\n",
       " 'Cardiac disorders: bradycardia , tachycardia .',\n",
       " 'Eye disorders: vision blurred.',\n",
       " 'Gastrointestinal disorders: abdominal pain, abdominal\\r\\npain upper, aphthous stomatitis, constipation, dry mouth , dyspepsia , gingival ulceration , impaired gastric emptying, lip ulceration, mouth ulceration,\\r\\nnausea, stomach discomfort, stomatitis, tongue disorder, vomiting.',\n",
       " 'General disorders and administration site conditions: asthenia , drug withdrawal syndrome, fatigue, malaise .',\n",
       " 'Immune system disorders: drug hypersensitivity.',\n",
       " 'Injury, poisoning and\\r\\nprocedural complications: accidental overdose.',\n",
       " 'Metabolism and nutrition\\r\\ndisorders: anorexia ,\\r\\ndecreased appetite.',\n",
       " 'Nervous system disorders: amnesia , disturbance in\\r\\nattention, dizziness, dysgeusia, headache, hypoesthesia, lethargy , parosmia,\\r\\nsomnolence, tremor .',\n",
       " 'Psychiatric disorders: affect lability , anxiety,\\r\\nconfusional state, depression, disorientation, dysphoria , euphoric mood,\\r\\ninsomnia, mental status changes, paranoia, sleep disorder.',\n",
       " 'Reproductive system and breast disorders: erectile\\r\\ndysfunction.',\n",
       " 'Respiratory, thoracic and mediastinal disorder: dyspnea ,\\r\\noropharyngeal pain, throat tightness.',\n",
       " 'Skin and subcutaneous disorders: hyperhidrosis , night sweats , pruritus , rash, skin lesion .',\n",
       " 'Vascular disorders: hypotension .',\n",
       " '',\n",
       " '',\n",
       " 'There are no data evaluating the simultaneous\\r\\nadministration of ACAM2000 with other vaccines.',\n",
       " 'ACAM2000 may induce false-positive tests for syphilis .\\r\\nPositive RPR tests results should be confirmed using a more specific test, such\\r\\nas the FTA assay.',\n",
       " 'ACAM2000 may induce temporary false-negative results for\\r\\nthe tuberculin skin test (purified protein derivative [ PPD ]) and possibly,\\r\\nblood tests for tuberculosis . Tuberculin testing should be delayed if possible\\r\\nfor 1 month following smallpox vaccination.',\n",
       " 'Included as part of  the PRECAUTIONS section.',\n",
       " 'Treatment with Campral in patients with moderate renal\\r\\nimpairment (creatinine clearance of 30-50 mL/min) requires a dose reduction.\\r\\nCampral is contraindicated in patients with severe renal impairment (creatinine\\r\\nclearance of  ≤ 30 mL/min). [see DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , Use in Specific\\r\\nPopulations , and CLINICAL PHARMACOLOGY ]',\n",
       " \"In controlled clinical trials of Campral, adverse events\\r\\nof a suicidal nature (suicidal ideation, suicide attempts, completed suicides)\\r\\nwere Infrequent overall, but were more common in Campral-treated patients\\r\\nthan in patients treated with placebo (1.4% vs. 0.5% in studies of 6 months or\\r\\nless; 2.4% vs. 0.8% in year-long studies). Completed suicides occurred in 3 of\\r\\n2272 (0.13%) patients in the pooled acamprosate group from all controlled\\r\\nstudies and 2 of 1962 patients (0.10%) in the placebo group. Adverse events\\r\\ncoded as “depression” were reported at similar rates in\\r\\nCampral-treated and placebotreated patients. Although many of these events\\r\\noccurred in the context of alcohol relapse, and the interrelationship between\\r\\nalcohol dependence, depression and suicidality is well-recognized and complex,\\r\\nno consistent pattern of relationship between the clinical course of recovery\\r\\nfrom alcoholism and the emergence of suicidality was identified.\\r\\nAlcohol-dependent patients, including those patients being treated with\\r\\nCampral, should be monitored for the development of symptoms of depression or suicidal\\r\\nthinking. Families and caregivers of patients being treated with Campral should\\r\\nbe alerted to the need to monitor patients for the emergence of symptoms of\\r\\ndepression or suicidality, and to report such symptoms to the patient's health\\r\\ncare provider.\",\n",
       " 'Use of Campral does not eliminate or diminish withdrawal\\r\\nsymptoms.',\n",
       " 'Dietary administration of acamprosate calcium for 2 years\\r\\nto Sprague-Dawley rats at doses of 25, 100 and 400 mg/kg/day (up to 3 times the\\r\\nmaximum recommended human daily (MRHD) oral dose on an AUC basis) and CD-1 mice\\r\\nat doses of 400, 1200 and 3600 mg/kg/day (up to 25 times the MRHD on an AUC basis)\\r\\nshowed no evidence of increased tumor incidence.',\n",
       " 'Acamprosate calcium was negative in all genetic toxicology studies conducted. Acamprosate calcium demonstrated no evidence of\\r\\ngenotoxicity in an bacterial reverse point mutation assay (Ames assay) or an\\r\\nmammalian cell gene mutation test using Chinese Hamster Lung V79 cells. No\\r\\nclastogenicity was observed in an chromosomal aberration assay in human\\r\\nlymphocytes and no chromosomal damage detected in an mouse micronucleus assay. in\\r\\nvitro in vitro in vitro in vivo',\n",
       " 'Acamprosate calcium had no effect on fertility after\\r\\ntreatment for 70 days prior to mating in male rats and for 14 days prior to\\r\\nmating, throughout mating, gestation and lactation in female rats at doses up\\r\\nto 1000 mg/kg/day (approximately 4 times the MRHD oral dose on a mg/m² basis).\\r\\nIn mice, acamprosate calcium administered orally for 60 days prior to mating\\r\\nand throughout gestation in females at doses up to 2400 mg/kg/day\\r\\n(approximately 5 times the MRHD oral dose on a mg/m² basis) had no effect on fertility.',\n",
       " 'Pregnancy Category C.',\n",
       " 'Acamprosate calcium has been shown to be teratogenic in\\r\\nrats when given in doses that are approximately equal to the human dose (on a\\r\\nmg/m² basis) and in rabbits when given in doses that are approximately 3 times\\r\\nthe human dose (on a mg/m² basis). Acamprosate calcium produced a dose-related increase\\r\\nin the number of fetuses with malformations in rats at oral doses of 300\\r\\nmg/kg/day or greater (approximately equal to the maximum recommended human\\r\\ndaily (MRHD) oral dose on a mg/m² basis). The malformations included hydronephrosis , malformed iris , retinal dysplasia , and retroesophageal subclavian artery. No findings were observed at an oral dose of 50 mg/kg/day\\r\\n(approximately one-fifth the MRHD oral dose on a mg/m² basis). An increased incidence\\r\\nof hydronephrosis was also noted in Burgundy Tawny rabbits at oral doses of 400\\r\\nmg/kg/day or greater (approximately 3 times the MRHD oral dose on a mg/m²\\r\\nbasis). No developmental effects were observed in New Zealand white rabbits at oral\\r\\ndoses up to 1000 mg/kg/day (approximately 8 times the MRHD oral dose on a mg/m²\\r\\nbasis). The findings in animals should be considered in relation to known\\r\\nadverse developmental effects of ethyl alcohol, which include the\\r\\ncharacteristics of fetal alcohol syndrome (craniofacial dysmorphism, intrauterine and postnatal growth retardation, retarded psychomotor and intellectual\\r\\ndevelopment) and milder forms of neurological and behavioral disorders in\\r\\nhumans. There are no adequate and well controlled studies in pregnant women.\\r\\nCampral should be used during pregnancy only if the potential benefit justifies\\r\\nthe potential risk to the fetus.',\n",
       " 'A study conducted in pregnant mice that were administered\\r\\nacamprosate calcium by the oral route starting on Day 15 of gestation through\\r\\nthe end of lactation on postnatal day 28 demonstrated an increased incidence of\\r\\nstill-born fetuses at doses of 960 mg/kg/day or greater (approximately 2 times the\\r\\nMRHD oral dose on a mg/m² basis). No effects were observed at a dose of 320 mg/kg/day\\r\\n(approximately one-half the MRHD dose on a mg/m² basis).',\n",
       " 'The potential for Campral to affect the duration of labor\\r\\nand delivery is unknown.',\n",
       " 'In animal studies, acamprosate was excreted in the milk\\r\\nof lactating rats dosed orally with acamprosate calcium. The concentration of\\r\\nacamprosate in milk compared to blood was 1.3:1. It is not known whether acamprosate\\r\\nis excreted in human milk. Because many drugs are excreted in human milk, caution\\r\\nshould be exercised when Campral is administered to a nursing woman.',\n",
       " 'The safety and efficacy of Campral have not been\\r\\nestablished in the pediatric population.',\n",
       " 'Forty-one of the 4234 patients in double-blind, placebo-controlled,\\r\\nclinical trials of Campral were 65 years of age or older, while none were 75\\r\\nyears of age or over. There were too few patients in the  ≥ 65 age group to\\r\\nevaluate any differences in safety or effectiveness for geriatric patients\\r\\ncompared to younger patients.',\n",
       " 'This drug is known to be substantially excreted by the\\r\\nkidney, and the risk of toxic reactions to this drug may be greater in patients\\r\\nwith impaired renal function. Because elderly patients are more likely to have decreased\\r\\nrenal function, care should be taken in dose selection, and it may be useful to\\r\\nmonitor renal function. [see CLINICAL PHARMACOLOGY , ADVERSE REACTIONS ,\\r\\nand DOSAGE AND ADMINISTRATION ]',\n",
       " 'Campral is contraindicated in patients with severe renal\\r\\nimpairment (creatinine clearance of  ≤ 30 mL/min).[See DOSAGE AND\\r\\nADMINISTRATION , CONTRAINDICATIONS , and CLINICAL PHARMACOLOGY ]',\n",
       " 'Included as part of the PRECAUTIONS section.',\n",
       " 'Systemic absorption of clindamycin has been demonstrated following topical use of clindamycin. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin. When significant diarrhea occurs, ACANYA Gel should be discontinued.',\n",
       " 'Severe colitis has occurred following oral and parenteral administration of clindamycin with an onset of up to several weeks following cessation of therapy. Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen severe colitis. Severe colitis may result in death.',\n",
       " 'Studies indicate toxin(s) produced by Clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Stool cultures for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically.',\n",
       " 'Minimize sun exposure including use of tanning beds or sun lamps following drug application.',\n",
       " 'Concomitant topical acne therapy should be used with caution since a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating, or abrasive agents. If irritancy or dermatitis occurs, reduce frequency of application or temporarily interrupt treatment and resume once the irritation subsides. Treatment should be discontinued if the irritation persists.',\n",
       " 'Advise the patient to read the FDA-approved patient labeling (Patient Information).',\n",
       " 'Carcinogenicity, mutagenicity, and impairment of fertility testing of ACANYA Gel have not been performed.',\n",
       " 'Benzoyl peroxide has been shown to be a tumor promoter and progression agent in a number of animal studies. Benzoyl peroxide in acetone at doses of 5 and 10 mg administered topically twice per week for 20 weeks induced skin tumors in transgenic Tg.AC mice. The clinical significance of this is unknown.',\n",
       " 'Carcinogenicity studies have been conducted with a gel formulation containing 1% clindamycin and 5% benzoyl peroxide. In a 2-year dermal carcinogenicity study in mice, treatment with the gel formulation at doses of 900, 2700, and 15000 mg/kg/day (1.8, 5.4, and 30 times the MRHD for clindamycin and 3.6, 10.8, and 60 times the MRHD for benzoyl peroxide, respectively, based on BSA comparisons) did not cause any increase in tumors. However, topical treatment with a different gel formulation containing 1% clindamycin and 5% benzoyl peroxide at doses of 100, 500, and 2000 mg/kg/day caused a dose-dependent increase in the incidence of keratoacanthoma at the treated skin site of male rats in a 2-year dermal carcinogenicity study in rats. In an oral (gavage) carcinogenicity study in rats, treatment with the gel formulation at doses of 300, 900, and 3000 mg/kg/day (1.2, 3.6, and 12 times the MRHD for clindamycin and 2.4, 7.2, and 24 times the MRHD for benzoyl peroxide, respectively, based on BSA comparisons) for up to 97 weeks did not cause any increase in tumors.',\n",
       " 'Clindamycin phosphate was not genotoxic in the human lymphocyte chromosome aberration assay. Benzoyl peroxide has been found to cause DNA strand breaks in a variety of mammalian cell types, to be mutagenic in S. typhimurium tests by some but not all investigators, and to cause sister chromatid exchanges in Chinese hamster ovary cells.',\n",
       " 'Fertility studies have not been performed with ACANYA Gel or benzoyl peroxide, but fertility and mating ability have been studied with clindamycin. Fertility studies in rats treated orally with up to 300 mg/kg/day of clindamycin (approximately 120 times the MRHD for clindamycin, based on BSA comparisons) revealed no effects on fertility or mating ability.',\n",
       " 'There are no available data on ACANYA Gel use in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. The limited published data on use of clindamycin in pregnant women with exposure during the first trimester are insufficient to inform a drug-associated risk of pregnancy-related adverse outcomes (see Data ). In limited published clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters has not been associated with an increased frequency of major birth defects.',\n",
       " 'In animal reproduction studies, clindamycin did not cause malformations or embryo-fetal development toxicity in pregnant rats and mice when administered during the period of organogenesis at systemic doses up to 240 times the maximum recommended human dose (MRHD) of 2.5 g ACANYA Gel, based on body surface area (BSA) comparisons (see Data ).',\n",
       " 'The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of major birth defects, loss, and other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 24% and 15-20%, respectively.',\n",
       " 'Human Data',\n",
       " 'In limited published trials in pregnant women administered clindamycin during the first trimester of pregnancy, there was no difference in the rate of major birth defects reported among in utero exposed infants compared to unexposed infants. These data cannot definitely establish or exclude any clindamycin-associated risk during pregnancy.',\n",
       " 'Animal Data',\n",
       " 'Animal reproductive/developmental toxicity studies have not been conducted with ACANYA Gel or benzoyl peroxide. Developmental toxicity studies of clindamycin performed in pregnant rats and mice administered during the period of organogenesis at oral doses of up to 600 mg/kg/day (240 and 120 times the MRHD for, respectively, based on BSA comparisons) or subcutaneous doses of up to 200 mg/kg/day (80 and 40 times the MRHD for clindamycin, respectively, based on BSA comparisons) revealed no malformations or embryo-fetal development toxicity.',\n",
       " 'There are no data on the presence of clindamycin or benzoyl peroxide in human milk, the effects on the breastfed child, or the effects on milk production following topical administration. However, clindamycin has been reported to be present in breast milk in small amounts following oral and parenteral administration. The developmental and health benefits of breastfeeding should be considered along with the motherâ€™s clinical need for ACANYA Gel and any potential adverse effects on the breastfed child from ACANYA Gel or from the underlying maternal condition.',\n",
       " 'If used during lactation and ACANYA Gel is applied to the chest, care should be taken to avoid accidental ingestion by the infant.',\n",
       " 'Safety and effectiveness of ACANYA Gel in pediatric patients under the age of 12 have not been evaluated.',\n",
       " 'Clinical trials of ACANYA Gel did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects.',\n",
       " 'Certain drugs tend to produce hyperglycemia and may lead to\\r\\nloss of blood glucose control. These drugs include the thiazides and other\\r\\ndiuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral\\r\\ncontraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium\\r\\nchannel-blocking drugs, and isoniazid. When such drugs are administered to a\\r\\npatient receiving PRECOSE, the patient should be closely observed for loss of\\r\\nblood glucose control. When such drugs are withdrawn from patients receiving\\r\\nPRECOSE in combination with sulfonylureas or insulin, patients should be\\r\\nobserved closely for any evidence of hypoglycemia .',\n",
       " 'Patients Receiving Sulfonylureas or Insulin: Sulfonylurea agents or insulin may cause hypoglycemia. PRECOSE given in combination with a\\r\\nsulfonylurea or insulin may cause a further lowering of blood glucose and may\\r\\nincrease the potential for hypoglycemia. If hypoglycemia occurs, appropriate\\r\\nadjustments in the dosage of these agents should be made. Very rarely,\\r\\nindividual cases of hypoglycemic shock have been reported in patients receiving\\r\\nPRECOSE therapy in combination with sulfonylureas and/or insulin.',\n",
       " 'Intestinal adsorbents (for example, charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (for example,\\r\\namylase, pancreatin) may reduce the effect of PRECOSE and should not be taken\\r\\nconcomitantly.',\n",
       " 'PRECOSE has been shown to change the bioavailability of\\r\\ndigoxin when they are coadministered, which may require digoxin dose\\r\\nadjustment. (See CLINICAL PHARMACOLOGY , Drug-Drug Interactions .)',\n",
       " 'In a drug interaction study in 16 healthy male\\r\\nvolunteers, coadministration of multiple doses of zafirlukast (160 mg/day) to\\r\\nsteady-state with a single 25 mg dose of warfarin resulted in a significant\\r\\nincrease in the mean AUC (+ 63%) and half-life (+36%) of S-warfarin. The mean prothrombin time (PT) increased by approximately 35%. This interaction is\\r\\nprobably due to an inhibition by zafirlukast of the cytochrome P450 2C9\\r\\nisoenzyme system. Patients on oral warfarin anticoagulant therapy and ACCOLATE\\r\\nshould have their prothrombin times monitored closely and anticoagulant dose\\r\\nadjusted accordingly (see WARNINGS , Concomitant Warfarin\\r\\nAdministration ). No formal drug-drug interaction studies with ACCOLATE and\\r\\nother drugs known to be metabolized by the cytochrome P450 2C9 isoenzyme (eg, tolbutamide,\\r\\nphenytoin, carbamazepine) have been conducted; however, care should be\\r\\nexercised when ACCOLATE is coadministered with these drugs.',\n",
       " 'In a drug interaction study in 11 asthmatic patients,\\r\\ncoadministration of a single dose of zafirlukast (40 mg) with erythromycin (500\\r\\nmg three times daily for 5 days) to steady-state resulted in decreased mean plasma\\r\\nlevels of zafirlukast by approximately 40% due to a decrease in zafirlukast\\r\\nbioavailability.',\n",
       " 'Coadministration of zafirlukast (20 mg/day) or placebo at\\r\\nsteady-state with a single dose of sustained release theophylline preparation\\r\\n(16 mg/kg) in 16 healthy boys and girls (6 through 11 years of age) resulted in\\r\\nno significant differences in the pharmacokinetic parameters of theophylline.',\n",
       " 'Coadministration of zafirlukast (80 mg/day) at\\r\\nsteady-state with a single dose of a liquid theophylline preparation (6 mg/kg)\\r\\nin 13 asthmatic patients, 18 to 44 years of age, resulted in decreased mean\\r\\nplasma levels of zafirlukast by approximately 30%, but no effect on plasma\\r\\ntheophylline levels was observed.',\n",
       " 'Rare cases of patients experiencing increased\\r\\ntheophylline levels with or without clinical signs or symptoms of theophylline\\r\\ntoxicity after the addition of ACCOLATE to an existing theophylline regimen have\\r\\nbeen reported. The mechanism of the interaction between ACCOLATE and\\r\\ntheophylline in these patients is unknown (see ADVERSE REACTIONS ).',\n",
       " 'Coadministration of zafirlukast (40 mg/day) with aspirin\\r\\n(650 mg four times daily) resulted in mean increased plasma levels of\\r\\nzafirlukast by approximately 45%.',\n",
       " 'In a single-blind, parallel-group, 3-week study in 39\\r\\nhealthy female subjects taking oral contraceptives, 40 mg twice daily of\\r\\nzafirlukast had no significant effect on ethinyl estradiol plasma\\r\\nconcentrations or contraceptive efficacy.',\n",
       " 'Coadministration of zafirlukast with fluconazole, a\\r\\nmoderate CYP2C9 inhibitor, resulted in increased plasma levels of zafirlukast,\\r\\nby approximately 58% (90% CI:28, 95). The clinical significance of this interaction\\r\\nis unknown. Zafirlukast exposure is likely to be increased by other moderate\\r\\nand strong CYP2C9 inhibitors. Coadministration of zafirlukast with\\r\\nitraconazole, a strong CYP3A4 inhibitor, caused no change in plasma levels of\\r\\nzafirlukast.',\n",
       " 'No other formal drug-drug interaction studies between\\r\\nACCOLATE and marketed drugs known to be metabolized by the P450 3A4 (CYP3A4)\\r\\nisoenzyme (eg, dihydropyridine calcium-channel blockers, cyclosporin, cisapride)\\r\\nhave been conducted. As ACCOLATE is known to be an inhibitor of CYP3A4 in vitro ,\\r\\nit is reasonable to employ appropriate clinical monitoring when these drugs are\\r\\ncoadministered with ACCOLATE.',\n",
       " 'Somatropin inhibits 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1) in adipose /hepatic tissue and may significantly impact the metabolism of cortisol and cortisone . As a consequence, in patients treated with somatropin, previously undiagnosed central (secondary) hypoadrenalism may be unmasked requiring glucocorticoid replacement therapy. In addition, patients treated with glucocorticoid replacement therapy for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses; this may be especially true for patients treated with cortisone acetate and prednisone since conversion of these drugs to their biologically active metabolites is dependent on the activity of the 11βHSD-1 enzyme.',\n",
       " 'Excessive glucocorticoid therapy may attenuate the growth promoting effects of somatropin in children. Therefore, glucocorticoid replacement therapy should be carefully adjusted in children with concomitant GH and glucocorticoid deficiency to avoid both hypoadrenalism and an inhibitory effect on growth.',\n",
       " 'Limited published data indicate that somatropin treatment increases cytochrome P450 (CP450) mediated antipyrine clearance in man. These data suggest that somatropin administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporine). Careful monitoring is advisable when somatropin is administered in combination with other drugs known to be metabolized by CP450 liver enzymes. However, formal drug interaction studies have not been conducted.',\n",
       " 'In patients with diabetes mellitus requiring drug therapy, the dose of insulin \\r\\n  and/or oral agent may require adjustment when somatropin therapy is initiated \\r\\n  (see PRECAUTIONS , General ).',\n",
       " 'There are no empirical data on avoiding drug interactions between ACCRUFER and concomitant oral medications. Concomitant use of some drugs may reduce the bioavailability of iron after administration of ACCRUFER. Separate the administration of ACCRUFER from these drugs. The duration of separation may depend on the absorption characteristics of the medication concomitantly administered, such as time to peak concentration or whether the drug is an immediate or extended release product. Monitor clinical response to ACCRUFER.',\n",
       " 'Concomitant use of iron products with dimercaprol may increase the risk of nephrotoxicity. Avoid concomitant use of ACCRUFER with dimercaprol.',\n",
       " 'Concomitant use of ACCRUFER may decrease the bioavailability of some drugs, including mycophenolate, ethynyl estradiol, ciprofloxacin and doxycycline [see CLINICAL PHARMACOLOGY ]. For oral drugs where reductions in bioavailability may cause clinically significant effects on its safety or efficacy, separate the administration of ACCRUFER by at least 4 hours. Monitor clinical responses to concomitant drugs as appropriate.',\n",
       " 'Other short-acting sympathomimetic aerosol bronchodilators or epinephrine should\\r\\n  not be used concomitantly with AccuNeb (albuterol sulfate inhalation solution) .',\n",
       " 'AccuNeb (albuterol sulfate inhalation solution)  should be administered with extreme caution to patients being treated\\r\\n  with monoamine oxidase inhibitors or tricyclic antidepressants or within 2 weeks\\r\\n  of discontinuation of such agents, since the action of albuterol on the vascular \\r\\n  system may be potentiated.',\n",
       " 'Beta-receptor blocking agents not only block the pulmonary effect of beta-agonists,\\r\\n  such as AccuNeb (albuterol sulfate inhalation solution) , but may produce severe bronchospasm in asthmatic patients.\\r\\n  Therefore, patients with asthma should not normally be treated with beta-blockers.\\r\\n  However, under certain circumstances (e.g., prophylaxis after myocardial infarction ),\\r\\n  there may be no acceptable alternatives to the use of beta-adrenergic blocking\\r\\n  agents in patients with asthma. In this setting, cardioselective beta-blockers\\r\\n  should be considered, although they should be administered with caution.',\n",
       " 'The ECG changes and/or hypokalemia that may result from the administration\\r\\n  of non-potassium sparing diuretics (such as loop or thiazide diuretics) can\\r\\n  be acutely worsened by beta-agonists, especially when the dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown,\\r\\n  caution is advised in the coadministration of beta-agonists with non-potassium\\r\\n  sparing diuretics.',\n",
       " 'Mean decreases of 16% to 22% in serum digoxin levels were demonstrated after\\r\\n  single dose intravenous and oral administration of albuterol, respectively,\\r\\n  to normal volunteers who had received digoxin for 10 days. The clinical significance\\r\\n  of these findings for patients with obstructive airway disease who are receiving\\r\\n  albuterol and digoxin on a chronic basis is unclear. Nevertheless, it would\\r\\n  be prudent to carefully evaluate the serum digoxin levels in patients who are\\r\\n  currently receiving digoxin and albuterol.',\n",
       " 'ACCUPRIL has been evaluated for safety in 4960 subjects and patients. Of these, 3203 patients, including 655 elderly patients, participated in controlled clinical trials. ACCUPRIL has been evaluated for long-term safety in over 1400 patients treated for 1 year or more.',\n",
       " 'Adverse experiences were usually mild and transient.',\n",
       " 'In placebo-controlled trials, discontinuation of therapy because of adverse events was required in 4.7% of patients with hypertension .',\n",
       " 'Adverse experiences probably or possibly related to therapy or of unknown relationship to therapy occurring in 1% or more of the 1563 patients in placebo-controlled hypertension trials who were treated with ACCUPRIL are shown below.',\n",
       " 'Adverse Events in Placebo-Controlled Trials',\n",
       " 'ACCUPRIL has been evaluated for safety in 1222 ACCUPRIL treated patients. Of these, 632 patients participated in controlled clinical trials. In placebo-controlled trials, discontinuation of therapy because of adverse events was required in 6.8% of patients with congestive heart failure .',\n",
       " 'Adverse experiences probably or possibly related or of unknown relationship to therapy occurring in 1% or more of the 585 patients in placebo-controlled congestive heart failure trials who were treated with ACCUPRIL are shown below.',\n",
       " '',\n",
       " 'See PRECAUTIONS , Cough.',\n",
       " 'Clinical adverse experiences probably, possibly, or definitely related, or of uncertain relationship to therapy occurring in 0.5% to 1.0% (except as noted) of the patients with CHF or hypertension treated with ACCUPRIL (with or without concomitant diuretic ) in controlled or uncontrolled trials (N=4847) and less frequent, clinically significant events seen in clinical trials or post-marketing experience (the rarer events are in italics) include (listed by body system):',\n",
       " 'General: back pain , malaise , viral infections, anaphylactoid reaction',\n",
       " 'Cardiovascular: palpitation, vasodilation , tachycardia , heart failure, hyperkalemia, myocardial infarction, cerebrovascular accident, hypertensive crisis, angina pectoris, orthostatic hypotension, cardiac rhythm disturbances, cardiogenic shock',\n",
       " 'Hematology: hemolytic anemia',\n",
       " 'Gastrointestinal: flatulence , dry mouth or throat, constipation, gastrointestinal hemorrhage, pancreatitis, abnormal liver function tests, dyspepsia',\n",
       " 'Metabolism and Nutrition Disorders : hyponatremia',\n",
       " 'Nervous/Psychiatric: somnolence , vertigo , syncope , nervousness, depression, insomnia, paresthesia',\n",
       " 'Integumentary: alopecia , increased sweating, pemphigus , pruritus , exfoliative dermatitis, photosensitivity reaction, dermatopolymyositis',\n",
       " 'Urogenital: urinary tract infection , impotence , acute renal failure, worsening renal failure',\n",
       " 'Respiratory: eosinophilic pneumonitis',\n",
       " 'Other: amblyopia , edema, arthralgia , pharyngitis , agranulocytosis, hepatitis, thrombocytopenia',\n",
       " 'Angioedema has been reported in patients receiving ACCUPRIL (0.1%). Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis , and/or larynx occurs, treatment with ACCUPRIL should be discontinued and appropriate therapy instituted immediately. (see WARNINGS .)',\n",
       " 'Hematology : (See WARNINGS )',\n",
       " 'Hyperkalemia : (See PRECAUTIONS )',\n",
       " 'Creatinine and Blood Urea Nitrogen',\n",
       " 'Increases (>1.25 times the upper limit of normal) in serum creatinine and blood urea nitrogen were observed in 2% and 2%, respectively, of all patients treated with ACCUPRIL alone. Increases are more likely to occur in patients receiving concomitant diuretic therapy than in those on ACCUPRIL alone. These increases often remit on continued therapy. In controlled studies of heart failure, increases in blood urea nitrogen and serum creatinine were observed in 11% and 8%, respectively, of patients treated with ACCUPRIL; most often these patients were receiving diuretics with or without digitalis.',\n",
       " 'ACCURETIC has been evaluated for safety in 1571 patients\\r\\nin controlled and uncontrolled studies. Of these, 498 were given quinapril plus\\r\\nhydrochlorothiazide for at least 1 year, with 153 patients extending\\r\\ncombination therapy for over 2 years. In clinical trials with ACCURETIC, no\\r\\nadverse experience specific to the combination has been observed. Adverse\\r\\nexperiences that have occurred have been limited to those that have been\\r\\npreviously reported with quinapril or hydrochlorothiazide.',\n",
       " 'Adverse experiences were usually mild and transient, and\\r\\nthere was no relationship between side effects and age, sex, race, or duration\\r\\nof therapy. Discontinuation of therapy because of adverse effects was required\\r\\nin 2.1% in patients in controlled studies. The most common reasons for\\r\\ndiscontinuation of therapy with ACCURETIC were cough (1.0%; see PRECAUTIONS )\\r\\nand headache (0.7%).',\n",
       " 'Adverse experiences probably or possibly related to\\r\\ntherapy or of unknown relationship to therapy occurring in 1% or more of the\\r\\n943 patients treated with quinapril plus hydrochlorothiazide in controlled\\r\\ntrials are shown below.',\n",
       " '',\n",
       " 'Clinical adverse experiences probably, possibly, or\\r\\ndefinitely related or of uncertain relationship to therapy occurring in  ≥ 0.5%\\r\\nto  < 1.0% (except as noted) of the patients treated with quinapril/HCTZ in\\r\\ncontrolled and uncontrolled trials (N=1571) and less frequent, clinically\\r\\nsignificant events seen in clinical trials or postmarketing experience (the\\r\\nrarer events are in italics) include (listed by body system):',\n",
       " 'BODY AS A WHOLE: Asthenia , Malaise',\n",
       " 'CARDIOVASCULAR: Palpitation, Tachycardia , Heart\\r\\nFailure, Hyperkalemia, Myocardial Infarction, Cerebrovascular Accident,\\r\\nHypertensive Crisis, Angina Pectoris, Orthostatic Hypotension, Cardiac Rhythm\\r\\nDisturbance',\n",
       " 'GASTROINTESTINAL: Mouth or Throat Dry, Gastrointestinal\\r\\nHemorrhage, Pancreatitis, Abnormal Liver Function Tests',\n",
       " 'NERVOUS/PSYCHIATRIC: Nervousness, Vertigo , Paresthesia',\n",
       " 'RESPIRATORY: Sinusitis , Dyspnea',\n",
       " 'INTEGUMENTARY: Pruritus , Sweating Increased, Erythema\\r\\nMultiforme, Exfoliative Dermatitis, Photosensitivity Reaction, Alopecia,\\r\\nPemphigus',\n",
       " 'UROGENITAL SYSTEM: Acute Renal Failure,\\r\\nImpotence',\n",
       " 'OTHER: Agranulocytosis, Thrombocytopenia,\\r\\nArthralgia',\n",
       " 'Angioedema: Angioedema has been reported in 0.1%\\r\\nof patients receiving quinapril (0.1%) (see WARNINGS ).',\n",
       " 'The following serious nonfatal\\r\\nadverse events, regardless of their relationship to quinapril and HCTZ\\r\\ncombination tablets, have been reported during extensive postmarketing\\r\\nexperience:',\n",
       " 'BODY AS A WHOLE: Shock , accidental injury, neoplasm , cellulitis , ascites ,\\r\\ngeneralized edema, hernia and anaphylactoid reaction.',\n",
       " 'CARDIOVASCULAR SYSTEM: Bradycardia , cor pulmonale , vasculitis , and deep thrombosis .',\n",
       " 'DIGESTIVE SYSTEM: Gastrointestinal carcinoma ,\\r\\ncholestatic jaundice , hepatitis , esophagitis , vomiting, and diarrhea.',\n",
       " 'EYE DISORDERS: Acute myopia and acute angle\\r\\nclosure glaucoma (see WARNINGS ).',\n",
       " 'HEMIC SYSTEM : Anemia .',\n",
       " 'METABOLIC AND NUTRITIONAL DISORDERS: Weight loss.',\n",
       " 'MUSCULOSKELETAL SYSTEM: Myopathy , myositis , and arthritis .',\n",
       " 'NERVOUS SYSTEM: Paralysis , hemiplegia , speech\\r\\ndisorder, abnormal gait , meningism, and amnesia .',\n",
       " 'RESPIRATORY SYSTEM: Pneumonia , asthma , respiratory\\r\\ninfiltration, and lung disorder.',\n",
       " 'SKIN AND APPENDAGES: Urticaria , macropapular rash,\\r\\nand petechiases.',\n",
       " 'SPECIAL SENSES: Abnormal vision.',\n",
       " 'UROGENITAL SYSTEM: Kidney function abnormal, albuminuria , pyuria , hematuria , and nephrosis .',\n",
       " 'Quinapril monotherapy has been evaluated for safety in\\r\\n4960 patients. In clinical trials adverse events which occurred with quinapril\\r\\nwere also seen with ACCURETIC. In addition, the following were reported for\\r\\nquinapril at an incidence  > 0.5%: depression, back pain , constipation, syncope , and amblyopia .',\n",
       " 'Hydrochlorothiazide has been extensively prescribed for\\r\\nmany years, but there has not been enough systematic collection of data to\\r\\nsupport an estimate of the frequency of the observed adverse reactions. Within\\r\\norgan-system groups, the reported reactions are listed here in decreasing order\\r\\nof severity, without regard to frequency.',\n",
       " 'BODY AS A WHOLE: Weakness.',\n",
       " 'CARDIOVASCULAR: Orthostatic hypotension (may be potentiated by alcohol,\\r\\nbarbiturates, or narcotics).',\n",
       " 'DIGESTIVE: Pancreatitis , jaundice ( intrahepatic cholestatic), sialadenitis,\\r\\nvomiting, diarrhea, cramping, nausea, gastric irritation, constipation, and anorexia .',\n",
       " 'NEUROLOGIC: Vertigo, lightheadedness , transient blurred vision, headache, paresthesia , xanthopsia , weakness, and restlessness.',\n",
       " 'MUSCULOSKELETAL: Muscle spasm .',\n",
       " 'HEMATOLOGIC: Aplastic anemia , agranulocytosis , leukopenia , thrombocytopenia ,\\r\\nand hemolytic anemia .',\n",
       " 'RENAL: Renal\\r\\nfailure, renal dysfunction, interstitial nephritis (see WARNINGS ).',\n",
       " 'METABOLIC: Hyperglycemia , glycosuria, and hyperuricemia .',\n",
       " 'HYPERSENSITIVITY: Necrotizing angiitis , Stevens-Johnson syndrome , respiratory\\r\\ndistress (including pneumonitis and pulmonary edema ), purpura , urticaria, rash,\\r\\nand photosensitivity .',\n",
       " 'See PRECAUTIONS .',\n",
       " 'Increases ( > 1.25 times the\\r\\nupper limit of normal) in serum creatinine and blood urea nitrogen were\\r\\nobserved in 3% and 4%, respectively, of patients treated with ACCURETIC. Most\\r\\nincreases were minor and reversible, which can occur in patients with essential hypertension but most frequently in patients with renal artery stenosis (see PRECAUTIONS ).',\n",
       " 'See PRECAUTIONS .',\n",
       " 'See WARNINGS .',\n",
       " 'Other clinically important\\r\\nchanges in standard laboratory tests were rarely associated with ACCURETIC\\r\\nadministration. Elevations in uric acid , glucose, magnesium, cholesterol , triglyceride, and calcium (see PRECAUTIONS ) have been\\r\\nreported.',\n",
       " 'The adverse reactions listed below reflect the experience from investigational\\r\\n  studies of Accutane (isotretinoin) , and the postmarketing experience. The relationship of some\\r\\n  of these events to Accutane (isotretinoin)  therapy is unknown. Many of the side effects and\\r\\n  adverse reactions seen in patients receiving Accutane (isotretinoin)  are similar to those described\\r\\n  in patients taking very high doses of vitamin A (dryness of the skin and mucous \\r\\n  membranes, eg, of the lips, nasal passage, and eyes).',\n",
       " 'Cheilitis and hypertriglyceridemia are usually dose related. Most adverse reactions \\r\\n  reported in clinical trials were reversible when therapy was discontinued; however, \\r\\n  some persisted after cessation of therapy (see WARNINGS and ADVERSE REACTIONS ).',\n",
       " 'allergic reactions, including vasculitis, systemic hypersensitivity (see PRECAUTIONS : \\r\\n  Hypersensitivity ), edema , fatigue, lymphadenopathy , weight loss',\n",
       " 'palpitation, tachycardia , vascular thrombotic disease, stroke',\n",
       " 'hypertriglyceridemia (see WARNINGS : Lipids ), \\r\\n  alterations in blood sugar levels (see PRECAUTIONS : \\r\\n  Laboratory Tests )',\n",
       " 'inflammatory bowel disease (see WARNINGS : Inflammatory \\r\\n  Bowel Disease ), hepatitis (see WARNINGS : \\r\\n  Hepatotoxicity ), pancreatitis (see WARNINGS : \\r\\n  Lipids ), bleeding and inflammation of the gums, colitis, esophagitis/esophageal ulceration, ileitis, nausea , other nonspecific gastrointestinal symptoms',\n",
       " 'allergic reactions (see PRECAUTIONS : Hypersensitivity ), anemia , thrombocytopenia , neutropenia , rare reports of agranulocytosis (see PATIENT INFORMATION ). See PRECAUTIONS : \\r\\n  Laboratory Tests for other hematological parameters.',\n",
       " 'skeletal hyperostosis , calcification of tendons and ligaments, premature epiphyseal \\r\\n  closure, decreases in bone mineral density (see WARNINGS : \\r\\n  Skeletal ), musculoskeletal symptoms (sometimes severe) including back pain, myalgia , and arthralgia (see PATIENT INFORMATION ), \\r\\n  transient pain in the chest (see PATIENT INFORMATION ), arthritis, tendonitis, other types of bone abnormalities, elevations \\r\\n  of CPK/rare reports of rhabdomyolysis (see PRECAUTIONS : \\r\\n  Laboratory Tests ).',\n",
       " 'pseudotumor cerebri (see WARNINGS : Pseudotumor \\r\\n  Cerebri ), dizziness, drowsiness, headache, insomnia , lethargy , malaise , \\r\\n  nervousness, paresthesias, seizures, stroke, syncope , weakness',\n",
       " 'suicidal ideation, suicide attempts, suicide, depression , psychosis , aggression, \\r\\n  violent behaviors (see WARNINGS : Psychiatric \\r\\n  Disorders ), emotional instability',\n",
       " 'Of the patients reporting depression, some reported that the depression subsided\\r\\n  with discontinuation of therapy and recurred with reinstitution of therapy.',\n",
       " 'abnormal menses',\n",
       " 'bronchospasms (with or without a history of asthma), respiratory infection,\\r\\n  voice alteration',\n",
       " \"acne fulminans, alopecia (which in some cases persists), bruising, cheilitis \\r\\n  (dry lips), dry mouth , dry nose, dry skin , epistaxis , eruptive xanthomas, 7 erythema multiforme , flushing, fragility of skin, hair abnormalities, hirsutism , \\r\\n  hyperpigmentation and hypopigmentation, infections (including disseminated herpes \\r\\n  simplex), nail dystrophy, paronychia , peeling of palms and soles, photoallergic/photosensitizing \\r\\n  reactions, pruritus , pyogenic granuloma, rash (including facial erythema, seborrhea , \\r\\n  and eczema), Stevens-Johnson syndrome , sunburn susceptibility increased, sweating , \\r\\n  toxic epidermal necrolysis, urticaria , vasculitis (including Wegener's granulomatosis; \\r\\n  see PRECAUTIONS : Hypersensitivity ), abnormal \\r\\n  wound healing (delayed healing or exuberant granulation tissue with crusting; \\r\\n  see PATIENT INFORMATION )\",\n",
       " 'Hearing - hearing impairment (see WARNINGS : \\r\\n  Hearing Impairment ), tinnitus .',\n",
       " 'Vision - corneal opacities (see WARNINGS : \\r\\n  Corneal Opacities ), decreased night vision which may persist (see WARNINGS : \\r\\n  Decreased Night Vision ), cataracts, color vision disorder, conjunctivitis , \\r\\n  dry eyes, eyelid inflammation, keratitis , optic neuritis, photophobia , visual \\r\\n  disturbances',\n",
       " 'glomerulonephritis (see PRECAUTIONS : Hypersensitivity ), \\r\\n  nonspecific urogenital findings (see PRECAUTIONS : \\r\\n  Laboratory Tests for other urological parameters)',\n",
       " 'Elevation of plasma triglycerides (see WARNINGS : \\r\\n  Lipids ), decrease in serum high-density lipoprotein (HDL) levels, elevations \\r\\n  of serum cholesterol during treatment',\n",
       " 'Increased alkaline phosphatase , SGOT (AST), SGPT (ALT), GGTP or LDH (see WARNINGS : \\r\\n  Hepatotoxicity )',\n",
       " 'Elevation of fasting blood sugar, elevations of CPK (see PRECAUTIONS : \\r\\n  Laboratory Tests ), hyperuricemia',\n",
       " 'Decreases in red blood cell parameters, decreases in white blood cell counts \\r\\n  (including severe neutropenia and rare reports of agranulocytosis; see PATIENT \\r\\n  INFORMATION ), elevated sedimentation rates, elevated platelet counts, \\r\\n  thrombocytopenia',\n",
       " 'White cells in the urine , proteinuria , microscopic or gross hematuria',\n",
       " 'No Information Provided.',\n",
       " 'See Dosage and Administration . Not to be used in eyes.',\n",
       " 'Catecholamine -depleting drugs, such as reserpine, may have an additive effect when given with β-blocking agents. Patients treated with Sectral plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo , syncope /presyncope, or orthostatic changes in blood pressure without compensatory tachycardia. Exaggerated hypertensive responses have been reported from the combined use ofβ-adrenergic antagonists and α-adrenergic stimulants, including those contained in proprietary cold remedies andvasoconstrictive nasal drops. Patients receiving β-blockers should be warned of this potential hazard.',\n",
       " 'Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non steroidal anti-inflammatory drugs has been reported.',\n",
       " 'No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.',\n",
       " 'Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.',\n",
       " 'There are no human data available on the consequences of CLANZA CR overdosage. If overdosage is observed, therapeutic measures should be taken according to symptoms; supportive and symptomatic treatment should be given for complications such as hypotension, gastro-intestinal irritation, respiratory depression, and convulsions.',\n",
       " 'Patients with allergy to these drugs or other analogues (diclofenac). Patients with asthma. Like NSAIDS, acetylsalicylic acid and other drugs which inhibit prostagladin-synthesis may precipitate attacks of asthma, acute rhinitis or urticaria. Patients with active peptic ulcer..',\n",
       " 'Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.',\n",
       " 'The following adverse reactions are discussed elsewhere in labeling:',\n",
       " 'ACEON has been evaluated for safety in approximately 3,400 patients with hypertension in U.S. and foreign clinical trials. The data presented here are based on results from the 1,417 ACEON-treated patients who participated in the U.S. clinical trials. Over 220 of these patients were treated with ACEON ® (perindopril erbumine) for at least one year.',\n",
       " 'In placebo-controlled U.S. clinical trials, the incidence of premature discontinuation of therapy due to adverse events was 6.5% in patients treated with ACEON and 6.7% in patients treated with placebo. The most common causes were cough, headache, asthenia and dizziness.',\n",
       " 'Among 1,012 patients in placebo-controlled U.S. trials, the overall frequency of reported adverse events was similar in patients treated with ACEON and in those treated with placebo (approximately 75% in each group). The only adverse\\r\\nevents whose incidence on ACEON was at least 2% greater than on placebo were cough (12% vs. 4.5%) and back pain (5.8% vs. 3.1%).',\n",
       " 'Dizziness was not reported more frequently in the perindopril group (8.2%) than in the placebo group (8.5%), but its\\r\\nlikelihood increased with dose, suggesting a causal relationship with perindopril.',\n",
       " 'Perindopril has been evaluated for safety in EUROPA, a double-blind, placebo-controlled study in 12,218 patients with stable coronary artery disease . The overall rate of discontinuation was about 22% on drug and placebo. The most common medical reasons for discontinuation that were more frequent on perindopril than placebo were cough, drug intolerance and hypotension.',\n",
       " 'Voluntary reports of adverse events in patients taking ACEON that have been received since market introduction and are of unknown causal relationship to ACEON include: cardiac arrest, eosinophilic pneumonitis, neutropenia/agranulocytosis, pancytopenia , anemia (including hemolytic and aplastic), thrombocytopenia , acute renal failure , nephritis , hepatic failure, jaundice (hepatocellular or cholestatic), symptomatic hyponatremia , bullous pemphigoid , pemphigus , acute pancreatitis , falls, psoriasis , exfoliative dermatitis and a syndrome which may include: arthralgia / arthritis , vasculitis , serositis , myalgia , fever, rash or other dermatologic manifestations, a positive antinuclear antibody ( ANA ), leukocytosis , eosinophilia or an elevated erythrocyte sedimentation rate ( ESR ).',\n",
       " 'Small decreases in hemoglobin and hematocrit occur frequently in hypertensive patients treated with ACEON, but are rarely of clinical importance. In controlled clinical trials, no patient was discontinued from therapy due to the development of anemia. Leukopenia (including neutropenia) was observed in 0.1% of patients in U.S. clinical trials [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Elevations in ALT (1.6% ACEON versus 0.9% placebo) and AST (0.5% ACEON versus 0.4% placebo) have been observed in placebo-controlled clinical trials. The elevations were generally mild and transient and resolved after discontinuation of therapy.',\n",
       " 'For rectal use only',\n",
       " 'Liver Warning : This product contains acetaminophen. Severe liver damage may occur if',\n",
       " 'Allergy alert : acetaminophen may cause severe skin reactions. Symptoms may include:',\n",
       " 'If a skin reaction occurs, stop use and seek medical help right away.',\n",
       " 'Do not use',\n",
       " 'Ask a doctor before use if',\n",
       " 'Stop use and ask a doctor if',\n",
       " 'These may be signs of a serious condition.',\n",
       " 'If pregnant or breast-feeding , ask a health professional before use.',\n",
       " 'Keep out of reach of children. If swallowed or in case of overdose, get medical help or contact a\\r\\n  Poison Control Center right away. Quick medical attention is critical in case of overdose for adults and for children even if you do not notice any signs or symptoms If swallowed, get medical help or contact a poison control center right away.',\n",
       " 'See WARNINGS above.',\n",
       " 'Included as part of the \"PRECAUTIONS\" Section',\n",
       " 'Serious acute hypersensitivity reactions during acetylcysteine administration including rash, hypotension , wheezing , and/or shortness of breath, have been observed in patients receiving intravenous acetylcysteine for acetaminophen overdose and occurred soon after initiation of the infusion [see ADVERSE REACTIONS ]. If a severe hypersensitivity reaction occurs, immediately stop the infusion of ACETADOTE and initiate appropriate treatment.',\n",
       " 'One patient with asthma developed bronchospasm and died after intravenous administration of acetylcysteine. ACETADOTE should be used with caution in patients with asthma, or where there is a history of bronchospasm. Patients with asthma should be closely monitored during initiation of ACETADOTE therapy and throughout ACETADOTE therapy.',\n",
       " 'Acute flushing and erythema of the skin may occur in patients receiving acetylcysteine intravenously. These reactions usually occur 30 to 60 minutes after initiating the infusion and often resolve spontaneously despite continued infusion of acetylcysteine. If a reaction to acetylcysteine involves more than simply flushing and erythema of the skin, it should be treated as a hypersensitivity reaction.',\n",
       " 'Management of less severe hypersensitivity reactions should be based upon the severity of the reaction and include temporary interruption of the infusion and/or administration of antihistaminic drugs. The ACETADOTE infusion may be carefully restarted after treatment of the hypersensitivity symptoms has been initiated; however, if the hypersensitivity reaction returns upon re-initiation of treatment or increases in severity, ACETADOTE should be discontinued and alternative patient management should be considered.',\n",
       " 'The total volume of ACETADOTE administered should be adjusted for patients less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as needed [see DOSAGE AND ADMINISTRATION ]. If volume is not adjusted fluid overload can occur, potentially resulting in hyponatremia , seizure and death.',\n",
       " 'Intravenous administration of ACETADOTE can cause fluid overload, potentially resulting in hyponatremia, seizure and death. To avoid fluid overload, use the recommended dilution shown in Tables 2, 3 and 4 [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'Long-term studies in animals have not been performed to evaluate the carcinogenic potential of acetylcysteine.',\n",
       " 'Acetylcysteine was not genotoxic in the Ames test or the in vivo mouse micronucleus test. It was, however, positive in the in vitro mouse lymphoma cell (L5178Y/TK +/- ) forward mutation test.',\n",
       " 'Treatment of male rats with acetylcysteine at an oral dose of 250 mg/kg/day for 15 weeks (0.1 times the recommended total human intravenous dose of 300 mg/kg based on body surface comparison) did not affect the fertility or general reproductive performance.',\n",
       " 'Limited published case reports and case series of pregnant women exposed to acetylcysteine during various trimesters are not sufficient to inform any drug associated risk. Delaying treatment of acetaminophen overdose may increase the risk of maternal or fetal morbidity and mortality [see Clinical Considerations ]. Reproduction studies in rats and rabbits following oral administration of acetylcysteine during the period of organogenesis at doses similar to the total intravenous dose (based on the body surface area) did not cause any adverse effects to the fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.',\n",
       " 'Disease-Associated Maternal and/or Embryo/Fetal Risk',\n",
       " 'Acetaminophen and acetylcysteine cross the placenta. Delaying treatment in pregnant women with acetaminophen overdose and potentially toxic acetaminophen plasma levels may increase the risk of maternal and fetal morbidity and mortality.',\n",
       " 'Animal Data',\n",
       " 'Reproduction studies have been performed following administration of acetylcysteine during the period of organogenesis in rats at oral doses up to 2000 mg/kg/day (1.1 times the recommended total human intravenous dose of 300 mg/kg based on body surface area comparison) and in rabbits at oral doses up to 1000 mg/kg/day (1.1 times the recommended total human intravenous dose of 300 mg/kg based on body surface area comparison). No adverse developmental outcomes due to acetylcysteine were observed.',\n",
       " \"There are no data on the presence of acetylcysteine in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ACETADOTE and any potential adverse effects on the breastfed child from ACETADOTE or from the underlying maternal condition.\",\n",
       " 'Based on the pharmacokinetic data, acetylcysteine should be nearly completely cleared 30 hours after administration. Breastfeeding women may consider pumping and discarding their milk for 30 hours after administration.',\n",
       " 'Safety and effectiveness of ACETADOTE in pediatric patients have not been established by adequate and well-controlled studies. Use of ACETADOTE in pediatric patients 5 kg and greater is based on clinical practice [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'No information provided.',\n",
       " 'No information provided.',\n",
       " 'In the presence of head injury or other intracranial lesions, the respiratory depressant effects of codeine and other narcotics may be markedly enhanced, \\r\\n  as well as their capacity for elevating cerebrospinal fluid pressure. Narcotics \\r\\n  also produce other CNS depressant effects, such as drowsiness, that may further \\r\\n  obscure the clinical course of the patients with head injuries.',\n",
       " 'Codeine or other narcotics may obscure signs on which to judge the diagnosis \\r\\n  or clinical course of patients with acute abdominal conditions.',\n",
       " 'Codeine is habit forming and potentially abusable. Consequently, the extended \\r\\n  use of this product is not recommended.',\n",
       " 'TYLENOL® with Codeine (acetaminophen and codeine phosphate) tablets contain \\r\\n  sodium metabisulfite, a sulfite that may cause allergic-type reactions including \\r\\n  anaphylactic symptoms and life-threatening or less severe asthmatic episodes \\r\\n  in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is \\r\\n  seen more frequently in asthmatic than in nonasthmatic people.',\n",
       " 'For rectal use only',\n",
       " 'Liver Warning : This product contains acetaminophen. Severe liver damage may occur if',\n",
       " 'Allergy alert : acetaminophen may cause severe skin reactions. Symptoms may include:',\n",
       " 'If a skin reaction occurs, stop use and seek medical help right away.',\n",
       " 'Do not use',\n",
       " 'Ask a doctor before use if',\n",
       " 'Stop use and ask a doctor if',\n",
       " 'These may be signs of a serious condition.',\n",
       " 'If pregnant or breast-feeding , ask a health professional before use.',\n",
       " 'Keep out of reach of children. If swallowed or in case of overdose, get medical help or contact a\\r\\n  Poison Control Center right away. Quick medical attention is critical in case of overdose for adults and for children even if you do not notice any signs or symptoms If swallowed, get medical help or contact a poison control center right away.',\n",
       " 'See WARNINGS above.',\n",
       " 'Dihydrocodeine in TREZIX™ is metabolized by CYP2D6 to form dihydromorphine . The concomitant use of TREZIX™ and CYP2D6 inhibitors (e.g., quinidine, fluoxetine , paroxetine, fluoxetine, bupropion, quinidine) can increase the plasma concentration of dihydrocodeine, but can decrease the plasma concentration of active metabolite dihydromorphine which could result in reduced analgesic efficacy or symptoms of opioid withdrawal, particularly when an inhibitor is added after a stable dose of TREZIX™ is achieved.',\n",
       " 'After stopping a CYP2D6 inhibitor, as the effects of the inhibitor decline, the dihydrocodeine plasma concentration will decrease but the active metabolite dihydromorphine plasma concentration will increase, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. If concomitant use with a CYP2D6 inhibitor is necessary or if a CYP2D6 inhibitor is discontinued after concomitant use, consider dosage adjustment of TREZIX™ and monitor patients closely at frequent intervals. If concomitant use with CYP2D6 inhibitors is necessary, follow the patient for reduced efficacy or signs and symptoms of opioid withdrawal and consider increasing the TREZIX™ as needed. After stopping use of a CYP2D6 inhibitor, consider reducing the TREZIX™ and monitor the patient for signs and symptoms of respiratory depression or sedation',\n",
       " 'The concomitant use of TREZIX™ with CYP3A4 inhibitors such as macrolide antibiotics (e.g., erythromycin ), azole- antifungal agents (e.g. ketoconazole), and protease inhibitors (e.g., ritonavir), may result in an increase in dihydrocodeine plasma concentration with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater dihydromorphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of TREZIX™ is achieved.',\n",
       " 'After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower dihydrocodeine plasma levels, greater dihydronorcodeine levels, and less metabolism via 2D6 with resultant lower dihyromorphine levels, resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to dihydrocodeine. If concomitant use with CYP3A4 inhibitor is necessary, consider dosage reduction of TREZIX™ until stable drug effects are achieved. Monitor patients for respiratory depression and sedation at frequent intervals.',\n",
       " 'If a CYP3A4 inhibitor is discontinued, consider increasing the TREZIX™ dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal.',\n",
       " 'The concomitant use of TREZIX™ and CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin), can result in lower dihydrocodeine levels, greater dihydronorcodeine levels, and less metabolism via 2D6 with resultant lower dihyromorphine levels, resulting in decreased efficacy or a withdrawal syndrome in patients who had developed physical dependence to dihydrocodeine.',\n",
       " 'After stopping a CYP3A4 inducer, as the effects of the inhibitor decline, the dihydrocodeine plasma concentration may increase with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater dihyromorphine levels, which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression.',\n",
       " 'If concomitant use with CYP3A4 inducer is necessary, follow the patient for reduced efficacy and signs of opioid withdrawal and consider increasing the TREZIX™ dosage as needed.',\n",
       " 'If a CYP3A4 inducer is discontinued, consider TREZIX™ dosage reduction and monitor for signs of respiratory depression and sedation at frequent intervals.',\n",
       " 'Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics and other opioids, can increase the risk of hypotension , respiratory depression, profound sedation, coma, and death.',\n",
       " 'Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation [see WARNINGS ].',\n",
       " 'The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone , tramadol), and monoamine oxidase (MAO) inhibitors (used to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) [see PRECAUTIONS ; Information For Patients ].',\n",
       " 'If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue TREZIX™ immediately if serotonin syndrome is suspected.',\n",
       " 'Dihydrocodeine, like all opioid analgesics, interacts with monoamine oxidase inhibitors causing central nervous system excitation and hypertension .',\n",
       " 'Agonist / antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine ) may reduce the analgesic effect of this combination product.',\n",
       " 'Chronic and excessive consumption of alcohol may increase the hepatotoxic risk of acetaminophen. The potential for hepatotoxicity with acetaminophen also may be increased in patients receiving anticonvulsants that induce hepatic microsomal enzymes (including phenytoin, barbiturates , and carbamazepine) or isoniazide. Chronic ingestion of large doses of acetaminophen may slightly potentiate the effects of warfarin-and indandione-derivative anticoagulants. Severe hypothermia is possible in patients receiving acetaminophen concomitantly with phenothiazines.',\n",
       " 'Caffeine may enhance the cardiac inotropic effects of beta-adrenergic stimulating agents. Co-administration of caffeine and disulfiram may lead to a substantial decrease in caffeine clearance. Caffeine may increase the metabolism of other drugs such as phenobarbital and aspirin. Caffeine accumulation may occur when products or foods containing caffeine are consumed concomitantly with quinolones such as ciprofloxacin.',\n",
       " 'TREZIX™ contains dihydrocodeine bitartrate, a Schedule III controlled substance.',\n",
       " 'TREZIX™ contains dihydrocodeine bitartrate, a substance with a high potential for abuse similar to other Schedule III opioids. TREZIX™ can be abused and is subject to misuse, addiction, and criminal diversion [see WARNINGS ].',\n",
       " 'All patients treated with opioids require careful monitoring for signs of abuse and addiction, since use of opioid analgesic products carries the risk of addiction even under appropriate medical use.',\n",
       " 'Prescription drug abuse is the intentional non-therapeutic use of a prescription drug, even once, for its rewarding psychological or physiological effects.',\n",
       " 'Drug addiction is a cluster of behavioral, cognitive , and physiological phenomena that develop after repeated substance use and includes: a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal.',\n",
       " '“Drug-seeking” behavior is very common in persons with substance use disorders. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral , repeated “loss” of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating health care provider(s). “Doctor shopping” (visiting multiple prescribers) to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control.',\n",
       " 'Abuse and addiction are separate and distinct from physical dependence and tolerance. Health care providers should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of true addiction.',\n",
       " 'TREZIX™, like other opioids, can be diverted for non-medical use into illicit channels of distribution. Careful record keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised.',\n",
       " 'Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.',\n",
       " 'Risks Specific to Abuse of TREZIX™',\n",
       " 'TREZIX™ is for oral use only. Abuse of TREZIX™ poses a risk of overdose and death. The risk is increased with concurrent use of TREZIX™ with alcohol and other central nervous system depressants.',\n",
       " 'Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV .',\n",
       " 'Both tolerance and physical dependence can develop during chronic opioid therapy. Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors).',\n",
       " 'Tolerance may occur to both the desired and undesired effects of drugs, and may develop at different rates for different effects. Physical dependence results in withdrawal symptoms after abrupt discontinuation or a significant dosage reduction of a drug. Withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone , nalmefene), mixed agonist/antagonist analgesics (pentazocine, butorphanol, nalbuphine), or partial agonists (buprenorphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued opioid usage.',\n",
       " 'TREZIX™ should not be abruptly discontinued [see DOSAGE AND ADMINISTRATION ]. If TREZIX™ is abruptly discontinued in a physicallydependent patient, a withdrawal syndrome may occur. Some or all of the following can characterize this syndrome: restlessness, lacrimation , rhinorrhea , yawning , perspiration , chills, myalgia , and mydriasis . Other signs and symptoms also may develop, including: irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate , or heart rate.',\n",
       " 'Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs [see PRECAUTIONS ; Pregnancy ].',\n",
       " 'No information provided.',\n",
       " 'Caution should be observed in hypertension , peripheral vascular disease and \\r\\n  after recent cardio-vascular attacks.',\n",
       " 'Substances that induce or regulate hepatic cytochrome enzyme CYP2E1 may alter the metabolism of acetaminophen and increase its hepatotoxic potential. The clinical consequences of these effects have not been established. Effects of ethanol are complex, because excessive alcohol usage can induce hepatic cytochromes, but ethanol also acts as a competitive inhibitor of the metabolism of acetaminophen.',\n",
       " 'Chronic oral acetaminophen use at a dose of 4000 mg/day has been shown to cause an increase in international normalized ratio (INR) in some patients who have been stabilized on sodium warfarin as an anticoagulant . As no studies have been performed evaluating the short-term use of OFIRMEV in patients on oral anticoagulants, more frequent assessment of INR may be appropriate in such circumstances.',\n",
       " 'Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome , toxic epidermal necrolysis, fulminant hepatic \\r\\n  necrosis, agranulocytosis , aplastic anemia , and other blood dyscrasias. Sensitizations \\r\\n  may recur when a sulfonamide is readministered irrespective of the route of \\r\\n  administration. If signs of hypersensitivity or other serious reactions occur, \\r\\n  discontinue use of this drug.',\n",
       " 'Caution is advised for patients receiving concomitant high-dose aspirin and \\r\\n  acetazolamide, as anorexia , tachypnea , lethargy , coma and death have been reported.',\n",
       " 'Adverse reactions, occurring most often early in therapy,\\r\\ninclude paresthesias, particularly a “tingling” feeling in the\\r\\nextremities, hearing dysfunction or tinnitus , loss of appetite, taste\\r\\nalteration and gastrointestinal disturbances such as nausea, vomiting and\\r\\ndiarrhea, polyuria , and occasional instances of drowsiness and confusion.',\n",
       " 'Metabolic acidosis and electrolyte imbalance may occur.',\n",
       " 'Transient myopia has been reported. This condition\\r\\ninvariably subsides upon diminution or discontinuance of the medication. Other\\r\\noccasional adverse reactions include urticaria , melena , hematuria , glycosuria,\\r\\nhepatic insufficiency, flaccid paralysis , photosensitivity and convulsions.\\r\\nAlso see PATIENT INFORMATION for possible reactions\\r\\ncommon to sulfonamide derivatives. Fatalities have occurred although rarely,\\r\\ndue to severe reactions to sulfonamides including Stevens-Johnson syndrome ,\\r\\ntoxic epidermal necrolysis, fulminant hepatic necrosis , agranulocytosis , aplastic anemia and other blood dyscrasias (see WARNINGS ).',\n",
       " 'No information provided.',\n",
       " 'Aspirin - See WARNINGS .',\n",
       " 'DIAMOX ® modifies phenytoin metabolism with increased serum levels of phenytoin. This may increase or enhance the occurrence of osteomalacia in some patients receiving chronic phenytoin therapy. Caution is advised in patients receiving chronic concomitant therapy.',\n",
       " 'By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.',\n",
       " 'Because of possible additive effects with other carbonic anhydrase inhibitors, concomitant use is not advisable.',\n",
       " 'Acetazolamide may increase the effects of other folic acid antagonists.',\n",
       " 'Acetazolamide may increase or decrease blood glucose levels. Consideration should be taken in patients being treated with antidiabetic agents.',\n",
       " 'Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.',\n",
       " 'Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.',\n",
       " 'Acetazolamide may prevent the urinary antiseptic effect of methenamine.',\n",
       " 'Acetazolamide increases lithium excretion and the lithium may be decreased.',\n",
       " 'Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.',\n",
       " 'Acetazolamide may elevate cyclosporine levels.',\n",
       " 'Aspirin - See WARNINGS',\n",
       " 'DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin. \\r\\n  This may increase or enhance the occurrence of osteomalacia in some patients \\r\\n  receiving chronic phenytoin therapy. Caution is advised in patients receiving \\r\\n  chronic concomitant therapy. By decreasing the gastrointestinal absorption of \\r\\n  primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, \\r\\n  with a consequent possible decrease in anticonvulsant effect. Caution is advised \\r\\n  when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving \\r\\n  primidone.',\n",
       " 'Because of possible additive effects with other carbonic anhydrase inhibitors, concomitant use is not advisable.',\n",
       " 'Acetazolamide may increase the effects of other folic acid antagonists.',\n",
       " 'Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.',\n",
       " 'Acetazolamide reduces urinary excretion of quinidine and may enhance its effect. Acetazolamide may prevent the urinary antiseptic effect of methenamine. Acetazolamide increases lithium excretion and the lithium may be decreased.',\n",
       " 'Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.',\n",
       " 'Acetazolamide may elevate cyclosporine levels.',\n",
       " 'Sulfonamides may give false negative or decreased values for urinary phenolsulfonphthalein and phenol red elimination values for urinary protein, serum non-protein, and serum uric acid .  Acetazolamide may produce an increased level of crystals in the urine.',\n",
       " 'Acetazolamide interferes with the HPLC method of assay for theophylline.  Interference with the theophylline assay by acetazolamide depends on the solvent used in the extraction; acetazolamide may not interfere with other assay methods for theophylline.',\n",
       " 'Discontinue promptly if sensitization or irritation occurs.',\n",
       " 'Transient stinging or burning may be noted occasionally when the solution is first instilled into the acutely inflamed ear .',\n",
       " 'Safety and effectiveness in pediatric patients below the age of 3 years have not been established.',\n",
       " 'AHA has been used concomitantly with insulin , oral and parenteral antibiotics, and progestational\\r\\nagents. No clinically significant interactions have been noted, but until wider clinical experience is\\r\\nobtained, AHA should be used with caution in patients receiving other therapeutic agents.',\n",
       " 'AHA taken in association with alcoholic beverages has resulted in a rash. (See ADVERSE REACTIONS .)',\n",
       " 'AHA chelates heavy metals-notably iron. The absorption of iron and AHA from the intestinal lumen may\\r\\nbe reduced when both drugs are taken concomitantly. When iron administration is indicated, intramuscular iron is probably the product of choice.',\n",
       " 'It has been reported that sulfisoxazole may prolong the prothrombin time in\\r\\n  patients who are receiving anticoagulants, including warfarin . This interaction\\r\\n  should be kept in mind when Gantrisin (acetyl sulfisoxazole pediatric suspension)  is given to patients already on anticoagulant\\r\\n  therapy, and prothrombin time or other suitable coagulation test should be monitored.',\n",
       " 'It has been proposed that sulfisoxazole competes with thiopental for plasma protein binding. In one study involving 48 patients, intravenous sulfisoxazole\\r\\n  resulted in a decrease in the amount of thiopental required for anesthesia and\\r\\n  in a shortening of the awakening time. It is not known whether chronic oral\\r\\n  doses of sulfisoxazole would have a similar effect. Until more is known about\\r\\n  this interaction, physicians should be aware that patients receiving sulfisoxazole\\r\\n  might require less thiopental for anesthesia.',\n",
       " 'Sulfonamides can displace methotrexate from plasma protein-binding sites, thus\\r\\n  increasing free methotrexate concentrations. Studies in man have shown sulfisoxazole\\r\\n  infusions to decrease plasma protein-bound methotrexate by one-fourth.',\n",
       " 'Sulfisoxazole can also potentiate the blood sugar lowering activity of sulfonylureas,\\r\\n  as well as cause hypoglycemia by itself.',\n",
       " 'DO NOT GAS STERILIZE. If blister or peelable backing is damaged or broken, sterility of the\\r\\nenclosed vial and ampoule cannot be assured. Open under aseptic conditions only.',\n",
       " 'If miosis is to be obtained quickly with Miochol ® -E ( acetylcholine chloride intraocular solution),\\r\\nanatomical hindrances to miosis, such as anterior or posterior synechiae, must be released, prior to\\r\\nadministration of Miochol-E. During cataract surgery , use Miochol-E only after delivery of the lens .',\n",
       " 'Aqueous solutions of acetylcholine chloride are unstable. Prepare solution immediately before use. Do\\r\\nnot use solution which is not clear and colorless. Discard any solution that has not been used.',\n",
       " 'Safety and effectiveness in pediatric patients have not been established.',\n",
       " 'Included as part of the \"PRECAUTIONS\" Section',\n",
       " 'Hypersensitivity reactions, including generalized urticaria have been observed in patients receiving oral\\r\\nacetylcysteine for acetaminophen overdose. If hypersensitivity reactions occur, CETYLEV should be\\r\\ndiscontinued unless it is deemed essential for patient management and the reactions can be otherwise controlled.',\n",
       " 'Occasionally severe and persistent vomiting occurs as a symptom of acute acetaminophen overdose. Treatment\\r\\nwith CETYLEV may aggravate the vomiting and increase the risk of upper gastrointestinal hemorrhage in at\\r\\nrisk patients (e.g., those with esophageal varices, peptic ulcers, etc.). Consider the risk/benefit for patients at\\r\\nrisk of hemorrhage versus the risk of developing hepatic toxicity, and treat with CETYLEV as needed.',\n",
       " 'Advise the patient to read the FDA-approved patient labeling ( PATIENT INFORMATION ).',\n",
       " 'Advise patients that hypersensitivity reactions, including generalized urticaria may occur and to report any signs\\r\\nor symptoms to their healthcare provider immediately [see WARNINGS AND PRECAUTIONS ].',\n",
       " 'Carcinogenicity studies in laboratory animals have not been performed with acetylcysteine.',\n",
       " 'Acetylcysteine was negative in the Ames test.',\n",
       " 'In a fertility study of acetylcysteine in rats, intravenous administration of 1000 mg/kg/day (0.3 times the\\r\\nrecommended human oral dose based on body surface area) caused a profound reduction of fertility in females,\\r\\nwhich was correlated with morphological changes in oocytes and severe impairment of implantation (18 of 20\\r\\nmated females had no implantations). The reversibility of this effect was not evaluated. No effects on fertility\\r\\nwere observed in female rats at intravenous doses up to 300 mg/kg/day (0.1 times the recommended human oral\\r\\ndose based on body surface area), or in male rats at intravenous doses up to 1000 mg/kg/day. Mating was\\r\\nunaffected in this study.',\n",
       " 'In a reproduction study of acetylcysteine, male rats were treated orally for 15 weeks prior to mating and during\\r\\nthe mating period. A slight non-dose related reduction in fertility was observed at oral doses of 500 and 1000\\r\\nmg/kg/day (0.1 and 0.3 times the recommended human dose, respectively, based on body surface area).',\n",
       " 'Limited published case reports and case series on acetylcysteine use during pregnancy are insufficient to inform\\r\\na drug-associated risk of birth defects and miscarriage. However, there are clinical considerations [see Clinical\\r\\nConsiderations ]. In animal reproduction studies, no teratogenic effects were observed with oral administration\\r\\nof acetylcysteine to pregnant rats and rabbits during organogenesis at doses up to 0.6 times the maximum\\r\\nrecommended human dose (based on body surface area) of about 560 mg/kg (total dose on first day of\\r\\ntreatment) [see Data ].',\n",
       " 'The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.\\r\\nIn the U.S. general population, the estimated background risk of major birth defects and miscarriage in\\r\\nclinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.',\n",
       " 'Disease-Associated Maternal and/or Embryo/Fetal Risk',\n",
       " 'Acetaminophen and acetylcysteine cross the placenta. Delaying treatment in pregnant women with\\r\\nacetaminophen overdose and potentially toxic acetaminophen plasma levels may increase the risk of maternal\\r\\nand fetal morbidity and mortality.',\n",
       " 'Animal Data',\n",
       " 'No teratogenic effects were observed in embryo-fetal development studies in rats at oral doses up to 2000\\r\\nmg/kg/day (0.6 times the maximum recommended human dose based on body surface area) or in rabbits at oral\\r\\ndoses up to 1000 mg/kg/day (0.6 times the maximum recommended human dose based on body surface area)\\r\\nadministered during organogenesis.',\n",
       " 'There is no information regarding the presence of acetylcysteine in human milk, or the effects of acetylcysteine\\r\\non the breastfed infant or on milk production. The development and health benefits of breastfeeding should be\\r\\nconsidered along with the mother’s clinical need for CETYLEV and any potential adverse effects on the\\r\\nbreastfed infant from CETYLEV or from the underlying maternal condition.',\n",
       " 'Pediatric approval, including dosing, is not based on adequate and well-controlled clinical studies. Pediatric\\r\\ndosing recommendations are based on clinical experience [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'Clinical studies of acetylcysteine did not include sufficient numbers of subjects aged 65 and over to determine\\r\\nwhether they respond differently from younger subjects. Other reported clinical experience with acetylcysteine\\r\\nhas not identified differences in the responses between elderly and younger patients. In general, dose selection\\r\\nfor an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater\\r\\nfrequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.',\n",
       " 'CETYLEV tablets contain sodium. Consider the total sodium content from dietary and non-dietary sources in\\r\\npatients who may be sensitive to excess sodium intake, such as those with congestive heart failure , hypertension , or renal impairment.',\n",
       " 'At the recommended dosage an average sized adult (60 kg) may receive a total of 7 grams of sodium (304.3\\r\\nmEq) on the first day of treatment, 5.3 grams of sodium (230.4 mEq) on the second day of treatment, and 4.4\\r\\ngrams of sodium (191.3 mEq) on the third day of treatment.',\n",
       " 'If sodium intake is a concern, please refer to Table 3 for the amount of sodium in each tablet [see DESCRIPTION ] and to Tables 1 and 2 for the recommended dosage in adults and pediatrics based on body weight in order\\r\\nto calculate the amount of sodium administered to an individual patient [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'Included as part of the \"PRECAUTIONS\" Section',\n",
       " 'Serious acute hypersensitivity reactions during acetylcysteine administration including rash, hypotension , wheezing , and/or shortness of breath, have been observed in patients receiving intravenous acetylcysteine for acetaminophen overdose and occurred soon after initiation of the infusion [see ADVERSE REACTIONS ]. If a severe hypersensitivity reaction occurs, immediately stop the infusion of ACETADOTE and initiate appropriate treatment.',\n",
       " 'One patient with asthma developed bronchospasm and died after intravenous administration of acetylcysteine. ACETADOTE should be used with caution in patients with asthma, or where there is a history of bronchospasm. Patients with asthma should be closely monitored during initiation of ACETADOTE therapy and throughout ACETADOTE therapy.',\n",
       " 'Acute flushing and erythema of the skin may occur in patients receiving acetylcysteine intravenously. These reactions usually occur 30 to 60 minutes after initiating the infusion and often resolve spontaneously despite continued infusion of acetylcysteine. If a reaction to acetylcysteine involves more than simply flushing and erythema of the skin, it should be treated as a hypersensitivity reaction.',\n",
       " 'Management of less severe hypersensitivity reactions should be based upon the severity of the reaction and include temporary interruption of the infusion and/or administration of antihistaminic drugs. The ACETADOTE infusion may be carefully restarted after treatment of the hypersensitivity symptoms has been initiated; however, if the hypersensitivity reaction returns upon re-initiation of treatment or increases in severity, ACETADOTE should be discontinued and alternative patient management should be considered.',\n",
       " 'The total volume of ACETADOTE administered should be adjusted for patients less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as needed [see DOSAGE AND ADMINISTRATION ]. If volume is not adjusted fluid overload can occur, potentially resulting in hyponatremia , seizure and death.',\n",
       " 'Intravenous administration of ACETADOTE can cause fluid overload, potentially resulting in hyponatremia, seizure and death. To avoid fluid overload, use the recommended dilution shown in Tables 2, 3 and 4 [see DOSAGE AND ADMINISTRATION ].',\n",
       " 'Long-term studies in animals have not been performed to evaluate the carcinogenic potential of acetylcysteine.',\n",
       " 'Acetylcysteine was not genotoxic in the Ames test or the in vivo mouse micronucleus test. It was, however, positive in the in vitro mouse lymphoma cell (L5178Y/TK +/- ) forward mutation test.',\n",
       " 'Treatment of male rats with acetylcysteine at an oral dose of 250 mg/kg/day for 15 weeks (0.1 times the recommended total human intravenous dose of 300 mg/kg based on body surface comparison) did not affect the fertility or general reproductive performance.',\n",
       " 'Limited published case reports and case series of pregnant women exposed to acetylcysteine during various trimesters are not sufficient to inform any drug associated risk. Delaying treatment of acetaminophen overdose may increase the risk of maternal or fetal morbidity and mortality [see Clinical Considerations ]. Reproduction studies in rats and rabbits following oral administration of acetylcysteine during the period of organogenesis at doses similar to the total intravenous dose (based on the body surface area) did not cause any adverse effects to the fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.',\n",
       " 'Disease-Associated Maternal and/or Embryo/Fetal Risk',\n",
       " 'Acetaminophen and acetylcysteine cross the placenta. Delaying treatment in pregnant women with acetaminophen overdose and potentially toxic acetaminophen plasma levels may increase the risk of maternal and fetal morbidity and mortality.',\n",
       " 'Animal Data',\n",
       " 'Reproduction studies have been performed following administration of acetylcysteine during the period of organogenesis in rats at oral doses up to 2000 mg/kg/day (1.1 times the recommended total human intravenous dose of 300 mg/kg based on body surface area comparison) and in rabbits at oral doses up to 1000 mg/kg/day (1.1 times the recommended total human intravenous dose of 300 mg/kg based on body surface area comparison). No adverse developmental outcomes due to acetylcysteine were observed.',\n",
       " \"There are no data on the presence of acetylcysteine in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ACETADOTE and any potential adverse effects on the breastfed child from ACETADOTE or from the underlying maternal condition.\",\n",
       " ...]"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "side_efects_and_drug_intratns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "de98e36c",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.12"
  },
  "toc": {
   "base_numbering": 1,
   "nav_menu": {},
   "number_sections": true,
   "sideBar": true,
   "skip_h1_title": false,
   "title_cell": "Table of Contents",
   "title_sidebar": "Contents",
   "toc_cell": false,
   "toc_position": {},
   "toc_section_display": true,
   "toc_window_display": false
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
